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Abstract
Since the discovery and isolation of the didemnin family of marine depsipeptides in 1981, the synthesis and
biological activity of its congeners have been of great interest to the scientific community. Of those, didemnin
B was the first marine natural product to reach phase II clinical trials, stimulating many analogue syntheses to
date. Almost two decades later, tamandarins A and B were reported and found to possess a structure similar to
that of the didemnins. Significant efforts have been devoted to the syntheses of tamandarin analogues to find
whether they behaved as didemnin mimics or as individual therapeutic agents. The biological and synthetic
significance of the didemnins, tamandarins, and related natural products are discussed in Chapter 1.
The improved second-generation synthesis of the tamandarin B macrocycle and its successful application to
the syntheses of three novel tamandarin B side chain analogues are presented in Chapter 2. The results of
these investigations could help elucidate the structure-activity relationship as well as mode of action of these
natural products.
Chapter 3 deals with the generation of structurally intriguing azabicyclic [3.1.0]- and
[4.1.0]aminocyclopropanes and their application in an unprecedented ring-opening conditions to afford
corresponding 3-piperidinone and 3-azepinone derivatives which are important pharmaceutical motifs.
Chapter 4 introduces a rapidly growing family of natural diketopiperazine alkaloids:
epipolythiodiketopiperazine (ETP) alkaloids, and related synthetic efforts in the generation of these alkaloids.
Extensive synthetic investigation towards the formal synthesis of (−)-epicoccin G and other related
epidithiodiketopiperazine alkaloids have been conducted. A novel methodology to access the 6-5-6-5-6
pentacyclic framework present in many ETP alkaloids is presented. Further application of this methodology
in total synthesis could provide ETP alkaloids that have not been synthesized.
Chapter 5 deals with the development and successful application of 1,2-indanedione functionalized gold
nanoparticles in a modified multi-metal deposition process for the development of latent fingerprints on
paper. Although a wide variety of ninhydrin-like compounds have been developed as chemical agents for this
process over the years, considerable portions of latent fingerprints still escape detection. The new approach
provides an alternative method of fingerprint detection that could be utilized in challenging situations.
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ABSTRACT 
 
PART I. SYNTHETIC INVESTIGATIONS OF HETEROCYCLIC  
NATURAL AND UNNATURAL COMPOUNDS  
PART II. NEW APPROACH TO LATENT FINGERPRINT DETECTION ON PAPER 
Jisun Lee 
Madeleine M. Joullié 
Since the discovery and isolation of the didemnin family of marine depsipeptides in 1981, 
the synthesis and biological activity of its congeners have been of great interest to the 
scientific community. Of those, didemnin B was the first marine natural product to reach 
phase II clinical trials, stimulating many analogue syntheses to date. Almost two decades 
later, tamandarins A and B were reported and found to possess a structure similar to that 
of the didemnins. Significant efforts have been devoted to the syntheses of tamandarin 
analogues to find whether they behaved as didemnin mimics or as individual therapeutic 
agents. The biological and synthetic significance of the didemnins, tamandarins, and 
related natural products are discussed in Chapter 1.  
The improved second-generation synthesis of the tamandarin B macrocycle and its 
successful application to the syntheses of three novel tamandarin B side chain analogues 
are presented in Chapter 2. The results of these investigations could help elucidate the 
structure-activity relationship as well as mode of action of these natural products.  
Chapter 3 deals with the generation of structurally intriguing azabicyclic [3.1.0]- and 
[4.1.0]aminocyclopropanes and their application in an unprecedented ring-opening 
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conditions to afford corresponding 3-piperidinone and 3-azepinone derivatives which are 
important pharmaceutical motifs.  
Chapter 4 introduces a rapidly growing family of natural diketopiperazine alkaloids: 
epipolythiodiketopiperazine (ETP) alkaloids, and related synthetic efforts in the 
generation of these alkaloids. Extensive synthetic investigation towards the formal 
synthesis of (−)-epicoccin G and other related epidithiodiketopiperazine alkaloids have 
been conducted. A novel methodology to access the 6-5-6-5-6 pentacyclic framework 
present in many ETP alkaloids is presented. Further application of this methodology in 
total synthesis could provide ETP alkaloids that have not been synthesized.  
Chapter 5 deals with the development and successful application of 1,2-indanedione 
functionalized gold nanoparticles in a modified multi-metal deposition process for the 
development of latent fingerprints on paper. Although a wide variety of ninhydrin-like 
compounds have been developed as chemical agents for this process over the years, 
considerable portions of latent fingerprints still escape detection. The new approach 
provides an alternative method of fingerprint detection that could be utilized in 
challenging situations.  
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Chapter 1: Didemnins, tamandarins and related natural products 
 
 
1.1) Discovery and isolation 
 
Marine invertebrates of the class Ascidiacea (phylum Chordata, subphylum Urochordata) 
have been found to produce nitrogen-containing metabolites that often exhibit potent 
anticancer properties.1,2 Of such, ascidians, more commonly known as sea squirts or 
tunicates, are marine invertebrates that are characterized by a tough outer tunic and their 
ability to attach themselves to rocks and shells. Ascidians possess a fascinating defense 
mechanism in which they produce secondary metabolites that significantly reduce 
predation on both adults and larvae. This chemical defense mechanism is crucial in 
allowing the release of large larvae during daylight periods when the larvae have the 
greatest probability to select appropriate settlement sites when exposure to fish predation 
is the highest.  
 
The colonial ascidian Trididemnum solidum (Figure 1.1) is found in a broad range of 
geographical locations, and forms large mats, actively growing and harming live coral.3 
Larvae of Trididemnum solidum have been found to owe their unpalatability to chemical 
rather than structural defenses. The didemnins (1-5, Figure 1.2) were isolated from 
Trididemnum solidum, including several from Trididemnum cyanophorum, in which the 
presence of didemnin cyclic peptides in the larvae supports a chemical 
defense.4,5,6,7,8,9,10,11,12 Interestingly, there are chemical differences between larvae and 
adults, where the larvae contain only four of the six didemnins found in the adult colonies. 
! 2 
The larvae either receive a selected transfusion of adult chemistry or synthesize 
secondary metabolites to better adapt to or enhance their chance of survival.3 Comparison 
of the chemistries of the larvae and the colonies that produce them should aid in the 
identification of factors affecting secondary metabolites at different life stages.13 Of note, 
studies by Lindquist, Hays, and Fenical suggest that ascidians may be able to avoid 
autotoxicity from their chemical defense mechanism by possessing a well-developed 
circulatory system that allow the encapsulation of bioactive compounds within blood 
cells.3,13  
 
 
Figure 1.1   Photographs of Trididemnum solidum and Aplidium albicans: (a) Trididemnum solidum, (b) 
Trididemnum solidum overgrowing an Agaricia coral species, and (c) Aplidium albicans. 
Sources: (a) Photograph courtesy of François Rebufat. Reprinted from http://www.pictolife.net/photos.php?table=ascidies. (b) 
Photograph courtesy of Miriam C. Goldstein, Scripps Institution of Oceanography. (c) Photograph courtesy of PharmaMar, S.A 
Sociedad Unipersonal. All rights reserved. 
 
 
1.2) Structural features 
 
The didemnins (1-5, Figure 1.2) are a family of cyclic depsipeptides isolated from 
tunicates of the family Didemnidae, while as aplidine or dehydrodidemnin B (4, Figure 
1.2) was extracted from the ascidian Aplidium albicans (Figure 1.1).14 While these 
ascidians were found in the Caribbean and Mediterranean coasts, the tamandarins (6, 7, 
Figure 1.2) were isolated from an unidentified Brazilian marine ascidian also from the 
family Didemnidae.15,16 Interestingly, although the two species that generated these 
ascidians were found in remote geographic locations, they were found to use a common 
method to defend their vulnerable larvae by producing structurally similar, but not 
! 3 
identical depsipeptides (Figure 1.2).17 More recently, another didemnin congener, N,N’-
methyleno-didemnin A, was isolated from Trididemnum solidum.18  
 
 
Figure 1.2. Structures of naturally occurring didemnins and tamandarins. 
 
Tamandarins A (6) and B (7) are closely related to 2 and nordidemnin B (3), respectively, 
varying only by the presence of α-hydroxyisovaleric acid (Hiv2) instead of the [α-(α-
hydroxyisovaleryl)propionic acid] (Hip2) present in all didemnin congeners (Figure 1.2). 
Didemnins and tamandarins display similar biological properties, which suggest that the 
propionic acid unit leads to only a minor conformational modification. Tamandarin A 
contains an isostatine residue (Ist1) in the macrocycle, while tamandarin B possess a 
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norstatine residue (Nst1) (Figure 1.2). Extensive conformational studies to assess the ring 
modifications in 6 showed that tamandarin A is rigid, and that all peptide bonds have 
trans conformations, as in 2.15 Furthermore, the keto group, present in the Hip2 unit but 
absent in the Hiv2 unit, does not seem to affect the bioactivity even though it was 
believed that its position, extending outwards from the macrocycle, allowed it to interact 
with its associated protein targets.19 It is of interest to note that removal of the stereogenic 
methyl group in didemnin B led to complete loss of bioactivity, while its absence in the 
tamandarins does not affect the bioactivity. This suggests that its absence in the 
didemnins may produce a change in conformation that could be due to enolization. 
 
1.3) Function as chemical defense agents in nature 
 
Perhaps one of the most important ecological questions is the effect of consuming 
chemically defended prey on the fitness of marine consumers and consequently the 
evolution of effective chemical defenses in marine prey.20 Trididemnum solidum larvae 
are recognized and avoided by marine predators. When ingested at ecologically realistic 
doses, they can decrease or destroy consumer fitness. The ascidian tunic is the first 
physical and chemical defense barrier against microbial and fungal organisms, fouling 
organisms, and predation.3  
 
In 2003, Joullié and coworkers synthesized fluorescent analogues of didemnin B (8) and 
tamandarin A (9, Figure 1.3) to investigate the potential chemical defense mechanisms of 
tunicates of the family Didemnidae.17 
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Figure 1.3. Fluorescent probes developed from the didemnin and tamandarin depsipeptides. 
 
When mosquito larvae containing the fluorescent derivatives were fed to six species of 
fish, a rapid response was observed, where the rate of absorption and physiological 
processing were the same for both synthetic products. The effect was dependent on the 
dose, leading to association of the larval species with distaste, and after five daily 
feedings, 50% of the fish that consumed 50 ± 4 ng of depsipeptide avoided the treated 
larvae. Predator fitness increased with their ability to recognize the treated larvae, but 
produced an overall decrease in hunting. Ingestion and absorption of the treated larvae 
resulted in accumulation of fluorescent material in the joint tissue of the fish. This was 
the first report that showed that didemnin B and tamandarin A fluorescent probes 8 and 9, 
although structurally different, possessed similar activity (Figure 1.3).  
 
1.4) Crystallographic and NMR studies 
 
Only three crystal structures for the cyclic depsipetides have been elucidated to date, 
which includes didemnin B (2),19 didemnin A (1),21 and the cyclic depsipeptide backbone 
(Figure 1.4).22 The features of these structures may be relevant to their biological activity, 
especially as conformational consistency from crystal to solution structure is well 
established in a range of solvents.9,19,23,24,25 
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  (a) didemnin B              (b) didemnin A         (c) didemnin B macrocyclic salt 
Figure 1.4. Computer-generated representations of (a) didemnin B (2); (b) didemnin A (1); (c) didemnin B 
macrocyclic salt. These structures were generated using a Java application called Jmol, an open-source Java 
viewer for chemical structures in 3D. (http://www.jmol.org/).    
 
Didemnin B (2) exhibits an irregular shape, described as a “bent figure eight” (Figure 
1.4). There are three hydrogen bonds stabilizing the structure: a) the only hydrogen bond 
in the macrocycle that stretches from the L-proline carbonyl to the isostatine NH (3.020 
Å), b) the hydrogen bond in the linear chain goes from the lactyl proline carbonyl to the 
NH of N-Me-D-leucine (3.087 Å) which is responsible for the β(II)-turn of the side chain, 
and c) finally the strongest hydrogen bond which links the linear side chain to the 
backbone (2.90 Å), stretches from the NH of the macrocycle leucine to the N-Me-D-
leucine carbonyl of the side chain.  
 
All oxygen atoms in the macrocycle point away from the interior of the cavity, which 
explains why 2 is not an ionophore and does not complex alkali cations. Didemnin B (2) 
also forms three strong hydrogen bonds with a water molecule. Moreover, although 
Hossain and coworkers originally recognized more than one group on 2 that could bind to 
receptors, they suggested that the linear peptide chain, particularly the lactylproline 
moiety, was the most significant structural feature for the biological activity.19  
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The crystal structure and packing of didemnin A (1) are different from those of 2, 
because the molecules form a dimeric pair, in which each molecule preserves the folded 
conformation of a “bent figure eight.” They are also stabilized by two intramolecular 
hydrogen bonds similar to hydrogen bonds present in didemnin B (a and c mentioned 
above), but stronger (2.83 Å vs. 3.02 Å and 2.88 Å vs. 2.90 Å), suggesting a more rigid 
macrocycle. An analysis of selected torsional angles also showed some variations.21  
 
Finally, the crystal structure for the macrocycle hydrobromide salt, Figure 1.4 (c), 
displays a more flattened oval shape, due to lack of a side chain. Two separate 
conformations were identified, where one of them more closely resembled didemnin B. A 
comparison of the torsional angles also showed good agreement with those of didemnin 
B for only one of the two conformations. The bromide ion was situated in the center of 
the molecule, suggesting possible ionophoric properties.22  
 
Spectroscopic properties of both didemnins and tamandarins have been well investigated 
in conjugation with their discovery.16 However, recent reports in this area are few, since 
the earlier investigation of 4 revealed the existence of two slowly interconverting 
conformers that could only be resolved by HPLC.26 The conformers are due to hydrogen 
bonding from the NH of Thr6 and the two carbonyls of the pyruvyl unit, resulting in 
restricted rotation around the pyruvyl-proline bond of the side chain. The different 
hydrogen bonds result in cis (with keto carbonyl) and trans (with amide carbonyl) 
isomers for aplidine (Figure 1.5) but do not affect the three-dimensional structure of the 
macrocycle.  
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Figure 1.5. Hydrogen bonds between Thr6-NH and the pyruvyl unit of aplidine (4)  
in the cis- and trans- conformation. 
 
Didemnin B (2), which has a lactyl unit instead of a pyruvyl unit, exists as only one 
major conformer in solution with either CDCl3 or DMSO-d6 as the NMR solvent. 
However, the cis-/trans- isomers of aplidine (4) exist as a 45:55 mixture in CDCl3. 
Interestingly, a more recent NMR study of aplidine (4) in DMSO-d6 done by Cárdenas 
and coworkers shows four interconverting structures in a ratio of 47:33:13:7, and 
represents the first observation of conformational isomers for the didemnins.27 The major 
isomers are the same cis- and trans- isomers observed in CDCl3, but with a preference for 
cis. The minor isomers arise from similar cis/trans isomers in structures in which the N-
Me-D-Leu7-Pro8 is the cis isomer. It is important to note that all conformational isomers 
retain the three-dimensional structure of 4, but a significant difference in the disposition 
of the side chain is observed between the major and minor pairs of conformations. In the 
major isomers, the side chains adopt the well-established type II β-turn-like 
conformation, while as in the minor conformations, due to the presence of the N-Me-D-
Leu7-Pro8 cis-amide bond, the side chains adopt an open, extended conformation that 
cannot form a hydrogen bond to the macrocycle. The authors believe that this finding 
may suggest that the adoption of a β-turn-type conformation in the didemnin side chain 
may not be the only prerequisite for biological activity.  
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1.5) Biological activity and clinical trials 
 
In 1981 Rinehart and coworkers isolated didemnin B (2) from extracts of the tunicate 
Trididemnum solidum, and this compound went through preclinical and clinical trials as 
an anticancer, antiviral, and immunosuppressive drug. 28  Although it was the first 
compound that was characterized from a marine source to go into clinical trials for 
human diseases, the NCI trials were terminated in 1990 due to toxicity issues.3 While 
some progress was made in understanding its protein biosynthesis and structure/activity 
relationships (SARs), the complex mechanistic issues of antitumor potency still need to 
be elucidated.16   
 
Didemnin B was found to induce apoptosis in a wide range of transformed cell lines, 
while resting normal lymphocytes were unaffected by exposure to the drug.29 In order to 
investigate whether cell transformation, and/or cell proliferation was necessary for the 
drug to induce apoptosis, the effect of didemnin B on freshly harvested human 
lymphocytes before and after stimulation with concanavalin A was examined. Excitingly, 
didemnin B induced apoptosis in normal lymphocytes only after mitogenic stimulation, 
warranting further examination for its potential use as a chemotherapeutic agent, 
especially for the treatment of leukemia.29 
 
Aplidine (4) is one of the most biologically active metabolites from an ascidian of the 
genus Aplidium.30 It is widely known as an antitumor agent, which is currently obtained 
by chemical synthesis. It is also PharmaMar’s second most advanced compound, and is 
currently in phase II clinical trials for solid and hematological malignant neoplasms, T 
! 10 
cell lymphoma, and myelofibrosis, and in phase III clinical trials for multiple myeloma.3 
In 2003, the European Commission granted approval to PharmaMar SA Sociedad 
Unipersonal, Spain, to use aplidine in the treatment of acute lymphoblastic leukemia.31 
Moreover, the Food and Drug Administration (FDA) has accepted the proposal made by 
PharmaMar for the production process of the drug Aplidin®. Unlike didemnin B (2), 
which was not successful in clinical trials, aplidine (4) showed no cardiotoxicity and 
exhibited stronger antitumor activity.32,33,34,35 
 
1.6) Structural modifications of didemnins 
 
On the basis of spatial relationships, three particular sites of the didemnin macrocycle 
were considered essential for the biological activity: the tyrosine side chain of the 
tetrapeptide region, the hydroxyl group of isostatine, and the side chain attached to the 
amino group of threonine. These three regions were found to be at the periphery of the 
macrocycle as established by X-ray and solution conformation of 2.3 In an effort to better 
understand the structure-activity relationships of the didemnins, several analogues were 
prepared with modifications in the side chain, Hip-isostatine region, tetrapeptide region, 
and macrocycle backbone. These investigations were thoroughly reviewed by Dr. 
Matthew Vera.36  
 
Although several modifications in the Hip-isostatine region were reported, results 
consistently showed low tolerance for changes in this region, as all analogues exhibited 
dramatically decreased bioactivity, albeit with small differences between cytotoxicity and 
immunosuppressive activity.16 Nordidemnin B (3) was the only congener with a 
structural modification in this portion of the macrolide, in which isostatine was replaced 
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by norstatine without affecting the bioactivity.12,37 Another successful modification in 
this region was displayed in the tamandarins, which contain a drastically modified Hip2 
residue. The tamandarins showed comparable bioactivity with respect to didmenin B.15  
 
With regards to the modifications in the macrocyclic backbone, it was originally thought 
that the ester group in the macrocycle was a source of instability, hence the replacement 
of this group with an amide was the focus of several investigations.3 Although 
replacement of the Thr6 ester resulted in a significant decrease in cytotoxicity, 
replacement of both Thr6 and Hip2 ester groups or replacement with a short chain, such as 
diaminopropionic acid, did not alter the cytotoxicity.38   
 
The approach of using covalent linkers to replace amino acids that do not participate in 
receptor activation has led to the syntheses of comparable or more active analogues. 
Joullié and coworkers synthesized the first reduced ring analogue, where three important 
moieties were kept in their bioactive conformations.39 Specifically, the leucine-proline 
portion of the macrocycle was replaced with a n-butyl linker. However, no biological 
data were given for this compound (12, Figure 1.6). Another conformationally 
constrained analogue (11) was synthesized shortly thereafter, in which the isostatine 
moiety was replaced by a (S,S,S)-β-hydroxy-γ-aminocyclohexanecarboxylic acid, to 
probe the biological conformation of didemnin B.40 This constrained analogue (11) was 
tested for protein biosynthesis inhibition and showed about 20-fold decrease in activity 
with respect to didemnin B.3  
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Figure 1.6. Modifications in the macrocyclic backbone of didemnin B. 
 
Based on the X-ray data of didemnin B that was obtained earlier, the tyrosine side chain 
was thought to be involved in binding to the receptor since it protrudes outward from the 
molecule (Figure 1.4).19 Therefore, Joullié and coworkers synthesized a didemnin B 
analogue (10a) containing Tic (L-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) as a 
conformationally restrained replacement for tyrosine, which showed comparable potency 
as a protein biosynthesis inhibitor.41 Two other didemnin B analogues were subsequently 
synthesized, in which the tyrosine moiety was replaced with N-Me-leucine and N-Me-
phenylalanine.42 These analogues were found to retain both antitumor activity and the 
ability to inhibit protein synthesis, suggesting that variations in this region are tolerated. 
With these encouraging results, another constrained analogue (L-1,2,3,4-tetrahydro-7-
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methoxyisoquinoline-3-carboxylic acid)didemnin B (10b) was synthesized. 43 
Interestingly, the results showed that the MeO-Tic was less active but also less toxic than 
the Tic. Taken together, these results support the hypothesis that this residue exists in a 
hydrophobic pocket of the target protein that must be filled by the protein-ligand complex 
to achieve optimal binding.3  
 
Schreiber and coworkers were interested in investigating the mechanisms behind the 
various bioactivity displayed by didemnin B in the mid 1990s. Three particular biological 
activities of didemnin B was of interest: its ability to inhibit protein synthesis, induce G1 
cell cycle arrest, and suppress a mixed lymphocyte reaction. Interestingly, these activities 
ranged in effective concentrations over five orders of magnitude, suggesting that they 
may be mediated by different mechanisms.44 In order to elucidate these mechanisms, 
Schreiber and coworkers characterized proteins that bind didemnin B, and found that a 
major intracellular didemnin-binding protein is the translation elongation factor 1α (EF-
1α).45 They reported that didemnin B binds uniquely to the activated GTP-bound form of 
EF-1α, albeit with modest affinity.45 To investigate the mechanisms involved in the 
cytostatic and immunosuppressive activities displayed by didemnin B observed at low 
concentrations, Schreiber and coworkers sought out for additional didemnin-binding 
proteins.44 They successfully purified and cloned a new didemnin-binding protein with 
sequence similarity to palmitoyl protein thioesterase (PPT).44 Both EF-1α and PPT1 are 
the only didemnin-binding proteins isolated to date, where the study utilized side chain 
modifications of didemnin A (1).3 As this immobilized didemnin had a substantially 
modified side chain that lacks the important lactylproline unit, it is possible that 
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molecular targets mediating other activities did not recognize the immobilized didemnin. 
Therefore, a didemnin macrocycle that could be attached at a position that would free the 
side chain was of interest. To address this hypothesis, [Lys3]didemnin B was synthesized 
(13, Figure 1.6). Although the analogue showed a drop in potency, its residual 
antiproliferative and cytotoxic activities suggested potential use for the compound.46  
 
Compared to analogues generated from modifications of the macrocycle, there have been 
numerous analogues generated from modifications in the side chains, since they could be 
more efficiently synthesized (14-23, Figure 1.7). Modifications in the side chain region 
were also found to be beneficial in that the corresponding analogues displayed diverse 
effects on bioactivity.16 More specifically, the side chain amide bond between N-Me-D-
leucine7 and L-proline8 is known to be an important site, because acylation on the leucine 
residue was thought to play a role in bioactivity.3 The use of amide surrogates is one way 
to modify the bioactivity of peptides, and the ψ[CH2NH]amide surrogate is generally 
known as one of the simplest isosteres of the amide bond. Hence, the amide bond 
between N-Me-D-leucine7 and L-proline8 was replaced by the ψ[CH2NH]amide surrogate, 
with lactyl (20) or pyruvyl (21) residues at the terminal position (Figure 1.7). The 
corresponding biological data showed that although 21 was unstable, 20 displayed an 
increase in growth inhibition and a large increase in cytotoxicity. 47  Since the 
ψ[CH2NH]amide surrogate (20) exhibited comparable bioactivity to that of didemnin B, 
this result suggests that the N-acylation of N-Me-D-leucine7 is not a strict requirement for 
intact biological activity and that the presence of a basic nitrogen is tolerated.3  
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In the hopes of evaluating protein biosynthesis inhibition, benzophenone-based didemnin 
photoaffinity labeling reagents, such as 23, were synthesized and tested.46 All the 
analogues that were generated were shown to retain functional activity, although 
compounds having longer linkers were less reactive. These compounds were then 
evaluated in the NCI-60 tumor cell screen, where all the analogues were found to have 
potency comparable to didemnin B regardless of chain length.38  
 
Yet another approach in clarifying the mode of action (MOA) of didemnin B was 
undertaken. Developing a receptor-binding assay using radiolabeled didemnin ligand was 
thought to be crucial in establishing the relationship between binding to a given receptor 
and a given biological effect. Furthermore, a radioactive didemnin analogue could be a 
useful probe molecule for studying a variety of related phenomena, including drug 
metabolism, cell-uptake, and interaction with other macromolecules.16 The placement of 
tritium on the didemnin B molecule was carefully thought out, since it would be 
undesirable to alter the stereo-electronic nature of the ligand. Thus, a peptide containing 
an unsaturated proline residue was synthesized and subsequently subjected to catalytic 
tritiation, furnishing radioactive didemnin B side chain, which was then coupled to an 
advanced macrocyclic intermediate to yield [3,4-ditritioPro8]didemnin B analogue (22, 
Figure 1.7).16 As expected, the tritiated analogue was found to be equipotent with the 
natural didemnin B as an in vitro protein biosynthesis inhibitor.16 However, one 
surprising result was the failure to observe direct binding between tritiated didemnin B 
and purified EF-1α which was comparable to either the IC50 value obtained for protein 
biosynthesis inhibition in cell-free assay or the dissociation constant estimated by 
! 16 
Schreiber and coworkers.16 Only after extensive experimentation was any binding 
interaction was verified, indicating that binding affinity was substantially lower than 
expected. This also suggests that the role of EF-1α in mediating the protein biosynthesis 
inhibition was more complex than previously expected.16 
 
 
Figure 1.7. Modifications in the side chain of didemnin B (2). 
 
1.7) Structural modifications of tamandarins 
 
Upon isolation and characterization of tamandarins, Fenical and coworkers reported that 
tamandarin A (6) retained similar levels of in vitro antitumor activity in clonogenic 
assays and protein inhibition properties.15 However, no biological data were reported for 
tamandarin B (7) due to the isolation of insufficient material. This problem ignited a 
synthetic program designed to prepare both natural products, as well as a number of 
relevant analogues having the same biologically active side chains present in the 
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didemnins.3 All equivalent structural modifications resulted in comparable biological 
properties, although the cytotoxicities of tamandarin A and B being somewhat higher 
than that of didemnin B.48 As mentioned above, fluorescence studies revealed similar 
behavior for both depsipeptide families.17  
 
Since modifications in the tetrapeptide region of didemnin B were found to be tolerated, 
two tamandarin B analogues were prepared by Joullié and coworkers in which the N,O-
Me2Tyr5 residue was replaced with N-Me-phenylalanine (N-MePhe5) (24) and (S)-2-
methylamino-3-(naphthalen-2-yl)propanoic acid (N-MeNaphth5) (26) (Figure 1.8). These 
two analogues were evaluated in a panel of 14 tumor cell lines and compared to the 
results from tamandarin B.49 The two analogues were found to perform better than 
tamandarin B, and showed similar in vitro cytotoxicities relative to each other, suggesting 
that changes to the macrocyclic scaffold at position 5 with more lipophilic aromatic 
amino acids were well tolerated.3 Also, although studies have been done in which D-
proline was substituted for L-proline, tolerance for other modifications at the Pro4 and 
Thr6 positions had not been investigated.9 Therefore, the Ala4-tamandarin B (25) and 
Ser6-tamandarin B (27) were prepared by Joullié and coworkers.50 It was found that 
modifications at the N,O-Me2Thr5 residue and at the Thr6 position were well tolerated and 
even displayed enhanced cytotoxic activity against several human tumor cell lines.3 
However, the substitution of Pro4 by alanine resulted in significantly reduced activity, 
suggesting that conformational and spatial effects are critical for antitumor activity 
(Figure 1.8).  
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Figure 1.8. Tamandarin modifications. 
 
In 2010, Joullié and coworkers successfully synthesized three novel tamandarin B 
analogues and tested their corresponding biological activities, which will be discussed in 
detail in Chapter 2.  
 
1.8) Synthetic studies of didemnins, aplidine, tamandarins and related compounds 
 
1.8.1) Syntheses of didemnin analogues 
Since 1987, there have been several total syntheses of the didemnins, where the synthetic 
strategies differ mainly by the site of the macrocyclic ring closure and the choice of 
coupling reagent employed (Figure 1.9).  
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Figure 1.9. Cyclization sites for the didemnins by various groups,  
their choice of coupling reagent, and yield. 
 
The first total synthesis of the didemnins was achieved by Rinehart in 1987. The site of 
macrocylization that they chose was at the Ist1-Thr6 junction using EDC as the coupling 
reagent (Figure 1.9). There were some drawbacks to this synthesis besides the modest 
yield for the key macrocylization step. The synthesis was not conducted in a 
stereocontrolled manner, in that the methyl group of the Hip2 residue was carried through 
the synthesis as a mixture of epimers, which was only eventually resolved by HPLC at 
the final steps of the synthesis.51 Furthermore, the side chain was installed earlier on in 
the synthesis, rather than after the macrocylization step, which would have made the 
synthesis more convergent. Although this synthetic route lacked overall efficiency, 
Rinehart’s total synthesis was an important contribution, especially given that clinical 
trials of didemnin B were already underway with no other synthetic route yet available. 
Moreover, didemnin B is the less abundant congener of Trididemnum solidum, making 
isolation of the natural product not an effective option at the time.16  
 
Schmidt’s synthesis of the didemnins afforded one of the highest-yielding 
macrocyclizations reported in the didemnin field (Figure 1.9).52,53,54 Another key feature 
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of this synthesis was that it included a stereocontrolled preparation of the isostatine 
residue, and a synthetic route to the expensive D-allo-isoleucine to allow more synthetic 
flexibility to generate analogues from a common late-stage intermediate.16 Interestingly, 
Schmidt and coworkers also found that epimerization of the undesired (2R)-epimer to the 
desired (2S)-epimer of the Hip2 moiety could be done under either acidic (with TFA) or 
basic (with DBU) conditions in quantitative yield.52,53,54  
 
Shioiri and coworker’s synthetic strategy was similar to the Rinehart and Schmidt 
syntheses, because they also deferred the issue of stereocontrol within the Hip2 moiety 
until after cyclization.16 More specifically, they utilized Schmidt’s epimerization 
conditions to obtain the desired epimer towards the end of their synthesis. However, 
Shioiri’s synthesis is distinguished by a successful use of BOPCl mediated 
macrocylization protocol employing a secondary amine as their nucleophile (Figure 
1.9).55  
 
Joullié’s synthesis differed conceptually from the previously discussed synthetic efforts 
in that it incorporated strategic elements of stereocontrol at both the Ist1 and Hip2 
moieties from the outset.56 Although this led to additional post-cyclization manipulation 
of advanced intermediates that lengthened the approach, the synthesis did not rely on the 
inversion of the methyl group configuration at Hip2. Like the Schmidt synthesis, Joullié’s 
method did not incorporate the N-Me-D-Leu7 residue of the side chain into the synthesis 
of the macrolide, which allowed them to synthesize various analogues.16  
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Jouin’s synthetic approach to the stereochemical challenges of the Hip2 and norstatine 
fragments were generally similar to other efforts within the field.57 However, their 
synthesis was somewhat different due to the fact that they synthesized nordidemnin B (3) 
(Figure 1.2). The synthesis of nordidemnin B was particularly important, because it 
permitted a direct biological comparison with didemnin B. They also utilized a late stage 
coupling of the side chain, which permitted the synthesis of several analogues for the 
purpose of defining structure-activity trends.16 Jouin and coworkers were also able to 
dramatically increase the yield of macrocyclization by employing a relatively newer 
coupling reagent (Figure 1.9).  
 
Jou and coworkers accomplished the most recent syntheses of didemnins in 1997.58 Jou’s 
synthesis of didemnin A (1) and dehydrodidemnin B (4) successfully employed more 
modern coupling reagents, which led to high cyclization yields comparable to that of 
Schmidt’s (Figure 1.9). Their use of uronium and phosphonium salt-based coupling 
reagents ushered the increasing popularity of using HATU, HBTU, and PyBroP in very 
demanding coupling reactions.16  
 
1.8.2) Didemnin M 
Didemnin M (5) was first reported in 1994 by Banaigs, who originally named it didemnin 
H (Figure 1.2).11 It was found to possess potent in vitro antitumor and 
immunosuppressive activities. While no total synthesis of this molecule was reported 
since isolation, a few semi-synthetic methods have been published.59,60 ,61,62 Joullié 
developed a route to an analogue with a simplified didemnin macrocycle and the 
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didemnin M side chain,59 while Crews devised a solution and solid phase semi-synthetic 
route to didemnin M.62 Rinehart, however, used a different approach in their semi-
synthetic route to didemnin M.16 They used didemnin B as the natural product starting 
point, and their synthesis worked inward from the terminal residue instead of working 
outward (Scheme 1.1).3  
 
 
Scheme 1.1. Rinehart’s semi-synthetic route to didemnin M. 
 
Rinehart synthesized didemnin M using a three-step, one pot procedure starting from 
pGlu-OH (28) and didemnin B (2) (Scheme 1.1). Activation of pGlu-OH (28) as a mixed 
anhydride, followed by condensation with Gln-OtBu, afforded the desired amide bond. 
Acidic workup removed the ester group to give the desired acid (29). Finally, mixed 
anhydride formation followed by addition of didemnin B yielded didemnin M (5) in 79% 
yield.60  
 
1.8.3) Didemnin B amide bond surrogate (ψ[CH2NH2]) analogue 
As discussed in previous sections, Joullié and coworkers synthesized several side chain 
analogues of didemnin B, in which the most biologically active being the amide bond 
surrogate (ψ[CH2NH2]) analogue (20, Figure 1.7). The major structural difference is the 
reduction of the proline carbonyl to a methylene group.47,63 The synthesis began with N-
methylation of N-Boc-D-Leu-OBn (30) followed by Boc removal and subsequent 
reductive amination with N-Boc-prolinal to afford amine 32 in good yield (Scheme 1.2).  
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Scheme 1.2. Synthesis of ψ[CH2NH2] surrogate analogue of didemnin B. 
 
Removal of the Boc group, followed by coupling to L-lactic acid afforded the fully 
functionalized side chain (33). Finally, hydrogenolysis, followed by coupling to the 
didemnin marocyclic salt yielded the desired amide surrogate analogue (20) (Scheme 1.2).  
 
1.8.4) Synthesis of the tamandarin macrocycle 
Both tamandarins A and B were first synthesized by Joullié and coworkers using 
convergent syntheses that utilized the same cyclization strategy to form the parent 
macrocycles.48,64,65 The retrosynthetic analysis divided the parent natural products into 
the protected macrocycle (34) and the side chain acid (35) (Scheme 1.3).  
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Scheme 1.3. Joullié’s retrosynthetic analysis of tamandarins A and B. 
 
Unlike their didemnin synthesis discussed in previous sections (Figure 1.9), the point of 
macrocyclization for the two tamandarin syntheses was at the Thr6-Nst/Ist1 junction 
(Scheme 1.3). Cleavage of the linear precursor 36 at the Leu3-Hiv2 junction formed the 
corresponding tetrapeptide 37 and allyl ester 38. The greatest challenge in the syntheses 
of tamandarins A and B was the low yielding macrocyclization (23% yield using HATU 
as the coupling reagent).48,64,65 Nonetheless, the syntheses of the two natural products 
proved to be essential for biological evaluation in relation to various didemnin analogues.  
 
1.8.5) Synthesis and activity of tamandarin A analogues 
Two additional analogues using the tamandarin A macrocycle and the side chains of 
didemnin M and dehydrodidemnin B were synthesized by Joullié using similar synthetic 
strategies (Figure 1.10).48  
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Figure 1.10. Tamandarin A analogues. 
 
Both compounds were submitted to the NCI-60 tumor cell screen for in vitro testing. The 
cytotoxicity data showed that these compounds were more potent than didemnin B, 
where the tamadarin A/dehydrodidemnin B analogue (40) being the most potent, 
followed by the tamandarin A/didemnin M analogue (41), and finally tamandarin B 
(Table 1.1).66  
 
Table 1.1. Biological activity of selected compounds 
Compound GI50 LC50 
didemnin B 13 nM 3.8 µM 
tamandarin B 2.3 nM 1.4 µM 
tamandarin A/dehydrodidemnin B 1 nM 2.7 µM 
tamandarin A/didemnin M 4 nM 7.6 µM 
GI50 = median lethal dose, 50%; growth inhibitory power; LC50 = lethal concentration, 50%. 
 
 
1.8.6) Synthesis and activity of tamandarin B macrocyclic analogues 
As mentioned in previous sections, Joullié and coworkers synthesized two tamandarin B 
macrocyclic analogues in 2006, in which the N,O-Me2Thr5 residue was replaced by a N-
MePhe residue in one analogue (24) and a N-MeNapth reside in the other (26, Figure 1.8). 
Interestingly, the site of macrocyclization was different for the syntheses of these 
analogues (Figure 1.11). 67  The N-MePhe5 analogue was synthesized by using an 
approach similar to that of tamandarin A and B, in which the macrocyclization took place 
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at the Nst1-Thr6 junction, albeit in low yield (16%). For the N-MeNapth5 analogue, 
however, the site of macrocyclization was at the Pro4-N-MePhe5 junction, which resulted 
in significantly higher yield (65%).3 As discussed above, the two new analogues 
performed better than tamandarin B when their cytotoxicities were evaluated in a panel of 
14 tumor cell lines.  
 
Figure 1.11. Tamandarin B analogues highlighting site of macrocylization. 
 
In another study, Joullié and coworkers synthesized yet another two additional 
macrocyclic analogues Ala4 tamandarin B (25) and Ser6 tamandarin B (27, Figure 1.8).50 
Based on the success of the macrocyclization of the N-MeNapth5 analogue, they selected 
the Pro4-N-MePhe5 function as the site of macrocyclization for these analogues. These 
analogues were tested against the same panel of 14 tumor cell lines as briefly mentioned 
above, and the results suggested that the proline residue is essential for biological activity, 
whereas modification at Thr6 could be moderately tolerated.3  
 
1.9) Conclusions 
 
Didemnin B (2) was the most investigated of all didemnin congeners in order to develop 
this class of compounds for therapeutic use. Although the development of didemnin B as 
a therapeutic agent was discontinued during phase II trials due to undesirable 
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better understand the mode of action of this family of natural products. Furthermore, 
significant amount of effort has been devoted to the syntheses of various tamandarin 
analogues to test whether the tamandarins would act as mere didemnin mimics or as 
individual therapeutic agents. In order to fully elucidate the structure-activity relationship 
as well as mode of action of these natural products, synthetically efficient generation of 
more side chain analogues of tamandarin B could be of great value.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 28 
1.10) References 
!
1  Wang, W., Namikoshi, M. “Bioactive Nitrogenous Metabolites from Ascidians.” 
Heterocycles 2007, 74, 53-88. 
2 Pawlik, J. R. “Marine Invertebrate Chemical Defenses.” Chem. Rev. 1993, 93, 1911-
1922. 
3 Lee, J., Currano, J. N., Carroll, P. J., Joullié, M. M. “Didemnins, tamandarins and 
related natural products.” Nat. Prod. Rep. 2012, 29, 404-424. 
4 Rinehart, K. L. US Patent, 4 493 796-A, 1985.  
5 Rinehart, K. L. “Antitumor compounds from tunicates.” Med. Res. Rev. 2000, 20, 1-27. 
6 Rinehart, K. L., Jr., Gloer, J. B., Cook, J. C., Jr., Mizsak, S. A. & Scahill, T. A. 
"Structures of the Didemnins, Antiviral and Cytotoxic Depsipeptides from a Caribbean 
Tunicate." J. Am. Chem. Soc. 1981, 103, 1857-1859.  
7 Rinehart, K. L., Jr. et al. "Didemnins: Antiviral and Antitumor Depsipeptides from a 
Caribbean Tunicate." Science 1981, 212, 933-935.  
8 Rinehart, K. L., Jr., Gloer, J. B., Wilson, G. R., Hughes, G. J., Li, L. H., Renis, H. E., 
McGovern, J. P. “Antiviral and antitumor compounds from tunicates.” Fed. Proc. 1983, 
42, 87-90. 
9 Abou-Mansour, E., Boulanger, A., Badre, A., Bonnard, I., Banaigs, B., Combaut, G., 
Francisco, C. “[Tyr5]didemnin B and [D-Pro4]didemnin B; Two New Natural Didemnins 
with a Modified Macrocycle.” Tetrahedron 1995, 51, 12591-12600. 
10 Banaigs, B., Abou-Mansour, E., Bonnard, I., Boulanger, A., Francisco, C. “[Hysp2] and 
[Hap2]Didemnin B, two new [Hip2]-modified didemnin B from the tunicate Trididemnum 
cyanophorum.” Tetrahedron 1999, 55, 9559-9574. 
! 29 
!
11 Boulanger, A., Abou-Mansour, A., Badre, B., Banaigs, G., Combaut, G., Francisco, C. 
“The complete spectra assignment of didemnin H a new constituent of the tunicate 
Tridemnum cyanophorum.” Tetrahedron Lett. 1994, 35, 4345-4348. 
12 Jouin, P., Poncet, J., Dufour, M.-N., Pantaloni, A. & Castro, B. "Synthesis of the 
Cyclodepsipeptide Nordidemnin B, a Cytotoxic Minor Product Isolated from the Sea 
Tunicate Trididemnum cyanophorum." J. Org. Chem. 1989, 54, 617-627.  
13 Lindquist, N., Hay, M. E., Fenical, W. “Chemical defense of ascidians and their 
conspicuous larvae.” Ecol. Monogr. 1992, 62, 547-568. 
14 Rinehart, K. L., Lithgow-Bertelloni, A. M. PTC Int. Pat., WO 9104985-A1, 1991. 
15 Vervoort, H., Fenical, W. & de A. Epifanio, R. "Tamandarins A and B: New Cytotoxic 
Depsipeptides from a Brazilian Ascidian of the Family Didemnidae." J. Org. Chem. 2000, 
65, 782-792.  
16 Vera, M. D. & Joullie, M. M. "Natural Products as Probes of Cell Biology: 20 Years of 
Didemnin Research." Med. Res. Rev. 2002, 22, 102-145.  
17 Joullié, M. M.; Leonard, M. S.; Portonovo, P.; Liang, B.; Ding, X.; LaClair, J. J. 
“Chemical Defense in Ascidians of the Didemnidae Family.” Bioconjugate Chem. 2003, 
14, 30-37. 
18 Molinski, T. F., Ko, J., Reynolds, K. A., Lievens, S. C., Skarda, K. R. “N,N’-
methyleno-didemnin A from the ascidian Trididemnum solidum. Complete NMR 
assignments and confirmation of the imidazolidinone ring by strategic analysis of 
1J(CH).” J. Nat. Prod. 2011, 74, 882-887. 
! 30 
!
19 Hossain, M. B., van der Helm, D., Antel, J., Sheldrick, G. M., Sanduja, S. K., 
Weinheimer, A. J. “Crystal and molecular structure of didemnin B, and antiviral and 
cytotoxic depsipeptide.” Proc. Natl. Acad. Sci. U. S. A. 1988, 85, 4118-4122. 
20 Lindquist, N., Hay, M. E. “Can small rare prey be chemically defended? The case for 
marine larvae.” Ecology 1995, 76, 1347-1358. 
21 Bilayethossain, M., van der Helm, D., Antel, J., Sheldrick, G. M., Weinheimer, A. J., 
Sanduja, S. K. “Crystal and molecular structure of didemnin A, an antiviral depsipeptide.” 
Int. J. Peptide Protein Res. 1996, 47, 20-27. 
22 Mayer, S. C., Carroll, P. J., Joullié, M. M. “The cyclic depsipeptide backbone of the 
didemnins.” Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 1995, C51, 1609-1614. 
23  Kessler, H., Mronga, S., Will, M., Schmidt, U. “Solution structure of [Me-L-
Leu7]Didemnin B determined by NMR spectroscopy and refined by MD calculation.” 
Helv. Chim. Acta 1990, 73, 25-47. 
24 Kessler, H., Will, M., Antel, J., Beck, H., Sheldrick, G. M. “Conformational analysis of 
didemnins. A multidisciplinary approach by means of X-Ray, NMR, molecular-dynamics, 
and molecular-mechanics techniques.” Helv. Chim. Acta 1989, 72, 530-555. 
25 Searle, M. S., Hall, J. G., Kyratzis, I., Wakelin, L. P. G. “Didemnin B conformation 
and dynamics of an antitumour and antiviral depsipeptide studied in solution by 1H and 
13C NMR spectroscopy.” Int. J. Pept. Protein Res. 1989, 34, 445-454. 
26 Cárdenas, F., Thormann, M., Feliz, M., Caba, J.-M., Lloyd-Williams, P., Giralt, E. 
“Analysis of dehydrodidemnin B (Aplidine) by NMR spectroscopy and molecular 
mechanics/dynamics calculations.” J. Org. Chem. 2001, 66, 4580-4584. 
! 31 
!
27 Cárdenas, F., Caba, J. M., Feliz, M., Lloyd-Williams, P., Giralt, E. “Analysis of 
conformational equilibria in aplidine using selective excitation 2D NMR spectroscopy 
and molecular mechanics/dynamics calculations.” J. Org. Chem. 2003, 68, 9554-9562. 
28 Nuijen, B., Bouma, M., Manada, C., Jimeno, J. M., Schellens, J. H., Bult, A., Beijnen, 
J. H. “Pharmaceutical development of anticancer agents derived from marine sources.” 
Anticancer Drugs 2000, 11, 793-811. 
29 Baker, M. A., Grubb, D. R., Lawen, A. “Didemnin B induces apoptosis in proliferating 
but not resting peripheral blood mononuclear cells.” Apoptosis 2002, 7, 407-412. 
30 Zubia, E., Ortega, M. J., Salva, J. “Natural products chemistry in marine ascidians of 
the genus aplidium.” Mini-Rev. Org. Chem. 2005, 2, 389-399. 
31 Annual report of the European Medicines Agency 2005, Management Board Report 
EMEA/MB/63019/2006, European Medicines Agency, London, 2006. 
32 Gómez-Fabre, P. M., de Pedro, E., Medina, M. A., Núñez de Castro, I., Márquez, J. 
“Polyamine contents of human breast cancer cells treated with the cytotoxic agents 
chlorpheniramine and dehydrodidemnin B.” Cancer Lett. 1997, 113, 141-144. 
33  Lobo, C. G., Garcia,-Pozo, S. G., Núñez de Castro, I., Alonso, F. “Effect of 
dehydrodidemnin B on human colon carcinoma cell lines.” Anticancer Res. 1997, 17, 
333-336. 
34 Newman, D. J., Cragg, G. M. “Marine natural products and related compounds in 
clinical and advanced preclinical trials.” J. Nat. Prod. 2004, 67, 1216-1238. 
! 32 
!
35 Urdiales, J. L., Morata, P., Núñez de Castro, I., Sánchez-Jiménez, F. “Antiproliferative 
effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean 
tunicates.” Cancer Lett. 1996, 102, 31-37. 
36 Vera, M. D. "Synthetic and Medicinal Chemistry of the Didemnins", University of 
Pennsylvania, Philadelphia, PA, 2000.  
37 Jouin, P., Poncet, J., Dufour, M. N., Aumelas, A., Pantaloni, A., Cros, S., Francois, G. 
“Antineoplastic activity of didemnin congeners: nordidemnin and modified chain 
analogues.” J. Med. Chem. 1991, 34, 486-491. 
38 Marchini, S., Chiorino, G., Faircloth, G. T., D’Incalci, M. “Changes in gene expression 
profile induced by the anticancer agent Aplidine in Molt-4 leukemic cell lines.” J. Biol. 
Regul. Homeostatic Agents 2002, 16, 241-248. 
39 Ramanjulu, J. M., Ding, X., Li, W.-R., Joullié, M. M. “Synthesis of a reduced ring 
analog of didemnin B.” J. Org. Chem. 1997, 62, 4961-4969. 
40 Xiao, D., Vera, M. D., Liang, B., Joullié, M. M. “Total synthesis of a conformationally 
constrained didemnin B analog.” 2001, 66, 2734-2742. 
41 Pfizenmayer, A., Ramanjulu, J. M., Vera, M., Ding, X., Xiao, D., Chen, W. C., Joullié, 
M. M., Tandon, D., Toogood, P. L. “Synthesis and biological activity of 
[Tic(5)]didemnin B.” Bioorg. Med. Chem. Lett. 1998, 8, 3653-3656. 
42 Pfizenmayer, A., Ramanjulu, J. M., Vera, M. D., Ding, D., Xiao, D., Chen, W.-C., 
Joullié, M. M. “Synthesis and biological activities of [N-MeLeu5]- and [N-MePhe5]-
didemnin B.” Tetrahedron 1999, 55, 313-334. 
! 33 
!
43  Tarver, Jr., J. E., Pfizenmayer, A. J., Joullié, M. M. “Total syntheses of 
conformationally constrained didemnin B analogues. Replacement of N,O-
dimethyltyrosine with L-1,2,3,4-tetrahydroisoquinoline, and L-1,2,3,4-tetrahydro-7-
methoxyisoquinoline.” J. Org. Chem. 2001, 66, 7575-7587. 
44 Crews, C. M., Lane, W. S. & Schreiber, S. L. "Didemnin binds to the protein palmitoyl 
thioesterase responsible for infantile neuronal ceroid lipofuscinosis." Proc. Natl. Acad. 
Sci. USA 1996, 93, 4316-4319. 
45 Crews, C. M., Collins, J. L., Lane, W. S., Snapper, M. L. & Schreiber, S. L. "GTP-
dependent Binding of the Antiproliferative Agent Didemnin to Elongation Factor 1α." J. 
Biol. Chem. 1994, 269, 15411-15414. 
46  Vera, M. D., Pfizenmayer, A. J., Ding, X., Xiao, D. & Joullie, M. M. 
"[Lys3]Didemnins as Potential Affinity Ligands." Bioorg. Med. Chem. Lett. 2001, 11, 13-
16.  
47 Ding, X. et al. "Structure-Activity Relationships of Side-Chain Modified Didemnins." 
Bioorg. Med. Chem. Lett. 2001, 11, 231-234.  
48 Liang, B., Richard, D. J., Portonovo, P. & Joullie, M. M. "Total Syntheses and 
Biological Investigations of Tamandarins A and B and Tamandarin A Analogs." J. Am. 
Chem. Soc. 2001, 123, 4469-4474.  
49 Adrio, J., Cuevas, C., Manzanares, I. & Joullie, M. M. "Synthesis and Biological 
Evaluation of Tamandarin B Analogues." Org. Lett. 2006, 8, 511–514.  
50 Adrio, J., Cuevas, C., Manzanares, I. & Joullie, M. M. "Total Synthesis and Biological 
Evaluation of Tamandarin B analogues." J. Org. Chem. 2007, 72, 5129–5138.  
! 34 
!
51 Rinehart, K. L., Jr. et al. "Total Synthesis of Didemnins A, B and C." J. Am. Chem. Soc. 
1987, 109, 6846-6848.  
52 Schmidt, U., Kroner, M. & Griesser, H. "Total Synthesis of the Didemnins - 1. 
Synthesis of the Peptolide Ring." Tetrahedron Lett. 1988, 29, 3057-3060 and 4407-4408.  
53 Schmidt, U., Kroner, M. & Griesser, H. "Total Synthesis of The Didemnins -2. 
Synthesis of Didemnin A, B, C and Prolyldidemnin A." Tetrahedron Lett. 1988, 29, 
4407-4408.  
54 Schmidt, U., Kroner, M. & Griesser, H. "Total Synthesis of the Didemnins; III. 
Synthesis of Protected (2R, 3S)-Alloisoleucine and (3S, 4R, 5S)-Isostatine Derivatives-
Amino Acids from Hydroxy Acids." Synthesis 1989, 832-835.  
55 Hamada, Y., Kondo, Y., Shibata, M. & Shioiri, T. "Efficient Total Synthesis of 
Didemnins A and B." J. Am. Chem. Soc. 1989, 111, 669-673.  
56 Li, W.-R., Ewing, W. R., Harris, B. D. & Joullié, M. M. "Total Synthesis and 
Structural Investigations of Didemnins A, B, and C." J. Am. Chem. Soc. 1990, 112, 7659-
7672.  
57 Jouin, P., Poncet, J., Dufour, M.-N., Pantaloni, A. & Castro, B. "Synthesis of the 
Cyclodepsipeptide Nordidemnin B, a Cytotoxic Minor Product Isolated from the Sea 
Tunicate Trididemnum cyanophorum." J. Org. Chem. 1989, 54, 617-627.  
58 Jou, G., Gonzales, I., Albericio, F., Lloyd-Williams, P. & Giralt, E. "Total Synthesis of 
Dehydrodidemnin B. Use of Uronium and Phosphonium Salt Coupling Reagents in 
Peptide Synthesis in Solution." J. Org. Chem. 1997, 62, 354-366.  
! 35 
!
59 Liang, B., Vera, M. D. & Joullié, M. M. "Total Synthesis of [(2S)-Hiv2]Didemnin M." 
J. Org. Chem. 2000, 65, 4762-4765.  
60  Rinehart, K. L. & Katauskas, A. J. "Semi-synthetic studies toward didemnin 
analogues." WO patent 9817275 1998.  
61 Rinehart, K. L., Sakai, R., Stroh, J. G. US Pat., 4 948 791, 1990; Chem. Abstr. 1991, 
114: p. 214413h. 
62 Wen, J. J. & Crews, C. M. "Towards the semi-synthesis of didemnin M. Solution and 
solid phase syntheses of the pseudotetrapeptide: pGlu-Gln psi COO Ala-Pro- OH." 
Tetrahedron Lett. 1998, 39, 779-782.  
63 Ding, X. "Total Synthesis of Didemnin B Analogs", University of Pennsylvania, 
Philadelphia, PA, 2000.  
64 Joullié, M. M., Portonovo, P., Liang, B. & Richard, D. J. "Total Synthesis of 
Tamandarin B." Tetrahedron Lett. 2000, 41, 9373-9376.  
65 Liang, B., Portonovo, P., Vera, M. D., Xiao, D. & Joullié, M. M. "The First Total 
Synthesis of (−)-Tamandarin A." Org. Lett, 1999, 1, 1319-1322.  
66 K. M. Lassen, “The synthesis and biological evaluation of tamandarin B analogues”, 
University of Pennsylvania, Philadelphia, PA, 2011. 
67 Adrio, J., Cuevas, C., Manzanares, I. & Joullie, M. M. "Synthesis and Biological 
Evaluation of Tamandarin B Analogues." Org. Lett. 2006, 8, 511–514.  
 
! 36 
Chapter 2: Preparation of Tamandarin B/Didemnin Hybrid Analogues 
 
2.1) Second-generation synthesis of the tamandarin B macrocycle 
 
Developing an improved strategy that could address synthetic challenges that were 
present in the first synthesis of tamandarin B macrocycle1 was thought to be crucial, since 
the structure-activity relationship as well as mode of action of these natural products still 
remained unclear. An efficient synthesis would allow the generation of various analogues 
that could be tested in a timely manner. One of the main synthetic challenges was to 
devise a consistently high yielding macrocyclization methodology. When Joullié and 
coworkers synthesized two tamandarin B macrocyclic analogues in 2006, two different 
methods of cyclization were used (Figure 2.1).  
 
Figure 2.1. Tamandarin B analogues highlighting site of macrocyclization. 
 
Interestingly, the site of macrocyclization utilized for N-MePhe5 analogue was at the 
Nst1-Thr6 junction, while as in the N-MeNapth5 analogue, the Pro4-N-MePhe5 junction 
was chosen instead.2,3 The corresponding yields for this step varied drastically, as the 
former methodology provided 16% yield, while the other afforded 65%.2,3 Furthermore, 
previous didemnin syntheses also showed that macrocyclization at the Pro4-N-MePhe5 
junction generally resulted in higher yields.4,5   
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Another synthetic challenge was to devise a convergent synthesis that would increase the 
overall efficiency. In the first-generation synthesis, the linear precursor (1) was formed 
by two main fragments (tetrapeptide (2) and Nst/Hiv (3)) (Scheme 2.1). Dividing the 
macrocycle into three fragments would make its synthesis more accessible and 
convergent, as it would shorten the longest linear sequence.  
 
Scheme 2.1. Two-fragment approach to tamandarin B macrocycle. 
 
Finally, the last synthetic challenge was to develop an efficient protecting group strategy. 
One particular difficulty in the route was the removal of an allyl group to form a 
carboxylic acid, a step that proved to be low yielding and had to be carried on through 
another step as an impure mixture.2,3 The synthetic strategy lacked protecting group 
orthogonality, as forming the free linear precursor before cyclization took two steps 
(Scheme 2.2).  
 
Scheme 2.2. First-generation approach towards tamandarin B macrocycle. 
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A protecting group strategy that allows for a one step removal of the terminal protecting 
groups would make the synthesis more efficient. More specifically, a new protecting 
group strategy that entails quantitative removal of all protecting groups so that the 
resulting product could be used without further purification would be of great value.  
In an effort to improve the previous approaches, a second-generation retrosynthesis was 
proposed (Scheme 2.3).6   
 
Scheme 2.3. Second-generation retrosynthesis of tamandarin B macrocycle. 
 
The site of macrocyclization at the Pro4-Me2Tyr5 junction was chosen based on previous 
studies. The linear precursor (5) could be further divided into three fragments: Tyr-Thr 
acid (6), norstatine acid (7), and Hiv-Leu-Pro-OBn (8). The terminal protecting groups of 
linear precursor 5 were the benzyl ester and Cbz carbamate, which would allow 
simultaneous removal of both protecting groups under hydrogenolysis conditions. The 
Hiv2 residue was incorporated into 5, requiring fewer protection/deprotection steps than 
in the first-generation synthesis. Finally, the TBS and Boc protecting groups on the 
norstatine fragment (7) could be simultaneously removed under acidic conditions, 
thereby increasing the efficiency of synthesis.7  
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The forward synthesis was commenced with the synthesis of Hiv-Leu-Pro-OBn fragment 
(12) (Scheme 2.4). Pro-OBn!HCl (12) was coupled to Boc-Leu using 
diethylcyanophosphonate (DEPC) as the coupling reagent.4 DEPC was the particular 
coupling reagent that was utilized in previous syntheses, and was proven to afford higher 
yields compared to dicyclohexylcarbodiimide (DCC)2 or 4-(4,6-dimethoxy[1,3,5]triazi-2-
yl)methylmorpholinium chloride (DMTMM)8. Removal of the Boc group under acidic 
conditions afforded the corresponding amine HCl salt, which was directly coupled to 2S-
hydroxyisovaleric acid (11) to afford alcohol 12 in 93% yield.  
 
Scheme 2.4. The synthesis of fragment 8. 
 
The norstatine fragment (7) was synthesized next. The carboxylic acid of N-Boc-D-valine 
(12) was activated as its pentafluorophenylester (PfP) (13) using pentafluorophenyl 
trifluoroacetate (Scheme 2.5). The lithium enolate of methyl acetate was condensed onto 
the activated ester to form the β-ketomethyl ester (14). The resulting ketone was reduced 
using KBH4 to afford the corresponding β-hydroxymethyl ester (15) as a mixture of 
separable diastereomers (major diastereomer shown). The alcohol was then protected as 
its TBS ether to yield 16. Finally, lithium hydroxide mediated hydrolysis of the methyl 
ester resulted in norstatine fragment 7.  
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Scheme 2.5. Synthesis of norstatine fragment 7. 
 
The final fragment to be synthesized was the Tyr-Thr acid (6) (Scheme 2.6). Methylation 
of commercially available N-Cbz-L-Tyr (17) under basic conditions followed by 
hydrolysis of the resulting methyl ester afforded acid (18). Following Joullié’s previous 
synthesis of didemnin B macrocycle,9 18 was esterified with N-Boc-L-Thr-OSEM (19) 
using isopropenyl chloroformate to yield 20. The SEM group was chosen as the ideal 
protecting group because of its previous success in the synthesis of the didemnins and the 
first generation synthesis of tamandarins A and B.1,9 Unfortunately, removal of the SEM 
group proved to be difficult under standard conditions (MgBr2!Et2O)10, where the only 
product of this reaction was removal of the Boc group on the adjacent nitrogen. When 
fluoride based reagents, such as HF!pyridine, TAS-F, and TBAF on silica gel were used, 
no apparent reaction occurred.  
 
Scheme 2.6. First attempt at the synthesis of fragment 6. 
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These unforeseen results led to the reconsideration of protecting group strategy. An allyl 
group was used as the protecting group for the Tyr-Thr acid fragment instead of the SEM 
group (Scheme 2.7). 
 
Scheme 2.7. Second attempt at the synthesis of fragment 6. 
 
Esterification of acid 18 with N-Boc-L-Thr-OAllyl (21) was accomplished by EDCI 
rather than isopropenyl chloroformate, since it afforded a higher yield of the desired allyl 
ester (22) (75% vs. <40%). However, this new protecting group strategy also presented 
problems. Removal of the allyl group using catalytic palladium was achievable only at 
small scales. On scales less than 100 mg, the reaction went to completion in about 6 h, 
while at larger scales, the rate of the reaction significantly slowed down and never went 
to completion even after 3 days. Increased catalyst loading or increased addition of 
morpholine did not improve the transformation.  
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trimethyltin hydroxide to selectively hydrolyze methyl esters in the presence of other 
esters.11 The desired substrate (24) was synthesized via esterification of the acid 18 with 
N-Boc-Thr-OMe (23) using EDCI as the coupling reagent (Scheme 2.8). Surprisingly, 
when Nicolaou’s methodology was utilized in the present system, the hydrolysis of the 
methyl ester (24) afforded the desired acid (6) in almost quantitative yield in only 3 h.  
 
Scheme 2.8. The synthesis of Tyr-Thr fragment (6). 
 
Finally, with all three desired fragments made, the next step was to synthesize the linear 
precursor (5). Esterification of acid 7 and alcohol 8 using EDCI and DMAP unfortunately 
led to poor reaction yields of <20% of the product (25) (Scheme 2.9). Using other 
coupling reagents, such as DCC, isopropenyl chloroformate, or isobutyl chloroformate 
instead of EDC only led to a similar result.7   
 
Scheme 2.9. Initial attempts at formation of 25. 
 
In all cases, undesired side product (26) was formed in a higher yield. The side product 
lactam 26 is the result of intramolecular cyclization of the activated intermediate of acid 7. 
This problem was also present in the first generation synthesis of tamandarins A and B1 
on a similar substrate as well as on the analogue synthesis on the exact same reaction2. 
Hence, a modification to the norstatine acid was deemed necessary. The simplest solution 
to this challenge would be to decrease the nucleophilicity of the Boc protected nitrogen 
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by the formation of N,O-isopropylidene acetal with the neighboring alcohol. This portion 
of the investigation was done by Dr. Kenneth M. Lassen, and it is described in detail in 
his dissertation.7 After much optimization to form the desired N,O-isopropylidene acetal 
(27), the best condition was the use of stoichiometric (±)-10-camphorsulfonic acid in 2,2-
dimethoxypropane and acetone at room temperature, which resulted in 56% yield 
(Scheme 2.10). The methyl ester (27) was then hydrolyzed to 28 with lithium hydroxide 
in quantitative yield.  
 
Scheme 2.10. Synthesis of acid 28. 
 
Satisfyingly, with the acid 28 in hand, esterification with alcohol 8 afforded a 94% yield 
of 29 using the original conditions of EDCI and DMAP, completely suppressing the 
formation of the undesired lactam 26 (Scheme 2.11).  
 
Scheme 2.11. Synthesis of 29. 
 
The next steps involved removing the Boc group, fragmenting the N,O acetal, and 
coupling the resulting amine salt to acid 6 to form the linear precursor (5). Under protic 
acid conditions, both the Boc group and the N,O acetal were removed in less than 2 h to 
afford the corresponding amine HCl salt, which was then subsequently coupled to 6 using 
BOP as the coupling reagent to afford the desired linear precursor (5) in 76% yield 
(Scheme 2.12). 
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Scheme 2.12. Synthesis of linear precursor 5. 
 
With the protected linear precursor 5 in hand, the next step was to remove both the Cbz 
and benzyl protecting groups in one transformation. Initial hydrogenolysis attempts using 
10% Pd/C at ambient temperature and 1atm resulted in quantitative yield, although the 
reaction took 2 days to reach full conversion. When the reaction was conducted at 45 psi 
using a Parr hydrogenator, the reaction was completed in 4 h, but the yield decreased to 
80%. Finally, replacing 10% Pd/C with 10% Pd(OH)2/C allowed the reaction to go to full 
conversion in 10 h, under 1 atm (Scheme 2.13). It is important to note that 
hydrogenolysis labile protecting groups were used purposefully on the linear precursor 
for synthetic convenience, as most hydrogenolysis often result in very clean reactions, 
making column chromatography purification unnecessary.   
 
Scheme 2.13. Formation of macrocycle 1. 
 
Perhaps one of the most important steps of the reaction—the macrocyclizaiton step was 
next to be investigated. Based on previous knowledge of Shioiri’s accomplishment in his 
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didemnin B synthesis,4 BOPCl was the first coupling reagent that was utilized in our 
many attempts at macrocyclization. More specifically, Shioiri’s exact reaction conditions 
were used, where Et3N was used as the base in CH2Cl2 at 1 mM concentration. 
Unfortunately, unlike Shioiri’s successful yield (76%), the present system only resulted 
in 18% yield. The significant decrease in yield could be attributed to the difference in the 
linear precursor. First of all, the didemnins possess a 23-membered ring macrocycle, 
while as tamandarin B has a 21-membered ring. Secondly, the two molecules were 
functionalized differently, where Shioiri protected the alcohol of the norstatine as its TBS 
ether, while as in the present system, the secondary alcohol was left unprotected. 
Furthermore, his synthesis also had the Me-Leu7 residue of the side chain in place prior to 
cyclization. Taken together, these seemingly small structural differences may result in 
vastly different conformations of the molecule in solution that could inhibit the molecule 
from cyclization. Since such structural behavior is exceedingly difficult to predict, the 
only viable option was to try a different known macrocyclization method.  
 
The next set of conditions that was tried was the one used by Giralt in his synthesis of 
dehydrodidemnin B, where he employed HATU, HOAt, and iPr2NEt in THF.5 Giralt’s 
conditions gave a slightly improved 23% yield. The only deviation from his step was the 
ring size and dilution. Interestingly, Giralt’s macrocyclization was done at 1.15 M in THF, 
which seemed too concentrated for an intramolecular reaction. Therefore when his 
conditions were utilized, they were conducted in a much more dilute 1 mM concentration 
in the hopes of promoting the desired reaction. However, similar to the present system, 
Giralt also left the norstatine alcohol unprotected and the Thr6 protected as a Boc group. 
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Changing the amine base to NMM and solvent to CH3CN also did not improve the yield 
(25%). The next set of conditions that was tried was DMTMM, NMM in acetonitrile, 
which only resulted in a 20% yield.12 Yet another condition was tried, where T3P, 
iPr2NEt, CH2Cl2 was used.13 Although the resultant yield increased to 30%, one more 
coupling reagent was investigated. When PyAOP14,15 and NMM in DMF at 1 mM 
concentration was used, the yield resulted in a much significant increase (49%), though 
the reaction took 48 h (Scheme 2.13). However, this set of condition was deemed most 
optimal, as the reaction proved to be highly scalable.  
 
The second-generation synthesis of the tamandarin B macrocycle was completed in a 
longest linear sequence of 10 steps and an overall yield of 6.6%.6 This was a significant 
improvement in comparison to the first-generation synthesis, which was 12 steps and 
afforded an overall yield of 3.2%.  
 
2.2) Synthesis of three tamandarin B/didemnin hybrid analogues 
 
As discussed in the previous chapter, the natural product didemnin M, 16 
dehydrodidemnin B,5, 17  and Ψ[CH2NH] didemnin B 18  are potent molecules with 
interesting biological activities. When the analogues containing the tamandarin 
A/didemnin M19 side chain and tamandarin A/dehydrodidemnin B1 side chain were made, 
in vitro testing of these molecules showed similar activity to that of the parent natural 
products. However, the tamandarin B versions of these compounds have never been made. 
Therefore, with a new and improved second-generation synthesis of the tamandarin B 
macrocycle in hand, a relatively more efficient generation of these biologically intriguing 
analogues was available. This study would ultimately help determine the effects of side 
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chain structure on the biological activity of tamandarin B and may produce compounds 
with potential therapeutic value. The synthetic strategy to access these analogues was to 
selectively couple the side chain to the macrocyclic amine salt as the final step of the 
synthesis (Figure 2.2).  
 
Figure 2.2. Structure of tamandarin B/didemnin hybrid analogues. 
 
These particular side chains have been previously synthesized by Joullié and 
coworkers1,18,19 using three different routes each having a distinctive strategy.7 A more 
unified approach, which allows the production of these side chains from as many 
common intermediates as possible, would be highly beneficial.  
 
2.2.1) Synthesis of dehydrotamandarin B 
Synthesis of dehydrotamandarin B commenced with the protection of L-leucine (33) as 
its Boc carbamate (Scheme 2.14). Benzyl ester formation followed by N-methylation, and 
subsequent Boc group removal under acidic conditions afforded 34. BOP-Cl mediated 
coupling with Boc-proline resulted in good yield. Removal of the Boc group, followed by 
BOP mediated coupling to lactic acid afforded 36. Oxidation of the secondary alcohol 36 
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using Dess-Martin periodinane and subsequent hydrogenolysis of its benzyl ester yielded 
the desired free acid side chain 37.  
 
Scheme 2.14. Synthesis of dehydrodidemnin B side chain. 
 
This side chain synthesis was two steps shorter than the previous synthesis and proved to 
be more synthetically efficient. The free acid side chain (37) was then coupled to the 
tamandarin B macrocyclic HCl salt via BOP mediated coupling, affording 30 in good 
yield (Scheme 2.15).20 
 
Scheme 2.15. Completion of dehydrotamandarin B analogue synthesis. 
 
 
2.2.2) Synthesis of tamandarin M 
Synthesis of tamandarin M side chain began with a common intermediate (36) used in the 
dehydrodidemnin B side chain synthesis, thereby making this synthesis more convergent 
(Scheme 2.16). The alcohol 36 was esterified with BocGln(Xan)OH21 to afford 38. 
Removal of the Boc and xanthyl groups under acidic conditions, followed by 
condensation with N-Cbz-p-GlnOPfP, yielded the fully functionalized side chain. 
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Hydrogenolysis conditions removed the Cbz and benzyl groups to afford the desired free 
side chain 40.  
 
Scheme 2.16. Synthesis of didemnin M side chain. 
 
Synthesis of tamandarin M was completed using the same set of reagents employed in the 
synthesis of dehydrotamandarin B (Scheme 2.17). Removal of the Boc group of the 
tamandarin B macrocycle, followed by coupling with the free acid side chain 40 using 
BOP as the coupling reagent, afforded tamandarin M analogue (31) in 81% yield.20 It is 
important to note that the final coupling step was a great improvement over the 32% 
obtained in the corresponding reaction with the tamandarin A macrocyclic salt.19  
 
Scheme 2.17. Completion of tamandarin B analogue synthesis. 
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2.2.3) Synthesis of Ψ[CH2NH]tamandarin B analogue 
The final tamandarin B/didemnin hybrid analogue synthesized was the 
Ψ[CH2NH]tamandarin B analogue. Commercially available N-Boc-L-proline (41) was 
converted to the corresponding aldehyde (42) using a known reduction/oxidation 
sequence (Scheme 2.18).7 Reductive amination of 42 with the amine salt 34, previously 
utilized in the synthesis of dehydrotamandarin B, led to 43.22 Subsequent Boc removal 
followed by amide bond formation between the corresponding amine salt and L-lactic 
acid yielded the protected side chain 44. Finally, benzyl group removal afforded the 
desired side chain 45.  
 
Scheme 2.18. Synthesis of Ψ[CH2NH]tamandarin B side chain. 
 
Unlike the previous tamandarin B analogue syntheses, the free acid side chain (45) was 
coupled to the tamandarin B macrocyclic salt in good yield using HATU as the coupling 
reagent based on the premise that HATU afforded higher yield than BOP (Scheme 
2.19).20 
 
Scheme 2.19. Completion of Ψ[CH2NH]tamandarin B analogue synthesis. 
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2.3) Activity of tamandarin B/didemnin hybrid analogues. 
All three tamandarin B/didemnin hybrid analogues were tested in the NCI-60 tumor cell 
screen. Dehydrotamandarin B (30) performed well in the cell based assays with GI50 
values of less than 10 nM in 23 of the 60 cell lines tested, along with LC50 values greater 
than 1 mM in 55 of the 60 lines tested.7 Ψ[CH2NH]tamandarin B (32) tested comparably, 
with GI50 values less than 10 nM in 28 of the 60 cell lines and LC50 values of greater than 
1 mM in 48 of the 60 cell lines tested.7 Interestingly, tamandarin M (31) proved to be the 
most potent analogue in these tests. It displayed GI50 values of less than 10 nM in all of 
the cell lines tested, and LC50 values of greater than 1 mM in 45 of the 60 cell lines.7 
With these impressive preliminary results, a collaboration began with the Crews 
laboratory at Yale University to further study the bioactivity of these analogues. 
Dehydrotamandarin B (30) and tamandarin M (31) were tested for activity in HeLa cells 
and for immunosuppressive reactivity via mixed lymphocyte reaction. 
Dehydrotamandarin B (30) displayed an IC50 of 0.608 nM in HeLa cells, and gave an 
IC50 of 0.765 nM in the mixed lymphocyte reaction.7 In accordance with previous 
biological activity studies, 31 showed extremely potent activity in both assays, where in 
HeLa cells it displayed an IC50 of 0.851 fM and in mixed lymphocyte reaction it 
displayed an IC50 of 1.78 fM.7 Next, the tamandarin B macrocyclic salt and the M side 
chain (40) were tested separately. Surprisingly, while the tamandarin B macrocyclic salt 
was inactive (IC50 >>10 nM), the free acid M side chain (40) showed good activity, with 
an IC50 of 0.385 nM.7  
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2.4) Conclusions 
The second-generation synthesis of the tamandarin B macrocycle was successfully 
accomplished. The number of synthetic steps was reduced, and the overall yield was 
doubled relative to the first-generation synthesis. These findings will inevitably aid in the 
generation of more diverse tamandarin B analogues in the future. For example, 
combinatorial syntheses of side chain analogues using high-throughput experimentation 
would efficiently provide necessary compounds for further biological testing. Based on 
our previous knowledge from the didemnins, three particular side chain analogues were 
synthesized in high yields and showed impressive in vitro biological activities. While 
these results are promising, the source of biological activity is still unclear, and the 
mechanism of action of this class of natural products still needs to be elucidated. One 
particularly interesting result was the activity of the free acid M side chain (40), while the 
tamandarin B macrocyclic salt was found to be comparably inactive. Rigorous biological 
studies on the free acid M side chain should be done in order to assess its potential 
therapeutic value. Since the generation of the side chain is synthetically simpler in 
comparison to the macrocycle, further biological testing could be done in more time 
efficient manner. Taken together, more interesting experiments could be built upon our 
findings in the hopes of ultimately discovering new therapeutics.  
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2.5) Experimental results 
General Methods. All reactions were performed under an argon atmosphere except 
where otherwise noted. Tetrahydrofuran was distilled over sodium-benzophenone, 
dichloromethane was distilled over calcium hydride, DMF in Acroseal bottles were used 
without further purification prior to use. Flash chromatography was carried out on Merck 
silica gel 60 (240-400 mesh) using the solvent conditions listed under individual 
experiments. Analytical thin-layer chromatography was performed on Merck silica gel 
(60F-254) plates (0.25 mm). Visualization was effected with ultraviolet light, 
phosphomolybdic acid, ammonium molybdate, or ninhydrin stain. Proton magnetic 
resonance spectra (1H NMR) and Carbon magnetic resonance spectra (13C NMR) were 
performed on a Bruker DRX-500 operating at 500 and 125 MHz respectively. Infrared 
spectra (IR) were obtained on a Perkin-Elmer 281-B spectrometer. High resolution mass 
spectra (HRMS) were obtained on a Micromass Autospec or a Waters LCTOF-Xe 
premier. Optical rotations were measured on a Jasco P-1010 polarimeter. 
 
General procedure for removal of benzyl and Cbz groups. The desired substrate was 
dissolved in a 1:1 mixture of anhydrous MeOH/EtOAc (0.1 M). To this solution was 
added 10% Pd/C (10% wt). The reaction was monitored by TLC and was filtered through 
a pad of Celite when complete. Removal of solvent under reduced pressure provided the 
product, which was used without further purification. 
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N-Boc-Leu-Pro-OBn (10). Proline benzyl ester hydrochloride (115 mg, 
0.48 mmol) and Boc-leucine (100 mg, 0.43 mmol) were dissolved in anhydrous DMF (3 
mL) and cooled to 0 °C. To this mixture was added DEPC (72 mL, 0.48 mmol) and 
triethylamine (120 mL, 0.86 mmol). The resulting reaction was allowed to warm to room 
temperature and stir overnight. The mixture was diluted with ethyl acetate (15 mL) and 
washed with 10% citric acid (10 mL), saturated NaHCO3 (10 mL), water (10 mL) and 
brine (10 mL). The organic layer was dried over Na2SO4, filtered, and concentrated. 
Purification by column chromatography (10% acetone/hexanes) led to the product as a 
yellow oil (178 mg, 98%). Rf 0.32 (30% acetone/hexanes); 1H NMR (500 MHz, CDCl3) δ 
0.82 (d, J=6.7 Hz, 3H), 0.88 (d, J=6.5 Hz, 3H), 1.34 (s, 9H), 1.66 (septet, J=6.7 Hz, 1H), 
1.92 (m, 3H), 2.12 (m, 2H), 3.50 (m, 1H), 3.68 (q, J=9.2 Hz, 1H), 4.38 (q, J=7.6 Hz, 1H), 
4.50 (dd, J=8.5, 3.9 Hz, 1H), 4.59 (s, 1H), 5.05 (m, 1H), 5.10 (m, 2H), 7.25 (m, 5H); 13C 
NMR (125 MHz, CDCl3) δ 21.9, 23.6, 24.8, 25.1, 29.2, 42.2, 46.9, 50.5, 65.2, 67.1, 79.7, 
127.2, 127.6, 127.6, 128.5, 128.6, 135.8, 141.6, 156.0, 172.1; IR (cm-1) 3311, 2958, 2871, 
1745, 1708, 1647, 1499, 1437, 1168; ΗRMS (ESI) m/z calculated for C23H34N2O5Na (M 
+ Na)+: 441.2366, found: 441.2355; α[ ]D
21.6 59.97 (c 0.90, CHCl3). 
Hiv-Leu-Pro-OBn (8). N-Boc-Leu-Pro-OBn (100 mg, 0.24 mmol) was 
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dissolved in 4.0 M HCl in dioxane (3 mL) and the solution was allowed to stir at room 
temperature for 3 h at which point the reaction solvent was removed to yield the salt as a 
white solid, which was used without further purification. The salt (94 mg, 0.24 mmol) 
was dissolved in anhydrous dichloromethane (1 mL) and cooled to 0 °C. To this was 
added hydroxyisovaleric acid 11 (33 mg, 0. 28 mmol), NMM (66 mL, 0.59 mmol), and 
BOP (116 mg, 0.26 mmol). The reaction was then allowed to warm to room temperature 
and stir overnight. The mixture was diluted with ethyl acetate (20 mL), and washed with 
10% HCl (10 mL), saturated NaHCO3 (10 mL), and brine (10 mL). The organic layer was 
dried over Na2SO4, filtered and concentrated to yield the crude product. Purification by 
column chromatography (20 " 40% acetone/hexanes) yielded the product as a yellow oil 
(101 mg, quantitative). Rf 0.36 (30% acetone/hexanes); 1H NMR: (500 MHz, CDCl3) δ 
0.81 (d, J=6.45 Hz, 3H), 0.89 (m, 6H), 0.97 (d, J=6.55 Hz, 3H), 1.45 (t, J=9.69 Hz, 1H), 
1.57 (t, J=9.99 Hz, 1H), 1.65 (m, 1H), 1.99 (m, 3H), 2.17 (m, 3H), 3.58 (d, J=7.70 Hz, 
1H), 3.76-3.79 (m, 1H), 3.93 (s, 1H), 4.50 (s, 1H), 4.76 (m, 1H), 5.03-5.15 (m, 2H), 7.31 
(m, 5H); 13C NMR: (125 MHz, CDCl3) δ 15.5, 19.2, 21.6, 23.3, 24.6, 24.8, 28.9, 31.6, 
40.8, 46.9, 48.4, 59.0, 66.9, 75.9, 128.1, 128.3, 128.5, 135.5, 171.5, 172.0, 175.9; IR (cm-
1): 3382, 2960, 2873, 1745, 1639, 1520, 1454, 1260, 1173, 1261; ΗRMS (ESI) m/z 
calculated for C23H34N2O5Na (M + Na)
+: 441.2365, found: 441.2359; α[ ]D
23.6 -91.71 (c 
0.60, CH2Cl2).  
N-Boc-D-Val-OPfP (13). Boc-D-Valine (8.41 g, 38.70 mmol) was dissolved 
in anhydrous dichloromethane (97 mL) and cooled to 0 °C. To this solution was added 
NHBoc
O
OPfP
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distilled pyridine (3.42 mL, 42.8 mmol) and pentafluorophenyl trifluoroacetate (8.0 mL, 
46.4 mmol). The reaction was allowed to warm to room temperature and stir overnight. 
The reaction was quenched with saturated NH4Cl and allowed to stir for 15 min. The 
mixture was diluted with dichloromethane (30 mL) and the layers were separated. The 
organic layer was washed with 10% KHSO4 (20 mL), saturated NaHCO3 (20 mL), and 
brine (20 mL). The organic layer was dried over MgSO4, filtered and concentrated to 
yield the product as an oil that eventually formed a white foam upon standing. The 
product was used without further purification (13.01 g, 87%).  
β-Ketoester (14). n-Butyllithium (52.0 mL, 130.69 mmol, 2.5 M in 
hexanes) was added to distilled diisopropylamine (18.0 mL, 130.69 mmol) in anhydrous 
tetrahydrofuran (70 mL) at 0 °C and allowed to stir for 30 min at which time it was 
cooled to -78 °C. Methyl acetate (10.4 mL, 130.69 mmol) was added dropwise to this 
solution to form the lithium enolate. The mixture was stirred for 1 h. In a separate flask, 
PfP ester 13 (11.65 g, 30.39 mmol) was dissolved in anhydrous tetrahydrofuran (98 mL) 
and cooled to -78 °C. The PfP ester solution was transferred to the lithium enolate 
solution via cannula. The reaction was allowed to stir at -78°C for 3 h at which time the 
cooling bath was removed and the reaction was quenched with saturated NH4Cl (40 mL). 
The mixture was allowed to warm to room temperature and is diluted with 
dichloromethane (100 mL). The organic layer was washed with 10% HCl (40 mL), 
saturated NaHCO3 (40 mL), and brine (40 mL). The organic layer was dried over Na2SO4, 
filtered, and evaporated to yield the crude product as an orange oil. Purification by 
NHBoc
O
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column chromatography (5"10"15% EtOAc/hexanes) yielded the product as a yellow 
oil (6.86 g, 83%). Rf 0.56 (30% EtOAc/Hexanes); 
1H NMR: (500 MHz, CDCl3) δ 0.77-
1.03 (m, 6H), 1.43 (s, 9H), 2.22 (m, 1H), 3.56 (s, 2H), 3.73 (s, 3H), 4.30 (s, 1H), 5.02 (d, 
J=7.03 Hz, 1H); 13C NMR: (125 MHz, CDCl3) δ 17.6, 19.7, 28.3, 29.5, 46.9, 52.4, 64.3, 
80.0, 158.8, 167.1, 202.0; IR (cm -1): 3373, 2933, 2967, 1748, 1715, 1643, 1367, 1170, 
1019; HRMS (ESI) m/z calculated for C13H23NO5Na (M +Na)
+: 296.1474, found: 
296.1486; α[ ]D
21.115.94 (c 2.0, CHCl3).  
β-Hydroxyester (15). β-Ketoester 14 (6.86 g, 25.10 mmol) was 
dissolved in anhydrous methanol (251 mL) and cooled to -78 °C. To this solution was 
added potassium borohydride (4.74 g, 87.84 mmol) and the reaction was stirred at -78 °C 
for 20 min. The temperature of the reaction was then increased to -20 °C for an additional 
1 h. The cooling bath was removed and glacial acetic acid (3 mL) was added and the 
mixture was allowed to stir until all solids dissolved. The solvent was evaporated and the 
remaining residue was dissolved in EtOAc/H2O (1:1, 100 mL). The organic layer was 
separated and dried over Na2SO4, filtered, and concentrated to yield the crude product. 
Purification by column chromatography (5"40% EtOAc/hexanes) afforded the product 
as a white solid (3.65 g, 53%). Rf 0.34 (30% EtOAc/hexanes); 
1H NMR: (500 MHz, 
CDCl3) δ 0.85 (d, J=6.80 Hz, 3H), 0.91 (d, J=6.85 Hz, 3H), 1.41 (s, 9H), 2.08 (m, 1H), 
2.45 (dd, J=16.3, 9.0 Hz, 1H), 2.45 (dd, J=16.3, 2.25 Hz, 1H), 3.25 (d, J=4.95 Hz, 1H), 
3.49 (m, 1H), 3.68 (s, 3H), 3.89 (s, 1H), 4.41 (d, J=9.64 Hz, 1H); 13C NMR: (125 MHz, 
CDCl3) δ 16.2, 20.1, 27.5, 28.3, 38.2, 51.9, 58.8, 79.5, 156.4, 173.6; IR (cm
-1): 3450, 
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3370, 2964, 1718, 1694, 1524, 1367, 1172; HRMS (ESI) m/z calculated for 
C13H25NO5Na (M + Na)
+: 298.1631, found: 298.1630; α[ ]D
21.1 -4.16 (c 0.75, CH2Cl2). 
N-Boc-Thr-OMe (23). N-Boc-Thr (100 mg, 0.46 mmol) was dissolved in 
anhydrous DMF (2 mL). To this was added methyl iodide (57 mL, 0.91 mmol) and 
sodium carbonate (145 mg, 1.37 mmol). The reaction was allowed to stir overnight then 
was diluted with ethyl acetate (20 mL) and washed with water (2 x 10 mL), 10% HCl (10 
mL), and brine. The organic layer was dried over Na2SO4, filtered, and concentrated to 
yield the product, which was used without any further purification (92 mg, 86%). Rf 0.26 
(30% EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 1.25 (d, J=6.36Hz, 1.46 (s, 9H), 
1.93 (s, 9H), 3.78 (s, 3H), 4.28 (m, 2H) 5.27 (bs, 1H); 13C NMR: (125 MHz, CDCl3) δ 
14.1, 19.8, 28.2, 52.3, 58.7, 60.3, 80.0, 156.1, 171.9; IR (cm-1): 3436, 2979, 2935, 1744, 
1718, 1510, 1368, 1167; HRMS (ESI) m/z calculated for C10H19NO5Na (M + Na)
+: 
256.1161; found: 256.1162; α[ ]D
21.4 -8.77 (c 0.75, CH2Cl2).  
Cbz-N,O-Dimethyltyrosine-O-Boc-threonine-OMe (24). Cbz-N,O-
Dimethyltyrosine (176 mg, 0.51 mmol) and N-Boc-Thr-OMe (23) (92 mg, 0.39 mmol) 
were dissolved in anhydrous tetrahydrofuran (4.5 mL) and cooled to 0 °C. To this was 
added EDCI (98 mg, 0.51 mmol) and DMAP (96 mg, 0.79 mmol). The reaction was 
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allowed to warm to room temperature and stir for 24 h. The reaction was diluted with 
ethyl acetate (20 mL) and washed with 10% HCl (10 mL), saturated NaHCO3 (10 mL), 
and brine (10 mL). The organic layer was dried over Na2SO4, filtered and concentrated to 
yield the crude product. Purification by column chromatography (20% ethyl 
acetate/hexanes) yielded the product as an oil (202 mg, 92%). Rf 0.50 (30% 
acetone/hexanes); 1H NMR: (500 MHz, CDCl3) δ 1.25 (m, 3H), 1.43 (s, 9H), 2.75 (m, 
3H), 2.83-2.97 (m, 1H), 3.17 (m, 1H), 3.67 (m, 3H), 3.75 (s, 3H), 4.42 (s, 1H), 4.75 (d, 
J=6.03 Hz, 1H), 5.03-5.11 (m, 2H), 5.25 (d,J=9.05 Hz, 1H), 5.39 (s, 1H), 6.77 (d, J=7.80 
Hz, 2H), 6.95-7.10 (m, 2H), 7.29 (m, 5H); 13C NMR (125 MHz, CDCl3) δ 16.9, 28.2, 
31.9, 34.1, 52.5, 55.1, 56.9, 60.4, 67.3, 71.6, 80.2, 113.9, 127.5, 127.6, 127.8, 127.9, 
128.4, 128.8, 129.7, 129.8, 136.6, 155.9, 156.4, 158.3, 169.8, 170.4; IR (cm-1): 3350, 
2978, 1746, 1712, 1514, 1248, 1166; HRMS (ESI) m/z Calculated for C29H38N2O9Na 
(M+Na)+: 581.2475, found: 581.2475; α[ ]D
22.0 -13.90 (c 0.9, CH2Cl2).  
Cbz-N,O-Dimethyltyrosine-O-Boc-threonine-OH (6). Methyl ester 
24 (279 mg, 50 mmol) was dissolved in anhydrous 1,2-dichloroethane (5.6 mL) in a 
microwave vial. To this was added trimethyltin hydroxide (361 mg, 200 mmol) and the 
reaction vessel was heated in a microwave reactor (3 h, 70 °C, 100 W). The solvent was 
evaporated and the remaining residue was dissolved in ethyl acetate (20 mL). This 
solution was washed with 10% KHSO4 (10 mL) and brine (10 mL). The organic layer 
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was dried over Na2SO4, filtered and concentrated to yield the product as a white solid 
which was used without further purification (268 mg, 99%).  
Oxazolidine methyl ester (27). β-Hydroxy ester 15 (2.01g, 7.3 mmol) 
was dissolved in acetone (18.5 mL) and 2,2-dimethoxypropane (18.5 mL). To this 
solution was added 10 (±)-camphorsulfonic acid (1.69 g, 7.3 mmol). The reaction was 
allowed to stir at room temperature for 24 h, at which time it was diluted with ethyl 
acetate (75 mL) and washed with saturated NaHCO3 (40 mL), and brine (40 mL). The 
organic layer was dried over Na2SO4, filtered and concentrated to yield the crude product. 
Purification by column chromatography (0"10% EtOAc/hexanes) yielded the product as 
an oil (1.28g, 56%). Rf 0.65 (20% EtOAc/hexanes); 
1H NMR: (500 MHz, CDCl3) δ 0.84 
(d, J=5.05 Hz, 6H), 1.35 (s, 9H), 1.43 (s, 6H), 1.72 (m, 1H), 2.54 (m, 2H), 3.59 (s, 3H), 
3.66-3.80 (m, 1H), 4.36 (d, J=6.54 Hz, 1H); 13C NMR: (125 MHz, CDCl3) δ 19.0, 21.5, 
23.1, 24.7, 25.9, 26.6, 28.2, 34.2, 51.6, 62.9, 73.0, 79.4, 92.7, 153.1, 170.9; IR (cm-1): 
2971, 2930, 1742, 1697, 1375, 1173; HRMS (ESI) m/z calculated for C16H29NO5Na (M 
+Na)+: 338.1944, found: 338.1953; α[ ]D
22.5+24.34 (c 0.9 CH2Cl2).  
Oxazolidine carboxylic acid (28). Oxazolidine 27 (1.28 g, 4.10 mmol) 
was dissolved in 1:1 THF/MeOH (20 mL) and cooled to 0 °C. To this was added 0.1M 
LiOH (8 mL) dropwise. The reaction was allowed to warm to room temperature and stir 
overnight. The solvent was evaporated and the remaining aqueous solution was acidified 
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with 10% KHSO4. This solution was then extracted with ethyl acetate (3 x 30 mL) and 
the combined aqueous extracts were dried over Na2SO4, filtered and concentrated to yield 
the product (1.22 g, quantitative) as an oil which was used without further purification.  
Coupled oxazolidine (29). Hiv-Leu-Pro-OBn (8) (50 mg, 
0.119 mmol) and carboxylic acid 28 (40 mg, 0.131 mmol) were dissolved in anhydrous 
tetrahydrofuran (1 mL) and cooled to 0 °C. To this solution was added EDCI (27 mg, 
0.143 mmol) and DMAP (1.4 mg, 0.0119 mmol). The reaction was allowed to warm to 
room temperature and stir overnight. The reaction was diluted with ethyl acetate (50 mL) 
and washed with 10% HCl (20 mL), saturated NaHCO3 (20 mL), and brine (20 mL). The 
organic layer was dried over Na2SO4, filtered and concentrated to yield the crude product. 
Purification by column chromatography (20"40% EtOAc/hexanes) yielded the product 
as a white solid (78 mg, 94%). Rf 0.25 (30% EtOAc/hexanes); 
1H NMR (500 MHz, 
CDCl3) δ 0.85-0.99 (m, 18H), 1.44 (s, 9H), 1.52 (m, 6H), 1.40 (m, 1H), 1.86 (s, 2H), 1.99 
(m, 3H), 2.13-2.31 (m, 2H), 2.76 (d, J= 5.85 Hz, 2H), 3.56 (q, J= 7.45 Hz, 1H), 3.70 (m, 
1H), 3.87 (s, 1H), 4.41 (m, 1H) 4.51 (dd, J=8.52, 4.23 Hz, 1H), 4.88 (q, J= 8.20 Hz, 1H), 
5.00-5.19 (m, 3H), 6.66 (d, J= 8.70 Hz, 1H), 7.31 (m, 5H); 13C NMR (125 MHz, CDCl3) 
δ 17.0, 18.7, 21.7, 23.3, 24.6, 24.8, 28.3, 28.9, 30.6, 34.9, 42.1, 46.8, 48.5, 58.8, 63.2, 
66.9, 67.8, 72.8, 78.3 79.8, 92.9, 128.1, 128.4, 128.5, 135.5, 164.9, 168.8, 169.9, 170.6, 
171.6; IR (cm-1): 3306, 2966, 2935, 2876, 1745, 1694, 1648, 1451, 1367, 1173; HRMS 
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(ESI) m/z calculated for C38H60N3O9 (M + H)
+: 702.4251, found: 702.4330; α[ ]D
19.6 -42.04 
(c 1.00, CH2Cl2). 
Protected linear precursor (5). Coupled oxazolidine 
29 (215 mg, 0.306 mmol) was dissolved in 4.0 M HCl in dioxane (5 mL) and allowed to 
stir for 3 h. The solvent was evaporated and to the residue was added Et2O and the 
solution was subsequently evaporated and kept under reduced pressure overnight to yield 
the HCl salt as a white solid. The HCl salt (183 mg, 0.306 mmol) was dissolved in 
anhydrous dichloromethane (3.8 mL) and the solution was cooled to 0 °C. Acid 6 (200 
mg, 0.367 mmol), BOP (169 mg, 0.383 mmol), and iPr2NEt (187 mL, 1.07 mmol) were 
added successively to the reaction flask. The reaction was allowed to warm to room 
temperature and stir for 24 h. The mixture was diluted with ethyl acetate (10 mL) and 
washed with 10% HCl (5 mL), saturated NaHCO3 (5 mL), and brine (5 mL). The organic 
layer was dried over Na2SO4, filtered, and concentrated to yield the crude product. 
Purification by column chromatography (30"40% EtOAc/hexanes) yielded the product 
as an amorphous solid (251 mg, 76%). Rf 0.28 (30% acetone/hexanes); 
1H NMR (500 
MHz, CDCl3) δ 0.74-0.98 (m, 18H), 1.22 (d, J=5.34 Hz, 3H), 1.43 (s, 9H), 1.64 (m, 2H), 
1.96 (m, 5H), 2.17 (m, 3H), 2.54 (m, 1H), 2.70 (m, 1H), 2.80 (m, 3H), 2.94 (m, 1H), 3.19 
(dd, J=12.9, 5.2 Hz, 1H), 3.58 (m, 1H), 3.63 (s, 1H), 3.73 (s, 3H), 3.80 (m, 1H), 4.04 (t, 
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J= 6.70 Hz, 1H), 4.10 (m, 1H), 4.35 (s, 1H), 4.45 (m, 1H), 4.77-4.89 (m, 2H), 4.92 (d, 
J=4.81 Hz, 1H), 5.00 (m, 2H), 5.05-5.14 (m, 1H), 5.19 (m, 1H), 5.26 (m, 1H), 5.50 (d, J= 
8.44 Hz, 1H), 6.74 (d, J= 8.00 Hz, 2H), 7.01 (m, 2H), 7.29 (m, 10H), 7.46 (m, 1H); 13C 
NMR (125 MHz, CDCl3) δ 13.6, 16.9, 17.7, 18.3, 18.5, 19.1, 20.2, 20.9, 21.1, 23.3, 24.7, 
28.1, 28.8, 30.4, 31.9, 34.0, 38.7, 40.1, 46.9, 48.4, 55.1, 58.9, 64.3, 66.9, 67.3, 68.6, 70.2, 
78.6, 80.2, 113.9, 127.6, 127.9, 128.1, 128.4, 128.5, 129.7, 129.8, 135.4, 156.1, 156.8, 
158.3, 169.9, 170.0, 171.3, 171.6, 171.9; IR (cm-1): 3329, 2961, 2935, 2875, 1744, 1686, 
1637, 1514, 1454, 1248, 1173; HRMS (ESI) m/z calculated for C58H81N5O15Na (M+Na)
+: 
1110.5627, found: 1110.5609; α[ ]D
20.2 -44.34 (c 1.00, CH2Cl2).  
Tamandarin B macrocycle (1). Protected linear precursor 
5 (40 mg, 0.037 mmol) was dissolved in anhydrous methanol (4 mL). To this was added 
10% Pd(OH)2/C (4 mg, 10% wt.). The flask was evacuated, purged with hydrogen for 
three cycles, and allowed to stir overnight. The reaction mixture was diluted with 
dichloromethane (15 mL) and the solution was filtered through a pad of Celite, and 
concentrated to yield the product (32 mg, quantitative) as a white solid, which was used 
without further purification. This deprotected product (32 mg, 0.037 mmol) was 
dissolved in anhydrous DMF (37 mL) and cooled to 0 °C. To this was added PyAOP (33 
mg, 0.063 mmol) and NMM (20 mL, 0.19 mmol). The reaction was allowed to warm to 
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room temperature and stir overnight. After 24 h additional PyAOP (19 mg, 0.36 mmol) 
and NMM (4 µL) were added and the reaction was stirred for an additional 24 h. To the 
reaction mixture was added water (50 mL). This solution was then extracted with EtOAc 
(4 x 50 mL). The combined organic phases were washed with 10% KHSO4 (30 mL), 5% 
NaHCO3 (30 mL), and brine (30 mL). The organic layer was dried over Na2SO4, filtered 
and evaporated to yield the crude product. Purification by column chromatography (40% 
EtOAc/CH2Cl2) afforded the product (14 mg, 48%) as a white solid. Rf 0.2 (50% 
EtOAc/CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 0.80- 1.03 (m, 18H), 1.25 (d, J= 6.45 Hz, 
3H), 1.43 (s, 9H), 1.53-1.71 (m, 4H), 1.73-1.80 (m, 4H), 1.96-2.21 (m, 4H), 2.46 (dd, 
J=16.96, 6.72 Hz), 2.56 (s, 3H), 2.85-2.94 (m, 1H), 3.14 (dd, J= 14.44, 10.89 Hz,1H), 
3.36 (dd, J= 14.22, 4.32 Hz, 1H), 3.55 (dd, J= 10.47, 4.47 Hz, 1H), 3.64 (d, J= 6.00 Hz, 
2H), 3.70 (t, J= 9.29 Hz, 1H), 3.77 (s, 3H), 3.98 (t, J= 6.16 Hz, 1H), 4.32 (dd, J= 10.37, 
3.12 Hz, 1H), 4.58 (dd, J= 7.85, 4.60 Hz, 1H), 4.88 (t, J= 9.92 Hz, 1H), 4.95 (m, 2H), 
5.00 (dd, J= 6.30, 3.20 Hz, 1H), 6.82 (d, J= 8.44 Hz, 2H), 7.06 (d, J= 8.44 Hz, 2H), 7.53 
(d, J= 9.64 Hz, 1H), 7.95 (d, J= 8.49 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 15.1, 18.0, 
18.5, 20.2, 20.7, 23.5, 24.9, 27.6, 28.0, 30.4, 34.0, 38.5, 38.9, 46.7, 48.3, 55.2, 55.8, 57.1, 
60.3, 65.8, 68.9, 71.4, 79.2, 80.2, 114.1, 129.9, 130.3, 155.8, 158.6, 168.6, 169.7, 170.4, 
171.3, 171.6, 172.8; IR (cm-1): 3341, 2961, 2873, 1741, 1669, 1636, 1514, 1166; HRMS 
(ESI) m/z calculated for C43H68N5O12 (M +H)
+: 846.4864, found: 846.4869; α[ ]D
18.7 -90.1 
(c 0.7, CH2Cl2). 
Boc-D-Leucine benzyl ester (46). D-Leucine (5 g, 38.1 mmol) was 
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suspended in 1 M NaOH (76 mL) and dioxane (23 mL) and cooled to 0 °C. To this was 
added Boc anhydride (9.15 g, 41.9 mmol) in dioxane (30 mL). The resulting reaction was 
allowed to warm to room temperature and stir overnight. The reaction mixture was 
diluted with water (100 mL) and extracted with hexanes (3 x 100 mL). The remaining 
aqueous layer was acidified with solid citric acid and extracted with ethyl acetate (3 x 
100 mL). The organic extracts were washed with water (50 mL), brine (50 mL) and dried 
over MgSO4. Filtration and concentration under reduced pressure led to the product as 
clear oil (8.51 g, 97%) that was used directly in the next step. The Boc protected product 
(8.51 g, 36.8 mmol) was dissolved in anhydrous DMF (75 mL) and cooled to 0 °C. To 
this solution was added cesium carbonate (12.0 g, 36.8 mmol) and the reaction was 
allowed to stir for 20 min. Benzyl bromide (4.37 mL, 36.8 mmol) was added to the 
reaction mixture via syringe. This mixture was allowed to warm to room temperature and 
stir overnight. Water (300 mL) was added to the reaction and was then extracted with 
hexanes (3 x 150 mL). The combined organic extracts were washed with water, brine, 
and dried over MgSO4. Concentration under reduced pressure led to the product as a clear 
oil (10.76 g, 91%): Rf 0.41 (10% EtOAc/hexanes); 
1H NMR (500 MHz, CDCl3) δ 0.92 (d, 
J= 4.10 Hz, 3H), 0.93 (d, J= 4.10 Hz), 1.46 (s, 9H), 1.49 (m, 1H), 1.65 (m, 2H), 4.49 (s, 
1H), 4.89 (s, 1H), 5.16 (q, J= 13.4 Hz, 2H), 7.32 (m, 5H); 13C NMR (125 MHz, CDCl3) δ 
21.9, 22.8, 24.8, 28.3, 41.7, 52.1, 66.9, 79.8, 128.1, 128.3, 128.5, 135.7, 155.5, 173.5; IR 
(neat, cm-1): 3365, 2958, 1718, 1508, 1366, 1251, 1164; HRMS (ESI) m/z calculated for 
C18H27NO4Na (M+Na)
+: 344.1838, found: 344.1850; α[ ]D
22.8+32.56 (c 1.12, MeOH). 
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N-Me-N-Boc-D-Leucine benzyl ester (47). N-Boc-Leucine benzyl ester 
46 (3.61 g, 11.2 mmol) was dissolved in anhydrous tetrahydrofuran (56 mL) and cooled 
to 0 °C. Methyl iodide (3.54 mL, 56.2 mmol) was added to this solution followed by 1M 
NaHMDS (16.8 mL, 16.8 mmol). The reaction mixture was allowed to warm to room 
temperature and stir overnight. The reaction was quenched by addition of saturated 
ammonium chloride (50 mL). The reaction mixture was extracted with diethyl ether (2 x 
50 mL). The combined organic phases were washed with 10% HCl (30 mL), saturated 
NaHCO3 (30 mL), brine (30 mL), and dried over MgSO4. The solvent was evaporated to 
yield the crude product as a brown oil. Purification by column chromatography (2"4% 
EtOAc/hexanes) yielded the product as a clear oil (2.76g, 73%): Rf 0.40 (10% 
EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 0.92 (d, J= 6.55 Hz, 3H), 0.94 (d, J= 
5.83 Hz, 3H), 1.43 (s, 9H), 1.56 (m, 1H), 1.68 (m, 2H), 2.79 (m, 3H), 4.6-4.8 (m, 1H), 
5.15 (m, 2H), 7.33 (m, 5H); 13C NMR (125 MHz, CDCl3) δ 21.2, 23.7, 24.6, 28.2, 32.4, 
37.4, 56.0, 57.2, 66.5, 80.1, 127.3, 128.2, 128.5, 135.7, 155.4, 156.2, 172.26; IR (neat, 
cm-1) 2958, 1740, 1702, 1455, 1391, 1367, 1323, 1156, 970; HRMS (ESI) m/z calculated 
for C19H29NO4Na (M + Na)
+: 358.1995, found: 358.1990; α[ ]D
24.8+23.96 (c 1.0, MeOH). 
N-Me-D-Leucine benzyl ester hydrochloride (34). N-Me-N-Boc-D-
Leucine benzyl ester (6.47 g, 19.29 mmol) was dissolved in 4.0 M HCl in dioxane (20 
mL) at room temperature. The reaction was complete after 2 h. The solvent was 
evaporated to yield the product (5.24 g, quantitative) as a white solid, which was used 
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without further purification. 
N-Boc-Proline-N-Me-D-Leucine benzyl ester (35). Boc-Proline (2.99 
g, 13.9 mmol) was dissolved in anhydrous dichloromethane (46 mL) and cooled to -
15 °C. To this solution was added BOP-Cl (3.72 g, 14.6 mmol) and NMM (1. 64 mL, 
14.8 mmol). This mixture was stirred for 30 minutes, then N-methyl-D-leucine-benzyl 
ester hydrochloride (3.78 g, 13.9 mmol) and NMM (5 mL, 45.9 mmol) were added. The 
reaction was allowed to warm to room temperature and stir for 24 h. The mixture was 
diluted with ethyl acetate (100 mL), washed with 10% HCl (30 mL), saturated NaHCO3 
(30 mL), brine (30 mL), dried over MgSO4, and filtered. After solvent evaporation the 
crude product was purified by column chromatography (10"20% acetone/hexanes) to 
yield the product (4.75 g, 92%) as a white solid: Rf 0.5 (30% acetone/hexanes); 
1H NMR 
(500 MHz, CDCl3) δ 0.91 (m, 6H) 1.40 (m, 9H), 1.63 (s, 1H) 1.70-1.78 (m, 1H), 1.79-
2.20 (m, 3H), 3.02 (m, 3H) 3.37- 3.48 (m, 1H), 3.53-3.69 (m, 1H), 4.60 (dd, J=8.59, 3.39 
Hz), 5.14 (m, 2H), 7.32 (m, 5H); 13C NMR (125MHz, CDCl3) δ 21.2, 23.3, 25.1, 28.2, 
30.4, 31.7, 32.6, 37.8, 46.4, 55.2, 57.1, 66.7, 79.5, 128.1, 128.5, 135.6, 153.9, 171.6, 
173.3; IR (neat, cm-1): 2958, 2931, 2872, 1741, 1699, 1661, 1396, 1169; HRMS (ESI) 
m/z calculated for C24H36N2O5Na (M + Na)
+: 455.2522, found: 455.2515; α[ ]D
25.8 -1.54 (c 
1.0, CH2Cl2). 
L-Lactyl-L-Prolyl-N-methyl-D-Leucine benzyl ester (36). Benzyl 
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ester 35 (300 mg, 0.69 mmol) was dissolved in 4.0 M HCl in dioxane (3 mL) and allowed 
to stir at room temperature for 2 h. The solvent was removed and the resulting salt was 
re-dissolved in anhydrous CH2Cl2 (3 mL) and cooled to 0 °C. To this solution was added 
L-lactic acid (52 µL, 0.69 mmol), BOP (368 mg, 0.83 mmol), and NMM (0.31 mL, 2.78 
mmol). The mixture was allowed to warm to room temperature and stir overnight. The 
reaction was diluted with CH2Cl2 (25 mL) and washed with 10% HCl (10 mL), saturated 
NaHCO3 (10 mL), and brine (10 mL). The organic phase was dried over Na2SO4, filtered, 
and concentrated. The crude product was purified by column chromatography (25% 
acetone/hexanes) to yield the product (0.172 g, 61%) as a clear oil: Rf 0.48 (50% 
acetone/hexanes); 1H NMR (500 MHz, CDCl3) δ 0.78-1.01 (m, 6H), 1.33 (m, 6H), 1.43 
(m, 2H), 1.74 (m, 2H), 1.91 (m, 2H), 2.09 (m, 2H), 3.01 (s, 3H), 3.52 (t, J=6.75 Hz, 2H), 
4.29 (q, J=5.98 Hz, 1H), 5.15 (m, 3H), 7.31 (m, 5H); 13C NMR (125 MHz, CDCl3) δ 
20.4, 21.3, 23.1, 24.8, 28.3, 32.1, 37.4, 46.5, 55.6, 568, 65.5, 66.6, 128.0, 128.4, 128.6, 
135.6, 171.1, 172.1, 173.2; IR (neat, cm-1): 3415, 2957, 2873, 1739, 1651, 1456, 1129, 
843; HRMS (ESI) m/z calculated for C22H32N2O5Na (M + Na)
+: 427.2209, found: 
427.2194; α[ ]D
25.6 -14.07 (c 0.76, CHCl3). 
Pyruvyl-Prolyl-N-methyl-D-Leucine benzyl ester (48). Lactyl-
Prolyl-N-methyl-D-Leucine benzyl ester 36 (120 mg, 0.296 mmol) was dissolved in 
anhydrous dichloromethane (1 mL) and dimethyl sulfoxide (0.30 mL). To this solution 
was added Dess-Martin periodinane (629 mg, 1.48 mmol). The reaction was allowed to 
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stir for 24 h at which time it was quenched with 5% Na2S2O3 (5 mL) and diluted with 
Et2O (25 mL). The organic layer was separated and washed with saturated NaHCO3 (5 
mL), water (5 mL), dried over Na2SO4, filtered and concentrated. The crude product was 
purified by column chromatography (20% acetone/hexanes) to yield the product (87 mg, 
73%) as a yellow oil: Rf 0.27 (30% acetone/hexanes); 
1H NMR (CDCl3, 500 MHz) δ 0.91 
(m, 6H), 1.43 (m, 1H), 1.60-1.90 (m, 6H), 2.20-2.45 (m, 3H), 2.81-3.10 (m, 3H), 3.52-
3.92 (m, 2H), 4.92 (m, 1H), 5.04-5.22 (m, 3H), 7.36 (m, 3H); 13C NMR (CDCl3, 125 
MHz) δ 21.2, 22.3, 23.3, 24.9, 26.1, 31.1, 32.1 37.2, 47.5, 57.8, 58.5, 66.9, 128.1, 128.3, 
128.5, 136.5, 163.6, 170.9 172.6, 198.7; IR (neat, cm-1): 3460, 2958, 2873, 1739, 1715, 
1652, 1455, 1206; HRMS (ESI) m/z calculated for C22H30N2O5Na (M + Na)
+: 425.2052, 
found: 425.2040; α[ ]D
20.5 -2.58 (c 0.96, CHCl3). 
 
Procedure for preparation of tamandarin B macrocyclic salt. Macrocycle (14 mg, 
0.017 mmol) was dissolved in ethyl acetate (4 mL) and cooled to -30 °C. HCl gas was 
bubbled over this solution while keeping the temperature at -30 °C for 10 min. The flow 
of HCl gas was stopped and stirring continued at -30 °C for an additional 30 min. The 
temperature was raised to 0 °C for 1 h. At this point TLC showed that the starting 
material had been consumed. The solvent was removed under reduced pressure to yield 
the macrocyclic salt (13 mg, quantitative) as a yellow solid, which was used without 
further purification. 
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Dehydrotamandarin B (30). The tamandarin 
B macrocyclic salt (8.0 mg, 0.010 mmol) was dissolved in anhydrous dichloromethane (1 
mL) and cooled to 0 °C. To this solution was added side chain (37) (5.0 mg, 0.015 mmol), 
BOP (7.0 mg, 0.15 mmol) and NMM (4.5 mL, 0.041 mmol). The reaction was allowed to 
warm to room temperature and stir overnight. The reaction was quenched with brine (4 
mL) and the mixture was extracted with EtOAc (3 x 10 mL). The organic phase was 
washed with 10% HCl (5 mL), 5% NaHCO3 aq. (5 mL), brine (5 mL), dried over Na2SO4, 
filtered and concentrated to yield the crude product. The product was purified by reverse 
phase HPLC (10% MeOH/H2O"100% MeOH gradient over 40 min) to yield the 
product (8 mg, 73%) as a white solid. Rf 0.26 (30% acetone/hexanes); 
1H NMR (500 
MHz, CDCl3) δ 0.78-1.07 (m, 24H), 1.25 (m, 10H) 1.40 (t, J= 7.49 Hz, 3H), 1.45 (m, 1H), 
1.61 (m, 5H), 1.72-2.28 (m, 10H), 2.43-2.50 (m, 1H), 2.53-2.62 (m, 3H), 3.03-3.12 (m, 
3H), 3.13-3.20 (m, 1H), 3.55-3.74 (m, 3H), 3.79 (s, 3H), 3.81-3.89 (m, 1H), 3.91-4.04 
(m,1H), 4.28-4.40 (m, 1H), 4.63 (m, 1H), 4.89 (t, J= 10.17 Hz, 1H), 5.05 (d, J=4.49 Hz, 
1H), 5.16-5.27 (m, 1H), 5.28-5.36 (m, 1H), 6.84 (m, 2H), 7.08 (d, J= 7.91 Hz, 2H), 7.42-
7.56 (m, 1H), 7.72-7.85 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 14.1, 16.6, 17.0, 17.4, 
18.9, 20.4, 20.8, 21.4, 22.7, 23.5, 23.8, 24.9, 26.3, 27.1, 28.0, 29.4, 29.7, 30.0, 30.6, 31.2, 
34.0, 35.8, 38.7, 39.2, 46.7, 48.7, 48.8, 54.7, 55.2, 56.9, 57.3, 58.3, 58.9, 66.0, 70.9, 78.7, 
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114.1, 129.8, 130.3, 158.6, 161.3, 168.6, 169.6, 170.4, 170.5, 171.7, 172.2, 172.9, 173.9, 
201.11. IR (cm-1) 3340, 2957, 2926, 2871, 1741, 1662, 1636, 1514, 1457, 1170, 1078; 
HRMS (ESI) m/z calcd for C53H81N7O14Na (M + Na)
+: 1062.5739, found: 1062.5760; 
α[ ]D
17.0 -18.68 (c 0.2, CH2Cl2). 
N2-Boc-N5-Xanthyl-Glutaminyl-O-L-Lactyl-L-Prolyl-
N-methyl-D-Leucine benzyl ester (38). L-Lactyl-L-Prolyl-N-methyl-D-Leucine benzyl 
ester 36 (2.24 g, 5.5 mmol) was dissolved in anhydrous tetrahydrofuran (30 mL) and 
cooled to 0 °C. To this solution was added N2-Boc-N5-glutamine (3.07 g, 7.2 mmol), 
followed by EDCI (1.48 g, 7.7 mmol) and DMAP (1.34 g, 11 mmol). The reaction was 
allowed to warm to room temperature and stir overnight. EtOAc (50 mL) was added and 
the solution was washed sequentially with 10% HCl (25 mL), saturated NaHCO3 (25 mL), 
brine (25 mL), dried over MgSO4, filtered, and concentrated. The crude product was 
purified by column chromatography (15"20% acetone/hexanes) to yield the product 
(3.70 g, 83%) as a white solid: Rf 0.54 (50% acetone/hexanes); 
1H NMR (500 MHz, 
CDCl3) δ 0.73 (t, J= 6.63 Hz, 2H), 0.80 (d, J= 6.50 Hz, 2H), 0.86 (d, J= 6.65 Hz, 3H), 
0.97 (dd, J= 16.2, 6.53 Hz, 1H), 1.35 (d, J= 5.85 Hz, 3H), 1.43 (s, 9H), 1.60-1.69 (m, 2H), 
1.78-1.88 (m, 2H), 1.88-2.20 (m, 3H), 2.22-2.42 (m, 2H), 2.70 (m, 3H), 2.89-2.98 (m, 
1H), 3.43-3.69 (m, 2H), 3.72 (t, J= 6.25 Hz, 2H), 4.31-4.64 (m, 1H), 4.91 (m, 2H), 5.11 
(m, 2H), 6.50 (m, 1H), 7.00-7.12 (m, 4H), 7.18-7.37 (m, 7H), 7.39- 7.51 (m, 2H); 13C 
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NMR (125 MHz, CDCl3) δ 11.4, 14.1, 16.0, 21.3, 22.5, 23.1, 24.9, 25.3, 28.3, 29.0, 31.5, 
32.0, 34.6, 36.0, 37.3, 43.5, 46.7, 55.8, 56.7, 66.3, 116.2, 121.2, 123.3, 123.5, 127.9, 
128.4, 128.8, 129.4, 135.7, 151.1, 168.6, 170.1, 171.9, 172.1; IR (neat, cm-1): 3305, 2959, 
1743, 1712, 1652, 1481, 1456, 1258; HRMS (ESI) m/z calculated for C45H56N4O10Na (M 
+ Na+): 835.3894, found: 835.3992; α[ ]D
24.0 -27.24 (c 0.89, CHCl3).  
Protected tamandarin M side chain (39). N2-Boc-
N5-Xanthyl-glutaminyl-O-L-Lactyl-L-Prolyl-N-methyl-D-Leucine benzyl ester (407 mg, 
0.50 mmol) was dissolved in ethyl acetate (4.75 mL) and anisole (0.25 mL) and cooled to 
-20 °C. Gaseous HCl was bubbled in the reaction mixture over a 5 min period, and the 
reaction changed colors from yellow to red. The resulting mixture was allowed to stir at -
20 °C for 1 h and at 0 °C for another 1 h. Argon was then bubbled through the solution as 
it was allowed to warm to room temperature. The solvent was evaporated and the 
remaining residue was triturated with diethyl ether (10 mL) to produce a white solid, 
which was obtained by filtration. The remaining ether solution was evaporated and 
triturated again to produce a second crop of the hydrochloride salt. The product was 
isolated as a white solid (0.182 g, 64%) that was used in the next step without further 
purification. The HCl salt (0.182 g, 32 mmol) was dissolved in anhydrous 
dichloromethane (1.4 mL) and cooled to 0 °C. To this solution was added N-Cbz-pGlu-
OPfP (0.140 g, 32 mmol) and iPr2NEt (225 µL, 1.28 mmol). The mixture was allowed to 
O
BnO N
O
N
O
O
O
O NH2
N
H
O
CbzN
O
! 73 
warm to room temperature and stir overnight. The reaction was quenched with brine (3 
mL) and diluted with CH2Cl2 (5 mL). The layers were separated and the aqueous layer 
was extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were washed with 
10 % HCl (5 mL), 5% NaHCO3 aq. (5 mL), and brine (5 mL). The organic layer was 
dried (MgSO4), filtered and concentrated to yield the crude product which was purified 
by column chromatography (1"5% MeOH/CH2Cl2) to yield the product (77 mg, 31%) 
as a white solid: Rf 0.41 (10% MeOH/CH2Cl2); 
1H NMR (CDCl3, 500 MHz) δ 0.86 (d, J= 
6.52 Hz, 3H), 0.91 (d, J= 6.67 Hz, 3H), 1.38 (m, 1H), 1.44-1.57 (m, 3H), 1.69-1.79 (m, 
3H), 1.93-2.33 (m, 9H), 2.35-2.47 (m, 2H), 2.68 (t, J= 9.87 Hz, 1H), 2.71 (t, J= 9.97 Hz, 
1H), 2.99 (s, 3H), 3.57 (q, J= 7.68 Hz, 1H), 3.70 (q, J= 7.75 Hz, 1H), 4.46-4.60 (m, 2H), 
4.86 (dd, J= 8.40, 4.76 Hz, 1H, 5.05-5.28 (m, 4H), 5.42 (m, 1H), 6.93 (s, 1H), 7.24-7.39 
(m, 10H), 7.51 (d, J= 6.55 Hz, 1H); 13C NMR (CDCl3, 125 MHz) δ 15.8, 21.1, 22.2, 23.2, 
24.9, 25.1, 27.1, 28.3, 31.1, 31.3, 31.6, 37.4, 46.7, 51.9, 55.0, 57.2, 59.5, 66.8, 68.2, 69.2, 
127.9, 128.2, 128.5, 128.6, 135.1, 135.5, 151.3, 168.6, 170.7, 171.1, 171.5, 171.9, 173.5, 
175.6; IR (neat, cm-1): 3432, 3328, 3214, 2951, 1791, 1742, 1661, 1452, 1304, 1189; 
HRMS (ESI) m/z calculated for C40H51N5O11Na (M + Na)
+: 800.3483, found: 800.3495; 
α[ ]D
27.0 -57.03 (c 0.77, CHCl3). 
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Tamandarin M (31). The 
tamandarin B macrocyclic salt (10.0 mg, 0.013 mmol) was dissolved in anhydrous 
dichloromethane (1 mL) and cooled to 0 °C. To this solution was added side chain 40 
(11.0 mg, 0.019 mmol), BOP (9.0 mg, 0.019 mmol), and NMM (6.0 µL, 0.051 mmol). 
The reaction was allowed to warm to room temperature and stir overnight. The reaction 
was quenched with brine (4 mL) and the resulting mixture was extracted with EtOAc (3 x 
10 mL). The organic phase was washed with 10 % HCl (5 mL), 5% NaHCO3 aq. (5 mL), 
brine (5 mL), dried over Na2SO4, filtered, and concentrated to yield the crude product. 
The product was purified by reverse phase HPLC (10% MeOH/H2O"100% MeOH 
gradient over 40 min) to yield the product (13 mg, 81%) as a white solid. Rf 0.21 (50% 
EtOAc/CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 0.76-1.05 (m, 24H), 1.15-1.32 (m, 10H), 
1.36-1.42 (m, 5H), 1.46 (d, J= 7.07 Hz, 2H), 1.52-1.66 (m, 3H), 1.72 (m, 2H), 1.89 (m, 
2H), 1.96-2.31 (m, 9H), 2.34-2.46 (m, 2H), 2.54 (s, 3H), 2.61 (m, 1H), 2.92 (m, 1H), 2.97 
(s, 2H), 3.06-3.16 (m, 2H), 3.32 (dd, J= 14.16, 3.95 Hz, 1H), 3.53-3.74 (m, 4H), 3.77 (s, 
3H), 3.87 (m, 2H), 4.15 (t, J= 4.16 Hz, 1H), 4.49 (m, 2H), 4.57 (dd, J= 7.73, 4.68 Hz, 
1H), 4.74 (t, J= 7.05 Hz, 1H), 4.87 (m, 1H), 4.91 (d, J= 5.05 Hz, 1H), 5.01 (m, 1H), 5.11 
(q, J= 6.70 Hz, 1H), 5.25 (dd, J= 9.45, 6.00 Hz, 1H), 5.94 (s, 1H), 6.81 (d, J= 8.30 Hz, 
2H), 7.05 (d, J= 8.35 Hz, 2H), 7.75 (d, J= 9.40 Hz, 1H), 7.80 (d, J= 9.80 Hz, 1H), 8.52 (d, 
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J= 6.35 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 14.2, 15.9, 16.1, 16.9, 17.9, 18.8, 20.3, 
20.9, 21.4, 22.7, 23.6, 23.7, 24.6, 24.9, 25.7, 27.2, 27.9, 28.8, 29.3, 29.7, 30.2, 31.1, 31.8, 
31.9, 34.0, 26.1, 38.6, 39.2, 39.5, 46.8, 47.1, 48.3, 51.8, 53.8, 54.3, 55.3, 56.3, 56.6, 56.8, 
57.0, 58.4, 66.1, 68.7, 69.5, 71.2, 79.4, 114.1, 129.8, 130.4,158.6, 168.8, 169.4, 169.5, 
170.5, 170.8, 171.1, 171.3, 172.6, 173.3, 173.5, 176.5, 178.8; IR (cm-1) 3337, 2958, 1928, 
2873, 1741, 1662, 1636, 1514, 1456, 1248; HRMS (ESI) m/z calculated for 
C63H96N10O18Na (M + Na)
+ : 1303.6802, found: 1303.6832; α[ ]D
17.0 -35.49 (c 0.65, 
CH2Cl2). 
N-Boc-Prolinal (42). This compound was prepared according to a procedure by 
Reed.23 The obtained product was in good agreement with the reported spectra and 
physical characteristics.  
N-Boc-Pro Ψ(NHCH2) N-methyl-D-leucine-benzyl ester (43). Boc-
Prolinal (42) (430 mg, 2.15 mmol) and N-methyl leucine benzyl ester (34) (508 mg, 2.15 
mmol) were dissolved in anhydrous 1,2-dichloroethane (5 mL). The reaction was cooled 
to 0 °C and acetic acid (0.5 mL) was added and the solution and stirred for 20 min. 
Sodium triacetoxyborohydride (637 mg, 3.01 mmol) was added to the reaction and the 
mixture was allowed to warm to room temperature and to stir for 3 h. The reaction was 
quenched with saturated NH4Cl and diluted with CH2Cl2 (15 mL). The organic layer was 
washed with 10% HCl (10 mL), 5% NaHCO3 aq. (10 mL), brine (10 mL), dried over 
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Na2SO4, filtered, and concentrated to yield the crude product. The crude product was 
purified by column chromatography (10"20% EtOAc/hexanes) to afford the product 
(580 mg, 65%) as a yellow oil: Rf 0.68 (30% EtOAc/hexanes); 
1H NMR (500 MHz, 
CDCl3) δ 0.89 (m, 6H), 1.42 (s, 9H), 1.56 (m, 1H), 1.68 (m, 1H), 1.80 (m, 4H), 2.30 (m, 
4H), 2.51-2.80 (m, 1H), 3.31 (m, 3H), 3.70-3.95 (m, 1H), 5.13 (m, 2H), 7.35 (m, 5H); 13C 
NMR (125 MHz, CDCl3) δ 22.4, 22.9, 24.7, 28.5, 36.8, 39.2, 40.3, 46.1, 55.9, 66.1, 79.1, 
128.2, 128.3, 128.5, 136.0, 154.4, 172.8; IR (neat, cm-1): 2958, 2873, 1731, 1694, 1456, 
1394, 1171; HRMS (ESI) m/z Calculated for C24H38N2O4Na (M + Na)
+: 441.2730, found: 
441.2741; α[ ]D
22.0 +10.7 (c 0.8, CHCl3). 
L-Lactyl-Pro Ψ(NHCH2) N-methyl-D-leucine benzyl ester (44). 
N-Boc-Pro Y(NHCH2) N-methyl-D-leucine-benzyl ester (43) (0.128 g, 0.316 mmol) was 
dissolved in 4.0 M HCl in dioxane (5 mL). The reaction was stirred for 2 h and the 
solvent was evaporated to yield the hydrochloride salt in quantitative yield. The resulting 
salt (0.122 g, 0.316 mmol) was dissolved in anhydrous dichloromethane (2 mL) and 
cooled to 0 °C. To this solution was added L-lactic acid (25 µL, 0.332 mmol), BOP 
(0.154 g, 0.348 mmol), and NMM (173 µL, 1.58 mmol). The reaction was allowed to 
warm to room temperature and stir overnight. The reaction was diluted with EtOAc (20 
mL) and washed with 10% HCl (10 mL), 5% NaHCO3 aq. (10 mL), and brine (10 mL). 
The organic layer was dried over Na2SO4, filtered, and concentrated to yield the crude 
product. The crude product was purified by column chromatography (20"50% 
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EtOAc/hexanes) to yield the product (75 mg, 61%) as a yellow oil: Rf 0.30 (50% 
EtOAc/hexanes); 1H NMR (500 MHz, CDCl3) δ 0.83-0.92 (m, 6H), 1.29 (d, J= 6.55 Hz, 
3H), 1.38-1.70 (m, 4H), 1.76-2.01 (m, 4H), 2.28-2.48 (m, 5H), 2.64-2.87 (m, 1H), 3.24-
3.50 (m, 3H), 4.06-4.40 (m, 1H), 5.12 (d, J= 4.75 Hz, 2H), 7.33 (m, 5H); 13C NMR (125 
MHz, CDCl3) δ 20.3, 20.9, 22.3, 22.7, 23.4, 23.9, 24.8, 27.7, 29.6, 37.4, 38.4, 46.0, 56.6, 
65.4, 66.0, 128.1, 128.3, 128.4, 135.8, 172.5, 173.6; IR (neat, cm-1): 3426, 2957, 2925, 
2863, 1731, 1639, 1452, 1127; HRMS (ESI) m/z calculated for C22H35N2O4 (M + H)
+: 
391.2597, found: 391.2585; α[ ]D
19.0 -1.55 (c 0.58, CHCl3). 
Ψ[CH2NH] Amide surrogate tamadarin B 
(32). The tamandarin B macrocyclic salt (15.0 mg, 0.019 mmol) was dissolved in 
anhydrous dichloromethane (1 mL) and cooled to 0 °C. To this solution was added side 
chain 45 (12 mg, 0.038 mmol), HATU (12 mg, 0.031 mmol), and iPr2NEt (14 µL, 0.077 
mmol). The reaction was allowed to warm to room temperature and stir overnight. The 
reaction was diluted with EtOAc (15 mL) and washed with 10% HCl (5 mL), 5% 
NaHCO3 aq. (5 mL), brine (5 mL), dried over Na2SO4, filtered and concentrated to yield 
the product (15 mg, 83 %) as a white solid. Rf 0.46 (10 % MeOH/CH2Cl2); 
1H NMR (500 
MHz, CDCl3) δ 0.0-1.05 (m, 24H), 1.19 (m, 1H), 1.25 (t, J= 7.09 Hz, 3H),1.29-1.39 (m, 
5H), 1.40-1.52 (m, 3H), 1.57-1.81 (m, 5H), 1.82-2.05 (m, 3H), 2.07-2.18 (m, 3H), 2.33 (d, 
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J= 10.00 Hz, 3H), 2.41 (m, 1H), 2.53 (s, 2H), 2.77 (s, 3H), 2.89 (m, 1H), 3.12 (m, 2H), 
3.28-3.50 (m, 3H), 3.52-3.71 (m, 3H), 3.76 (s, 3H), 3.94 (m, 1H), 4.26 (m, 2H), 4.56 (m, 
2H), 4.84 (d, J= 6.05 Hz, 2H), 5.01 (m, 1H), 6.80 (d, J= 8.15 Hz, 2H), 7.05 (d, J= 7.95 
Hz, 2H), 7.62 (d, J= 9.15 Hz, 1H) 7.68 (d, J= 8.34 Hz, 1H), 7.77 (d, J= 8.53 Hz, 1H), 
8.00 (t, J= 8.90 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 15.5, 16.5, 18.1,18.5, 20.3, 20.8, 
21.1, 22.0, 22.6, 23.0, 23.5, 24.4, 24.9, 25.1 25.6, 27.6, 28.0, 30.3, 34.1, 36.0, 36.7, 38.6, 
45.8, 46.4, 46.8, 48.3, 54.5, 56.4, 57.1, 57.2, 58.9, 63.6, 64.6, 65.1, 65.4, 65.8, 68.8, 69.3, 
71.3, 79.3, 114.0, 129.8, 130.4, 158.6, 165.8, 168.8, 169.8, 170.3, 171.2, 172.5, 172.9, 
173.2; IR (cm-1) 3339, 2956, 2920, 2868, 1742, 1661, 1654, 1633, 1511, 1094; HRMS 
(ESI) m/z calculated for C53H86N7O13 (M + H)
+: 1028.6284, found: 1028.6300; α[ ]D
18.0 -
65.55 (c 0.34, CH2Cl2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 79 
2.6) References 
!
1 Liang, B., Richard, D. J., Portonovo, P. & Joullie, M. M. "Total Syntheses and 
Biological Investigations of Tamandarins A and B and Tamandarin A Analogs." J. Am. 
Chem. Soc. 2001, 123, 4469-4474. 
2 Adrio, J., Cuevas, C., Manzanares, I. & Joullie, M. M. "Synthesis and Biological 
Evaluation of Tamandarin B Analogues." Org. Lett. 2006, 8, 511–514.  
3 Adrio, J., Cuevas, C., Manzanares, I. & Joullie, M. M. "Total Synthesis and Biological 
Evaluation of Tamandarin B analogues." J. Org. Chem. 2007, 72, 5129–5138.  
4 Hamada, Y., Kondo, Y., Shibata, M. & Shioiri, T. "Efficient Total Synthesis of 
Didemnins A and B." J. Am. Chem. Soc. 1989, 111, 669-673.  
5 Jou, G., Gonzales, I., Albericio, F., Lloyd-Williams, P. & Giralt, E. "Total Synthesis of 
Dehydrodidemnin B. Use of Uronium and Phosphonium Salt Coupling Reagents in 
Peptide Synthesis in Solution." J. Org. Chem. 1997, 62, 354-366.  
6 Lassen, K. M., Lee, J. & Joullie, M. M. "An efficient synthesis of the tamandarin B 
macrocycle." Tetrahedron Lett. 2010, 51, 1635-1638.  
7 K. M. Lassen, “The synthesis and biological evaluation of tamandarin B analogues”, 
University of Pennsylvania, Philadelphia, PA, 2011. 
8 Long, C. M. "Investigations of Novel Ascidian Metabolites" Ph. D. thesis, University of 
Pennsylvania, Philadelphia, 2006.  
9 Li, W.-R., Ewing, W. R., Harris, B. D. & Joullié, M. M. "Total Synthesis and Structural 
Investigations of Didemnins A, B, and C." J. Am. Chem. Soc. 1990, 112, 7659-7672.  
10 Chen, W.-C., Vera, M. D. & Joullié, M. M. "Mild, selective cleavage of amino acid 
!
! 80 
!
and peptide [beta]-(trimethylsilyl)ethoxymethyl (SEM) esters by magnesium bromide." 
Tetrahedron Lett. 1997, 38, 4025-4028.  
11 Nicolaou, K. C., Estrada, A. A., Zak, M., Lee, S. H. & Safina, B. S. "A mild and 
selective method for the hydrolysis of esters with trimethyltin hydroxide." Angew. Chem., 
Int. Ed. Engl. 2005, 44, 1378-1382.  
12 Kunishima, M., Kawachi, C., Iwasaki, F., Terao, K. & Tani, S. "Synthesis and 
characterization of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium 
chloride." Tetrahedron Lett. 1999, 40, 5327-5330.  
13 Hiebl, J. et al. "Large-scale synthesis of hematoregulatory nonapeptide SK&F 107647 
by fragment coupling." J. Pept. Res. 1999, 54, 54-65.  
14 Carpino, L. A., Elfaham, A., Minor, C. A., Albericio, F. "Advantageous Applications 
of Azabenzotriazole (Triazolopyridine)-Based Coupling Reagents to Solid-Phase 
Peptide-Synthesis." J. Chem. Soc., Chem. Commun. 1994, 201-203.  
15  HoegJensen, T., Holm, A. & Sorensen, H. "Peptide thioacylation with high 
stereochemical preservation." Synthesis 1996, 383-&.  
16  Rinehart, K. L. & Katauskas, A. J. "Semi-synthetic studies toward didemnin 
analogues." WO patent 9817275 1998.  
17 Rinehart, K. L. & Lithgow-Bertelloni, A. M. P. in GB patent W22026,1990 Vol. 115 
(ed Appl. WO 91 04 PTC Int, 985) 248086q (GB, 1991).  
18 Ding, X. et al. "Structure-Activity Relationships of Side-Chain Modified Didemnins." 
Bioorg. Med. Chem. Lett. 2001, 11, 231-234.  
19 Liang, B., Vera, M. D. & Joullié, M. M. "Total Synthesis of [(2S)-Hiv2]Didemnin M." 
!
! 81 
!
J. Org. Chem. 2000, 65, 4762-4765.  
20 Lassen, K. M., Lee, J. & Joullie, M. M. "Synthetic Studies of Tamandarin B Side 
Chain Analogues." J. Org. Chem. 2010, 75, 3027-3036.  
21 Atherton, E. et al. "Peptide synthesis. Part 3. Comparative solid-phase syntheses of 
human [small beta]-endorphin on polyamide supports using t-butoxycarbonyl and 
fluorenylmethoxycarbonyl protecting groups." J. Chem. Soc., Perkin Trans. 1 1983, 65-
73.  
22 Abdel-Magid, A. F., Carson, K. G., Harris, B. D., Maryanoff, C. A. & Shah, R. D. 
"Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. 
Studies on Direct and Indirect Reductive Amination Procedures." J. Org. Chem. 1996, 61, 
3849-3862.  
23 Reed, P. E. & Katzenellenbogen, J. A. "Synthesis of proline-valine pseudodipeptide 
enol lactones, serine protease inhibitors." J. Org. Chem. 1991, 56, 2624-2634.  
 
 
 
 
 
 
 
 
 
! 82 
2.7) Appendix A. Nuclear Magnetic Resonance and Infrared Spectra Relevant to 
Chapter 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 83 
 
 
 
 
 
 93 
 
N
O
O
Bn
O
N
H
Bo
c
Fi
gu
re
 1
: 1
H
 N
M
R
 (C
D
C
l 3
, 5
00
 M
H
z)
 o
f 1
3.
 
Fi
gu
re
 1
: 1
H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 1
0  
 
! 84 
 
 
 
  94 
 
N
O
O
Bn
O
N
H
Bo
c
Fi
gu
re
 2
: 1
3 C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 
13
. 
 
Fi
gu
re
 2
: 1
3 C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 1
0  
 
! 85 
 
 
 
 
 95 
 
N
O
O
Bn
O
N
H
Bo
c
Fi
gu
re
 3
: I
nf
ra
re
d 
Sp
ec
tr
a 
(n
ea
t)
 o
f 
9.
 
Fi
gu
re
 3
: I
nf
ra
re
d 
sp
ec
tra
 (n
ea
t) 
of
 1
0  
 
! 86 
 
 
 
 
  96 
 
N
O
O
Bn
O
N
H
O
O
H
Fi
gu
re
 4
: 1
H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 
9.
 
 
Fi
gu
re
 4
: 1
H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 8
 
 
! 87 
 
 
 
 
 
  97 
 
N
O
O
Bn
O
N
H
O
O
H
Fi
gu
re
 5
: 1
3 C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 9
. 
  
Fi
gu
re
 5
: 1
3 C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 8
 
 
! 88 
 
 98 
 
N
O
O
Bn
O
NH
O
O
H
Fi
gu
re
 6
: I
nf
ra
re
d 
Sp
ec
tra
 (n
ea
t) 
of
 9
. 
 
Fi
gu
re
 6
: I
nf
ra
re
d 
sp
ec
tra
 (n
ea
t) 
of
 8
 
 
! 89 
 
 
 
 
 
 99 
 
N
HB
oc
O
O
M
e
O
Fi
gu
re
 7
: 1
H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 1
7.
 
  
Fi
gu
re
 7
: 1
H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 1
4  
 
! 90 
 
 
 
 
 
 100 
 
N
HB
oc
O
O
M
e
O
Fi
gu
re
 8
: 1
3 C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 
17
. 
    
Fi
gu
re
 8
: 1
3 C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 1
4  
 
! 91 
 
 
 
 
 101 
 
N
HB
oc
O
O
M
e
O
Fi
gu
re
 9
: I
nf
ra
re
d 
Sp
ec
tr
a 
(n
ea
t) 
of
 1
7.
 
   
Fi
gu
re
 9
: I
nf
ra
re
d 
sp
ec
tra
 (n
ea
t) 
of
 1
4  
 
! 92 
 
 
 
 
 
 
 102 
 
N
H
Bo
c
O
M
e
O
O
H
Fi
gu
re
 1
0:
 1
H
 N
M
R
 (
C
D
C
l 3
, 5
00
 M
H
z)
 o
f 
18
. 
    
Fi
gu
re
 1
0:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 1
5  
 
! 93 
 
 
 
 
 
  103 
 
N
HB
oc
O
M
e
O
O
H
Fi
gu
re
 1
1:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 1
8.
 
    
Fi
gu
re
 1
1:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 1
5  
 
! 94 
 
  104 
 
NH
Bo
c
O
M
e
O
O
H
Fi
gu
re
 1
2:
 In
fr
ar
ed
 S
pe
ct
ra
 (n
ea
t) 
of
 1
8.
 
   
Fi
gu
re
 1
2:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 1
5  
 
! 95 
 
 
 
 
 
 
 105 
 
O
O
M
e
NH
Bo
c
O
H
Fi
gu
re
 1
3:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 2
7.
 
    
Fi
gu
re
 1
3:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 2
3  
 
! 96 
 
 
 
 
  106 
 
O
O
M
e
NH
Bo
c
O
H
Fi
gu
re
 1
4:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 2
7.
 
    
Fi
gu
re
 1
4:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 2
3  
 
! 97 
 
 
 
 
  107 
 
O
O
M
e
NH
Bo
c
O
H
Fi
gu
re
 1
5:
 In
fr
ar
ed
 S
pe
ct
ra
 (n
ea
t) 
of
 2
7.
 
   
Fi
gu
re
 1
5:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 2
3  
 
! 98 
 
 
 
  108 
 
O
M
e NC
bzO
O
NH
Bo
c
O
O
M
e
Fi
gu
re
 1
6:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 2
6.
 
    
Fi
gu
re
 1
6:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 2
4  
 
! 99 
 
 
 
 
 
 109 
 
O
M
e NC
bzO
O
NH
Bo
c
O
O
M
e
Fi
gu
re
 1
7:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 2
6.
 
    
Fi
gu
re
 1
7:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 2
4  
 
! 100 
 
 
 
 
  110 
 
O
M
e N
Cb
z
O
O
NH
Bo
c
O
O
M
e
Fi
gu
re
 1
8:
 In
fr
ar
ed
 S
pe
ct
ra
 (n
ea
t) 
of
 2
6.
 
   
Fi
gu
re
 1
8:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 2
4  
 
! 101 
 
 
 
 
 
 111 
 
OM
e
O
O
Bo
cN
Fi
gu
re
 1
9:
 1 H
 N
M
R 
(C
D
Cl
3, 
50
0 
M
H
z)
 o
f 3
2.
 
    
Fi
gu
re
 1
9:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 2
7  
 
! 102 
 
 
 
 112 
 
O
M
e
O
O
Bo
cN
Fi
gu
re
 2
0:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 3
2.
 
    
Fi
gu
re
 2
0:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 2
7  
 
! 103 
 
 
 
 113 
 
O
M
e
O
O
Bo
cN
Fi
gu
re
 2
1:
 In
fr
ar
ed
 S
pe
ct
ra
 (n
ea
t) 
of
  3
2.
 
   
Fi
gu
re
 2
1:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 2
7  
 
! 104 
 
 
 
 
 
 114 
 
O
Bn
O
O
N
H
O
O
O
O
N
Bo
c
Fi
gu
re
 2
2:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 3
3.
 
    
Fi
gu
re
 2
2:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 2
9  
 
N
O
B
n
O O
N
H
O
O
O
O
N
B
oc
! 105 
 
 
 
 
 
  115 
 
O
Bn
O
O
N
H
O
O
O
O
N
Bo
c Fi
gu
re
 2
3:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 3
3.
 
    
Fi
gu
re
 2
3:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 2
9  
 
N
O
B
n
O O
N
H
O
O
O
O
N
B
oc
! 106 
 
 
 116 
 
O
Bn
O
O
N
H
O
O
O
O
N
Bo
c
Fi
gu
re
 2
4:
 In
fr
ar
ed
 S
pe
ct
ra
 (n
ea
t) 
of
  3
3.
 
   Fi
gu
re
 2
4:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 2
9  
 
N
O
B
n
O O
N
H
O
O
O
O
N
B
oc
! 107 
 
 
 
 
 
 117 
 
O
Bn
O
O
NH
O
O
O
O
HHNO
NH
Bo
c
O
O
Cb
zN
O
M
e
Fi
gu
re
 2
5:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 8
. 
    
Fi
gu
re
 2
5:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 5
 
 
O
N
H
O
O
O
HH
N
O
N
O
O
B
n
O
O
N
H
B
oc
O
C
bz
N
O
M
e
! 108 
 
 
 
 
 
 
 
 118 
 
O
Bn
O
O
NH
O
O
O
O
HHNO
NH
Bo
c
O
O
Cb
zN
O
M
e
Fi
gu
re
 2
6:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 
8.
 
    
Fi
gu
re
 2
6:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 5
 
 
O
N
H
O
O
O
HH
N
O
N
O
O
B
n
O
O
N
H
B
oc
O
C
bz
N
O
M
e
! 109 
 
Fi
gu
re
 2
7:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 5
 
 O
N
H
O
O
O
HH
N
O
N
O
O
Bn
O
O
N
H
Bo
c
O
C
bz
N
O
M
e
! 110 
 
 
 
 
 
 120 
 
O
N
H
O
O
O
HH
N
ON
H
B
oc
O
ON
O
M
e
O
N
O
Fi
gu
re
 2
8:
 1 H
 N
M
R
 (C
D
C
l 3
, 5
00
 M
H
z)
 o
f 2
. 
 
Fi
gu
re
 2
8:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 1
 
 
! 111 
 
 
 
 
 
 
 121 
 
O
N
H
O
O
O
HH
N
ON
H
Bo
c
O
ON
O
M
e
O
N
O
Fi
gu
re
 2
9:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 
2.
 
 
Fi
gu
re
 2
9:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 1
 
 
! 112 
 
 
 
 
 
 122 
 
O
N
H
O
O
O
HH
N
ON
H
B
oc
O
ON
O
M
e
O
N
O
Fi
gu
re
 3
0:
 I
nf
ra
re
d 
Sp
ec
tr
a 
(n
ea
t)
 o
f 
2.
 
 
Fi
gu
re
 3
0:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 1
 
 
! 113 
 
 
 
 
 
 
 123 
 
O
O
Bn
NH
Bo
c
Fi
gu
re
 3
1:
 1 H
 N
M
R 
(C
D
Cl
3, 
50
0 
M
H
z)
 o
f B
oc
-L
eu
-O
Bn
. 
 Fi
gu
re
 3
1:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 4
6  
 
! 114 
 
 
 
 
 
 124 
 
O
O
Bn
N
H
Bo
c
Fi
gu
re
 3
2:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f B
oc
-L
eu
-
O
B
n.
 
 
Fi
gu
re
 3
2:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 4
6  
 
! 115 
 
 
 
 
 125 
  
O
O
Bn
NH
Bo
c
Fi
gu
re
 3
3:
 In
fr
ar
ed
 S
pe
ct
ra
 (n
ea
t) 
of
 B
oc
-L
eu
-O
B
n.
 
 
Fi
gu
re
 3
3:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 4
6  
 
! 116 
 
 
 
 
 
 126 
 
O
O
Bn
NB
oc
Fi
gu
re
 3
4:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 5
2.
 
 
Fi
gu
re
 3
4:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 4
7  
 
! 117 
 
 
 
 
  127 
 
O
O
Bn
NB
oc
Fi
gu
re
 3
5:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 5
2.
 
 
Fi
gu
re
 3
5:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 4
7  
 
! 118 
 
 
 
 
 128 
 
O
O
Bn
N
Bo
c
Fi
gu
re
 3
6:
 I
nf
ra
re
d 
Sp
ec
tr
a 
(n
ea
t)
 o
f 
52
. 
 
Fi
gu
re
 3
6:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 4
7  
 
! 119 
 
 
 
 
 
 
 
 129 
 
O
Bn
O
N
O
Bo
c
N
Fi
gu
re
 3
7:
 1 H
 N
M
R 
(C
D
Cl
3, 
50
0 
M
H
z)
 o
f 5
3.
 
 
Fi
gu
re
 3
7:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 3
5  
 
! 120 
 
 
 
  130 
 
O
Bn
O
N
O
Bo
c
N
Fi
gu
re
 3
8:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 5
3.
 
 
Fi
gu
re
 3
8:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 3
5  
 
! 121 
 
 
 
 
 131 
 
O
Bn
O
N
O
Bo
c
N
Fi
gu
re
 3
9:
 In
fr
ar
ed
 S
pe
ct
ra
 (n
ea
t) 
of
 5
3.
 
 F
ig
ur
e 
39
: I
nf
ra
re
d 
sp
ec
tra
 (n
ea
t) 
of
 3
5  
 
! 122 
 
 
 
 
 
 
 132 
 
O
Bn
O
N
O
N
O
O
H
Fi
gu
re
 4
0:
 1 H
 N
M
R 
(C
D
Cl
3, 
50
0 
M
H
z)
 o
f 4
1.
 
 
Fi
gu
re
 4
0:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 3
6  
 
! 123 
 
 
 
 
 
 
 133 
 
O
Bn
O
N
O
N
O
O
H
Fi
gu
re
 4
1:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 4
1.
 
 
Fi
gu
re
 4
1:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 3
6  
 
! 124 
 
 
 
 
 
 134 
 
O
Bn
O
N
O
N
O
O
H
Fi
gu
re
 4
2:
 In
fr
ar
ed
 S
pe
ct
ra
 (n
ea
t) 
of
 4
1.
 
 
Fi
gu
re
 4
2:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 3
6  
 
! 125 
 
 
 
 
 
 135 
 
O
Bn
O
N
O
N
O
O
Fi
gu
re
 4
3:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f o
xi
di
ze
d 
41
. 
 Fi
gu
re
 4
3:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 4
8  
 
! 126 
 
 
 
 
 
  136 
 
O
Bn
O
N
O
N
O
O
Fi
gu
re
 4
4:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f o
xi
di
ze
d 
41
. 
 
Fi
gu
re
 4
4:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 4
8  
 
! 127 
 
 
 
 
 
 
 137 
 
O
Bn
O
N
O
N
O
O
Fi
gu
re
 4
5:
 In
fr
ar
ed
 S
pe
ct
ra
 (n
ea
t) 
of
 o
xi
di
ze
d 
41
. 
 
Fi
gu
re
 4
5:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 4
8  
 
! 128 
 
 
 
 
 
 
 
 
 
 
 138 
 
O
N
H
O
O
O
HH
N
OH N
O
ON
O
M
e
O
N
O
O
N
O
N
O
O
Fi
gu
re
 4
6:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 3
5.
 
 
Fi
gu
re
 4
6:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 3
0  
 
! 129 
 
 
 
 
 
 
 139 
 
O
N
H
O
O
O
HH
N
OH N
O
ON
O
M
e
O
N
O
O
N
O
N
O
O
Fi
gu
re
 4
7:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 3
5.
 
 
Fi
gu
re
 4
7:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 3
0  
 
! 130 
 
 
 
 
 
 
 
 140 
 
O
N
H
O
O
O
HH
N
OH N
O
ON
O
M
e
O
N
O
O
N
O
N
O
O
Fi
gu
re
 4
8:
 I
nf
ra
re
d 
Sp
ec
tr
a 
(n
ea
t)
 o
f 
35
. 
 
Fi
gu
re
 4
8:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 3
0  
 
! 131 
 
 
 
 
 
 
 
 141 
 
N
N
O
O
O
Bn
O
O
O
NH
Bo
c
NH
Xa
n
O
Fi
gu
re
 4
9:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 4
2.
 
 Fi
gu
re
 4
9:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 3
8  
 
! 132 
 
 
 
 142 
 
N
N
O
O
O
Bn
O
O
O
NH
Bo
c
NH
Xa
n
O
Fi
gu
re
 5
0:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 4
2.
 
 
Fi
gu
re
 5
0:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 3
8  
 
! 133 
 
 
 
 143 
 
N
N
O
O
O
Bn
O
O
O
NH
Bo
c
NH
Xa
n
O
Fi
gu
re
 5
1:
 In
fr
ar
ed
 S
pe
ct
ra
 (n
ea
t) 
of
 4
2.
 
 Fi
gu
re
 5
1:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 3
8  
 
! 134 
 
 
 
 
 
 
 
 
 144 
 
N
N
O
O
O
Bn
O
O
O
H NNH
2
O
O
N Cb
z
O
Fi
gu
re
 5
2:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 4
3.
 
 Fi
gu
re
 5
2:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 3
9  
 
! 135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fi
gu
re
 5
3:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 3
9  
 
! 136 
 
 
 
 
 
 
 
 146 
 
N
N
O
O
O
Bn
O
O
O
H NNH
2
O
O
N Cb
z
O
Fi
gu
re
 5
4:
 In
fr
ar
ed
 S
pe
ct
ra
 (n
ea
t) 
of
 4
3.
 
 
Fi
gu
re
 5
4:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 3
9  
 
! 137 
 
 
 
 
 
 
 
 
 
 147 
 
O
N
O
N
O
O
OO
N
H
2
N HO
H
N
O
O
N
H
O
O
O
HH
N
OH N
O
ON
O
M
e
O
N
O
Fi
gu
re
 5
5:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 3
4.
 
 
Fi
gu
re
 5
5:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 3
1  
 
! 138 
 
 
 
 
 
 
 
 
 
 148 
 
O
N
O
N
O
O
OO
N
H
2
N HO
H
N
O
O
N
H
O
O
O
HH
N
OH N
O
ON
O
M
e
O
N
O
Fi
gu
re
 5
6:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 3
4.
 
 
Fi
gu
re
 5
6:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 3
1  
 
! 139 
 
 
 
 
 
 
 
 149 
 
O
N
O
N
O
O
OO
N
H
2
N HO
H
N
O
O
N
H
O
O
O
HH
N
OH N
O
ON
O
M
e
O
N
O
Fi
gu
re
 5
7:
 In
fr
ar
ed
 S
pe
ct
ra
 (n
ea
t) 
of
 3
4.
 
 
Fi
gu
re
 5
7:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 3
1  
 
! 140 
 
 
 
 
 
 150 
 
B
nO
O
N
B
oc
N
Fi
gu
re
 5
8:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 4
6.
 
 F
ig
ur
e 
58
: 1
H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 4
2  
 
! 141 
 
 
 
 
 
 
 
 151 
 
B
nO
O
N
B
oc
N Fi
gu
re
 5
9:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 4
6.
 
 
Fi
gu
re
 5
9:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 4
2  
 
! 142 
 
 
 
 
 
 152 
 
B
nO
O
N
B
oc
N
Fi
gu
re
 6
0:
 I
nf
ra
re
d 
Sp
ec
tr
a 
(n
ea
t)
 o
f 
46
. 
 Fi
gu
re
 6
0:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 4
2  
 
! 143 
 
 
 
 
 
 153 
 
B
nO
O
N
N
O
O
H
Fi
gu
re
 6
1:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 4
7.
 
 Fi
gu
re
 6
1:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 4
4  
 
! 144 
 
 
 
 
 
  154 
 
B
nO
O
N
N
O
O
H Fi
gu
re
 6
2:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 4
7.
 
 
Fi
gu
re
 6
2:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 4
4  
 
! 145 
 
 
 
 
 
 
 
 155 
 
B
nO
O
N
N
O
O
H
Fi
gu
re
 6
3:
 I
nf
ra
re
d 
Sp
ec
tr
a 
(n
ea
t)
 o
f 
47
. 
 
Fi
gu
re
 6
3:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 4
4  
 
! 146 
 
 
 
 
 
 
 
 156 
 
O
N
H
O
O
O
HH
N
OH N
O
ON
O
M
e
O
N
O
O
N
N
O
O
H
Fi
gu
re
 6
4:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 3
6.
 
 
Fi
gu
re
 6
4:
 1 H
 N
M
R
 (C
D
C
l 3,
 5
00
 M
H
z)
 o
f 3
2  
 
! 147 
 
 
 
 
 
 
 157 
 
O
N
H
O
O
O
HH
N
OH N
O
ON
O
M
e
O
N
O
O
N
N
O
O
H
Fi
gu
re
 6
5:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 3
6.
 
 
Fi
gu
re
 6
5:
 13
C
 N
M
R
 (C
D
C
l 3,
 1
25
 M
H
z)
 o
f 3
2  
 
! 148 
 
 158 
 
O
N
H
O
O
O
HH
N
OH N
O
ON
O
M
e
O
N
O
O
N
N
O
O
H
Fi
gu
re
 6
6:
 I
nf
ra
re
d 
Sp
ec
tr
a 
(n
ea
t)
 o
f 
36
. 
 
Fi
gu
re
 6
6:
 In
fr
ar
ed
 sp
ec
tra
 (n
ea
t) 
of
 3
2  
 
! 149 
Chapter 3: Synthesis of 3-piperidinone and 3-azepinone derivatives via 
ring-opening of azabicyclic [3.1.0]-and [4.1.0]aminocyclopropanes 
 
 
3.1) Synthesis of [3.1.0]-and [4.1.0]azabicycles via intramolecular Kulinkovich 
cyclopropanation of amino acid derivatives 
 
Since its discovery, the Kulinkovich reaction1 has been generally utilized to access a 
number of biologically and structurally interesting cyclopropanols and 
aminocyclopropanes from simple starting materials. The original Kulinkovich protocol1 
provided means to obtain hydroxycyclopropanes. This protocol was further expanded by 
de Meijere and coworkers to provide N,N-dialkylcyclopropylamines from N,N-
dialkylamides.2 Subsequent discovery of the ligand exchange for the generation of 
various substituted titanacyclopropane intermediates3 further improved the methodology 
and expanded the scope of the reaction.4 Reports of intramolecular cyclopropanations 
were then reported by Sato and Cha.5 More specifically, Cha and coworkers investigated 
intramolecular cyclopropanation of ω-vinyl esters as well as ω-vinyl amides.5d 
Accordingly, Joullié6 and de Meijere7 also utilized intramolecular Kulinkovich reaction 
to access various bicyclic aminocyclopropanes.    
In their synthesis of bicyclic N,N-dimethylcyclopropylamines, Joullié and coworkers 
utilized intermediates that were made from proteinogenic amino acids, such as 
phenylalanine, tyrosine, and tryptophan.6a The proposed mechanism is as follows.6a 
Reaction of ClTi(OiPr)3 with 2 equivalents of cyclopentylmagnesium chloride affords 
titanacyclopropane intermediate 4 (Scheme 3.1). Subsequent olefin exchange with allyl 
compound 1 leads to titanacyclopropane intermediate 5 and 7. The following step, 5 to 6 
! 150 
and 7 to 8 involves position-selective expansion of the titanacyclopropane ring by 
insertion of the amide carbonyl moiety between Ti and the more substituted carbon. The 
most favorable conformation (5) has the α-substituent of the amide group in a β-position 
and anti to the hydrogen of the most substituted carbon of the titanacyclopropane. This 
carbon retains its stereochemical integrity in the corresponding bicyclic intermediate (6). 
Conversion of 6 to major product 2 occurs with retention of configuration of the carbon 
carrying the dimethylamino group. The final conversion to the desired 
aminocyclopropane rather than the cyclopropanol could be explained by the oxophilicity 
of titanium and the poor leaving group properties of the amine.  
 
Scheme 3.1. Proposed mechanism and diastereoselectivity of products. 
 
Starting materials for the intramolecular Kulinkovich reaction were generated by amino 
acids (Scheme 3.2).6a An aromatic amino acid (9) was converted to the corresponding 
methyl ester, which then underwent reductive amination with benzaldehyde and sodium 
borohydride triacetate to afford the secondary amine 10. Subsequent allylation followed 
by aminolysis of the methyl ester furnished the amide 1, which was then treated under 
intramolecular aminocyclopropanation reaction to afford two diastereomeric bicyclic 
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compounds, 2 and 3 in isolated yields ranging from 78-83%. The diastereomeric ratio 
obtained was approximately 3:1 for all amino acid variants.  
 
Scheme 3.2. General synthetic scheme to generate azabicyclic [3.1.0]aminocyclopropanes. 
 
The absolute configuration of one of the major bicyclic compounds was determined by 
X-Ray analysis.6a Using a similar synthetic approach, [4.1.0] bicyclic systems were also 
made from phenylalanine and protected serine (Scheme 3.3).6b Homoallylation of 11 
using Grieco’s procedure 8  followed by aminolysis of the methyl ester afforded 
corresponding N-homoallylated products (12). Intramolecular aminocyclopropanation 
reaction of 12 furnished the desired [4.1.0] adducts 13 and 14 in greater 
diastereoselectivity (9:1) compared to [3.1.0] systems. The corresponding yields for this 
step were also acceptable (61-74%). 
 
Scheme 3.3. General synthetic scheme to generate azabicyclic [4.1.0]aminocyclopropanes. 
 
3.2) Ring-opening of bicyclic [3.1.0]-and [4.1.0]aminocyclopropanes  
 
Generally, ring-opening of cyclopropanols is a relatively facile process compared to ring-
opening of tertiary aminocyclopropanes, 9  which requires high temperatures, 10 
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photooxidative, or aerobic oxidative conditions.11 In 1973, in their pursuit of exploring 
aminocyclopropanes as synthetic homologues of enamines, Kuehne observed that unlike 
alkoxycyclopropanes, aminocyclopropanes are resistant to ring-opening under strongly 
acidic and basic conditions.10 However, heating the bicyclic [3.1.0]- or 
[4.1.0]aminocyclopropanes at high temperatures in aqueous methanol in a sealed tube 
afforded the desired ring-opened ketones (Scheme 3.4). 
 
Scheme 3.4. Kuehne’s thermolysis/hydrolysis ring-opening conditions. 
 
The direction of cyclopropane ring-opening was found to favor protonation at the least 
substituted carbon, resulting predominantly in methylation rather than ring-expanded 
product (Scheme 3.4).10 The relative increase in the ring-expanded product for bicyclic 
[3.1.0]aminocyclopropane relative to [4.1.0]-system could be attributed to more 
thermodynamically favorable release of ring strain. Efforts toward lowering the 
activation temperature for this reaction was also investigated by using 10% Pd/C as the 
adsorbing surface agent under refluxing aqueous methanol conditions. Interestingly, 
although the reaction time increased (1-2 days), Kuehne observed increased formation of 
ring-opened products, while almost completely suppressing the formation of ring-
expanded products. For bicyclic [3.1.0]aminocyclopropane system, no ring-expanded 
product was observed, while as for [4.1.0]-system, only 3% of the ring-expanded product 
was formed.10  
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In 1997, photosensitized oxidative ring-opening of tertiary aminocyclopropanes were 
reported by Cha and coworkers.11a They envisioned applying the well-known, rapid 
rearrangement of cyclopropylcarbinyl radical to homoallyl radical on tertiary 
cyclopropylamines to obtain the corresponding cyclopropylamine cation radical. This 
process is known in the literature for cyclopropanol and cyclopropylthiols. Furthermore, 
analogous ring opening of cyclopropylamine radical cation has been implicated in the 
inactivation of cytochrome P-450 and monoamine oxidase by enzymatic oxidation of 
cyclopropylamines, establishing the potential of using aminium radicals for the ring-
opening process.11a Tertiary amines have been widely utilized as efficient electron donors 
in electron transfer processes with excited states of various organic substrates due to their 
low ionization and oxidation potentials. Therefore, the photoinduced one-electron 
oxidation allows a convenient method for generating an amine radical cation. Cha and 
coworkers observed 1,4-dicyanobenzene (DCB) photosensitized oxidation of 
cyclopropylamine in degassed solution of 10:1 MeCN/MeOH containing K2CO3 by 
irradiation (254 or 300 nm) to give the corresponding ketone in good yield (Scheme 
3.5).11a 
 
Scheme 3.5. Ring-opening under photosensitized oxidative conditions. 
 
Although this methodology worked well for various monocyclic tertiary amines, 
application to bicyclic [4.1.0]aminocyclopropanes was unsuccessful. Addition of 
Cu(OAc)2 provided the desired ring-opened product, albeit in low starting material 
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O
! 154 
conversion.11a The proposed mechanism of this reaction is shown in Scheme 3.6. Initial 
formation of the tertiary aminium radical occurs by photoinduced electron transfer from 
the tertiary amine to DCB. The amine radical cation then undergoes either decay by back 
electron transfer or ring-opening to generate the β-iminium carbon radical. Subsequent 
hydrogen atom abstraction followed by aqueous workup affords the observed ring-
opened ketone.11a The source of the H-atom for the abstraction process was proven by 
deuterium studies.  
 
Scheme 3.6. Proposed mechanism for photosensitized oxidative ring-opening. 
 
Cha and coworkers then developed a stereocontrolled synthesis of bicyclo[5.3.0]decan-3-
ones, employing intramolecular Kulinkovich cyclopropanation of olefin-tethered amides 
followed by a tandem ring-expansion-cyclization sequence of the resulting bicyclic 
aminocyclopropanes by aerobic oxidation.11b As an extension to their previous study, 
they utilized p-anisidine as one of the substituents on the amine of the bicyclic 
[4.1.0]aminocyclopropane system in the hopes of lowering the amine oxidation potential. 
The lower potential was confirmed via cyclic voltammetry (CV). Their rationale was that 
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by lowering the oxidative potential, the formation of the tertiary aminium radical would 
be more facile. Surprisingly, they observed their intramolecular Kulinkovich adduct (15) 
to undergo oxidative ring-opening during silica gel column chromatography (Scheme 
3.7). Since molecular oxygen was the only oxidant present, they examined the use of 
silica gel and fluorocarbon solvents which are known to possess high solubility of 
oxygen.11b Silica gel was indeed found to be an important component, as the cyclization 
took 3 days in the absence of silica gel in acetonitrile as opposed to 1 day. As expected, 
use of fluorinated solvent accelerated the reaction in the presence of silica gel to 1 h. 
 
Scheme 3.7. Synthesis of bicyclo[5.3.0]decan-3-one by aerobic oxidation of cyclopropylamines. 
 
Particularly noteworthy is the good diastereoselectivity (17:1) for 17 (as 1:1 epimers at 
the hydroxyl stereocenter following reduction with triethyl phosphite).11b Also, when N-
phenyl derivative instead of N-p-anisidine derivative (15) was used under identical 
reaction conditions, it was found to be completely unreactive. Therefore, the presence of 
N-p-anisidine moiety is crucial to this methodology. The proposed mechanism is as 
follows (Scheme 3.8). Initial formation of the tertiary aminium radical A and superoxide 
occurs via one-electron oxidation with molecular oxygen. Subsequent ring cleavage 
generates the ring-expanded β-immonium carbon radical B, which then undergoes 5-
hexenyl cyclization to afford C. The observed stereochemistry involving the trans-fused 
ring junction and the cis-side chain is believed to arise from the chair-like conformation 
having the alkenyl side chain equatorial.11b Finally, trapping of the resultant radical by 
N
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oxygen affords the peroxy radical D as a 1:1 epimeric mixture. Although the precise 
mechanistic pathway for the last step is unknown, an electron transfer between the peroxy 
radical D and tertiary amine 15 could be involved as the chain propagation step. 
Alternatively, the hydroperoxide could be formed by an electron transfer with 
superoxide.11b Aqueous workup furnishes the desired ketone 16 (Scheme 3.8).11b 
 
Scheme 3.8. Proposed mechanism for the synthesis of bicyclo[5.3.0]decan-3-one by  
aerobic oxidation of cyclopropylamines. 
 
3.3) Ring-opening of azabicyclic [3.1.0]-and [4.1.0]aminocyclopropanes 
 
Ring-opening of azabicyclic [3.1.0]-and [4.1.0]aminocyclopropanes affords 3-
piperidinone and 3-azepinone derivatives respectively (Figure 3.1). Both piperidinones 
and azepinones are well-known in the literature for being biologically important motifs. 
More specifically, piperidinones are often used as intermediates in organic synthesis,12 
and azepinone moieties are found in pharmaceutically and biologically important 
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compounds.13 Furthermore, azepinones are often synthetically challenging compounds 
due to their nitrogen-containing seven-membered ring.14 
 
Figure 3.1. Ring-opening of azabicyclic [3.1.0]-and [4.1.0]aminocyclopropanes. 
 
Based on known literature precedence,10,11 we began our studies by testing traditional 
(i.e., SiO2 and FeCl3, pyridine, DMF) oxidative ring-opening of the strained 
aminocyclopropanes, which only resulted in decomposition of starting material. 15 
Furthermore, following Cha’s work,11b N-p-anisidine derivative was synthesized and 
employed under oxidative conditions, but these conditions also resulted in decomposition 
(Figure 3.2).15 
 
Figure 3.2. Failed ring-opening attempt under oxidative conditions. 
 
Hence, a different approach was considered based on the work of Schulte-Wülwer and 
coworkers. 16  We envisioned that formation of the highly reactive N-
chloroaminocyclopropane derivative followed by reaction with CuCl could induce a 
nitrogen radical formation/cleavage event (Scheme 3.9).17 
 
Scheme 3.9. CuCl approach to radical-induced cleavage of cyclopropylamines. 
 
When previously synthesized phenylalanine aminocyclopropane6 was employed in the 
proposed methodology, the desired selective monodeprotection of the N-
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methylbenzylamine and subsequent chlorination were unsuccessful. More specifically, 
traditionally palladium-catalyzed hydrogenolysis displayed poor selectivity over the two 
secondary amines, and the subsequent chlorination product was highly unstable upon 
isolation. Therefore, in order to establish orthogonality within the route, the cyclic amine 
was protected as its benzenesulfonamide (Scheme 3.10).17 
 
Scheme 3.10. Pd/C catalyzed hydrogenolysis/fragmentation. 
 
Synthesis of azabicyclic [3.1.0]aminocyclopropane sulfonamide (18) was accomplished 
using previously reported methods6 with minor changes in amine protecting group. We 
then turned our attention to hydrogenolysis of the benzylamine in order to proceed with 
N-chlorination. Although palladium-on-carbon catalyzed hydrogenolysis of benzylamines 
is generally known to be slow compared to hydrogenolysis of benzyl ethers, this process 
could be expedited in the presence of a protic acid.17 Therefore, 18 was treated with 10% 
Pd/C in the presence of formic acid under an atmosphere of hydrogen. Surprisingly, 
instead of affording the debenzylated product (19), the ring-opened product (20) was 
obtained in synthetically useful yield (Scheme 3.10). The ring-opening presumably 
occurs via debenzylation followed by protonation of the cyclopropane ring followed by 
hydrolysis of the intermediate imine to the ketone.17 
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Next, we synthesized a variety of azabicyclic [3.1.0]- and [4.1.0]aminocyclopropanes 
using a modified procedure to test the scope of the reaction (Scheme 3.11). 
 
Scheme 3.11. Synthesis of azabicyclic [3.1.0]- and [4.1.0]aminocyclopropane derivatives. 
 
The syntheses of allylsulfonamides (n = 1) 25, 27, 29, and 31 proceeded in good yields, 
where as the corresponding homoallylsulfonamides (n = 2) were found to be less reactive 
under the same reaction conditions due to the reduced nucleophilicity of the sulfonamide 
nitrogen and resulted in lower yields.17 Other homoallylation conditions were explored 
with various bases such as n-BuLi, LiHMDS, and NaH, but they resulted solely in the 
recovery of starting material. Reductive alkylation with allyltributylstannane6b also only 
afforded starting material, even after prolonged reaction times. Saponification of the 
methyl ester followed by BOPCl mediated coupling of the acid and N-
methylbenzylamine afforded 33-40 in good yields considering this difficult coupling. 
Finally, exposure of the allylsulfonamide or homoallylsulfonamide under previously 
established6 intramolecular Kulinkovich conditions furnished the corresponding 
aminocyclopropanes in moderate to good yields. It is important to note that for certain 
OMe
O
NH2
R
1) C6H5SO2Cl, Et3N,
CH2Cl2
2) Allyl bromide, Cs2CO3,
DMF or 4-bromobutene, 
Cs2CO3, DMF, 60 oC
OMe
O
N
R
O2S n
1) LiOH, THF:H2O:MeOH
2) N-Methylbenzylamine,
BOPCl, N,N '-iPr2NH, CH2Cl2
NBn
O
N
R
O2S n
ClTi(OiPr)3,
c-HexMgCl, THF N
NBn
R
Me
O2S n
21 = R = Ph
22 = R = Tyr-OBn
23 = R = 1-Me-Tryp
24 = R = Leu
25 = R = Ph, n = 1 (94%)
26 = R = Ph, n = 2 (63%)
27 = R = Tyr-OBn, n = 1 (75%)
28 = R = Tyr-OBn, n = 2 (57%)
29 = R = 1-Me-Tryp, n = 1 (95%)
30 = R = 1-Me-Tryp, n = 2 (76%)
31 = R = Leu, n = 1 (96%)
32 = R = Leu, n = 2 (74%)
33 = R = Ph, n = 1 (90%)
34 = R = Ph, n = 2 (96%)
35 = R = Tyr-OBn, n = 1 (65%)
36 = R = Tyr-OBn, n = 2 (58%)
37 = R = 1-Me-Tryp, n = 1 (89%)
38 = R = 1-Me-Tryp, n = 2 (95%)
39 = R = Leu, n = 1 (86%)
40 = R = Leu, n = 2 (87%)
18 = R = Ph, n = 1 (33%)
41 = R = Ph, n = 2 (51%)
42 = R = Tyr-OBn, n = 1 (65%)
43 = R = Tyr-OBn, n = 2 (69%)
44 = R = 1-Me-Tryp, n = 1 (30%)
45 = R = 1-Me-Tryp, n = 2 (95%)
46 = R = Leu, n = 1 (56%)
47 = R = Leu, n = 2 (68%)
! 160 
homoallylsulfonamide substrates, it was necessary to replace ClTi(OiPr)3 with 
MeTi(OiPr)3 to obtain the desired product, since the former resulted in no reaction.7c The 
general decrease in yield observed for the synthesis of azabicyclic [3.1.0] ring system 
compared to that of [4.1.0] system could be attributed to increase in ring strain of five-
membered compared to six-membered ring formations.17  
 
With the various Kulinkovich adducts in hand, the scope of the ring-opening reaction was 
investigated. Exposure of the aminocyclopropanes to 10% Pd/C and catalytic amount of 
formic acid (88% solution) afforded the corresponding 3-piperidinone and 3-azepinone 
derivatives in satisfactory yields (Table 3.1).17 
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Table 3.1. Scope of ring-opening reactions of azabicyclic [3.1.0]- and 
[4.1.0]aminocyclopropanes. 
 
 
The presence of catalytic amounts of both palladium and formic acid proved to be 
essential for the reaction (Table 3.1). For instance, subjecting the cyclopropylamine to a 
solution of formic acid resulted in recovery of starting material, proving the need for 
palladium (entry 10, Table 3.1). Alternatively, when the cyclopropylamine was subjected 
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 1                  0.1                   neat                     no reactiond11
or N
O
R
O2S
if n = 1 if n = 2 48 = R = Ph, n = 1
49 = R = Ph, n = 2
50 = R = Tyr, n = 1 
51 = R = Tyr, n = 2 
52 = R = 1-Me-Tryp, n = 1 
53 = R = 1-Me-Tryp, n = 2 
54 = R = Leu, n = 1 
55 = R = Leu, n = 2
a Silica gel chromatography yields
b Benzyl ether moiety of tyrosine transformed to afford the corresponding alcohol under the reaction conditions
c Reaction time was prolonged to 48h
d Recovery of starting material
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under a hydrogen atmosphere with catalytic amount of palladium in the absence of 
formic acid, only insignificant amount of debenzylated amine was obtained over 
prolonged reaction time (entry 9, Table 3.1). Moreover, the importance of catalytic 
addition of formic acid was evident when the cyclopropylamine was exposed under a 
hydrogen atmosphere with catalytic amount of palladium in neat formic acid (entry 11, 
Table 3.1). Overall, the ring-opening methodology on various azabicyclic [3.1.0] and 
[4.1.0] substrates proved to be generally acceptable, whereas in some cases the formation 
of 3-piperidinone is more favorable than 3-azepinone (Table 3.1). This observation could 
be attributed to the well-accepted fact that six-membered ring formations are more 
favorable than seven-membered ring formations.17 More specifically, 3-azepinone 
formations of structurally more complex tryptophan and leucine derivatives (entries 6 and 
8, Table 3.1) resulted in lower yields in comparison to the respective formations of 3-
piperidinone (entries 5 and 7, Table 3.1).  
 
3.4) Conclusions 
 
Though there have been reports18,19 of ring-opening of monocyclic aminocyclopropanes 
under catalytic hydrogenolysis conditions in the literature, ring-opening of corresponding 
azabicylic aminocyclopropanes under the same conditions was known to be synthetically 
challenging. To the best of our knowledge, no ring-opening reactions of azabicylic 
aminocyclopropanes have been reported under the conditions presented, thus establishing 
novelty in our methodology.17 The optimized reaction condition is rather mild in that it 
does not require heating or the use of harsh oxidants. Furthermore, the use of a 
sulfonamide as a protecting group may also provide interesting antimicrobial activities 
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when coupled with the conformationally constrained Kulinkovich products. These 
interesting substrates could be tested for biological activity in due course.  
 
 
3.5) Experimental results 
 
General Methods. All reactions were performed under an argon atmosphere except 
where otherwise noted. Tetrahydrofuran was distilled over sodium-benzophenone, 
dichloromethane was distilled over calcium hydride, DMF in Acroseal bottles were used 
without further purification prior to use. Flash chromatography was carried out on Merck 
silica gel 60 (240-400 mesh) using the solvent conditions listed under individual 
experiments. Analytical thin-layer chromatography was performed on Merck silica gel 
(60F-254) plates (0.25 mm). Visualization was effected with ultraviolet light or 
phosphomolybdic acid (PMA) stain. Proton magnetic resonance spectra (1H NMR) and 
Carbon magnetic resonance spectra (13C NMR) were performed on a Bruker DRX-500 
operating at 500 and 125 MHz respectively. Infrared spectra (IR) were obtained on a 
Perkin-Elmer 281-B spectrometer. High resolution mass spectra (HRMS) were obtained 
on a Micromass Autospec or a Waters LCTOF-Xe premier. Optical rotations were 
measured on a Jasco P-1010 polarimeter. 
 
General methodology of N-allylsulfonamide formation: 
 
 
To a solution of (L)-amino acid methyl ester hydrochloride salt (14 mmol) in 
dichloromethane (0.2 M) was added triethylamine (28 mmol) and benzenesulfonyl 
OMe
O
NH2 . HCl
R
i. C6H5SO2Cl, Et3N,
CH2Cl2
ii. Allyl bromide, Cs2CO3,
DMF
OMe
O
N
R
O2S
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chloride (15.4 mmol).  The solution was stirred until TLC analysis showed the reaction to 
be complete.  The reaction was quenched with H2O (10 mL) and the organics washed 
sequentially with 10% HCl (10 mL), NaHCO3 (20 mL), and brine (20 mL).  The organic 
layer was dried over MgSO4 and reduced in vacuo. The crude material was subjected to 
silica gel flash chromatography to afford the corresponding sulfonamide.  
 
To a solution of sulfonamide (2.3 mmol) in DMF (0.15 M) was added Cs2CO3 (3.5 
mmol), and the resultant mixture stirred for 30 mins. Allyl bromide (4.7 mmol) was 
added in one portion via syringe, and the mixture stirred until TLC analysis indicated 
reaction completion.  The solvent was removed in vacuo and the residue was dissolved in 
EtOAc, washed with H2O (2 x 10 mL) and the organics dried over Na2SO4 and reduced 
in vacuo.  The crude material was subjected to silica gel flash chromatography to yield 
the corresponding allylsulfonamide. 
 
General methodology of N-homoallylsulfonamide formation: 
 
To a solution of sulfonamide (1.7 mmol) in DMF (0.02 M) was added Cs2CO3 (1.7 
mmol), and the resultant mixture stirred at 60 ºC for 30 mins.  To this mixture was added 
4-bromobutene (3.5 mmol) dropwise via syringe, and the mixture stirred for a further 6 
hrs.  After this time the solvent was removed in vacuo and the residue was dissolved in 
EtOAc, washed with H2O (2 x 10 mL) and the organics dried over Na2SO4 and reduced 
in vacuo.  The crude material was subjected to silica gel flash chromatography to yield 
the corresponding homoallylsulfonamide. 
OMe
O
NH
R 4-bromobutene, 
Cs2CO3, DMF, 60 oC
OMe
O
N
R
O2SO2S
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General methodology of (S)-2-(N-allylphenylsulfonamido)-N-benzyl-N-methyl amide 
formation: 
 
The N-allylsulfonamide (1.8 mmol) was dissolved in an equal mixture of THF, MeOH, 
and H2O (0.1 M) and cooled to 0 ºC. To this was added LiOH.H2O (5.4 mmol) and the 
stirred reaction mixture was warmed to room temperature over 3 hrs.  After this time the 
volatiles were reduced in vacuo and the aqueous layer washed with Et2O (10 mL).  The 
aqueous portion was acidified to pH 3 with 10% HCl solution and extracted with EtOAc 
(3 x 30 mL).  The organics were dried over Na2SO4 and reduced in vacuo to provide the 
crude acid, which was carried on without further purification. 
The crude acid (1.4 mmol) was dissolved in CH2Cl2 (0.2 M) and cooled to 0 ºC under an 
argon atmosphere.  To this solution was added N-methylbenzylamine (1.5 mmol), BOPCl 
(1.6 mmol), and Et3N (1.7 mmol). The resultant solution was stirred for 12 hrs and after 
this time diluted with EtOAc (10 mL) and washed with 10% HCl (5 mL), sat. NaHCO3 
(10 mL), and brine (10 mL).  The organics were dried over Na2SO4 and reduced in vacuo 
and the crude material was subjected to silica gel flash chromatography to afford the 
corresponding N-methylamide. 
 
 
 
 
 
 
 
OMe
O
N
R
O2S
i. LiOH, THF:H2O:MeOH
ii. N-Methylbenzylamine,
BOPCl, N,N '-iPr2NH, CH2Cl2
NBn
O
N
R
O2S
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General methodology of (S)-N-benzyl-2-(N-(but-3-en-1-yl)phenylsulfonamido)-N-
methyl amide formation: 
 
The sulfonamide (0.4 mmol) was dissolved in an equal mixture of THF, MeOH, and H2O 
(0.1 M) and cooled to 0 ºC. To this was added LiOH.H2O (1.1 mmol) and the stirred 
reaction mixture was warmed to rt over 3 hrs.  After this time the volatiles were reduced 
in vacuo and the aqueous layer washed with Et2O (10 mL).  The aqueous portion was 
acidified to pH 3 with 10% HCl solution and extracted with EtOAc (3 x 20 mL).  The 
organics were dried over Na2SO4 and reduced in vacuo to provide the crude acid, which 
was carried on without further purification. 
The crude acid (0.2 mmol) was dissolved in CH2Cl2 (0.2 M) and cooled to 0 ºC under an 
argon atmosphere.  To this solution was added N-methylbenzylamine (0.25 mmol), 
BOPCl (0.25 mmol), and Et3N (0.26 mmol). The resultant solution was stirred for 12 hrs 
and after this time diluted with EtOAc (10 mL) and washed with 10% HCl (5 mL), sat. 
NaHCO3 (10 mL), and brine (10 mL).  The organics were dried over Na2SO4 and reduced 
in vacuo and the crude material was subjected to silica gel flash chromatography to afford 
the corresponding N-methylamide. 
 
General methodology of azabicyclic [3.1.0] aminocyclopropane formation: 
 
OMe
O
N
R
O2S
i. LiOH, THF:H2O:MeOH
ii. N-Methylbenzylamine,
BOPCl, N,N '-iPr2NH, CH2Cl2
NBn
O
N
R
O2S
NBn
O
N
R
O2S
ClTi(OiPr)3,
c-HexMgCl, THF N
NBn
R
O2S
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To a solution of the N-methylamide (1.1 mmol) in THF (0.1M) under an argon 
atmosphere was added ClTi(OiPr)3 (1.1 mL, 1M) dropwise via syringe.  To this solution 
was added cyclohexylMgCl or cyclohexylMgBr (2.5 mL, 2M) dropwise via syringe 
pump addition over 1 hr.  The solution gradually changed color from colorless to dark 
yellow and finally black over the course of 3 hrs.  TLC analysis showed reaction 
completion, and the reaction mixture was poured onto ice water (20 mL) and stirred for 
15 mins.  The crude mixture was filtered thorough celite to remove titanium residues, and 
the two layers separated.  The aqueous layer was extracted once with EtOAc (20 mL) and 
the combined organics washed with brine (20 mL) and dried over Na2SO4.  The crude 
mixture was subjected to silica gel flash chromatography to isolate the corresponding 
major diastereomer aminocyclopropane.  
 
General methodology of azabicyclic [4.1.0] aminocyclopropane formation: 
 
To a solution of the N-methylamide (0.3 mmol) in THF (0.05M) under an argon 
atmosphere was added ClTi(OiPr)3 or MeTi(OiPr)3 (1.3 mL, 0.3M) dropwise via syringe.  
To this solution was added cyclohexylMgCl or cyclohexyl MgBr (0.8 mL, 2M) dropwise 
via syringe pump addition over 1 hr.  The solution gradually changed color from 
colorless to dark yellow and finally black over the course of 4 hrs.  TLC analysis showed 
reaction completion, and the reaction mixture was poured onto ice water (20 mL) and 
stirred for 15 mins.  The crude mixture was filtered thorough celite to remove titanium 
residues, and the two layers separated.  The aqueous layer was extracted once with 
NBn
O
N
R
O2S
ClTi(OiPr)3,
c-HexMgCl, THF N
NBn
R
O2S
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EtOAc (20 mL) and the combined organics washed with brine (20 mL) and dried over 
Na2SO4.  The crude mixture was subjected to silica gel flash chromatography to isolate 
the corresponding major diastereomer aminocyclopropane. 
 
General methodology of 3-piperidinone formation: 
 
A solution of aminocyclopropane (21 mg, 38 µmol) in EtOH (0.4 mL, 0.1M) was 
charged with 10% Pd/C (4 mg, 3.8 µmol) and 88% formic acid (14.6 µL, 0.3 µmol) and 
the system purged with H2 three times.  The mixture was stirred for 16-20 hrs at room 
temperature under an atmosphere of H2, after which time the inorganic material was 
removed via filtration and the solvent reduced in vacuo.  The crude material was 
subjected to silica gel flash chromatography to give the corresponding piperidinone. 
 
General methodology of 3-azepinone formation: 
 
A solution of aminocyclopropane (21 mg, 38 µmol) in EtOH (0.4 mL, 0.1M) was 
charged with 10% Pd/C (4 mg, 3.8 µmol) and 88% formic acid (14.6 µL, 0.3 µmol) and 
the system purged with H2 three times.  The mixture was stirred for 16-20 hrs at room 
temperature under an atmosphere of H2, after which time the inorganic material was 
removed via filtration and the solvent reduced in vacuo.  The crude material was 
subjected to silica gel flash chromatography to give the corresponding 3-azepinone. 
N
NBn
R
O2S
H2 (1 atm), 
10% Pd/C, 
HCOOH, EtOH N
O
R
O2S16 - 20h , r.t.
H2 (1 atm), 
10% Pd/C, 
HCOOH, EtOH
16 - 20h , r.t. N
O
R
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N
NBn
R
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! 169 
Specific experimental procedures & characterizations 
 (S)-methyl 2-(N-allylphenylsulfonamido)-3-phenylpropanoate (25). 
Following general procedure for N-allylsulfonamide formation, in a solution of the 
known sulfonamidei (0.50 g, 1.56 mmol) in DMF (10.4 mL) was added Cs2CO3 (0.76 g, 
2.35 mmol) at room temperature. After 30 min, allylbromide (0.27 mL, 3.13 mmol) was 
added, and the resulting mixture was left to stir at room temperature for 6 h to afford the 
crude N-allylphenylsulfonamide upon work-up. Purification by silica gel chromatography 
(20% ethyl acetate in hexanes) gave the title compound as light orange oil (0.56 g, quant.).   
Rf = 0.4 (20% ethyl acetate in hexanes). 
€ 
α[ ]D
29.4
= −37.6 (c = 0.5 CH2Cl2). FTIR (thin 
film) cm-1: 3065, 3029, 2952, 1743, 1641, 1604, 1585, 1497, 1479, 1447, 1420, 1346, 
1288, 1224, 1162, 1128, 1091, 1072, 1057, 1031, 999, 928, 875, 836, 743, 700, 690, 613, 
596, 573, 510. HRMS (ESI) m/z calcd. C19H21NO4NaS [M+Na]+ 382.1089, found 
382.1081. 1H-NMR (500 MHz; CDCl3): δ  7.69 (dd, J = 8.4, 1.3 Hz, 2H), 7.53 (dd, J = 
7.7, 1.4 Hz, 1H), 7.44-7.41 (m, 2H), 7.30-7.19 (m, 5H), 5.73 (ddt, J = 17.0, 10.3, 6.5 Hz, 
1H), 5.20 (dd, J = 17.2, 1.4 Hz, 1H), 5.11 (dd, J = 10.2, 1.3 Hz, 1H), 4.84 (t, J = 7.6 Hz, 
1H), 3.98-3.86 (m, 2H), 3.47-3.46 (m, 3H), 3.32 (dd, J = 14.0, 7.7 Hz, 1H), 2.98 (dd, J = 
14.1, 7.6 Hz, 1H). 13C-NMR (CDCl3, 125 MHz): 170.9, 140.1, 136.8, 134.6, 132.6, 129.3, 
128.9, 128.7, 127.6, 127.0, 118.2, 61.0, 52.1, 48.5, 36.7. 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
i!Ruano, J. L. G.; Parra, A.; Yuste, F.; Mastranzo, V. M. Synthesis 2008, 2, 311.!
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 (S)-methyl 2-(N-(but-3-en-1-yl)phenylsulfonamido)-3-
phenylpropanoate (26). Following the general procedure for N-homoallylsulfonamide 
formation, in a solution of the known sulfonamidei (0.54 g, 1.70 mmol) in DMF (85 mL) 
was added Cs2CO3 (0.55 g, 1.70 mmol), and the resultant mixture stirred at 60 ºC for 30 
mins.  To this mixture was added 4-bromobutene (0.35 mL, 3.50 mmol) dropwise via 
syringe, and the mixture stirred for a further 6 hrs. Upon work-up, the crude product was 
obtained as an oil. Purification by silica gel chromatography (15% ethyl acetate in 
hexanes) afforded the title compound as an oil (0.33 g, 53%). Rf = 0.3 (15% ethyl acetate 
in hexanes). 
€ 
α[ ]D
28.5
= −36.8  (c = 0.4 CHCl3). FTIR (thin film) cm-1: 3065, 3029, 3003, 
2978, 2951, 1742, 1641, 1604, 1585, 1496, 1479, 1446, 1345, 1289, 1222, 1163, 1130, 
1090, 1072, 1000, 920, 839, 740, 699, 691, 598, 574, 556, 511. HRMS (ESI) m/z calcd. 
C20H23NO4NaS [M+Na]+ 396.1245, found 396.1254. 1H-NMR (500 MHz; CDCl3): δ  
7.73 (d, J = 7.2 Hz, 2H), 7.54 (tt, J = 7.4, 1.5 Hz, 1H), 7.44 (t, J = 7.9 Hz, 2H), 7.29-7.18 
(m, 6H), 5.70 (ddt, J = 17.1, 10.3, 6.8 Hz, 1H), 5.08-5.02 (m, 2H), 4.79 (dd, J = 8.2, 7.1 
Hz, 1H), 3.46-3.42 (m, 3H), 3.37 (ddd, J = 15.3, 10.3, 5.3 Hz, 1H), 3.31-3.25 (m, 2H), 
2.94 (dd, J = 13.9, 7.0 Hz, 1H), 2.43-2.27 (m, 2H). 13C-NMR (CDCl3, 125 MHz): 170.9, 
140.0, 136.6, 134.8, 132.7, 129.2, 128.9, 128.7, 127.5, 127.1, 117.2, 61.2, 52.1, 45.5, 37.0, 
35.0. 
 
OMe
O
NO2S
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 (S)-methyl 3-(4-(benzyloxy)phenyl)-2-
(phenylsulfonamido)propanoate (22). Following general procedure of N-sulfonamide 
formation, to a solution of OBn-tyrosine methyl ester hydrochloride salt (4.5 g, 14 mmol) 
in CH2Cl2 (28 mL) was added triethylamine (4 mL, 28 mmol) and benzenesulfonyl 
chloride (2 mL, 15.4 mmol). The solution was stirred for 30 min, whereupon TLC 
analysis showed the reaction to be complete. The reaction was quenched with H2O (10 
mL) and the organics washed sequentially with 10% HCl (10 mL), NaHCO3 (20 mL), 
and brine (20 mL). The organic layer was dried over MgSO4, filtered, and reduced in 
vacuo to afford a white solid that was recrystallized from Et2O to give the title compound 
(5.1 g, 86%) as a white crystalline solid. Rf = 0.45 (30% ethyl acetate in hexanes). 
€ 
α[ ]D
18.6
= +2.46 (c = 1.09 CHCl3). FTIR (thin film) cm-1: 3290, 1740, 1613, 1586, 1513, 
1448, 1350, 1329, 1249, 1164, 1155. HRMS (ESI) m/z calcd. C23H23NNaO5S [M+Na]+ 
444.1195, found 448.1182. 1H-NMR (500 MHz; CDCl3): δ  7.76-7.74 (m, 2H), 7.52 (tt, J 
= 7.4, 1.6 Hz, 1H), 7.45-7.36 (m, 7H), 7.32 (ddt, J = 7.6, 2.5, 2.1 Hz, 1H), 6.98-6.95 (m, 
2H), 6.85-6.82 (m, 2H), 5.01 (d, J = 6.8 Hz, 3H), 4.18 (dt, J = 9.2, 5.9 Hz, 1H), 3.47 (s, 
3H), 2.97 (dd, J = 5.9, 1.6 Hz, 2H). 13C-NMR (CDCl3, 125 MHz): 171.1, 158.0, 139.6, 
136.9, 132.6, 130.4, 128.9, 128.5, 127.9, 127.4, 127.1, 127.0, 114.9, 69.9, 56.7, 52.3, 38.5. 
 
OMe
O
NHO2SBnO
! 172 
 (S)-methyl 2-(N-allylphenylsulfonamido)-3-(4-
(benzyloxy)phenyl)propanoate (27). Following the general procedure of N-
allylsulfonamide formation, to a solution of sulfonamide 22 (1 g, 2.3 mmol) in DMF (16 
mL, 0.15 M) was added Cs2CO3 (1.1g, 3.5 mmol), and the resultant mixture stirred at RT 
for 30 mins, whereupon a color change of white to straw yellow was observed.  
Allylbromide (0.4 mL, 4.7 mmol) was added and the mixture stirred for a further 1 hr.  
TLC analysis indicated reaction completion.  The solvent was removed in vacuo and the 
residue was dissolved in EtOAc, washed with H2O (2 x 10 mL) and the organics dried 
over Na2SO4 and reduced in vacuo.  The crude material was subjected to silica gel 
chromatography (20% ethyl acetate in hexanes) to yield the allylsulfonamide 10 (0.8 g, 
75%) as a clear oil. Rf = 0.3 (20% ethyl acetate in hexanes). 
€ 
α[ ]D
20.2
= −26.55  (c = 1.0 
CHCl3). FTIR (thin film) cm-1: 3007, 3064, 3022, 2950, 1741, 1640, 1611, 1584, 1512, 
1447, 1345, 1243, 1160, 1091, 1024. HRMS (ESI) m/z calcd. C26H28NNaO5S [M+Na]+ 
466.1688, found 466.1686. 1H-NMR (500 MHz; CDCl3): δ  7.72-7.70 (m, 2H), 7.52 (t, J 
= 7.4 Hz, 1H), 7.46-7.38 (m, 6H), 7.32 (t, J = 7.23 Hz, 1H), 7.10 (d, J = 8.57 Hz, 2H), 
6.88 (d, J = 8.59 2H), 5.74 (ddt, J = 17.0, 10.4, 6.4 Hz, 1H), 5.19 (dd, J = 17.2, 1.2 Hz, 
1H), 5.12-5.10 (m, 1H), 5.03 (s, 2H), 4.77 (t, J = 7.6 Hz, 1H), 3.93 (qd, J = 17.3, 6.3 Hz, 
2H), 3.48 (s, 3H), 3.25 (dd, J = 14.1, 7.8 Hz, 1H), 2.92 (dd, J = 14.1, 7.5 Hz, 1H). 13C-
NMR (CDCl3, 125 MHz): 170.8, 157.7, 140.1, 137.0, 134.5, 132.4, 130.2, 128.9, 128.6, 
128.5, 127.8, 127.43, 127.41, 127.0, 117.9, 114.9, 69.9, 61.0, 53.3, 51.8, 48.3, 35.8 
OMe
O
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 (S)-methyl 3-(4-(benzyloxy)phenyl)-2-(N-(but-3-en-1-
yl)phenylsulfonamido)propanoate (28). Following the general procedure for N-
homoallylsulfonamide formation, to a solution of sulfonamide 22 (0.7 g, 1.7 mmol) in 
DMF (70 mL) was added Cs2CO3 (0.5 g, 1.7 mmol), and the resultant mixture stirred at 
60 ºC for 30 mins.  To this mixture was added 4-bromobutene (0.3 mL, 3.5 mmol) 
dropwise via syringe, and the mixture stirred for a further 6 hrs.  Aqueous work-up 
afforded the crude material which was subjected to silica gel chromatography (5% ethyl 
acetate in hexanes) to afford the title compound as a clear oil (0.4 g, 57%). Rf = 0.3 (20% 
ethyl acetate in hexanes). 
€ 
α[ ]D
20.2
= −26.55  (c = 1.0 CHCl3). FTIR (thin film) cm-1: 3007, 
3064, 3022, 2950, 1741, 1640, 1611, 1584, 1512, 1447, 1345, 1243, 1160, 1091, 1024. 
HRMS (ESI) m/z calcd. C26H28NNaO5S [M+Na]+ 466.1688, found 466.1686. 1H-NMR 
(500 MHz; CDCl3): δ  7.76-7.72 (m, 2H), 7.53 (t, J = 7.4 Hz, 1H), 7.45-7.36 (m, 7H), 
7.34 (dt, J = 11.6, 5.6 Hz, 1H), 7.11 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 5.72 
(ddt, J = 17.1, 10.3, 6.8 Hz, 1H), 5.09-5.01 (m, 4H), 4.75 (t, J = 8.0 Hz, 1H), 3.47-3.42 
(m, 3H), 3.41-3.27 (m, 2H), 3.25 (dt, J = 14.2, 7.2 Hz, 1H), 2.90 (dd, J = 14.0, 6.9 Hz, 
1H), 2.46-2.28 (m, 2H). 13C-NMR (CDCl3, 125 MHz): 170.8, 157.7, 140.1, 137.0, 134.5, 
132.4, 130.2, 128.9, 128.6, 128.5, 127.8, 127.43, 127.41, 127.0, 117.9, 114.9, 69.9, 61.0, 
53.3, 51.8, 48.3, 35.8. 
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O
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 (S)-methyl 3-(1-methyl-1H-indol-3-yl)-2-
(phenylsulfonamido)propanoate (23). Following the general procedure for N-
allylphenylsulfonamide formation, the sulfonamide was synthesized by treating (2S)-2-
Amino-3-(1-methyl-1H-indol-3-yl)propionic acid methyl ester hydrochloride (1.06 g, 
4.56 mmol) in CH2Cl2 (23 mL) with triethylamine (0.73 mL, 11.4 mmol), and 
benzenesulfonyl chloride (0.58 mL, 4.56 mmol) at room temperature for 6 h to afford the 
crude sulfonamide product. Purification by silica gel column (35% ethyl acetate in 
hexanes) afforded the sulfonamide as a tan solid (1.51 g, 89%). Rf = 0.2 (30% ethyl 
acetate in hexanes). 
€ 
α[ ]D
27.3
= +7.2 (c = 1.1 CH2Cl2). FTIR (thin film) cm-1: 3283, 3057, 
2952, 1744, 1615, 1585, 1550, 1475, 1447, 1331, 1277, 1253, 1204, 1164, 1129, 1092, 
1012, 944, 916, 848, 822, 743, 721, 688, 591, 564, 522. HRMS (ESI) m/z calcd. 
C19H20N2O4NaS [M+Na]+ 395.1041, found 395.1048. 1H-NMR (500 MHz; CDCl3): δ  
7.73 (d, J = 7.9 Hz, 2H), 7.52-7.49 (m, 1H), 7.41 (dd, J = 6.8, 5.7 Hz, 3H), 7.26-7.18 (m, 
2H), 7.06 (dd, J = 7.9, 7.0 Hz, 1H), 6.88-6.86 (m, 1H), 5.14 (t, J = 0.3 Hz, 1H), 4.29-4.26 
(m, 1H), 3.71 (s, 3H), 3.42 (s, 3H), 3.24 (d, J = 5.4 Hz, 2H). 13C- NMR (CDCl3, 125 
MHz): 171.6, 139.9, 137.0, 132.7, 129.0, 128.1, 127.9, 127.2, 121.9, 119.4, 118.7, 109.4, 
107.4, 56.3, 52.5, 32.9, 29.4. 
 
OMe
O
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 (S)-methyl 2-(N-allylphenylsulfonamido)-3-(1-methyl-1H-indol-3-
yl)propanoate (29). Following general procedure for N-allylsulfonamide formation, 
sulfonamide 23 (0.5 g, 1.34 mmol) in DMF (9 mL) was added Cs2CO3 (0.66 g, 2.01 
mmol) at room temperature. After 30 min, allylbromide (0.23 mL, 2.68 mmol) was added, 
and the resulting mixture was left to stir at room temperature for 6 h to afford the crude 
N-allylphenylsulfonamide. Purification by silica gel chromatography (20% ethyl acetate 
in hexanes) afforded the title compound as yellow oil (0.55 g, quant.). Rf = 0.4 (30% 
ethyl acetate in hexanes). 
€ 
α[ ]D
30.1
= −2.9 (c = 0.8 CH2Cl2). FTIR (thin film) cm-1: 3057, 
3026, 2950, 1741, 1640, 1616, 1585, 1554, 1475, 1446, 1375, 1331, 1287, 1254, 1222, 
1204, 1162, 1131, 1091, 1072, 1013, 999, 927, 879, 832, 742, 714, 690, 669, 585. HRMS 
(ESI) m/z calcd. C22H24N2O4NaS [M+Na]+ 435.1354, found 435.1363. 1H-NMR (500 
MHz; CDCl3): δ  7.68 (d, J = 8.0 Hz, 2H), 7.58-7.47 (m, 2H), 7.38-7.36 (m, 2H), 7.27-
7.20 (m, 3H), 7.13-7.10 (m, 1H), 6.93-6.79 (m, 1H), 5.77 (ddt, J = 16.9, 10.4, 6.4 Hz, 
1H), 5.18 (d, J = 17.2 Hz, 1H), 5.07 (d, J = 10.2 Hz, 1H), 4.87 (t, J = 7.5 Hz, 1H), 4.03-
3.90 (m, 2H), 3.67 (s, 3H), 3.46 (s, 4H), 3.12 (dd, J = 14.8, 7.3 Hz, 1H). 13C-NMR 
(CDCl3, 125 MHz): 171.3, 140.4, 137.0, 134.9, 132.5, 128.8, 128.0, 127.7, 127.5, 121.8, 
119.2, 118.8, 118.0, 109.4, 109.2, 60.0, 52.1, 48.4, 32.8, 26.7. 
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 (S)-methyl 2-(N-(but-3-en-1-yl)phenylsulfonamido)-3-(1-methyl-
1H-indol-3-yl)propanoate (30). Following the general procedure for N-
homoallylsulfonamide formation, in a solution of sulfonamide 23 (0.50 g, 1.34 mmol) in 
DMF (67 mL) was added Cs2CO3 (0.44 g, 1.34 mmol), and the resultant mixture stirred 
at 60 ºC for 30 mins.  To this mixture was added 4-bromobutene (0.28 mL, 2.77 mmol) 
dropwise via syringe, and the mixture stirred for a further 6 hrs. Upon work-up, the crude 
product was obtained as an oil. Purification by silica gel chromatography (20% ethyl 
acetate in hexanes) afforded the title compound as an oil (0.36 g, 63%). Rf = 0.3 (20% 
ethyl acetate in hexanes). 
€ 
α[ ]D
26.2
= +4.1 (c = 0.5 CHCl3). FTIR (thin film) cm-1: 3059, 
2950, 1741, 1640, 1615, 1553, 1475, 1446, 1375, 1342, 1254, 1222, 1203, 1162, 1132, 
1090, 1073, 1012, 922, 838, 811, 741, 690, 666, 583, 550. HRMS (ESI) m/z calcd. 
C23H26N2O4NaS [M+Na]+ 449.1511, found 449.1528. 1H-NMR (500 MHz; CDCl3): δ  
7.72 (d, J = 8.5 Hz, 2H), 7.57-7.49 (m, 2H), 7.39 (t, J = 7.1 Hz, 2H), 7.27-7.22 (m, 3H), 
7.11 (t, J = 7.4 Hz, 1H), 6.88 (s, 1H), 5.74-5.65 (m, 1H), 5.04-4.99 (m, 2H), 4.84 (t, J = 
7.5 Hz, 1H), 3.68 (s, 3H), 3.41 (s, 5H), 3.32 (dd, J = 10.2, 5.0 Hz, 1H), 3.10 (dd, J = 14.8, 
7.2 Hz, 1H), 2.46-2.28 (m, 2H). 13C-NMR (CDCl3, 125 MHz): 171.3, 140.1, 137.0, 134.9, 
132.5, 128.8, 127.8, 127.7, 127.5, 121.9, 119.3, 118.7, 117.1, 109.4, 109.1, 60.1, 52.0, 
45.4, 35.3, 32.8, 26.9. 
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(S)-methyl 2-(N-allylphenylsulfonamido)-4-methylpentanoate (31). 
Following general procedure for N-allylsulfonamide formation, in a solution of the 
known sulfonamideii (1.94 g, 7.01 mmol) in DMF (45 mL) was added Cs2CO3 (3.32 g, 
10.5 mmol) at room temperature. After 30 min, allylbromide (1.15 mL, 14.0 mmol) was 
added, and the resulting mixture was left to stir at room temperature for 6 h to afford the 
crude N-allylphenylsulfonamide. Purification by silica gel chromatography (20% ethyl 
acetate in hexanes) gave the title compound as clear oil (2.11 g, 93%). Rf = 0.6 (30% 
ethyl acetate in hexanes). 
€ 
α[ ]D
27.2
= −64.1 (c = 4.7 CH2Cl2). FTIR (thin film) cm-1: 3069, 
2956, 2868, 1742, 1447, 1345, 1165, 1090, 1048, 926, 869, 746, 690. HRMS (ESI) m/z 
calcd. C16H24NO4S [M+H]+ 326.1426, found 326.1420. 1H-NMR (500 MHz; CDCl3): δ  
7.83 (d, J = 7.9 Hz, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.50-7.47 (m, 2H), 5.88 (dddd, J = 17.2, 
10.1, 7.2, 5.5 Hz, 1H), 5.17 (d, J = 17.2 Hz, 1H), 5.10 (d, J = 10.2 Hz, 1H), 4.61 (dd, J = 
9.4, 5.6 Hz, 1H), 3.99 (dd, J = 16.6, 5.5 Hz, 1H), 3.82 (dd, J = 16.7, 7.2 Hz, 1H), 3.46 (s, 
3H), 1.73-1.57 (m, 3H), 0.95 (d, J = 6.4 Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H). 13C-NMR 
(CDCl3, 125 MHz): 172.0, 140.0, 135.8, 132.7, 128.9, 127.6, 117.4, 58.1, 52.0, 48.3, 39.2, 
24.3, 22.7, 21.4. 
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 (S)-methyl 2-(N-(but-3-en-1-yl)phenylsulfonamido)-4-
methylpentanoate (32). Following the general procedure for N-homoallylsulfonamide 
formation, in a solution of the known sulfonamideii (0.50 g, 1.75 mmol) in DMF (88 mL) 
was added Cs2CO3 (0.57 g, 1.75 mmol), and the resultant mixture stirred at 60 ºC for 30 
mins.  To this mixture was added 4-bromobutene (0.37 mL, 3.61 mmol) dropwise via 
syringe, and the mixture stirred for a further 6 hrs. Upon work-up, the crude product was 
obtained as an oil. Purification by silica gel chromatography (10% ethyl acetate in 
hexanes) afforded the title compound as an oil (0.29 g, 49%). Rf = 0.2 (5% ethyl acetate 
in hexanes). 
€ 
α[ ]D
24.5
= −64.5  (c = 1.5 CH2Cl2). FTIR (thin film) cm-1: 3065, 2955, 2868, 
1742, 1635, 1447, 1344, 1269, 1248, 1165, 1152, 1090, 922, 740, 690. HRMS (ESI) m/z 
calcd. C17H26NO4S [M+H]+ 340.1583, found 340.1597. 1H-NMR (500 MHz; CDCl3): δ  
7.83 (d, J = 7.2 Hz, 3H), 7.58-7.55 (m, 1H), 7.51-7.47 (m, 3H), 5.77-5.69 (m, 1H), 5.09-
5.02 (m, 2H), 4.57 (dd, J = 9.4, 5.5 Hz, 1H), 3.44-3.40 (m, 3H), 3.34 (ddd, J = 15.5, 10.7, 
4.9 Hz, 1H), 3.18 (ddd, J = 15.6, 10.7, 5.2 Hz, 1H), 2.58-2.51 (m, 1H), 2.33-2.24 (m, 1H), 
1.74-1.56 (m, 4H), 0.96 (dd, J = 9.6, 6.5 Hz, 7H). 13C-NMR (CDCl3, 125 MHz): 171.9, 
139.8, 135.0, 132.7, 128.9, 127.6, 117.1, 58.2, 52.0, 45.5, 39.6, 35.8, 24.6, 23.0, 21.7. 
  (S)-2-(N-allylphenylsulfonamido)-N-benzyl-N-methyl-3-
phenylpropanamide (33). Following the general procedure for the amide formation, The 
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N-allylsulfonamide 25 (0.54 g, 1.57 mmol) was dissolved in an equal mixture of THF, 
MeOH, and H2O (0.1 M) and cooled to 0 ºC. To this was added LiOH.H2O (0.19 g, 4.55 
mmol) and the stirred reaction mixture was warmed to room temperature over 3 hrs.  
After this time the volatiles were reduced in vacuo and the aqueous layer washed with 
Et2O.  The aqueous portion was acidified to pH 3 with 10% HCl solution and extracted 
with EtOAc.  The organics were dried over Na2SO4 and reduced in vacuo to provide the 
crude acid, which was carried on without further purification. The crude acid (0.54 g, 
1.57 mmol) was dissolved in CH2Cl2 (8 mL) and cooled to 0 ºC under an argon 
atmosphere.  To this solution was added N-methylbenzylamine (0.22 mL, 1.73 mmol), 
BOPCl (0.48 g, 1.89 mmol), and Et3N (0.26 mL, 1.89 mmol). The resultant solution was 
stirred for 12 hrs. Aqueous work-up afforded the crude material which was purified by 
silica gel chromatography (20% ethyl acetate in hexanes) to afford the title compound as 
a white solid (0.56 g, 80%). Rf = 0.3 (20% ethyl acetate in hexanes). 
€ 
α[ ]D
24.1
= −35.1 (c = 
0.7 CH2Cl2). FTIR (thin film) cm-1: 3063, 3028, 2931, 1649, 1494, 1446, 1342, 1162, 
1090, 1020, 928, 846, 799, 772, 730, 698, 596, 568. HRMS (ESI) m/z calcd. 
C26H28N2O3NaS [M+Na]+ 471.1718, found 471.1720. 1H-NMR (500 MHz; CDCl3): δ  
7.86-7.84 (m, 2H), 7.60-7.49 (m, 3H), 7.26-7.12 (m, 8H), 7.04-7.03 (m, 1H), 6.92-6.90 
(m, 1H), 6.64 (d, J = 7.7 Hz, 1H), 5.85 (dtt, J = 16.6, 11.0, 5.6 Hz, 1H), 5.17-5.08 (m, 
2H), 4.14-4.02 (m, 3H), 3.36-3.28 (m, 1H), 2.73 (rotameric d, 3H). 13C-NMR (CDCl3, 
125 MHz): 169.2, 140.4, 136.6, 136.5, 135.7, 133.0, 129.8, 129.6, 129.3, 128.8, 128.7, 
128.6, 128.1, 127.5, 127.0, 126.5, 117.3, 57.4, 56.7, 52.8, 51.4, 47.5, 47.2, 36.8, 35.5, 
34.8, 34.4. 
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  (S)-N-benzyl-2-(N-(but-3-en-1-yl)phenylsulfonamido)-N-methyl-
3-phenylpropanamide (34). Following the general procedure for the amide formation, 
the sulfonamide 26 (0.33 g, 0.88 mmol) was dissolved in an equal mixture of THF, 
MeOH, and H2O (0.1 M) and cooled to 0 ºC. To this was added LiOH.H2O (0.10, 2.42 
mmol) and the stirred reaction mixture was warmed to rt over 3 hrs.  After this time the 
volatiles were reduced in vacuo and the aqueous layer washed with Et2O.  The aqueous 
portion was acidified to pH 3 with 10% HCl solution and extracted with EtOAc.  The 
organics were dried over Na2SO4 and reduced in vacuo to provide the crude acid, which 
was carried on without further purification. The crude acid (0.30 g, 0.84 mmol) was 
dissolved in CH2Cl2 (4.2 mL) and cooled to 0 ºC under an argon atmosphere.  To this 
solution was added N-methylbenzylamine (0.12 mL, 0.93 mmol), BOPCl (0.26 g, 1.01 
mmol), and Et3N (0.14 mL, 1.01 mmol). The resultant solution was stirred for 12 hrs and 
after this time diluted with EtOAc and washed with 10% HCl, sat. NaHCO3, and brine.  
The organics were dried over Na2SO4 and reduced in vacuo and the crude material was 
subjected to silica gel flash chromatography (15% ethyl acetate in hexanes) to afford the 
corresponding N-methylamide as an opaque oil (0.36 g, 93%). Rf = 0.32 (15% ethyl 
acetate in hexanes). 
€ 
α[ ]D
26.7
= −33.3 (c = 0.8 CHCl3). FTIR (thin film) cm-1: 3064, 3029, 
3003, 2933, 1739, 1650, 1584, 1495, 1480, 1447, 1415, 1344, 1243, 1224, 1162, 1128, 
1090, 1051, 1028, 999, 923, 863, 802, 751, 727, 697, 635, 609, 571. HRMS (ESI) m/z 
calcd. C27H30N2O3NaS [M+Na]+ 485.1875, found 485.1884. 1H-NMR (rotamers present) 
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(500 MHz; CDCl3): δ  7.88 (t, J = 8.3 Hz, 2H), 7.61-7.58 (m, 1H), 7.54 (dd, J = 9.6, 5.7 
Hz, 2H), 7.25-7.11 (m, 8H), 6.92-6.90 (m, 1H), 6.61 (d, J = 7.4 Hz, 1H), 5.75 (d, J = 6.9 
Hz, 1H), 5.11-5.02 (m, 3H), 4.09-4.06 (m, 1H), 3.57 (d, J = 0.2 Hz, 1H), 3.46 (dt, J = 
11.8, 6.1 Hz, 1H), 3.30 (q, J = 11.8 Hz, 2H), 2.79 (s, J = 19.0 Hz, 3H), 2.47-2.38 (m, 3H). 
13C-NMR (rotamers present) (CDCl3, 125 MHz): 168.8, 140.1, 136.2, 134.9, 132.9, 129.6, 
129.4, 129.3, 129.2, 129.0, 128.9, 128.6, 128.6, 128.5, 128.5, 127.9, 127.3, 127.3, 127.2, 
126.8, 126.2, 116.8, 56.7, 51.4, 35.7, 35.5, 34.7. 
(S)-2-(N-allylphenylsulfonamido)-N-benzyl-3-(4-
(benzyloxy)phenyl)-N-methylpropanamide (35). Following the general procedure for 
the amide formation, the N-allylsulfonamide 27 (0.8 g, 1.8 mmol) was dissolved in an 
equal mixture of THF, MeOH, and H2O (0.1 M) and cooled to 0 oC. To this was added 
LiOH.H2O (0.2 g, 5.4 mmol) and the stirred reaction mixture was warmed to room 
temperature over 3 hrs. The volatiles were reduced in vacuo and the aqueous layer was 
washed with Et2O. The aqueous portion was acidified to pH 3 with 10% HCl solution and 
extracted with EtOAc. The organics were dried over Na2SO4 and reduced in vacuo to 
provide the crude acid, which was carried on without further purification. The crude acid 
(0.6 g, 1.4 mmol) was dissolved in CH2Cl2 (7 mL, 0.2 M) and cooled to 0 ºC under an 
argon atmosphere.  To this solution was added N-methylbenzylamine (0.2 mL, 1.5 mmol), 
BOPCl (0.4 g, 1.6 mmol), and Et3N (0.2 mL, 1.7 mmol). The resultant solution was 
stirred for 12 hrs and after this time diluted with EtOAc (10 mL) and washed with 10% 
HCl (5 mL), sat. NaHCO3 (10 mL), and brine (10 mL).  The organics were dried over 
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Na2SO4 and reduced in vacuo and the crude material was subjected to flash 
chromatography (20% ethyl acetate in hexanes) to afford the N-methylamide 18, as a 
white foam (0.3 g, 43%). Rf = 0.3 (20% ethyl acetate in hexanes). 
€ 
α[ ]D
20.0
= −60.17  (c = 
0.61 CHCl3). FTIR (thin film) cm-1: 3063, 3030, 2979, 1650, 1609, 1583, 1510, 1446, 
1340, 1241, 1160, 1108, 1090, 1020, 924. HRMS (ESI) m/z calcd. C33H34N2NaO4S 
[M+Na]+ 577.2137, found 577.2154. 1H-NMR (500 MHz; CDCl3): (Rotamers present) δ  
7.85-7.81 (m, 2H), 7.60-7.54 (m, 1H), 7.54-7.48 (m, 2H), 7.48-7.44 (m, 1H), 7.43-7.36 
(m, 3H), 7.36-7.31 (m, 1H), 7.25-7.19 (m, 2H), 7.12-7.09 (m, 1H), 7.06-7.02 (m, 1H), 
6.97-6.91 (m, 2H), 6.84-6.79 (m, 2H), 6.66-6.64 (m, 1H), 5.90-5.80 (m, 1H), 5.27-5.22 
(m, 1H), 5.12-5.04 (m, 2H), 5.04-5.00 (m, 1H), 4.64 (d, J = 14.6 Hz, 1H), 4.34-4.29 (m, 
1H), 4.16-4.01 (m, 2H), 3.29-3.21 (m, 1H), 2.77-2.68 (m, 3H), 2.58-2.55 (m, 1H). 13C-
NMR (CDCl3, 125 MHz): 169.1,168.3, 157.6, 140.4, 140.3, 136.9, 135.5, 134.9, 132.7, 
132.6, 130.5, 130.4, 129.1, 129.0, 128.9, 128.6, 128.54, 128.51, 128, 36, 127.96, 127.9, 
127.27, 127.22, 127.16, 126.2, 117.0, 114.8, 69.9, 57.2, 56.4, 52.5, 51.1, 47.2, 35.8, 34.5, 
34.4, 34.1. 
 (S)-N-benzyl-3-(4-(benzyloxy)phenyl)-2-(N-(but-3-en-1-
yl)phenylsulfonamido)-N-methylpropanamide (36). Following the general procedure 
for the amide formation, the sulfonamide 28 (0.2 g, 0.4 mmol) was dissolved in an equal 
mixture of THF, MeOH, and H2O (0.1 M) and cooled to 0 oC. To this was added 
LiOH.H2O (0.05 g, 1.1 mmol) and the mixture was warmed to room temperature over 3 
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hrs. The volatiles were removed in vacuo and the aqueous layer was washed with Et2O. 
The aqueous portion was acidified to pH 3 with 10% HCl solution and extracted with 
EtOAc. The organics were dried over Na2SO4 and reduced in vacuo to provide the crude 
acid, which was carried on without further purification. The crude acid (0.1 g, 0.2 mmol) 
was dissolved in CH2Cl2 (1 mL, 0.2 M) and cooled to 0 ºC under an argon atmosphere.  
To this solution was added N-methylbenzylamine (30 µL, 0.25 mmol), BOPCl (60 mg, 
0.25 mmol), and Et3N (30 µL, 0.26 mmol). The resultant solution was stirred for 12 hrs 
and after this time diluted with EtOAc and washed with 10% HCl, sat. NaHCO3, and 
brine.  The organics were dried over Na2SO4 and reduced in vacuo and the crude material 
was subjected to flash chromatography (10% ethyl acetate in hexanes) to afford the N-
methylamide 19 as a clear oil (77 mg, 74%). Rf = 0.25 (10% ethyl acetate in hexanes). 
€ 
α[ ]D
20.0
= −38.72  (c = 1.2 CHCl3). FTIR (thin film) cm-1: 3065, 3032, 2999, 2997, 2950, 
2870, 1741, 1641, 1611, 1584, 1512, 1446, 1345, 1242, 1129, 1090. HRMS (ESI) m/z 
calcd. C34H36N2NaO4S [M+Na]+ 591.2293, found 591.2293. 1H-NMR (500 MHz; 
CDCl3): δ  7.80-7.74 (m, 2H), 7.51-7.46 (m, 1H), 7.44-7.39 (m, 2H), 7.39-7.21 (m, 5H), 
7.14-7.09 (m, 2H), 7.02-7.00 (m, 1H), 6.96-6.94 (m, 1H), 6.86-6.81 (m, 2H), 6.75-6.70 
(m, 2H), 6.56 (d, J = 7.3 Hz, 1H), 5.71-5.62 (m, 1H), 5.05-5.00 (m, 1H), 5.00-4.90 (m, 
4H), 4.78 (dd, J = 11.1, 3.2 Hz,), 4.64-4.61 (m, 1H), 4.01-3.97 (m, 1H), 3.52-3.46 (m, 
1H), 3.41-3.33 (m, 1H), 3.19-3.11 (m, 1H), 2.71-2.64 (m, 3H), 2.42-2.25 (m, 3H). 13C-
NMR (CDCl3, 125 MHz): 168.5, 140.1, 136.9, 136.3, 134.9, 134.8, 132.8, 130.6, 130.4, 
130.1, 129.2, 129.17, 129.13, 128.6, 128.57, 128.55, 128.4, 127.97, 127.95, 127.6, 127.39, 
127.38, 127.28, 127.25, 126.9, 126.2, 116.7, 114.8, 69.9, 56.6, 51.3, 44.4, 34.7, 34.4. 
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 (S)-2-(N-allylphenylsulfonamido)-N-benzyl-N-methyl-3-(1-
methyl-1H-indol-3-yl)propanamide (37). Following the general procedure for the 
amide formation, The N-allylsulfonamide 29 (0.56 g, 1.36 mmol) was dissolved in an 
equal mixture of THF, MeOH, and H2O (0.1 M) and cooled to 0 ºC. To this was added 
LiOH.H2O (0.17 g, 4.09 mmol) and the stirred reaction mixture was warmed to room 
temperature over 3 hrs.  After this time the volatiles were reduced in vacuo and the 
aqueous layer washed with Et2O.  The aqueous portion was acidified to pH 3 with 10% 
HCl solution and extracted with EtOAc.  The organics were dried over Na2SO4 and 
reduced in vacuo to provide the crude acid, which was carried on without further 
purification. The crude acid (0.56 g, 1.40 mmol) was dissolved in CH2Cl2 (7 mL) and 
cooled to 0 ºC under an argon atmosphere.  To this solution was added N-
methylbenzylamine (0.2 mL, 1.53 mmol), BOPCl (0.43 g, 1.67 mmol), and Et3N (0.23 
mL, 1.67 mmol). The resultant solution was stirred for 12 hrs. Aqueous work-up afforded 
the crude material which was purified by silica gel chromatography (25% ethyl acetate in 
hexanes) to afford the title compound as a solid (0.55 g, 79%). Rf = 0.25 (25% ethyl 
acetate in hexanes). 
€ 
α[ ]D
27.4
= −7.4  (c = 0.8 CH2Cl2). FTIR (thin film) cm-1: 3059, 2931, 
1736, 1648, 1551, 1475, 1446, 1375, 1330, 1252, 1204, 1161, 1090, 1012, 927, 839, 775, 
740, 691, 614, 581. HRMS (ESI) m/z calcd. C29H31N3O3NaS [M+Na]+ 524.1984, found 
524.1962. 1H-NMR (500 MHz; CDCl3): δ  7.86 (dd, J = 20.7, 8.1 Hz, 2H), 7.57-7.46 (m, 
4H), 7.27-7.16 (m, 5H), 7.10 (dd, J = 7.8, 7.0 Hz, 1H), 6.93 (s, 1H), 6.86 (d, J = 6.8 Hz, 
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1H), 6.76 (s, 1H), 6.56 (d, J = 7.6 Hz, 1H), 5.92-5.85 (m, 1H), 5.28-5.24 (m, 2H), 5.10-
5.08 (m, 1H), 4.69 (d, J = 14.6 Hz, 1H), 4.38-4.33 (m, 1H), 4.19 (d, J = 0.6 Hz, 1H), 3.93 
(d, J = 14.6 Hz, 1H), 3.63 (d, J = 9.5 Hz, 3H), 3.46-3.43 (m, 1H), 2.84 (dd, J = 13.5, 4.0 
Hz, 1H), 2.71 (s, 1H), 2.59 (s, 2H). 13C-NMR (CDCl3, 125 MHz): 169.9, 140.7, 140.7, 
136.9, 135.9, 132.9, 129.2, 129.2, 128.5, 128.5, 128.4, 127.6, 126.6, 121.8, 121.7, 119.3, 
117.2, 109.4, 55.9, 55.3, 52.8, 51.3, 47.3, 47.1, 34.9, 34.3, 32.7, 26.7, 25.7. 
 (S)-N-benzyl-2-(N-(but-3-en-1-yl)phenylsulfonamido)-N-
methyl-3-(1-methyl-1H-indol-3-yl)propanamide (38). Following the general procedure 
for the amide formation, the sulfonamide 30 (0.36 g, 0.84 mmol) was dissolved in an 
equal mixture of THF, MeOH, and H2O (0.1 M) and cooled to 0 ºC. To this was added 
LiOH.H2O (0.1, 2.3 mmol) and the stirred reaction mixture was warmed to rt over 3 hrs.  
After this time the volatiles were reduced in vacuo and the aqueous layer washed with 
Et2O.  The aqueous portion was acidified to pH 3 with 10% HCl solution and extracted 
with EtOAc.  The organics were dried over Na2SO4 and reduced in vacuo to provide the 
crude acid, which was carried on without further purification. The crude acid (0.31 g, 
0.75 mmol) was dissolved in CH2Cl2 (3.8 mL) and cooled to 0 ºC under an argon 
atmosphere.  To this solution was added N-methylbenzylamine (0.11 mL, 0.82 mmol), 
BOPCl (0.23 g, 0.9 mmol), and Et3N (0.12 mL, 0.9 mmol). The resultant solution was 
stirred for 12 hrs and after this time diluted with EtOAc and washed with 10% HCl, sat. 
NaHCO3, and brine.  The organics were dried over Na2SO4 and reduced in vacuo and the 
crude material was subjected to silica gel flash chromatography (25% ethyl acetate in 
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hexanes) to afford the corresponding N-methylamide as yellow oil (0.35 g, 90%). Rf = 
0.27 (25% ethyl acetate in hexanes). 
€ 
α[ ]D
27.8
= −13.6  (c = 0.6 CHCl3). FTIR (thin film) 
cm-1: 3061, 3028, 2930, 1648, 1585, 1551, 1475, 1446, 1375, 1330, 1252, 1204, 1160, 
1131, 1089, 1071, 1012, 999, 924, 855, 811, 740, 692, 665, 630, 613, 581, 547, 507. 
HRMS (ESI) m/z calcd. C30H33N3O3NaS [M+Na]+ 538.2140, found 538.2133. 1H-NMR 
(500 MHz; CDCl3): δ  7.58-7.47 (m, 4H), 7.37-7.10 (m, 6H), 6.94-6.86 (m, 2H), 6.77 (s, 
1H), 6.56 (d, J = 7.6 Hz, 1H), 5.79-5.72 (m, 1H), 5.21 (dd, J = 11.0, 3.9 Hz, 1H), 5.14-
5.01 (m, 3H), 4.74 (d, J = 14.6 Hz, 1H), 4.00 (t, J = 15.3 Hz, 1H), 3.59-3.41 (m, 6H), 
2.75-2.67 (m, 4H), 2.54-2.39 (m, 2H). 13C-NMR (CDCl3, 125 MHz): 169.7, 140.5, 136.9, 
136.7, 135.2, 132.9, 129.3, 128.5, 128.5, 128.4, 128.0, 127.5, 127.4, 126.6, 121.8, 119.3, 
118.7, 116.9, 109.4, 108.8, 56.1, 55.4, 52.8, 51.5, 44.5, 35.7, 35.0, 34.5, 32.7, 26.1. 
 (S)-2-(N-allylphenylsulfonamido)-N-benzyl-N,4-
dimethylpentanamide (39). Following the general procedure for the amide formation, 
The N-allylsulfonamide 31 (2.0 g, 6.16 mmol) was dissolved in an equal mixture of THF, 
MeOH, and H2O (0.1 M) and cooled to 0 ºC. To this was added LiOH.H2O (0.77 g, 18.4 
mmol) and the stirred reaction mixture was warmed to room temperature over 3 hrs.  
After this time the volatiles were reduced in vacuo and the aqueous layer washed with 
Et2O.  The aqueous portion was acidified to pH 3 with 10% HCl solution and extracted 
with EtOAc.  The organics were dried over Na2SO4 and reduced in vacuo to provide the 
crude acid, which was carried on without further purification. The crude acid (1.90 g, 
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6.10 mmol) was dissolved in CH2Cl2 (30 mL) and cooled to 0 ºC under an argon 
atmosphere.  To this solution was added N-methylbenzylamine (0.86 mL, 6.71 mmol), 
BOPCl (1.77 g, 6.95 mmol), and Et3N (1.0 mL, 7.32 mmol). The resultant solution was 
stirred for 12 hrs. Aqueous work-up afforded the crude material which was purified by 
silica gel chromatography (20% ethyl acetate in hexanes) to afford the title compound as 
a clear oil (1.80 g, 71%). Rf = 0.36 (20% ethyl acetate in hexanes). 
€ 
α[ ]D
23.8
= −10.4  (c = 
1.7 CH2Cl2). FTIR (thin film) cm-1: 3064, 3028, 2957, 2868, 1653, 1447, 1339, 1163, 
1089, 1015, 920, 742, 691. HRMS (ESI) m/z calcd. C23H31N2O3S [M+H]+ 415.2055, 
found 415.2051. 1H-NMR (500 MHz; CDCl3): δ  7.80-7.75 (m, 2H), 7.58-7.45 (m, 3H), 
7.39-7.27 (m, 4H), 7.23-7.16 (m, 2H), 5.91-5.85 (m, 1H), 5.23-5.16 (m, 1H), 5.09-5.04 
(m, 1H), 4.95 (dd, J = 3.8, 2.8 Hz, 1H), 4.58-4.55 (m, 1H), 4.36-4.20 (m, 2H), 4.14-3.99 
(m, 1H), 3.09-2.90 (m, 3H), 1.67-1.57 (m, 2H), 1.38-1.26 (m, 1H), 0.94-0.86 (m, 4H), 
0.69 (d, J = 6.5 Hz, 1H), 0.60 (d, J = 6.6 Hz, 1H). 13C-NMR (CDCl3, 125 MHz): 170.5, 
140.2, 136.9, 136.1, 132.8, 129.1, 128.8, 128.3, 127.6, 127.6, 127.5, 126.7, 116.9, 100.1, 
54.2, 52.9, 51.4, 47.6, 38.5, 34.8, 24.8, 22.4, 22.2. 
 (S)-N-benzyl-2-(N-(but-3-en-1-yl)phenylsulfonamido)-N,4-
dimethylpentanamide (40). Following the general procedure for the amide formation, 
the sulfonamide 32 (0.58 g, 1.71 mmol) was dissolved in an equal mixture of THF, 
MeOH, and H2O (0.1 M) and cooled to 0 ºC. To this was added LiOH.H2O (0.2, 4.7 
mmol) and the stirred reaction mixture was warmed to room temperature over 3 hrs.  
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After this time the volatiles were reduced in vacuo and the aqueous layer washed with 
Et2O.  The aqueous portion was acidified to pH 3 with 10% HCl solution and extracted 
with EtOAc.  The organics were dried over Na2SO4 and reduced in vacuo to provide the 
crude acid, which was carried on without further purification. The crude acid (0.54 g, 
1.66 mmol) was dissolved in CH2Cl2 (8.3 mL) and cooled to 0 ºC under an argon 
atmosphere.  To this solution was added N-methylbenzylamine (0.23 mL, 1.82 mmol), 
BOPCl (0.51 g, 1.99 mmol), and Et3N (0.3 mL, 1.99 mmol). The resultant solution was 
stirred for 12 hrs and after this time diluted with EtOAc and washed with 10% HCl, sat. 
NaHCO3, and brine.  The organics were dried over Na2SO4 and reduced in vacuo and the 
crude material was subjected to silica gel flash chromatography (15% ethyl acetate in 
hexanes) to afford the corresponding N-methylamide as an oil (0.55 g, 77%). Rf = 0.3 
(15% ethyl acetate in hexanes). 
€ 
α[ ]D
25.8
= −6.0  (c = 1.3 CH2Cl2). FTIR (thin film) cm-1: 
3065, 2956, 2869, 1653, 1447, 1342, 1164, 1090, 1048, 996, 923, 811, 740, 693, 587, 550. 
HRMS (ESI) m/z calcd. C24H33N2O3S [M+H]+ 429.2212, found 429.2194. 1H-NMR (500 
MHz; CDCl3): δ  7.81 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 7.2 Hz, 1H), 7.58-7.55 (m, 1H), 
7.50-7.47 (m, 2H), 7.37 (t, J = 7.5 Hz, 1H), 7.32-7.19 (m, 6H), 5.74-5.66 (m, 1H), 5.11-
4.99 (m, 2H), 4.87-4.84 (m, 1H), 4.62 (d, J = 14.6 Hz, 1H), 4.33 (d, J = 15.0 Hz, 1H), 
3.51-3.44 (m, 1H), 3.33-3.23 (m, 1H), 3.05 (s, 3H), 2.37-2.32 (m, 2H), 1.84-1.75 (m, 1H), 
1.04 (t, J = 6.7 Hz, 1H), 0.86 (dd, J = 8.6, 6.8 Hz, 4H), 0.68 (d, J = 6.6 Hz, 1H), 0.55 (d, J 
= 6.7 Hz, 1H). 13C-NMR (CDCl3, 125 MHz): 170.0, 140.1, 136.9, 135.2, 132.9, 129.2, 
129.0, 128.8, 128.4, 128.4, 127.7, 127.6, 127.5, 126.7, 119.6, 116.8, 54.3, 51.7, 44.6, 35.6, 
35.0, 25.2, 22.7, 22.5. 
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 (1R,2S,5S)-N,2-dibenzyl-N-methyl-3-(phenylsulfonyl)-3-
azabicyclo[3.1.0]hexan-1-amine (18). Following the general procedure for azabicyclic 
[3.1.0] formation, to a solution of the N-methylamide 33 (0.25 g, 0.56 mmol) in THF (5.6 
mL) under an argon atmosphere was added ClTi(OiPr)3 (0.56 mL, 1M) dropwise via 
syringe.  To this solution was added cyclohexylMgCl (1.25 mL, 2M) dropwise via 
syringe pump addition over 1 hr. After 12 hrs, the reaction mixture was poured onto ice 
water and stirred for 15 mins.  The crude mixture was filtered thorough celite, and the 
two layers separated.  The aqueous layer was extracted once with EtOAc and the 
combined organics washed with brine and dried over Na2SO4.  The crude mixture was 
subjected to silica gel flash chromatography (15% ethyl acetate in hexanes) to isolate the 
corresponding major diastereomer aminocyclopropane (0.08 g, 33%). Rf = 0.5 (20% ethyl 
acetate in hexanes). 
€ 
α[ ]D
25.9
= +49.87 (c = 0.4 CHCl3). FTIR (thin film) cm-1: 3062, 3027, 
2931, 2879, 2791, 1758, 1718, 1603, 1585, 1495, 1474, 1446, 1342, 1166, 1123, 1095, 
1030, 999, 750, 719, 699, 613, 603, 582, 571. HRMS (ESI) m/z calcd. C26H29N2O2S 
[M+H]+ 433.1950, found 433.1936. 1H-NMR (500 MHz; CDCl3): δ  7.87 (d, J = 8.1 Hz, 
2H), 7.58 (dq, J = 16.4, 7.8 Hz, 4H), 7.39 (d, J = 7.7 Hz, 2H), 7.33 (t, J = 7.2 Hz, 2H), 
7.27-7.22 (m, 6H), 7.13 (s, 3H), 6.82 (d, J = 7.5 Hz, 2H), 4.00 (dd, J = 8.4, 3.1 Hz, 1H), 
3.56 (dd, J = 14.4, 2.8 Hz, 1H), 3.39 (s, 2H), 3.21 (d, J = 13.8 Hz, 1H), 3.06 (dd, J = 14.2, 
8.51 Hz, 1H), 2.76-2.73 (m, 1H), 1.70 (d, J = 4.3 Hz, 3H), 1.36 (dt, J = 8.6, 4.3 Hz, 1H), 
0.98-0.96 (m, 1H), 0.85-0.83 (m, 1H). 13C-NMR (CDCl3, 125 MHz):139.3, 138.6, 136.4, 
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132.8, 129.9, 129.2, 129.0, 128.6, 128.3, 127.9, 127.6, 127.7, 127.0, 126.6, 126.3, 60.7, 
58.7, 58.3, 51.6, 39.4, 37.9, 23.3, 18.2. 
(S)-2-benzyl-1-(phenylsulfonyl)piperidin-3-one (48). Following the 
general procedure for 3-piperidinone formation, a solution of aminocyclopropane 18 (74 
mg, 0.17 mmol) in EtOH (2 mL) was charged with 10% Pd/C (18 mg, 0.02 mmol) and 
88% formic acid (79 µL, 1.7 µmol) and the system purged with H2 three times.  The 
mixture was stirred for 20 hrs at room temperature under an atmosphere of H2, after 
which time the inorganic material was removed via filtration and the solvent reduced in 
vacuo.  The crude material was subjected to silica gel flash chromatography (15% ethyl 
acetate in hexanes) to give the corresponding piperidinone as light yellow solid (29 mg, 
52%). Rf = 0.17 (25% ethyl acetate in hexanes). 
€ 
α[ ]D
20.2
= +18.69 (c = 1.16, CHCl3). FTIR 
(thin film) cm-1: 2951, 2930, 1720, 1447, 1346, 1314, 1157, 1095, 954, 748, 690. HRMS 
(ESI) m/z calcd. C18H19NNaO3S [M+Na]+ 352.0984, found 352.0990. 1H-NMR (500 
MHz; CDCl3): δ  7.58 (d, J = 8.1 Hz, 2H), 7.50 (t, J = 6.9 Hz, 1H), 7.40-7.37 (m, 2H), 
7.23 (dd, J = 5.7, 4.1 Hz, 3H), 7.09-7.08 (m, 2H), 4.58 (t, J = 6.7 Hz, 1H), 3.76-3.71 (m, 
1H), 3.22-3.21 (m, 1H), 3.07-3.05 (m, 2H), 2.37-2.21 (m, 2H), 1.81-1.63 (m, 2H). 13C-
NMR (CDCl3, 125 MHz): 206.5, 140.0, 136.1, 132.8, 129.6, 129.3, 128.8, 127.2, 127.2, 
65.7, 40.6, 37.9, 36.9, 23.1. 
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 (1R,2S,5S)-N-benzyl-2-(4-(benzyloxy)benzyl)-N-methyl-3-
(phenylsulfonyl)-3-azabicyclo[3.1.0]hexan-1-amine (42). Following the general 
procedure for azabicyclic [3.1.0] formation, to a solution of the N-methylamide 35 (0.5 g, 
1.1 mmol) in THF (11 mL, 0.1M) under an argon atmosphere was added ClTi(OiPr)3 (1.1 
mL, 1M) dropwise via syringe.  To this solution was added cyclohexylMgBr (2.5 mL, 
2M) dropwise via syringe pump addition over 1 hr.  The solution gradually changed color 
from colorless to dark yellow and finally black over the course of 3 hrs.  TLC analysis 
showed reaction completion, and the reaction mixture was poured onto ice water and 
stirred for 15 mins.  The crude mixture was filtered thorough celite, and the two layers 
were separated.  The aqueous layer was extracted once with EtOAc and the combined 
organics washed with brine and dried over Na2SO4.  The crude mixture was subjected to 
flash chromatography (20% ethyl acetate in hexanes) to afford two diastereomers as a 
1.3:1 ratio (0.3g, 62%) as a golden oil. Rf = 0.25 (20% ethyl acetate in hexanes). 
€ 
α[ ]D
19.4
= +51.06  (c = 0.67 CHCl3). FTIR (thin film) cm-1: 3368, 3029, 2929, 1609, 1583, 
1510, 1446, 1380, 1341, 1239, 1165, 1094, 1026, 806. HRMS (ESI) m/z calcd. 
C33H35N2NaO3S [M+Na]+ 539.2368, found 539.2363. 1H-NMR (500 MHz; CDCl3): δ  
7.89 (t, J = 7.8 Hz, 2H), 7.59 (dq, J = 16.1, 7.8 Hz, 3H), 7.48 (t, J = 8.5 Hz, 2H), 7.46-
7.33 (m, 7H), 7.23-7.14 (m, 3H), 6.99 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 6.1 Hz, 2H), 5.12-
5.07 (m, 2H), 3.98 (dd, J = 7.8, 2.6 Hz, 1H), 3.51 (dd, J = 14.3, 2.8 Hz, 1H), 3.44-3.39 
(m, 2H), 3.28 (d, J = 13.7 Hz, 1H), 3.10 (dd, J = 14.3, 8.0 Hz, 1H), 2.88 (d, J = 13.7 Hz, 
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1H), 1.77 (s, 3H), 1.37 (t, J = 4.3 Hz, 1H), 1.00-0.95 (m, 1H), 0.85 (q, J = 4.9 Hz, 1H).  
13C-NMR (CDCl3, 125 MHz): 157.3, 139.2, 137.0, 136.3, 132.7, 130.89, 130.87, 128.93, 
128.44, 127.9, 127.7, 127.6, 127.4, 127.3, 126.6, 114.6, 69.9, 60.6, 58.5, 58.3, 51.6, 38.4, 
38.01, 23.1, 18.1. 
 (S)-2-(4-hydroxybenzyl)-1-(phenylsulfonyl)piperidin-3-one (50). A 
solution of aminocyclopropane 42 (21 mg, 38 µmol) in EtOH (0.4 mL, 0.1M) was 
charged with 10% Pd/C (4 mg, 3.8 µmol) and 88% formic acid (14.6 µL, 0.3 µmol) and 
the system purged with H2 three times.  The mixture was stirred for 20 hrs at room 
temperature under an atmosphere of H2, after which time the inorganic material was 
removed via filtration and the solvent reduced in vacuo.  The crude material was 
subjected to flash chromatography (30% ethyl acetate in hexanes) to give the title 
compound (10.1 mg, 55%). Rf = 0.3 (30% ethyl acetate in hexanes). 
€ 
α[ ]D
17.1
= +3.95  (c = 
0.19, CHCl3). FTIR (thin film) cm-1: 3401, 2924, 1715, 1614, 1516, 1447, 1313, 1264, 
1155, 1091, 931. HRMS (ESI) m/z calcd. C24H21NNaO4S [M+Na]+ 382.1079, found 
382.1074. 1H-NMR (500 MHz; CDCl3): δ  7.64 (d, J = 7.7 Hz, 2H), 7.53 (t, J = 7.3 Hz, 
1H), 7.43 (t, J = 7.7 Hz, 2H), 6.97 (d, J = 8.2 Hz, 2H), 6.70 (d, J = 8.2 Hz, 2H), 4.98 
(s(b), 1H), 4.54 (t, J = 6.8 Hz, 1H), 3.76 (dt, J = 14.0, 4.8 Hz, 1H), 3.24 (ddd, J = 14.2, 
9.8, 4.4 Hz, 1H), 3.02 (d, J = 6.9 Hz, 2H), 2.35-2.23 (m, 2H), 1.77-1.66 (m, 2H), 1.26 (d, 
J = 8.7 Hz, 2H). 13C-NMR (CDCl3, 125 MHz): 207.3, 154.7, 140.2, 132.6, 130.4, 129.1, 
127.8, 127.0, 115.5, 65.7, 40.8, 36.6, 33.1, 30.9, 14.1, 14.0. 
N
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 (1R,2S,5S)-N-benzyl-N-methyl-2-((1-methyl-1H-indol-3-yl)methyl)-
3-(phenylsulfonyl)-3-azabicyclo[3.1.0]hexan-1-amine (44). Following the general 
procedure for azabicyclic [3.1.0] formation, to a solution of the N-methylamide 37 (0.25 
g, 0.49 mmol) in THF (5 mL) under an argon atmosphere was added ClTi(OiPr)3 (0.5 
mL, 1M) dropwise via syringe.  To this solution was added cyclohexylMgCl (1.12 mL, 
2M) dropwise via syringe pump addition over 1 hr. After 12 hrs, the reaction mixture was 
poured onto ice water and stirred for 15 mins.  The crude mixture was filtered thorough 
celite, and the two layers separated.  The aqueous layer was extracted once with EtOAc 
and the combined organics washed with brine and dried over Na2SO4.  The crude mixture 
was subjected to silica gel flash chromatography (20% ethyl acetate in hexanes) to isolate 
the corresponding major diastereomer aminocyclopropane as an orange oil (0.07 g, 30%). 
Rf = 0.32 (20% ethyl acetate in hexanes). 
€ 
α[ ]D
25.5
= +56.26 (c = 0.4, CHCl3). FTIR (thin 
film) cm-1: 3058, 3027, 2930, 2883, 2795, 1615, 1473, 1446, 1377, 1342, 1251, 1217, 
1165, 1128, 1095, 1073, 1031, 829, 742, 719, 694, 666, 613, 590, 570. HRMS (ESI) m/z 
calcd. C29H32N3O2S [M+H]+ 486.2215, found 486.2211.  1H-NMR (500 MHz; CDCl3): δ  
7.91 (d, J = 6.9 Hz, 2H), 7.77 (d, J = 7.9 Hz, 1H), 7.58-7.50 (m, 3H), 7.29 (d, J = 8.2 Hz, 
1H), 7.21 (dd, J = 8.1, 1.1 Hz, 1H), 7.13 (ddd, J = 7.9, 7.0, 0.9 Hz, 1H), 7.08-7.07 (m, 
3H), 7.02 (s, 1H), 6.71-6.69 (m, 2H), 4.15 (dd, J = 8.4, 3.0 Hz, 1H), 3.74-3.68 (m, 3H), 
3.64-3.60 (m, 1H), 3.46 (dd, J = 10.1, 5.8 Hz, 1H), 3.39-3.37 (m, 1H), 3.15-3.11 (m, 2H), 
2.66 (d, J = 13.7 Hz, 1H), 1. 58 (s, 3H), 1.34 (q, J = 6.8 Hz, 1H), 1.26-1.20 (m, 1H). 13C-
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NMR (CDCl3, 125 MHz): 139.4, 137.1, 136.9, 132.7, 129.0, 128.6, 128.0, 127.9, 127.72, 
127.71, 126.5, 121.4 119.3, 118.8, 110.9, 109.1, 60.0, 59.1, 58.2, 51.7, 37.7, 32.6, 29.1, 
23.4, 18.4. 
 (S)-2-((1-methyl-1H-indol-3-yl)methyl)-1-(phenylsulfonyl)piperidin-
3-one (52). Following the general procedure for 3-piperidinone formation, a solution of 
aminocyclopropane 44 (55 mg, 0.11 mmol) in EtOH (1.1 mL) was charged with 10% 
Pd/C (12 mg, 0.01 mmol) and 88% formic acid (52 µL, 1.1 µmol) and the system purged 
with H2 three times.  The mixture was stirred for 20 hrs at room temperature under an 
atmosphere of H2, after which time the inorganic material was removed via filtration and 
the solvent reduced in vacuo.  The crude material was subjected to silica gel flash 
chromatography (20% ethyl acetate in hexanes) to give the corresponding piperidinone 
(28 mg, 65%). Rf = 0.3 (20% ethyl acetate in hexanes). 
€ 
α[ ]D
25.6
= +32.6 (c = 1.34, CHCl3). 
FTIR (thin film) cm-1: 3057, 3026, 2928, 1720, 1615, 1552, 1474, 1447, 1425, 1376, 
1348, 1319, 1248, 1160, 1131, 1093, 1012, 956, 925, 881, 858, 745, 719, 690, 667, 650, 
587, 568. HRMS (ESI) m/z calcd. C21H23N2O3S [M+H]+ 383.1429, found 383.1447. 1H-
NMR (500 MHz; CDCl3): δ  7.61 (dd, J = 8.4, 1.2 Hz, 2H), 7.48 (dt, J = 17.4, 8.0 Hz, 
2H), 7.33 (t, J = 7.8 Hz, 2H), 7.22-7.17 (m, 2H), 7.07 (ddd, J = 7.9, 6.8, 1.1 Hz, 1H), 6.76 
(s, 1H), 4.62 (t, J = 6.6 Hz, 1H), 3.78 (dt, J = 14.4, 4.8 Hz, 1H), 3.68-3.63 (m, 3H), 3.28-
3.22 (m, 3H), 2.26 (td, J = 9.8, 6.3 Hz, 2H), 1.75-1.65 (m, 2H). 13C-NMR (CDCl3, 125 
N
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MHz): 206.9, 140.1, 136.8, 132.5, 129.0, 127.8, 127.7, 126.9, 126.8, 121.7, 119.3, 118.8, 
109.2, 108.5, 64.9, 40.7, 36.8, 32.7, 28.0, 23.1. 
 (1R,2S,5S)-N-benzyl-2-isobutyl-N-methyl-3-(phenylsulfonyl)-3-
azabicyclo[3.1.0]hexan-1-amine (46). Following the general procedure for azabicyclic 
[3.1.0] formation, to a solution of the N-methylamide 39 (0.5 g, 1.21 mmol) in THF (12 
mL) under an argon atmosphere was added ClTi(OiPr)3 (1.21 mL, 1M) dropwise via 
syringe.  To this solution was added cyclohexylMgCl (2.71 mL, 2M) dropwise via 
syringe pump addition over 1 hr. After 12 hrs, the reaction mixture was poured onto ice 
water and stirred for 15 mins.  The crude mixture was filtered thorough celite, and the 
two layers separated.  The aqueous layer was extracted once with EtOAc and the 
combined organics washed with brine and dried over Na2SO4.  The crude mixture was 
subjected to silica gel flash chromatography (15% ethyl acetate in hexanes) to isolate the 
corresponding major diastereomer aminocyclopropane as a dark orange oil (0.27 g, 56%). 
Rf = 0.6 (30% ethyl acetate in hexanes). 
€ 
α[ ]D
25.9
= +80.2 (c = 0.6, CH2Cl2). FTIR (thin 
film) cm-1: 3063, 3029, 2954, 2867, 2794, 1494, 1468, 1446, 1342, 1166, 1123, 1094, 
1071, 1028, 750, 717, 693, 615, 595, 570. HRMS (ESI) m/z calcd. C23H31N2O2S [M+H]+ 
399.2106, found 399.2106. 1H-NMR (500 MHz; CDCl3): δ  7.85 (d, J = 6.8 Hz, 2H), 
7.60-7.52 (m, 3H), 7.24-7.18 (m, 3H), 7.07 (d, J = 6.7 Hz, 2H), 3.72 (dd, J = 6.8, 4.8 Hz, 
1H), 3.43 (s, ), 3.40 (d, J = 3.6 Hz, 2H), 3.34 (s, 1H), 2.12-2.08 (m, 1H), 2.00-1.94 (m, 
4H), 1.62 (dt, J = 13.8, 6.8 Hz, 1H), 1.45 (dt, J = 7.5, 3.9 Hz, 1H), 1.04 (dd, J = 8.3, 6.6 
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Hz, 8H), 0.94 (t, J = 5.1 Hz, 2H). 13C-NMR (CDCl3, 125 MHz): 139.3, 137.2, 132.8, 
129.1, 128.3, 128.3, 128.0, 127.1, 60.1, 58.9, 58.6, 52.4, 43.2, 38.6, 25.4, 25.2, 23.9, 23.0, 
22.3, 17.5. 
 (S)-2-isobutyl-1-(phenylsulfonyl)piperidin-3-one (54). Following the 
general procedure for 3-piperidinone formation, a solution of aminocyclopropane 46 
(0.22 g, 0.56 mmol) in EtOH (5.6 mL) was charged with 10% Pd/C (0.06 g, 0.06 mmol) 
and 88% formic acid (0.26 mL, 5.6 µmol) and the system purged with H2 three times.  
The mixture was stirred for 20 hrs at room temperature under an atmosphere of H2, after 
which time the inorganic material was removed via filtration and the solvent reduced in 
vacuo.  The crude material was subjected to silica gel flash chromatography (20% ethyl 
acetate in hexanes) to give the corresponding piperidinone (0.11 g, 64%). Rf = 0.5 (30% 
ethyl acetate in hexanes). 
€ 
α[ ]D
26.4
= +38.9  (c = 0.6, CH2Cl2). FTIR (thin film) cm-1: 3066, 
2958, 2871, 1719, 1585, 1468, 1447, 1422, 1388, 1349, 1317, 1289, 1249, 1164, 1128, 
1091, 1072, 999, 939, 880, 849, 755, 733, 716, 691, 655, 591, 572, 508. HRMS (ESI) m/z 
calcd. C15H22NO3S [M+H]+ 296.1320, found 296.1320. 1H-NMR (500 MHz; CDCl3): δ  
7.82-7.80 (m, 2H), 7.59-7.56 (m, 1H), 7.53-7.49 (m, 2H), 4.40-4.37 (m, 1H), 3.91-3.86 
(m, 1H), 3.39 (ddd, J = 14.8, 11.0, 3.9 Hz, 1H), 2.38 (ddd, J = 16.0, 11.2, 6.3 Hz, 1H), 
2.12-2.07 (m, 1H), 1.82-1.78 (m, 1H), 1.71-1.57 (m, 3H), 1.44 (ddd, J = 13.6, 7.7, 6.1 Hz, 
1H), 0.94 (dd, J = 19.1, 6.5 Hz, 7H). 13C-NMR (CDCl3, 125 MHz): 207.2, 140.7, 133.0, 
129.5, 127.2, 63.1, 39.6, 39.5, 36.1, 24.5, 23.6, 22.9, 21.9 
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(1R,2S,6R)-N,2-dibenzyl-N-methyl-3-(phenylsulfonyl)-3-
azabicyclo[4.1.0]heptan-1-amine (41). Following the general procedure for azabicyclic 
[4.1.0] aminocyclopropane formation, to a solution of the N-methylamide 34 (0.36 g, 
0.78 mmol) in THF (15.7 mL) under an argon atmosphere was added ClTi(OiPr)3 (0.78 
mL, 1M) dropwise via syringe.  To this solution was added cyclohexylMgCl (1.76 mL, 
2M) dropwise via syringe pump addition over 1 hr.  After 12 hrs, the reaction mixture 
was poured onto ice water and stirred for 15 mins.  The crude mixture was filtered 
thorough celite, and the two layers were separated.  The aqueous layer was extracted once 
with EtOAc and the combined organics washed with brine and dried over Na2SO4.  The 
crude mixture was subjected to silica gel flash chromatography (15% ethyl acetate in 
hexanes) to isolate the corresponding major diastereomer aminocyclopropane as a light 
yellow solid (0.18 g, 51%). Rf = 0.4 (20% ethyl acetate in hexanes). 
€ 
α[ ]D
25.8
= +14.8 (c = 
0.4, CHCl3). FTIR (thin film) cm-1: 3063, 3027, 2926, 2857, 2788, 1651, 1603, 1495, 
1447, 1319, 1273, 1219, 1155, 1114, 1089, 1074, 1028, 979, 938, 908, 859, 786, 747, 720, 
694, 630, 591, 570, 519. HRMS (ESI) m/z calcd. C27H31N2O2S [M+H]+ 447.2106, found 
447.2107. 1H-NMR (500 MHz; CDCl3): δ  7.40-7.37 (m, 1H), 7.33-7.30 (m, 2H), 7.28-
7.22 (m, 8H), 7.21-7.18 (m, 4H), 5.05-5.02 (m, 1H), 3.70-3.67 (m, 1H), 3.33 (dd, J = 
14.8, 5.9 Hz, 1H), 2.84 (dd, J = 14.0, 4.9 Hz, 1H), 2.69 (dd, J = 14.1, 9.9 Hz, 1H), 2.59 
(ddd, J = 14.8, 12.8, 3.5 Hz, 1H), 2.22-2.13 (m, 4H), 1.61-1.57 (m, 1H), 1.27 (dt, J = 10.4, 
5.4 Hz, 2H), 0.86-0.83 (m, 1H), 0.72 (t, J = 5.8 Hz, 1H). 13C-NMR (CDCl3, 125 MHz): 
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140.7, 139.7, 138.5, 132.1, 129.9, 128.8, 128.6, 128.5, 128.3, 127.4, 126.9, 126.7, 58.8, 
58.8, 52.0, 48.6, 40.1, 37.6, 35.8, 22.4, 21.3, 15.8. 
(S)-2-benzyl-1-(phenylsulfonyl)azepan-3-one (49). Following the general 
procedure for 3-azepinone formation, a solution of aminocyclopropane 41 (49 mg, 0.11 
mmol) in EtOH (1.1 mL) was charged with 10% Pd/C (60 mg, 0.06 mmol) and 88% 
formic acid (52 µL, 1.1 µmol) and the system purged with H2 three times.  The mixture 
was stirred for 20 hrs at room temperature under an atmosphere of H2, after which time 
the inorganic material was removed via filtration and the solvent reduced in vacuo.  The 
crude material was subjected to silica gel flash chromatography (25% ethyl acetate in 
hexanes) to give the corresponding 3-azepinone as a light yellow solid (18 mg, 49%). Rf 
= 0.37 (20% ethyl acetate in hexanes). 
€ 
α[ ]D
26.1
= +19.5  (c = 0.75 CHCl3). FTIR (thin film) 
cm-1: 3063, 3029, 2931, 2875, 1723, 1651, 1603, 1585, 1496, 1447, 1333, 1291, 1260, 
1213, 1163, 1097, 1073, 1031, 999, 982, 950, 929, 906, 849, 784, 752, 721, 691, 651, 591, 
555. HRMS (ESI) m/z calcd. C19H22NO3S [M+H]+ 344.1320, found 344.1314. 1H-NMR 
(500 MHz; CDCl3): δ  7.54-7.48 (m, 3H), 7.37 (t, J = 7.8 Hz, 2H), 7.22-7.18 (m, 3H), 
7.07-7.06 (m, 2H), 4.69 (t, J = 6.2 Hz, 1H), 3.60-3.54 (m, 1H), 3.19-3.10 (m, 2H), 3.02 
(dd, J = 13.9, 7.4 Hz, 1H), 2.29-2.21 (m, 1H), 2.03-1.97 (m, 1H), 1.10-1.04 (m, 1H), 0.94 
(d, J = 6.6 Hz, 3H). 13C-NMR (CDCl3, 125 MHz): 210.2, 139.4, 137.0, 132.6, 132.5, 
129.7, 129.1, 129.0, 128.5, 127.0, 126.9, 65.5, 40.3, 39.8, 38.0, 27.7, 13.7. 
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 (1R,2S,6R)-N-benzyl-2-(4-(benzyloxy)benzyl)-N-methyl-3-
azabicyclo[4.1.0]heptan-1-amine (43). To a solution of the N-methylamide 36 (0.2 g, 
0.3 mmol) in THF (7.5 mL, 0.05M) under an argon atmosphere was added ClTi(OiPr)3 
(1.3 mL, 0.3M) dropwise via syringe.  To this solution was added cyclohexylMgBr (0.8 
mL, 2M) dropwise via syringe pump addition over 1 hr. After 4 hrs, the reaction mixture 
was poured onto ice water and stirred for 15 mins.  The crude mixture was filtered 
thorough celite, and the two layers were separated.  The aqueous layer was extracted once 
with EtOAc and the combined organics washed with brine and dried over Na2SO4.  The 
crude mixture was subjected to flash chromatography (10% ethyl acetate in hexanes) to 
afford the cyclopropane 13 (0.1g, 48%) as a golden oil.  Rf = 0.26 (10% ethyl acetate in 
hexanes). 
€ 
α[ ]D
19.5
= −1.45  (c = 0.33 CHCl3). FTIR (thin film) cm-1: 3294, 3005, 3063, 
3030, 2927, 2855, 1742, 1648, 1610, 1584, 1511, 1453, 1375, 1320, 1242, 1155, 1089, 
1026. HRMS (ESI) m/z calcd. C34H37N2NaO3S [M+Na]+ 553.2525, found 553.2521. 1H-
NMR (500 MHz; CDCl3): δ  7.51-7.22 (m, 15H), 7.10 (t, J = 13.8 Hz, 2H), 6.88 (q, J = 
10.3 Hz, 2H), 5.07-5.03 (m, 2H), 5.01 (dd, J = 9.6, 4.8 Hz, 1H), 3.39 (dd, J = 14.6, 5.7 
Hz, 1H), 2.80 (dt, J = 13.4, 6.3 Hz, 1H), 2.72-2.58 (m, 2H), 2.26-2.18 (m, 3H), 1.64-1.57 
(m, 1H), 1.32-1.22 (m, 2H), 0.87 (dd, J = 9.8, 5.2 Hz, 1H), 0.74 (t, J = 5.8 Hz, 1H). 13C-
NMR (CDCl3, 125 MHz): 157.5, 140.7, 139.5, 137.0, 131.8, 130.6, 130.5, 129.0, 128.5, 
128.4, 128.3, 128.0, 127.9, 127.4, 127.3, 127.1, 126.9, 126.6, 114.7, 70.2, 69.9, 58.6, 51.9, 
48.3, 39.0, 37.4, 35.6, 35.4, 25.3, 24.0, 22.4, 21.0, 15.5. 
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 (S)-2-(4-hydroxybenzyl)-1-(phenylsulfonyl)azepan-3-one (51). A 
solution of aminocyclopropane 43 (21 mg, 38 µmol) in EtOH (0.4 mL) was charged with 
10% Pd/C (4 mg, 3.8 µmol) and 88% formic acid (14.6 µL, 0.3 µmol) and the system 
purged with H2 three times.  The mixture was stirred for 20 hrs at room temperature 
under an atmosphere of H2, after which time the inorganic material was removed via 
filtration and the solvent reduced in vacuo.  The crude material was subjected to flash 
chromatography (30% ethyl acetate in hexanes) to give azepan-3-one 35 (10.1 mg, 55%). 
Rf = 0.3 (30% ethyl acetate in hexanes). 
€ 
α[ ]D
17.1
= +3.95  (c = 0.19, CHCl3). FTIR (thin 
film) cm-1: 3401, 2924, 1715, 1614, 1516, 1447, 1313, 1264, 1155, 1091, 931. HRMS 
(ESI) m/z calcd. C24H21NNaO4S [M+Na]+ 382.1079, found 382.1074. 1H-NMR (500 
MHz; CDCl3): δ  7.60 (t, J = 14.6 Hz, 2H), 7.51 (q, J = 7.7 Hz, 1H), 7.44-7.39 (m, 2H), 
6.95 (d, J = 8.3 Hz, 2H), 6.69 (d, J = 8.4 Hz, 2H), 4.52 (t, J = 7.4 Hz, 1H), 3.85 (d, J = 
14.7 Hz, 1H), 3.43-3.37 (m, 1H), 2.98 (qd, J = 14.6, 7.4 Hz, 2H), 2.45 (dquintet, J = 12.6, 
6.3 Hz, 1H), 2.07-1.95 (m, 2H), 1.83 (ddd, J = 10.8, 5.7, 2.8 Hz, 1H). 13C-NMR (CDCl3, 
125 MHz): 207.3, 154.7, 140.2, 132.6, 130.4, 129.1, 127.8, 127.0, 115.5, 65.7, 40.8, 36.6, 
33.1, 30.9, 14.1, 14.0. 
 (1R,2S,6R)-N-benzyl-N-methyl-2-((1-methyl-1H-indol-3-yl)methyl)-
3-(phenylsulfonyl)-3-azabicyclo[4.1.0]heptan-1-amine (45). Following the general 
N
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procedure for azabicyclic [4.1.0] aminocyclopropane formation, to a solution of the N-
methylamide 38 (0.34 g, 0.66 mmol) in THF (13.3 mL) under an argon atmosphere was 
added ClTi(OiPr)3 (0.66 mL, 1M) dropwise via syringe.  To this solution was added 
cyclohexylMgCl (1.50 mL, 2M) dropwise via syringe pump addition over 1 hr.  After 12 
hrs, the reaction mixture was poured onto ice water and stirred for 15 mins.  The crude 
mixture was filtered thorough celite, and the two layers were separated.  The aqueous 
layer was extracted once with EtOAc and the combined organics washed with brine and 
dried over Na2SO4.  The crude mixture was subjected to silica gel flash chromatography 
(20% ethyl acetate in hexanes) to isolate the corresponding major diastereomer 
aminocyclopropane as a light yellow solid (0.23 g, 69%). Rf = 0.3 (20% ethyl acetate in 
hexanes). 
€ 
α[ ]D
28.2
= +14.2 (c = 0.5, CHCl3). FTIR (thin film) cm-1: 3059, 3026, 2930, 
2855, 2789, 1615, 1585, 1555, 1493, 1473, 1446, 1424, 1376, 1343, 1323, 1271, 1252, 
1217, 1154, 1126, 1089, 1063, 1027, 1012, 981, 935, 861, 794, 738, 695, 665, 632, 614, 
585, 562, 525. HRMS (ESI) m/z calcd. C30H34N3O2S [M+H]+ 500.2372, found 500.2371. 
1H-NMR (500 MHz; CDCl3): δ  7.62 (d, J = 7.9 Hz, 1H), 7.30-7.06 (m, 13H), 6.75 (s, 
1H), 5.01 (t, J = 7.0 Hz, 1H), 3.66-3.59 (m, 5H), 3.50 (dt, J = 14.0, 6.3 Hz, 1H), 2.90 (t, J 
= 6.9 Hz, 2H), 2.73-2.67 (m, 1H), 2.22-2.16 (m, 4H), 1.90-1.86 (m, 1H), 1.75-1.70 (m, 
1H), 1.65 (d, J = 13.7 Hz, 1H), 1.55-1.52 (m, 1H), 1.31-1.23 (m, 4H), 0.85 (dd, J = 9.6, 
5.1 Hz, 1H), 0.79 (t, J = 5.8 Hz, 1H). 13C-NMR (CDCl3, 125 MHz): 141.0, 139.9, 136.9, 
131.6, 128.4, 128.2, 128.2, 127.7, 126.8, 126.8, 121.6, 119.1, 119.0, 110.9, 109.3, 77.4, 
70.4, 58.6, 51.1, 48.5, 37.6, 36.1, 35.7, 32.7, 29.5, 25.6, 24.3, 23.2, 21.3. 
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 (S)-2-((1-methyl-1H-indol-3-yl)methyl)-1-(phenylsulfonyl)azepan-3-
one (53). Following the general procedure for 3-azepinone formation, a solution of 
aminocyclopropane 45 (70 mg, 0.14 mmol) in EtOH (1.4 mL) was charged with 10% 
Pd/C (30 mg, 0.03 mmol) and 88% formic acid (65 µL, 1.4 µmol) and the system purged 
with H2 three times.  The mixture was stirred for 20 hrs at room temperature under an 
atmosphere of H2, after which time the inorganic material was removed via filtration and 
the solvent reduced in vacuo.  The crude material was subjected to silica gel flash 
chromatography (25% ethyl acetate in hexanes) to give the corresponding 3-azepinone as 
a yellow solid (15 mg, 27%). Rf = 0.3 (30% ethyl acetate in hexanes). 
€ 
α[ ]D
24.8
= +14.7(c = 
0.3, CHCl3). FTIR (thin film) cm-1: 3058, 2924, 2852, 1722, 1646, 1615, 1585, 1551, 
1470, 1446, 1377, 1328, 1290, 1260, 1217, 1159, 1094, 1073, 1036, 954, 925, 898, 849, 
802, 742, 722, 690, 667, 647, 627, 583, 567. HRMS (ESI) m/z calcd. C22H25N2O3S 
[M+H]+ 397.1586, found 397.1588. 1H-NMR (500 MHz; CDCl3): δ  7.56-7.55 (m, 2H), 
7.48 (dt, J = 7.8, 0.4 Hz, 2H), 7.35-7.32 (m, 2H), 7.24-7.19 (m, 3H), 7.09-7.06 (m, 1H), 
6.69 (s, 1H), 4.71-4.69 (m, 1H), 3.65 (d, J = 7.3 Hz, 3H), 3.64-3.60 (m, 1H), 3.31-3.28 
(m, 2H), 3.18-3.15 (m, 1H), 2.23-2.19 (m, 1H), 1.94-1.90 (m, 1H), 1.05-1.00 (m, 1H), 
0.93-0.90 (m, 2H). 13C-NMR (CDCl3, 125 MHz): 210.9, 139.9, 136.9, 132.5, 129.0, 
128.3, 127.9, 126.9, 121.8, 119.4, 119.3, 109.6, 109.2, 65.2, 40.8, 40.1, 32.8, 29.9, 28.3, 
27.9, 14.0. 
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 (1R,2S,6R)-N-benzyl-2-isobutyl-N-methyl-3-(phenylsulfonyl)-3-
azabicyclo[4.1.0]heptan-1-amine (47). Following the general procedure for azabicyclic 
[4.1.0] aminocyclopropane formation, to a solution of the N-methylamide 40 (0.27 g, 
0.62 mmol) in THF (12.5 mL) under an argon atmosphere was added ClTi(OiPr)3 (0.62 
mL, 1M) dropwise via syringe.  To this solution was added cyclohexylMgCl (1.40 mL, 
2M) dropwise via syringe pump addition over 1 hr.  After 12 hrs, the reaction mixture 
was poured onto ice water and stirred for 15 mins.  The crude mixture was filtered 
thorough celite, and the two layers were separated.  The aqueous layer was extracted once 
with EtOAc and the combined organics washed with brine and dried over Na2SO4.  The 
crude mixture was subjected to silica gel flash chromatography (15% ethyl acetate in 
hexanes) to isolate the corresponding major diastereomer aminocyclopropane (0.18 g, 
68%). Rf = 0.7 (30% ethyl acetate in hexanes). 
€ 
α[ ]D
28.6
= +65.2 (c = 0.6, CH2Cl2). FTIR 
(thin film) cm-1: 3064, 3027, 3005, 2954, 2867, 2837, 2787, 2704, 2333, 1961, 1896, 
1813, 1651, 1602, 1586, 1494, 1467, 1447, 1416, 1366, 1331, 1291, 1272, 1244, 1224, 
1162, 1129, 1089, 1072, 1063, 1028, 1004, 983, 951, 927, 854, 825, 789, 736, 696, 669, 
630, 612, 584, 568, 551, 515, 466. HRMS (ESI) m/z calcd. C24H33N2O2S [M+H]+ 
413.2263, found 413.2260. 1H-NMR (500 MHz; CDCl3): δ  7.89 (d, J = 7.4 Hz, 2H), 
7.53-7.43 (m, 4H), 7.28-7.19 (m, 8H), 4.68 (d, J = 10.4 Hz, 1H), 3.69 (d, J = 12.8 Hz, 
1H), 3.54 (d, J = 12.8 Hz, 1H), 3.45 (dd, J = 15.0, 5.6 Hz, 1H), 2.57 (ddd, J = 15.0, 13.1, 
3.3 Hz, 1H), 2.13 (s, 4H), 1.83 (tt, J = 12.8, 6.2 Hz, 1H), 1.68 (ddtd, J = 13.2, 9.9, 6.6, 3.3 
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Hz, 1H), 1.51 (ddd, J = 18.0, 14.9, 11.7 Hz, 3H), 1.14-1.09 (m, 2H), 1.06 (d, J = 6.4 Hz, 
3H), 0.88 (d, J = 6.7 Hz, 3H), 0.69 (dd, J = 9.7, 5.1 Hz, 1H), 0.56 (t, J = 5.7 Hz, 1H). 13C-
NMR (CDCl3, 125 MHz): 141.3, 139.4, 132.3, 128.8, 128.7, 128.3, 128.1, 128.1, 127.3, 
127.0, 126.7, 58.8, 48.5, 48.1, 43.4, 37.4, 35.5, 24.6, 24.1, 21.9, 21.7, 21.0, 14.9. 
 (S)-2-isobutyl-1-(phenylsulfonyl)azepan-3-one (55). Following the general 
procedure for 3-azepinone formation, a solution of aminocyclopropane 47 (47 mg, 0.11 
mmol) in EtOH (1.2 mL) was charged with 10% Pd/C (62 mg, 0.06 mmol) and 88% 
formic acid (54 µL, 1.2 µmol) and the system purged with H2 three times.  The mixture 
was stirred for 20 hrs at room temperature under an atmosphere of H2, after which time 
the inorganic material was removed via filtration and the solvent reduced in vacuo.  The 
crude material was subjected to silica gel flash chromatography (15% ethyl acetate in 
hexanes) to give the corresponding 3-azepinone (15 mg, 42%). Rf = 0.3 (20% ethyl 
acetate in hexanes). 
€ 
α[ ]D
28.4
= +20.9  (c = 1.5, CHCl3). FTIR (thin film) cm-1: 3299, 3066, 
2958, 2931, 2871, 1717, 1651, 1585, 1447, 1341, 1318, 1290, 1267, 1233, 1166, 1091, 
1072, 1032, 999, 981, 931, 884, 838, 748, 730, 691, 633, 585, 571. HRMS (ESI) m/z 
calcd. C16H23NO3NaS [M+Na]+ 332.1287, found 332.1287.1H-NMR (500 MHz; CDCl3): 
δ  7.77 (d, J = 7.9 Hz, 2H), 7.48-7.47 (m, 3H), 4.40-4.37 (m, 1H), 3.90-3.86 (m, 1H), 
3.47-3.41 (m, 1H), 2.51-2.48 (m, 1H), 1.78-1.74 (m, 1H), 1.70-1.62 (m, 2H), 1.49-1.47 
(m, 1H), 1.44-1.39 (m, 1H), 1.24-1.22 (m, 1H), 1.08-1.04 (m, 1H), 0.94-0.79 (m, 10H). 
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13C-NMR (CDCl3, 125 MHz): 208.2, 140.7, 132.8, 129.3, 129.2, 127.1, 63.2, 40.2, 39.5, 
39.1, 33.2, 24.4, 22.7, 21.9, 14.0. 
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Chapter 4: Synthetic investigations toward the formal synthesis of (−)-
epicoccin G and related epidithiodiketopiperazine alkaloids 
 
 
4.1) Biological significance of epidithiodiketopiperazine alkaloids 
 
Epipolythiodiketopiperazine (ETP) alkaloids constitute a rapidly growing family of 
natural diketopiperazine alkaloids, most of which are classified as fungal secondary 
metabolites (Figure 4.1).1,2,3 Diketopiperazines (DKPs) are the central precursors to ETPs, 
and are believed to be biosynthesized from amino acids either by nonribosomal peptide 
synthases (NRPS) or by tRNA-dependent enzymes called cyclodipeptide synthases 
(CDPS).3 ETPs are formed by oxidative modifications of corresponding DKPs. In 
addition to their unique structural features, ETP alkaloids possess a wide range of 
biological activities, including cytotoxic, antibacterial, antimicrobial, antitumor, apoptotic, 
antivirus, antiallergic, and antimalarial activities.1 However, the underlying molecular 
mechanisms of these biological activities have yet to be fully elucidated.  
 
Figure 4.1. Diversity of bridged diketopiperazine alkaloids. 
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The oldest and perhaps most well-known ETP alkaloid is gliotoxin, which was isolated in 
1943 (Figure 4.1).4 The chemical structure of gliotoxin was incorrectly assigned until 
1958, when Woodward and coworkers were able to establish the correct structure that 
included the unprecedented disulfide bridge in the DKP core via degradation studies.5 
The total synthesis of (±)-gliotoxin was subsequently accomplished by Fukuyama and 
Kishi in 19766 and the synthesis of the optically active form of gliotoxin immediately 
followed in 1981.7 The variety of biological properties, such as antiviral, antibacterial, 
and immunosuppressive activities, displayed by gliotoxin are thought to be a direct 
consequence of the reactivity of the disulfide bridge, which is capable of generating 
reactive oxygen species as well as engaging in protein conjugation (Figure 4.2).3,8  
 
Figure 4.2. Bioactivity of gliotoxin.3 
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precursors and intermediates, the genes and enzymes encoded by them are the main 
targets, which provides deeper insight into nature’s chemical craftsmanship.3 In 2005, the 
full genome sequencing of Aspergillus fumigatus was accomplished, enabling the 
identification of the 12 gene cluster that is responsible for the biosynthesis of gliotoxin.9 
The largest of these genes, gliP, was subsequently shown to code for a multimodular 
NRPS, which is responsible for the formation of the DKP that consists of L-
phenylalanine and L-serine. 10  Following this discovery, in a series of seminal 
publications from 2010-2013, Hertweck and coworkers achieved the landmark 
elucidation of all the remaining key steps in the biosynthesis of gliotoxin, from the 
introduction of the sulfur atoms into the DKP to the formation of the disulfide bridge.11 
Most notably, in 2010, Hertweck11a and Doyle12 groups independently showed that the 
formation of the disulfide bridge in gliotoxin is catalyzed by an FAD-dependent 
homodimeric enzyme GliT, which uses molecular oxygen as the stoichiometric oxidant to 
oxidize the dithiol to the disulfide (Figure 4.2). The X-ray structures of GliT as well as 
two related thiol oxidases were solved by Huber and Groll in collaboration with 
Hertweck recently, further proving the unequivocal mechanism behind the formation of 
the disulfide bridge.13 Taken together, these findings provide crucial foundations to 
further understand the biosynthesis of not only gliotoxin, but other related natural ETP 
alkaloids as well. Furthermore, by understanding the biosynthesis of these interesting 
natural products, implications in development of future therapeutics could be made. 
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4.2) Previous syntheses of epidithiodiketopiperazine alkaloids 
 
During the 1970s, Kishi published a series of landmark total syntheses of ETP alkaloids, 
which includes (±)-dehydrogliotoxin, 14  (±)-sporidesmin A, 15  (±)-gliotoxin,6 and (±)-
hyalodendrin.7 The main synthetic strategy featured an inside-out approach, in which the 
ETP core was formed in the early stage of the synthesis followed by its elaboration to the 
corresponding target compounds. This strategy was carefully designed, since the 
methodologies that existed at the time to incorporate sulfur atoms in the DKP involved 
the use of harsh reaction conditions,16 which may be detrimental if employed at later 
stages of the synthesis. Therefore, Kishi reasoned that sulfur should be incorporated 
earlier on, protected, and then revealed in the final stages of the synthesis.7 Similar to his 
synthetic approach undertaken for the syntheses of (±)-dehydrogliotoxin14 and (±)-
sporidesmin A15, Trown’s methodology16a was utilized to obtain dithiol 2 from DKP 1 en 
route to the synthesis of (±)-gliotoxin. (Scheme 4.1).6 More specifically, MOM 
protection of the DKP nitrogen followed by radical bromination using NBS and benzoyl 
peroxide (BPO), and subsequent elimination, and nucleophilic displacement with 
potassium thioacetate afforded a mixture of cis and trans isomers of dithioacetate. 
Hydrolysis of the thioesters afforded the dithiol 2. Reaction with p-anisaldehyde in the 
presence of boron trifluoride etherate gave a 1:1 diastereomeric mixture of thioacetal (±)-
3. N-alkylation with Michael acceptor 4 furnished the intermediate (±)-5 as a mixture of 
diastereomers. After functional group manipulations to generate benzylic chloride (±)-6, 
lithiation followed by intramolecular alkylation provided intermediate (±)-7, completing 
the formation of carbon skeleton. Finally, benzyl ether deprotection and subsequent 
oxidation unraveled the disulfide bridge, completing the synthesis of (±)-gliotoxin.6  
! 309 
 
Scheme 4.1. Kishi’s synthesis of (±)-gliotoxin.6 
 
Another pivotal synthesis of ETP alkaloid was reported in 2009 by the Movassaghi group 
in their total synthesis of (+)-11,11’-dideoxyverticillin A (Figure 4.1).17 Although the 
dimeric subset of ETP alkaloids in which their compound belongs to has been known for 
nearly 4 decades since the isolation of (+)-chaetocin A18 and (+)-verticillin A19, there was 
no known synthesis of such compounds, marking their accomplishment as the first 
example of chemical synthesis of a dimeric ETP alkaloid (Figure 4.1). (+)-11,11’-
dideoxyverticillin A was first isolated in 1999 from a marine-derived fungus of the genus 
Penicillum.17 In addition to its cytotoxicity, the alkaloid possess relatively potent tyrosine 
kinase-inhibitory activity of the epidermal growth factor receptor (IC50 = 0.14 nM).17 
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employ thiolation and subsequent disulfide bridge formation to be carried out after the 
complete assembly of the carbon framework (Scheme 4.2). 
 
Scheme 4.2. Movassaghi’s total synthesis of (+)-11,11’-dideoxyverticillin A. 
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sensitive dimerization precursor (+)-11. Reductive dimerization of the tertiary benzylic 
bromide (+)-11 using previously established methodology20 afforded the key dimeric 
octacyclic intermediate (+)-12. Based on their biosynthetic hypothesis, the 
tetrahydroxylation step was a critical part of their synthesis in order to incorporate sulfur 
atoms in their DKP. After much screening, they found bis(pyridine)-silver(I) 
permanganate (Py2AgMnO4) to be the optimal reagent to obtain the desired oxidized 
dimeric octacycle (+)-13 as a single diastereomer.17 Not surprisingly, the tetraol 
intermediate (+)-13 was highly sensitive to acidic and basic conditions. Therefore, careful 
control of reaction conditions was vital in order to keep the integrity of the oxidized 
dimeric octacyclic system. Silyl protection of the tetraol (+)-13 was realized as the best 
option. Using Fu’s (R)-(+)-4-pyrrolidinopyridinyl (pentamethylcyclopentadienyl)iron 
(PPY) catalyst21, the selective silyl protection was achieved. At this juncture, Schmidt’s 
protocol16d of installing the disulfide bridge was attempted and accomplished in low yield. 
Most of the intermediates that were involved in the last few steps were not only highly 
labile and prone to decomposition, but also the use of pressurized toxic hydrogen sulfide 
led them to seek an alternative strategy. Interestingly, the Movassaghi group opted to use 
potassium trithiocarbonate as the reagent to deliver a sulfurated product poised for mild 
unveiling of the desired tetrathiol at an advanced stage.17 The desired dimeric 
bisdithiepanethione (+)-16 was obtained, likely via kinetic trapping of iminium ion 15 
followed by intramolecular dithiepanethione formation. Addition of ethanolamine rapidly 
afforded the corresponding diaminotetrathiol, which was then treated with aqueous 
hydrochloric acid in dichloromethane followed by immediate addition of potassium 
triiodide to furnish the final compound (+)-11,11’-dideoxyverticillin A (Scheme 4.2). X-
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ray analysis confirmed the stereochemistry of their title compound.17 Since this landmark 
paper, the Movassaghi group reported more syntheses of structurally similar ETP 
alkaloids and has obtained interesting biological information of such compounds.22 More 
specifically, they found that chemical ablation of the sulfur bridge in naturally occurring 
alkaloids or the synthesis of such analogues without the sulfur atoms at the α-α’-
positions of the DKP result in biologically inactive compounds, further augmenting 
previous biological studies that suggested the importance of sulfur moiety in ETP 
alkaloids.22b 
 
In 2011, Nicolaou and coworkers reported the total synthesis of (−)-epicoccin G (Figure 
4.1).23 (−)-Epicoccin G was isolated from the endophytic fungus Epicoccum nigrum in 
2009, and it was shown to exhibit anti-HIV activity in C8166 cells (IC50 = 13.5 mM).23 
This ETP alkaloid possesses an interesting 6-5-6-5-6 diketopiperazine framework, which 
is also found in other similar natural products, such as rostratin B and exserohilone. 
Unlike the aforementioned ETP alkaloids, (−)-epicoccin G exhibits C2 symmetry, 
allowing for a general two-directional synthetic strategy. Interestingly, the incorporation 
of sulfur atoms was done in the intermediate stages of their synthesis, rather than in the 
beginning6 or the end17 of the synthesis as discussed in previous syntheses. The timing of 
the introduction of sulfur moieties in the molecule was deemed crucial, since early 
introduction of sulfur may not allow functional group tolerance for subsequent steps, 
while late installation should be avoided due to higher reactivity of the ketone groups 
(relative to the DKP moiety) under basic conditions needed for the sulfenylation step.23 
The synthesis of key intermediate 26 began with a known enone 18 through a two-step 
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procedure from N-Boc-L-tyrosine 17 (Scheme 4.3.24,23 Deoxygenation of the enone 18 
was accomplished through a three-step sequence involving acetylation, zinc reduction, 
and base-induced isomerization of the resulting β,γ-unsaturated ketone to afford the 
desired bicyclic enone 19. Subsequent Luche reduction of this enone gave the hydroxyl 
N-Boc methyl ester 20, which was treated under either acidic or basic conditions to afford 
the corresponding hydroxy amine 21 and hydroxy acid 22, respectively. Dimerization via 
BOPCl-mediated coupling of 21 and 22 resulted in the N-Boc methyl ester amide 23. 
Deprotection of the amine followed by Et3N-induced intramolecular ring closure gave the 
corresponding DKP 24. Conversion of the bisallylic alcohol 24 to the bistrifluoroacetate 
25 followed by Pd(0) mediated allylic elimination furnished the desired key intermediate 
26.23 
 
Scheme 4.3. Nicolaou’s synthesis of bisdiene key intermediate. 
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With the bisdiene key intermediate 26 in hand, various known sulfenylation protocols 
were screened. However, classical sulfenylation methods16 failed to provide the desired 
sulfenylated product. Instead they developed and successfully utilized a modified version 
of Schmidt’s sulfenylation method.16c The modified protocol entailed pretreatment of S8 
with 3 equiv. of NaHMDS at ambient temperature followed by sequential addition of 26 
and an additional 2 equiv. of NaHMDS to obtain a mixture of oligosulfenylated 
compounds 27, which was then subjected to reduction with NaBH4 followed by 
quenching of the resulting dianion with MeI to obtain the desired bismethylthio 
derivative 28 (Scheme 4.4). The stereochemical configuration of 28 was confirmed by 
NOESY correlations.23 Subsequent reaction of 28 with singlet oxygen (generated from 
triplet oxygen and light in the presence of meso-tetraphenylporphyrin (TPP) as a 
sensitizer) afforded bisendoperoxide 29, which underwent regioselective Kornblum—
DeLaMare rearrangement upon in situ treatment with DBU to furnish bishydroxy enone 
30. Finally, catalytic hydrogenation of 30 furnished (−)-epicoccin G.  
 
Scheme 4.4. Completion of the total synthesis of (−)-epicoccin G. 
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In the same report, they also synthesized 8,8’-epi-ent-rostratin B from the common 
bisdiene intermediate 26 using slight variation of the synthetic protocol.23 Following this 
seminal report, further publications ensued, further demonstrating the effectiveness of 
their modified Schmidt sulfenylation protocol in synthesizing structurally similar ETP 
alkaloids.25  
 
Although syntheses of ETP alkaloids were known since the 1970s6, their popularity have 
been exponentially growing since Movassaghi’s landmark paper in 2009.17 For example, 
Overman reported the syntheses of various indole based ETP alkaloids similar in 
structure to that of Movassaghi’s dideoxyverticillin A in 2011 and in 2013, where he 
employed functionalized trioxopiperazine as the key intermediate.26 Another example to 
note is, (−)-acetylaranotin, a C2 symmetric ETP alkaloid (Figure 4.1), which was 
synthesized by Reisman followed shortly thereafter by Tokuyama in 2012.27 Both groups 
utilized approaches similar to Nicolaou’s,23 where they synthesized functionalized 
bicyclic monomer followed by dimerization to the corresponding DKP using amide 
coupling methods.27 On other hand, they also used approaches similar to 
Movassaghi’s17,22 in that they left the sulfenylation to the end of their syntheses, where 
they used yet another variation of Nicolaou’s version of the Schmidt protocol.27  
 
4.3) Various synthetic approaches to dethiolated ETP alkaloid framework 
 
Many efforts have been made by various groups to provide alternative ways to easily 
access symmetric and unsymmetric ETP alkaloids. Although their focus was not 
necessarily to provide novel sulfenylation methods, they have nonetheless afforded 
synthetic variety towards this class of compounds.  
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Bräse made a significant contribution towards the synthesis of C2 symmetric as well as 
unsymmetric ETP alkaloids since 2007. 28  Of note, he has generated a unique 
methodology to synthesize symmetric and unsymmetric DKPs via phosphite-promoted 
dimerization of corresponding unprotected amino acids.28a In 2008, he reported the 
preparation of functionalized hexahydroindoles via intramolecular Diels-Alder 
reaction,28b which he made further improvements in 2011.28e As displayed elegantly in 
previous syntheses of ETP alkaloids,23,27 development of new methodologies to 
functionalized hexahydroindoles are important, since they could serve as building blocks 
for 6-5-6-5-6 framework present in C2 symmetric ETP alkaloids. In 2010, Bräse reported 
a unified strategy targeting various ETP alkaloids, such as exserohilone, gliotoxin, the 
epicoccins, the epicorazines, rostratin A, and aranotin, by the use of one common 
precursor 31 that was generated from L-pyroglutamic acid in five steps (Scheme 4.5).28d 
Briefly, isomerization of the terminal alkene of 31 followed by a 1,2-addition of vinyl 
Grignard afforded the corresponding lactol, which was treated under ring closing 
metathesis (RCM) conditions to provide the cis-annelated cyclohexenone which is the 
monomer of epicorazin B. Protection of the alcohol in the epicorazin B monomer 
followed by diastereoselective reduction of the ketone moiety, and further protecting 
group manipulation gave epicoccin F monomer, which ultimately underwent Pd0-
catalyzed Tsuji-Trost elimination conditions to furnish the gliotoxin and apoaranotin 
monomer. Alternatively, hydrogenolysis of epicorazin B monomer afforded epicoccin A-
D, and G monomer. The aranotin monomer was constructed by enol ether-olefin RCM of 
an intermediate derived from the ring opened of the lactol 32, while as the exserohilone 
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and epicorazin A monomer was obtained from epimerization at C4 and C5 of the proline 
derivative derived from the same intermediate 32, followed by RCM. Finally, the 
exserohilone and epicorazin A monomer was converted to rostratin A monomer via series 
of protecting group manipulations, diastereoselective reduction of the ketone moiety, and 
hydrogenolysis.  
 
Scheme 4.5. Bräse’s retrosynthetic analysis of various ETP alkaloids from one key intermediate.  
PG = protecting group. 
 
As a proof of principle, using their previous dimerization methodology,28a they 
synthesized the dethio analogue of the epicoccins A, C, and D 33 (Scheme 4.6). 
 
Scheme 4.6. Assembly of the core 33 found in epicoccins A, C, and D. 
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Diver’s group were also interested in employing their previous methodology towards the 
synthesis of the scabrosins (Figure 4.1), which is another class of ETP alkaloid that 
possess a potential as anticancer agents.29 Cyclohexadiene 34 was synthesized using their 
previously developed tandem enyne metathesis (Scheme 4.7).29 Subsequent Pd(II)-
promoted chloroacetoxylation using Bäckvall’s conditions30 followed by base-catalyzed 
cyclization afforded functionalized indoline 36. Using similar set of reactions as 
discussed in previous total syntheses of ETP alkaloids, they successfully synthesized the 
pentacyclic core (37) displayed in the scabrosins. The stereochemistry of the pentacycle 
37 was confirmed by X-ray analysis.29 
 
Scheme 4.7. Diver’s efforts toward the synthesis of the scabrosins. 
 
Recently, Carreira reported a novel strategy to access the core structure of 6-5-6-5-6 
framework present in various ETP alkaloids using his previously developed methodology 
as the key step of the synthesis.31 Alcohol 38 was synthesized in four steps from 
bromoacrolein using Corey and Loh’s enantioselective Diels-Alder protocol (Scheme 
4.8).32 Swern oxidation afforded the corresponding unstable aldehyde in situ, which was 
trapped under low temperatures via direct double condensation with N,N’-diacetylDKP 
39 to give olefin 40. This double condensation could also be done step-wise. Using a 
slightly modified version of their previously reported conditions, the double 
intramolecular opening of the oxabicyclio[2.2.1]heptenes proceeded smoothly to furnish 
CO2tBu
NHFmoc
5% Pd(OAc)2, AcOH
Acetone, LiCl, LiOAc
benzoquinone
CO2tBu
NHFmoc
AcO
Cl
1) DBU, PhMe3, rt
2) DBU, MeCN, 
    50 oC, 36 h
N
H
AcO
H
CO2tBu
H N
N
O
O
OAc
AcO
H
H
H
H
34                                                                                 35 (dr = 1:1)
36                                                                       37
! 319 
pentacycle 41, which was directly deprotected under basic conditions to give 42.31 X-ray 
analysis of 42 established the correct assignment of the structure. Since many ETP 
alkaloids contain pyrrolidines, protecting group exchanged version of 42 was subjected 
under hydrogenation conditions to afford 43 as a single diastereomer.31 
 
Scheme 4.8. Carreira’s synthesis of pentacyclic framework. 
 
 
4.4) Retrosynthetic analysis  
 
As discussed in previous sections, the most commonly used synthetic strategy to access 
C2 symmetric ETP alkaloids is via late-stage dimerization of functionalized bicyclic 
monomer (A,B rings) with the requisite stereochemistry already built into the system 
followed by installation of the disulfide bridge as one of the last remaining steps (Figure 
4.3). Although quite a number of C2 symmetric ETP alkaloids have been reported in the 
literature,33 only few23,25 have been synthesized in recent years (Figure 4.3).  
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Figure 4.3. Structurally similar C2 symmetric ETP alkaloids.33 
 
We were initially interested in developing a novel strategy that could lead to the total 
synthesis of rostratins A and B.33a We envisaged a drastically different approach to access 
C2 symmetric pentacyclic framework from a single synthetic transformation of a common 
key intermediate utilizing a diastereoselective double intramolecular Diels-Alder (IMDA) 
reaction (Figure 4.4). Depending on the chiral catalyst employed in the reaction, one 
could obtain either the cis (exo adduct) or trans (endo adduct) fused ring system, where 
the cis A,B ring system leads to rostratin B and the trans A,B ring system leads to 
rostratin A.  
 
Figure 4.4. Novel approach to C2 symmetric pentacyclic system in rostratins A & B.  
(Optimized at HF/AM1 level of theory using Spartan 04) 
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The common intermediate IMDA precursor (44) could be derived from transition metal 
mediated C-N coupling of 45 and 46 (Scheme 4.9). DKP 46 could be obtained from 
intramolecular dimerization of modified L-aspartic acid derivative. Diastereoselective 
IMDA of 44 could either afford the endo adduct 47 or the exo adduct 48. Secondary 
alcohol in 8,8’-positions of rostratins A and B could be derived from corresponding 
epoxides 49 and 50. Secondary alcohol or ketone functionalities present in 5,5’-positions 
of rostratins A and B respectively could arise from a decarbonylation-oxygenation 
sequence from the aldehyde in 47 and 48. Finally, disulfide bridge formation would be 
achieved last, as early incorporation would not display functional group tolerance.  
 
 
Scheme 4.9. Retrosynthetic analysis of rostratins A and B. 
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4.5) Synthesis of IMDA precursor 
 
Sutherland’s method34 was utilized to obtain allylic alcohol (+)-54 starting from L-
aspartic acid (Scheme 4.10). One-pot esterification followed by mono-Boc protection of 
commercially available L-aspartic acid led to the corresponding protected amino acid in 
good yield. Further treatment with di-tert-butyl dicarbonate in the presence of catalytic 
amounts of DMAP afforded N,N-ditert-butoxycarbonyl L-aspartic acid dimethyl ester 
(−)-51. As noted by Sutherland,34a the di-Boc protection of the amine allows excellent 
regioselective manipulation of the ester functional groups, which is also a well-known 
method. Regioselective reduction of the β-methyl ester (−)-51 afforded the L-aspartic 
acid aldehyde (−)-52 in good yield. Selective removal of one of the Boc-protecting 
groups is required for the Wittig reaction to obtain the E-α,β-unsaturated aldehyde (+)-53 
for steric reasons. Hence, (+)-53 was obtained via mono-Boc deprotection using lithium 
bromide followed by two-carbon homologation using a Wittig reaction with the stabilized 
ylide. Subsequent reduction of the terminal aldehyde led to the desired allylic alcohol 
(+)-54 in good yield.  
 
Scheme 4.10. Synthesis of allylic alcohol (+)-54. 
 
Initially, we sought out to employ a combination of Bräse’s dimerization protocol28a and 
method to install 1,3-butadiene moiety28b (Scheme 4.11). Protection of the allylic alcohol 
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crotonaldehyde would afford the corresponding imine. The conjugated imine could then 
isomerize to the desired enamine 56 upon treatment with base. Saponification of the 
methyl ester (56) followed by Bräse’s dimerization protocol28a should afford the 
corresponding DKP 58. Unfortunately, although protection of allylic alcohol (+)-54 was 
successful, subsequent Boc removal proved to be problematic. Treatment of (+)-54 with 
zinc bromide led to removal of both Boc and SEM protecting groups due to prolonged 
reaction time. Other methods (SiO2, µW irradiation) to mildly and selectively remove the 
Boc group were attempted without much success.  
 
Scheme 4.11. First attempt to utilize Bräse’s methodology. 
 
Therefore, a change in protecting group was deemed necessary. The more robust and less 
acid and base sensitive TBDPS ether intermediate (+)-59 was synthesized (Scheme 4.12). 
Although the desired Boc removal proceeded in good yield, subsequent one-pot enamine 
(60) formation resulted in complete decomposition of material, which could be attributed 
to the instability of enamine.  
 
Scheme 4.12. Second attempt to utilize Bräse’s methodology. 
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A more traditional route to form the desired DKP was envisioned instead, in which the 
silyl ether (+)-59 could either be treated under acidic conditions to afford the Boc 
removed amine salt, or under saponification conditions to afford the corresponding acid, 
which could then undergo amide bond formation reaction to afford the dipeptide (+)-63 
(Scheme 4.13). The Boc group on the dipeptide would be removed, followed by 
intramolecular cyclization to form the desired DKP.  
 
Scheme 4.13. Proposed synthesis of DKP intermediate. 
 
Initially, few acidic conditions (HCl (g), HCl in dioxane, TFA), were attempted to 
remove the Boc group of (+)-59, and proceeded equally well. However, based on 
previous experience in forming amine salts, TFA amine salts tend to be more 
operationally convenient, as they tend to be less hygroscopic. Therefore, TFA amine salt 
was utilized. For the saponification step, other conditions such as LiOH, 1M NaOH, and 
Me3SnOH were tried, but the use of KOSiMe3 proved to be most efficient, as the reaction 
time was drastically shortened (4 h-overnight to 2 h). Although Me3SnOH was relatively 
efficient reagent (4 h µW irradiation), it is not as cost effective in comparison to 
KOSiMe3, and the use of µW irradiation makes the reaction not as scalable. For the 
coupling step, other conditions were screened in the beginning using the HCl amine salt 
and acid derived from various saponification reactions (Table 4.1).  
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Table 4.1. Coupling reaction conditions.a 
Coupling reagent! Base! Solvent! Yield (%)d!
BOP! NMM! CH2Cl2! 20!
EDC, HOBt! NMM! DMF! 39!
EDC, HOBt! Et3N! CH2Cl2! 22!
EDC, HOBtb! NaHCO3c
! DMF! 20!
EDC, HOBt! DMAP (cat.)! DMF! 25!
Ipcfd! DMAP, Et3N! CH2Cl2! 17!
DEPC! Et3N! DMF! 35!
DEPBT! Et3N! CH2Cl2! 30!
HATU! iPr2EtN! DMF! 17!
[a] General procedure: amine HCl salt (1 equiv.), acid (1.1 equiv.), coupling reagent (1.1 – 1.2 equiv.), base (2 – 2.5 
equiv.), at 0.1 M concentration, rt, overnight. 
[b] Activated the acid as the pentafluorophenyl ester. 
[c] NaHCO3 was used in 5 equivalents. 
[d] Isolated yield. 
[d] Isopropyl chloroformate 
 
The surprisingly low yielding coupling step led to a thorough investigation of reaction 
parameters. The major side product of the reaction was the mono TBDPS cleaved 
dipeptide. The precise timing of when TBDPS group removal was occurring was 
examined. The use of non-nucleophilic base (NaHCO3, Et3N, iPr2EtN) did not improve 
the overall yield of the reaction, suggesting TBDPS removal was occurring prior to the 
coupling step (Table 4.1). In order to minimize the likelihood of TBDPS removal, the 
Boc deprotection step was conducted at lower temperatures using anhydrous conditions. 
As for the saponification step, use of milder, non-nucleophilic base, KOSiMe3, 
significantly minimized the undesired side reaction, thereby improving the overall yield. 
Interestingly, the rate of the saponification was increased with KOSiMe3 in comparison 
to more traditional hydroxide based reagents. When all these precautions were taken, the 
subsequent coupling step proceeded in much improved yield to afford the desired 
dipeptide (+)-63 (Scheme 4.14). Since the initial screening of coupling step resulted in 
very similar yields, it could be assumed that the use of other coupling reagents beside 
BOP would result in comparable yields.  
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Scheme 4.14. Optimized synthesis of dipeptide (+)-63. 
 
With the desired dipeptide (+)-63 in hand, DKP formation was investigated next. Acidic 
conditions similar to Boc removal of (+)-59 worked well on (+)-63, and provided the 
corresponding TFA amine salt. However, the subsequent intramolecular cyclization to 
form the DKP was not a trivial transformation. Since DKPs are well-known in the 
literature,35 there are numerous ways to synthetically access them. However, success in 
finding the optimum set of conditions depends on the substituents that make up the DKP 
ring, which may not necessarily be obvious. There were few concerns with the present 
system. First of all, due to decrease in reactivity of primary amines as nucleophiles in 
comparison to secondary or tertiary amines, the overall progress of the desired 
cyclization could be more difficult. Secondly, certain DKPs could isomerize36 more 
readily than others to yield a mixture of diastereomers. Eguchi and Kakuta determined 
thermodynamic constants in the equilibrium of the isomerization of various DKPs and 
found that DKPs that contain acyclic substituents (such as cyclo(Ala-Ala), cyclo(Leu-
Leu), etc.) exist in almost 1:1 ratio of cis and trans isomers, since they tend to be very 
flexible and could adopt various boat and planar conformations that are not discrete and 
easily interconvertible.36 On the other hand, DKPs that have cyclic substituents (such as 
cyclo(Pro-Pro)), predominantly exist as cis isomers, due to the added steric constraints.36 
Unfortunately, since the present system contains acyclic substituents, it was expected that 
the diastereoselectivity would not be as favorable. Finally, the concentration of the 
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intramolecular reaction was surprisingly not consistent in the literature.35 Although 
intramolecular cyclization reactions are generally performed at dilute concentrations, 
documented DKP forming methods displayed various concentrations. Therefore, much 
attention was given towards optimization of this step. Movassaghi’s conditions17 were 
investigated first using excess morpholine in a non-nucleophilic solvent, t-butanol (entry 
1, Table 4.2). At high dilution, the reaction was sluggish, although it did provide modest 
yield of the desired cis DKP (entries 1-5, Table 4.2). Slight increase in temperature, 
prolonged reaction time, and portion-wise addition of morpholine did not affect the yield 
significantly (entries 2-3, Table 4.2). A solvent effect was suggested when the reaction 
was performed in CH2Cl2 instead of t-butanol (entries 5-6, Table 4.2). Increasing the 
overall concentration also did not affect the yield (entry 7, Table 4.2). Potential use of 
alternative amines and inorganic bases were screened using high-throughput 
experimentation (96-well plate: 8 solvents, 12 bases), which suggested the use of NMM, 
TBD, and 2,6-lutidine in MeCN as a possible substitute. Alternative ways of activating 
the carbonyl moiety of the methyl ester electrophile was investigated by saponification of 
(+)-63, followed by pentafluorophenyl (pfp) ester formation using standard conditions. 
The product was then Boc deprotected and utilized in the reaction with various bases 
(entries 10-13, Table 4.2).  Unfortunately, amine bases (NMM, TBD, 2,6-lutidine) and 
inorganic bases (NaHCO3, K2CO3) produced a decrease in yield, recovery of starting 
material, or decomposition (major side products being TBDPS removed products) 
(entries 8-15, Table 4.2). Interestingly, using standard amide bond formation methods 
(entry 16, Table 4.2) resulted in no reaction, which may be due in part to increased sterics 
of the substrate. Lewis acid activation of the carbonyl moiety was explored via high-
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throughput screening using eight different Lewis acids (AlCl3, BiOTf3, CoCl2, FeCl3, 
Sc(OTf)3, SnCl2, Yb(OTf)3, ZnBr2) in three different solvents (t-BuOH, i-PrOH, 1,2-
DCE), which generally led to decomposition of material or no reaction. The most 
promising condition from the screen was scaled-up and tested (entry 21, Table 4.2), 
which resulted in significant formation of TBDPS removed side products.  
 
Table 4.2. Screening of DKP formation methodology. 
 
Entry! Reagent (equiv.)! Solvent [M]! Temp (oC)! Time! Yield (%)a!
1! Morpholine (50)! t-butanol [0.02]! rt! 5 d! 55!
2! Morpholine (50)! t-butanol [0.02]! 30! 7 d! 43!
3b! Morpholine (50)! t-butanol [0.01]! 30! 13 d! 46!
5! Morpholine (14)! t-butanol [0.05]! rt! 18 h! 32!
6! Morpholine (14)! CH2Cl2 [0.05]! rt! 3.5 d! 20!
7! Morpholine (14)! t-butanol [0.19]! rt! 5 d! 39!
8! NMM (3)! t-butanol [0.01]! reflux! 18 h! 32!
9! NMM (3)! t-butanol [0.06]! 122! 1 h! Decomposition!
10c! TBD (1)! MeCN [0.01]! 0 ! rt! 5 h! 25!
11d! TBD (2.2)! MeCN [0.05]! 0! 2 d! 7!
12d! 2,6-lutidine (0.5)! MeCN [0.05]! rt! 18 h! Decomposition!
13c! 5% NaHCO3 (1)! CH2Cl2 [0.01]! 0 ! rt! 5 h! 36!
14! (sat.) NaHCO3! EtOAc [0.1]! rt! 18 h! No reaction!
15! K2CO3 (4)! EtOH [0.1]! reflux! 20 h! Decomposition!
16e! BOP (1.2), NMM (2)! CH2Cl2 [0.01]! rt! 20 h! No reaction!
17! 2M NH3 in MeOH (5)! MeOH [0.1]! rt! 3 d! 36!
18! --! 2M NH3 in MeOH [0.01]! reflux! 6 h! 29!
19! DMAP (0.2),!NH4OH (15% of MeOH)!
MeOH [0.06]! rt! 6 d! 33!
20! DMAP (0.2),!NH4OH (10% of MeOH)!
MeOH [0.1]! rt! 18 h! 53!
21f! Sc(OTf)3 (1.5)! 1,2-DCE [0.05]! 30! 2 d! Decomposition!
[a] Isolated yield of cis diastereomer. Reaction monitored by 1H NMR and TLC analysis. 
[b] Portion-wise addition (10 equiv.) of morpholine over time. 
[c] Methyl ester hydrolyzed to acid then activated as pentafluorophenyl (pfp) ester before use, 1 h at 0 oC, then 4 h at rt. 
[d] Methyl ester hydrolyzed to acid then activated as pfp ester before use. 
[e] Methyl ester hydrolyzed to acid before use.  
[f] TFA amine salt substrate was free-based prior to use. 
 
Following a method used by Danishefsky, 37  NH3 in MeOH was used at varying 
concentration and temperature, which only led to a decrease in yield (entries 17-18, Table 
4.2). Surprisingly, use of NH4OH in MeOH, a method utilized in our group in the past38 
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with catalytic DMAP at increased concentration not only significantly reduced the 
reaction time, but it also resulted in a highest yield that was comparable to that of the 
initial conditions (entry 20, Table 4.2).  
With this promising result, the diastereoselectivity of the reaction was investigated (Table 
4.3). Although use of lower amounts of morpholine at higher concentrations generally led 
to an increase in overall yield, the diastereoselectivity decreased (entries 1-3, Table 4.3). 
Interestingly, shorter reaction times resulted in higher diastereoselectivity (entry 2, Table 
4.3), suggesting the possible epimerization of cis to trans diastereomer with time. This 
possibility was tested in previous experiments, where the reaction was held at lower 
temperatures (entries 10 & 13, Table 4.2). However, in those cases, the reaction rate 
tended to be sluggish. To further probe this result, the reaction was initiated at −78 oC 
and held at 0 oC for 1 d (entry 4, Table 4.3), which did not seem to drastically affect the 
diastereoselective outcome. From the NH4OH series, the best result was obtained when 
5% NH4OH was used in MeOH (entry 7, Table 4.3). Of note, there seemed to be some 
beneficial effect in free-basing the TFA amine salt prior to use. 
 
Table 4.3. DKP formation optimization. 
 
Entry Reagent (equiv.) Solvent [M] Temp 
(oC) 
Time Yield 
(%)a 
dr = cis:trans 
1 Morpholine (35) t-butanol [0.06] rt 4 d 48 1.3:1 
2 Morpholine (14) t-butanol [0.19] rt 20 h 65 1.66:1 
3 Morpholine (14) t-butanol [0.19] rt 2 d 86 1.09:1 
4 2M NH3 in MeOH (50) MeOH [0.1] −78!0 1 d 61 1.31:1 
5 DMAP (0.2), NH4OH  
(10% of MeOH) 
MeOH [0.06] rt 2 d 52 1.51:1 
6 NH4OH (3.5% of MeOH) MeOH [0.06] rt 3 d 74 1.68:1 
7b NH4OH (5% of MeOH) MeOH [0.11] rt 3 d 82 2.3:1 
[a] Isolated total yields of both diastereomers.  
[b] TFA amine salt substrate was free-based prior to use. 
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Finally, with optimized conditions for DKP formation in hand, various enamide forming 
methods were explored in order to install the requisite diene moiety on the DKP for 
IMDA. Using crotonaldehyde as the 1,3-butadiene precursor was revisited, as the 
stability of enamide was expected to be higher than that of the corresponding enamine 
(Scheme 4.12). Furthermore, synthesizing N-dienyl lactams and using them in 
intermolecular Diels-Alder reactions with electron deficient alkenes have been reported 
in the literature.39 Hoping that DKPs would react in similar manner as lactams, the 
method was probed using cyclo(Gly/Gly) and crotonaldehyde (Scheme 4.15). 
Unfortunately, the desired reaction did not proceed and resulted in decomposition and 
recovery of unreacted crotonaldehyde. Model DKP (+)-65 was synthesized and tested 
using same reaction conditions, but it also led to decomposition of starting material. 
(Synthesis of (+)-65 will be discussed later.) Specifically, the TBDPS group was 
removed during the course of the reaction, and the crude reaction mixture did not contain 
any 1,3-butadiene moieties. These results may be due to the fact that the nitrogen of the 
amide moiety in DKPs is less nucleophilic than that of lactams. To further support the 
hypothesis, 2-pyrrolidone was reacted under the same conditions, and as expected, 
resulted in higher yield (56%) (Scheme 4.15). 
 
Scheme 4.15. Attempted synthesis of doubly N-dienylated DKP. 
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Undeterred, the use of transition metal catalysis was investigated next. Gooβen’s 
hydroamidation protocol40 was recently reported at that time. The general procedure does 
not require a glove box, especially when tri-n-butylphosphine is substituted with its HBF4 
adduct, making it more air-stable and easy to handle. The active catalyst is generated in 
situ from ruthenium(III) chloride hydrate, tri-n-butylphosphine, DMAP, and K2CO3. The 
catalyst was shown to effectively promote the addition of secondary amides to terminal 
alkynes under formation of (E)-anti-Markovnikov enamides in good yield. When 
cyclo(Gly/Gly) was reacted under Gooβen’s optimized conditions using two different 
terminal alkynes, the corresponding products were formed in low yields (Scheme 4.16). 
Unfortunately, when 64 was reacted under the same conditions for prolonged period of 
time, only starting material DKP was recovered along with an unknown minor side 
product (Scheme 4.16). Although Gooβen reported the reaction of cyclo(Gly/Gly) with 1-
hexyne to undergo at much higher yield (71%)40, this result was not obtained even after 
several trials.  
 
Scheme 4.16. Attempted use of Gooβen’s hydroamidation protocol. 
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catalytic amount of copper(II) acetate under mild oxidative conditions. The reaction 
could be set up on the bench top as all reagents are air stable. To probe the reactivity of 
DKPs under the reported conditions, cyclo(Gly/Gly) was tested with various alkenyl 
trifluoroborate salts (Scheme 4.17). Application of Batey’s methodology successfully 
provided the desired doubly coupled DKP product in high yields when known alkenyl 
trifluoroborate salts were used. With this promising lead, the actual 1,3-butadiene 
substrate, 66, was synthesized and employed, which resulted in a synthetically useful 
yield of the desired product (Scheme 4.17). According to Batey’s report41, if the amide 
substrate has a low pKa (pKa =13-17 in DMSO), it is possible that N-methylimidazole 
serves as a base, leading to deprotonation of the amide proton and subsequent 
coordination of the deprotonated species to copper. While as with higher pKa (pKa =20-24 
in DMSO) amide substrates, N-methylimidazole may not serve this role, and instead its 
direct coordination to copper may result in inhibition of the desired coupling reaction. For 
the present system, addition of a catalytic amount of N-methylimidazole (20 mol%) did 
not improve the yield, and actually shut down the desired reaction. This observation 
suggests that the amide proton of the DKP may not possess a relatively low pKa value.  
 
Scheme 4.17. Application of Batey’s protocol to test system. 
 
The 1,3-butadiene trifluoroborate salt 66 can be easily accessed in four steps starting 
from 3-butyn-1-ol in good yields (Scheme 4.18). Mesylation of the alcohol followed by 
hydroboration 42  installs the corresponding pinacol boronate ester, which is then 
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immediately eliminated to afford the unstable 1,3-butadiene pinacol boronate ester 68.43 
Rapid conversion of the pinacol boronate ester 68 to the trifluoroborate44 affords 66 in 
good yield. Although much more stable than the pinacol boronate ester 68, once 
synthesized, 66’s lifetime is limited, and should be kept at cold temperatures up to few 
weeks to prevent undesired polymerization or Diels-Alder reaction with itself,45 which 
could be detected by 1H NMR and physical color change over time.  
 
Scheme 4.18. Synthesis of 1,3-butadiene trifluoroborate salt 67. 
 
Due to the success of application of Batey’s protocol41 to simple DKPs, the actual 
substrate DKP (−)-64 and coupling partner trifluoroborate 66 was employed (Scheme 
4.19). The copper loading was increased (10 mol% to 30 mol%), as previous experiments 
with cyclo(Gly/Gly) showed slight increase in yield with higher copper loading. The 
desired reaction occurred at a synthetically useful yield.  
 
Scheme 4.19. Application of Batey’s protocol. 
 
For further optimization, various reaction parameters were varied throughout an 
extensive time period to achieve consistent results (Table 4.4). Generally, the amount of 
66 added to the reaction seemed to affect the overall yield (Entry 1, Table 4.4). 
Concentration of the reaction also affected the yield and efficiency of the reaction 
(Entries 1, 13, 20, Table 4.4). Since the reaction is a bimolecular cross-coupling reaction, 
it could be assumed that higher concentration would result in better yield. However, 
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substrate solubility appeared to be one of the greatest concerns of the reaction. When the 
solvent was varied, it led to dramatic decrease in yield (Entries 9-12, 15, 25, Table 4.4), 
which strongly implies the importance of solubility of the substrates. This finding is in 
accordance with Batey’s report,41 as he also found the importance of solubilizing both the 
copper salt, trifluoroborate salt, as well as the amide substrate. As implied from the test 
reaction with cyclo(Gly/Gly), amine base additives did not improve the yield (Entries 2 & 
19, Table 4.4). The role of 4 Å molecular sieves (MS) was studied next. Batey had 
speculated that they may serve as a catalyst for hydrogen peroxide decomposition, or aid 
in the re-oxidation of copper by oxygen, or may facilitate ligand exchange on boron 
during transmetallation.41 When other zeolites were used46 in the reaction (Entries 5-8, 
Table 4.4), only starting material was recovered from the reaction even after prolonged 
period of time. When no 4 Å MS were used (Entry 4, Table 4.4), only trace amount of 
mono-coupled product was observed, further supporting the importance of having 4 Å 
MS in the reaction. Interestingly, when the 4 Å MS were thoroughly dried and activated 
(flame dried under vacuum), and the reaction was set up in the glove box scrupulously 
excluding the presence of moisture or water (Entry 21, Table 4.4), only starting material 
was recovered. This led to an investigation of water or moisture effect on the reaction 
conditions. When water was purposefully added to the reaction (Entry 3, Table 4.4), the 
yield dramatically decreased. However, when 4 Å MS were used directly from the bottle 
without further drying or activation, the yield was maintained or increased (Entry 13, 
Table 4.4) from the initial reaction condition (Scheme 4.19). These results support 
Batey’s hypothesis41 on the role of 4 Å MS, in that they may have roles other than to 
serve as simple dessicants. Moreover, since at least one of fluoride ions from the 
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trifluoroborate should be replaced by hydroxide for the transmetalation to occur, a source 
of water should be present in the reaction.41,47 Perhaps using “wet” 4 Å MS provide just 
enough water for successful transmetalation. However, during the course of the 
investigation, the partially optimized reaction suddenly failed to provide consistent 
results (Entry 13, Table 4.4). This disappointing result led to a set of thorough 
experimentation where each component of the reaction was examined. From previous 
results, although more equivalents of 66 seemed to result in higher yields, there seemed 
to be not much effect from 4-5 equivalents (Entries 13,14, Table 4.4). The reason for 
excess 66 may be due to the instability of 66, since the limited shelf-life of 66 was 
already noticed during its synthesis. Perhaps some of 66 undergo the desired cross-
coupling reaction, but some other portions of it could slowly oxidize, dimerize, or 
polymerize, which is reasonable considering the prolonged reaction times. Since the rate 
of the reaction seemed to be rather sluggish (up to 14 d), a portion-wise addition of 66 
was thought to be advantageous (Entry 14, Table 4.4). In terms of copper loading, 0.3 
equivalent appeared to be the most optimal loading, as decreasing (Entries 18, 21-23, 
Table 4.4) or increasing (Entry 24, Table 4.4) amount of copper resulted in dramatically 
lower yields. In Batey’s report,41 he specifically noted the use of Cu(OAc)2 that is of 97% 
purity as opposed to 99.9% purity, since extensive studies showed that catalytic presence 
of Cr(II) in Cu(OAc)2 of 97% purity facilitates the reaction. This was proven to be the 
case in the present system as well (Entry 21, Table 4.4). Oxygen supply was tested next. 
According to Batey, higher yields were obtained when the reaction was conducted under 
a slightly positive oxygen pressure using a gas manifold equipped with an oil bubbler, 
with the oxygen gas supplied from a cylinder passed through drierite, as opposed to using 
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oxygen balloon or air.41 However, there seemed to be not much difference between using 
oxygen balloon or direct oxygen supply in terms of yield, although the rate in some cases 
was accelerated. Use of air, however, did decrease the rate and the yield of the reaction. 
To test the importance of solubilizing oxygen in the reaction mixture, 2,2,2-
trifluoroethanol was used in conjugation with DMSO, since fluorinated solvents are 
generally known to dissolve and contain oxygen better (Entry 16, Table 4.4). 
Unfortunately, this solvent change actually decreased the yield. Substituting 1,2-
dichloroethane for dichloromethane was tolerated, as long as some amount of DMSO was 
used in conjugation. The use of DMSO is likely due to its ability to solvate the 
trifluoroborate salt. However, if the amount of DMSO is increased, the reaction is known 
to be inhibited, as DMSO could also act as a ligand to copper.41 Use of 1,2-
dichloroethane was found to be more beneficial than dichloromethane, since less 
evaporation occurred over time at 40 oC.  
 
Table 4.4. Copper-oxidative coupling reaction optimization. 
 
Entry! 66 (equiv.)!
Cu(OAc)2 
(equiv.)! Solvent [M]! Additive!
Temp
(oC)! Time!
Yielda 
(%)!
1! 3.3! 0.3! DMSO:DCM [0.1]! None! 40! 21 h! 0b!
2! 4! 0.3! DMSO:DCM [0.25]! Et3N (2 equiv.)! 40! 3 d! 20!
3! 4! 0.3! DMSO:DCM [0.25]! H2O (2% v/v)! 40! 2 d! 18!
4! 4! 0.3! DMSO:DCM [0.25]! No sieves! 40! 3 d! 0c!
5! 4! 0.3! DMSO:DCM [0.25]! 3Å MSd! 40! 3 d! 0!
6! 4! 0.3! DMSO:DCM [0.25]! Neutral Aluminad! 40! 3 d! 0!
7! 4! 0.3! DMSO:DCM [0.25]! SiO2d
! 40! 3 d! 0!
8! 4! 0.3! DMSO:DCM [0.25]! Celited! 40! 3 d! 0!
9! 4! 0.3! DCE [0.25]! None! 50! 38 h! 0c!
10! 4! 0.3! DCE [0.12]! None! 40! 2 d! 0e!
11! 4! 0.3! DCE [0.25]! MeOH (10 equiv.)! 50! 38 h! 0c!
12! 4! 0.3! MeOH [0.25]! None! 50! 38 h! 0c!
13! 4! 0.3! DMSO:DCM [0.25]! None! 40! 1-13d! 2-75g!
14! 5 then 2f! 0.3! DMSO:DCM [0.25]! None! 40! 14 d! 0-98g!
15! 5! 0.3! DCM [0.25]! None! 40! 1 d! 0!
16! 5! 0.3! DMSO:TFE [0.25]! None! 40! 4 d! 9!
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17! 5! 0.3! DMSO:DCE [0.25]! None! 40! 10 d! 86!
18! 3! 0.2! 25%DMSO:DCE [0.25]! None! 50! 8 d! 30h!
19! 3! 0.2! 25%DMSO:DCE [0.25]! NMI (0.4 equiv.)! 50! 8 d! 0c!
20! 3! 0.2! 25%DMSO:DCE [0.75]! None! 40! 42 h! 33!
21! 4! 0.1! DMSO:DCM [0.25]! None! 40! 1 d! 0i!
22! 5! 0.1! DMSO:DCM [0.25]! None! 40! 30 h! 41!
23! 5! 0.1! DMSO:DCM [0.25]! None! 40! 1.5 d! 0!
24! 5! 1! DMSO:DCM [0.25]! None! 40! 2.5 d! 9!
25! 4! 4! DCE:H2O 10:1 [0.07]! None! 40! 2 h! 0j
!
[a] Isolated yields. Otherwise specified, 4Å MS used in twice the amount relative to 66. 
[b] 21% of mono-coupled product was isolated. 
[c] Trace amount of mono-coupled product was detected. 
[d] Effect of different types of zeolites were investigated, used in the place of 4Å MS. 
[e] Reaction vessel sonicated for 5-10 min to facilitate solubility. 
[f] Added 5 equiv. first, then additional 2 equiv. after 2-5 days. 
[g] Effect of O2 supply tested. Used balloons or connected directly to O2 cylinder passed through drierite. 
[h] Obtained ~30% of mono-coupled product as well. 
[i] Used Cu(OAc)2 (99.9% purity), reaction set up in the glovebox, 4Å MS thoroughly dried and activated. 
[j] Reaction vessel charged with headspace of air, µW irradiation, 200 Watts, 300 psi. 
 
In line with the importance of solvation of all substrates, 1,2-dichloroethane was used 
with water, and subjected under microwave irradiation for more effective heating (Entry 
25, Table 4.4), which only led to recovery of starting material DKP, and 
protodeboronated and polymerized 66. Finally, rigorous stirring and large surface area 
with 5 equivalents of 66, 0.3 equivalent of Cu(OAc)2, in 1:1 ratio of DMSO and 1,2-
dichloroethane gave the more consistent result (Entry 17, Table 4.4), albeit in 10 days. 
Effective stirring is generally accepted as a crucial component in copper oxidative 
couplings (Chan-Lam type), since it facilitates oxygen solvation in the reaction mixture. 
Interestingly, in some cases, when dichloromethane was used instead of 1,2-
dichloroethane, slight oxidation of the product DKP (+)-69 was observed by 1H NMR. 
This may be due to the fact that over prolonged reaction time, dichloromethane may be 
more efficient in solubilizing oxygen, thereby facilitating oxidation of the 1,3-butadiene 
moiety. There may be a so-called “Goldilocks” modulation at play in terms of solubility, 
since too much solubility of oxygen (use of TFE or DCM instead of DCE) leads to 
oxidized side products, while as too little (MeOH, or use of air) impedes the reaction. A 
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multivariate high-throughput experimentation was done to scope out the chemical space 
of this transformation. The screens tested the possibility of using alternative copper 
sources (Cu(OTf)2, Cu(NO3)2), amine base/ligand additives (NMI, 1,10-phenanthroline, 
pyridine, Et3N), and solvents (dioxane, MeOH, chlorobenzene). The results from the 
screens suggested that Cu(OAc)2 is the optimal copper source, no addition of base/ligand 
was necessary, and mixture of DMSO and DCE (25% DMSO in DCE or 1:1 mixture) 
was tolerated.  
Although the specific copper oxidation states, spatial orientation of the complexes, and 
the sequence of events in the catalytic cycle remains to be clarified, Batey proposed a 
generic mechanism41 for the reaction based on supporters48 of the involvement of Cu(III) 
intermediate in the catalytic cycle (Figure 4.5). As mentioned, replacement of at least one 
of the fluoride ions from B must occur to afford the boron intermediate C, which then 
forms a bridging M-O-B species47b that is required for the transmetalation step. Based on 
Stahl’s work48b oxidation by molecular oxygen of Cu(I) species D to Cu(III) is believed 
to occur in a stepwise fashion via Cu(II). Transmetalation of C and coordination of amide 
substrate A may occur either at the Cu(II) or Cu(III) oxidation states, which leads to E. 
Finally, rapid reductive elimination of E furnishes the product enamide F and regenerates 
Cu(I) species A. As discussed earlier, the role of 4 Å MS could be to aid in the 
decomposition of hydrogen peroxide, re-oxidation of copper by oxygen, or facilitate 
ligand exchange on boron.41  
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Figure 4.5. Generic mechanism proposed by Batey.41 
 
To further prove the importance of this reaction over other well-known copper oxidative 
cross-coupling reactions, a Chan-Lam type reaction was conducted (Scheme 4.20). The 
desired product was not obtained under standard conditions even after 5 days.  
 
Scheme 4.20. Attempt to use Chan-Lam type cross-coupling. 
 
A model system was developed to test the feasibility of key steps in the synthesis. The 
model system (+)-65 contains half of the actual system, where the other half is left 
unsubstituted (Scheme 4.21). BOPCl-mediated amide formation with common 
intermediate acid 62 and sarcosine ethyl ester hydrochloride salt 70 affords the dipeptide 
(+)-71. Subsequent Boc removal followed by intramolecular cyclization furnishes the 
model system DKP (+)-65 in excellent yield. Interestingly, the DKP formation did not 
experience the diastereoselectivity problems seen in the actual system. The presence of 
two TBDPS groups on the actual system may have some influence on the 
diastereoselectivity of the reaction. Furthermore, the copper-oxidative coupling step was 
not problematic, as it consistently resulted in good yields. This may be reasonable, since 
coupling of one 1,3-butadiene moiety may be thermodynamically much easier than bis 
coupling.  
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Scheme 4.21. Synthesis of model system coupled DKP (+)-72. 
 
Subsequent removal of TBDPS occurred in excellent yield to afford the allylic alcohol 
(+)-73 (Scheme 4.22). Optimal condition for the oxidation step was obtained with Dess-
Martin periodinane (DMP) to obtain the unstable IMDA precursor 74. Other oxidants 
such as MnO2 and BaMnO4 were sluggish in comparison to DMP, where the starting 
material was completely consumed only after 4 d along with decomposed or polymerized 
material. Due to instability of 74, it was crucial to develop an efficient oxidative 
condition that would rapidly furnish the desired product in good yield. DMP was the 
reagent of choice, since the transformation occurred in about 20-30 min. A short plug 
silica gel column was required promptly after the reaction in order to minimize iodinane 
contamination. 
 
Scheme 4.22. Synthesis of model IMDA precursor 74. 
 
Optimized conditions obtained from model system DKP 74 translated well to the actual 
system (Scheme 4.23) to afford the desired IMDA precursor 44. Similar to experimental 
results obtained using the model system, use of other oxidation reagents, such as 
BaMnO4, MnO2, and Ley oxidation reagents (TPAP, NMO, 4Å MS), resulted in 
decomposition or polymerization due to sluggish conversion of the starting material to 
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the highly unstable product 44. Interestingly, Parikh—Doering oxidation (SO3"pyr, 
DMSO, Et3N) gave comparable results to that of DMP oxidation. While as, IBX was not 
as reactive as DMP, and resulted in lower yield. IMDA precursor 44 had to be used 
immediately after a prompt, short silica gel plug column to prevent 
decomposition/polymerization which occurred rapidly at room temperature.  
 
Scheme 4.23. Synthesis of IMDA precursor 44. 
 
4.6) Investigation of IMDA reaction 
 
IMDA reactions are one of the most popular reactions utilized in many total syntheses to 
date.49 There are two types of IMDA based on the point of connection between the diene 
and the dienophile (Figure 4.6). The system under investigation is in the category of Type 
I IMDA, since the dienophile is tethered from the terminus of the diene. The less 
prevalent Type II IMDA have the dienophile tethered from an internal position on the 
diene (Figure 4.6), which results in the formation of bridged bicycles that contain highly 
strained bridgehead double bonds (anti-Bredt alkene). Unlike Type I IMDAs, predicting 
the diastereoselectivity of type II IMDAs is simpler, since substrates with bridging chains 
of three or four atoms cyclize exclusively to give syn products, due to lower energy of the 
transition state in comparison to that of the anti diastereomer.50 
 
Figure 4.6. Type I vs. Type II IMDA. 
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For Type I IMDAs, the nature of the diene, dienophile, and tether could dictate the 
stereo- and regioselective outcome of these reactions (Figure 4.7). In other words, 
depending on the orientation of the diene and the dienophile on the ends of the tether 
could lead to the formation of the endo or exo IMDA adduct. Therefore, we envisioned 
the utilization of a common IMDA precursor 44 that could lead to the formation of either 
endo or exo IMDA adduct depending on the type of organocatalyst employed. Due to the 
abundance of endo selective organocatalysts, investigation of synthetic route towards (−)-
rostratin A was conducted first.  
 
Figure 4.7. Formation of trans-fused vs. cis-fused products in Type I IMDA. 
 
Inspired by MacMillan’s successful application of his second-generation imidazolidinone 
catalyst51a in the key IMDA step in the synthesis of marine metabolite solanapyrone D 
(Scheme 4.24),51b use of his organocatalyst was envisioned for the present system hoping 
to achieve high diastereoselectivity. In particular, the synthetic utility of MacMillan’s 
protocol was demonstrated by the preparation of various [4.3.0]- and [4.4.0]cycloadducts 
in good yield, enantio-and diastereoselectivity.51b  
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Scheme 4.24. Application of MacMillan’s catalyst in his synthesis of (−)-solanapyrone D.51b 
 
MacMillan’s catalysts function as the LUMO-lowering activator of α,β-unsaturated 
carbonyl of aldehydes via the reversible formation of iminium ion. In terms of selectivity, 
MacMillan utilized a MM3 force field simulation to show that his first-generation 
catalyst and the aldehyde selectively form an E-iminium ion, where the hydrogen atom in 
the α-position is able to avoid unfavorable interactions with the geminal methyl groups of 
the catalyst.52 The unfavorable interaction would be more pronounced by a t-butyl group 
present in his second-generation catalyst (Figure 4.8). Consequently, the diene 
approaches the iminium ion preferably from the si face.  
 
Figure 4.8. Selectivity explanation displayed using MacMillan’s catalyst. 
 
Taken together, when applied to the present system, the MacMillan’s second-generation 
catalyst should give predominantly endo adduct, where the diene would approach the 
dienophile in the si face (Scheme 4.25).  
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Scheme 4.25. Proposed utilization of MacMillan’s catalyst. 
 
Although MacMillan’s IMDA protocol has been widely used since his first report,51b the 
reaction lacks generality, in that each IMDA substrate has to be individually studied and 
optimized for maximal yield and selectivity. Yields are usually reported as percentage 
conversion as opposed to isolation, due to the propensity of undesired side reaction that 
could occur during the reaction.53 There are four main side reactions53 that should be 
considered. First, starting materials, such as trienals and tetraenals often polymerize 
under the reaction conditions. Since the present system contains a trienal moiety, 
polymerization was a big threat. Furthermore, unsbustituted 1,3-butadienes are notorious 
for their instability, which could further add to the likelihood of polymerization. Second, 
since protic acid co-catalysts are used together with the imidazolidinone catalyst, acid 
catalyzed racemic background reactions could occur. Since the diene and the dienophile 
are tethered together, dilution effect is not a viable solution in minimizing the racemic 
background reaction. Since these background reactions go through an achiral transition 
state, the outcome of the reaction is a racemic mixture of products, decreasing the optical 
purity (ee). Third, the IMDA adducts are prone to epimerization at the aldehyde 
stereocenter, which could result in an epimer of a diastereomer of the reaction. Since the 
α-proton of the aldehyde is relatively acidic, it is possible for the basic amine catalyst 
and/or the conjugate base of the protic acid co-catalyst to readily epimerize the center 
with time (Scheme 4.26).  
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Scheme 4.26. Possible epimerization side reaction.53 
 
Initial reports from the MacMillan group showed that a considerable amount of aromatic 
side product was being formed, presumably through dimerization (Scheme 4.27).53 
Following the formation of iminium ion (which is the activated form of the dienophile), 
the triene could be γ-deprotonated with the conjugate base of the protic acid co-catalyst to 
form the corresponding dienamine. The dienamine could be sufficiently electron rich to 
act as a diene and undergo dimerization via intermolecular DA. Hydrolysis of the 
iminium and subsequent elimination and oxidation would afford the aromatized side 
product. Though this particular side reaction seemed to be a big concern for flexible 
trienal systems, the system under consideration is not as flexible, so the undesired 
dimerization may be less likely to occur.  
 
Scheme 4.27. MacMillan’s proposed mechanism for the formation of dimerized side products.53 
 
The extent of these undesirable side reactions depends on the inherent activity of the 
IMDA substrate. Fortunately, the side reaction could be somewhat controlled by choice 
of catalyst, co-catalyst, temperature, and solvent. In terms of the catalyst, MacMillan’s 
second-generation imidazolidinone catalyst was selected based on his results of IMDA 
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reactions.51b In terms of the co-catalyst, more acidic protic acids (HClO4, TfOH) tend to 
decrease product epimerization and starting material dimerization, due to decreased 
basicity of the corresponding conjugate base.53 On the other hand, less acidic co-catalysts 
(TFA, TCA) tend to minimize acid promoted racemic background reaction and starting 
material polymerization.53 Therefore, less acidic co-catalysts are often used for more 
reactive substrates, while more acidic co-catalysts are used to help activate less reactive 
substrates. In terms of temperature, less racemic background, epimerization, and 
dimerization occurs at lower reaction temperatures, which tend to improve product 
diastereo- and eantioselectivities.53 However, higher temperatures tend to result in 
increased yields due to less starting material polymerization. Since starting materials 
polymerize when the rate of the desired reaction is slow, increasing temperature helps 
speed up the rate at the cost of obtaining mixtures of diastereomers and enantiomers. 
Hence, less reactive substrates are run at high temperatures. Finally, extensive studies 
done by the MacMillan group53 suggested the importance of water in the reaction. Since 
water is both a product of iminium formation as well as an agent for iminium hydrolysis, 
various rate studies were required to find the precise amount of water that would 
positively affect the reaction outcome. Kinetic studies done in the MacMillan group 
suggested the optimal solvent to water ratio to be about 98:2 to maximize the rate of 
catalyst turnover.53,54 They also found that solvents such as acetonitrile and chloroform 
effectively reduced the rate of polymerization and increased substrate and catalyst 
solubility, while butanol and isopropanol effectively minimized the epimerization side 
reaction.53 
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With these considerations in mind, IMDA using MacMillan’s second-generation catalyst 
was investigated (Table 4.5). Minimizing starting material polymerization and/or 
decomposition was a challenging task due to highly unstable nature of the IMDA 
precursor. Polymerization/decomposition was evident at times even prior to setting up the 
reaction. Therefore, it was crucial for the rate of the IMDA reaction to be much faster 
than the rate of polymerization/decomposition of the starting material. Although at least 
three different diastereomers (endo, epimer of endo, and exo) were expected if the 
cyclization occurred successfully, the initial goal of the optimization was to increase the 
overall yield. Since it is known53,54 that optimal solvent mixture is about 95:5 
acetonitrile:water or 98:2 acetonitrile:water to maximize the rate of catalyst turnover, 
such solvent mixtures were used. Generally, use of MacMillan’s second-generation 
catalyst resulted in faster reaction rates in comparison to first-generation catalysts (entries 
7-8 & 18, Table 4.5), which resulted in higher yields due to less polymerization and/or 
decomposition of starting material. Temperature appeared to have an effect on the yield. 
Yield of the reaction suffered at higher temperatures (entry 3, Table 4.5), which could be 
attributed to decomposition of material. However, yields decreased at lower temperatures 
(entries 13 & 16, Table 4.5), which is probably due to decreased rate of the reaction, 
promoting starting material polymerization. Room temperature seemed to afford the best 
overall yield, which is likely due to increased rate of the reaction, consequently 
decreasing the rate of starting material polymerization. This increase in yield may happen 
at the cost of obtaining poor diastereo- and enantioselectivity. Less acidic co-catalysts 
(TFA, DCA) led to increased reaction time and decreased yield (entries 7-8 & 18, Table 
4.5). Although less acidic co-catalysts were expected to decrease substrate 
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polymerization, resulting decrease in rate of the desired reaction could have a bigger 
impact on the overall yield. Kinetic studies done by the MacMillan group strongly 
implied that the rate of the reaction is directly proportional to acidity of the co-catalyst, 
since the rate of iminium ion formation is increased with increased acidity of the co-
catalyst.54 Therefore, more acidic co-catalysts (HBF4, HClO4) afforded comparably better 
results (entries 6 & 17, Table 4.5). Reaction time was important, as prolonged reaction 
time led to increased decomposition (entry 12 vs. 11, Table 4.5). Finally, concentration 
had an unexpected effect on the reaction rate. Since the diene and the dienophile are 
tethered together, overall concentration was expected to have less of an impact on rate. 
However, at drastically high concentration (entry 19, Table 4.5), the reaction was fully 
completed in 2 hours, albeit at the cost of decreased yield, which is probably due to 
increased decomposition.  
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Table 4.5. IMDA optimization using MacMillan’s catalyst. 
 
Entry Catalyst 
(mol%) 
HX (mol%) Solvent [M] Temp (oC) Time (h)a Yield (%)b 
1 2nd gen. (50) HClO4 (50) MeCN:H2O 95:5 [0.02] rt 24 22 
2 2nd gen. (20) HClO4 (20) MeCN:H2O 95:5 [0.05] rt 24 42 
3 2nd gen. (40) HClO4 (40) MeCN:H2O 95:5 [0.05] 40 22 <5c 
4 2nd gen. (40) HClO4 (40) MeCN:H2O 95:5 [0.05] rt 19 20 
5 2nd gen. (40) HCl (40) MeCN:H2O 95:5 [0.05] rt 19 15 
6 2nd gen. (20) HClO4 (20) MeCN:H2O 95:5 [0.1] rt 21 62 
7 1st gen. (40) DCA (40) MeCN:H2O 95:5 [0.1] rt 120 <30d 
8 1st gen. (40) TFA (40) MeCN:H2O 98:2 [0.3] −20!30e 72 0c 
9 2nd gen. (40) HClO4 (40) MeCN:H2O 98:2 [0.35] 4 4.5 36c 
10 2nd gen. (40) HCl (40) MeCN:H2O 98:2 [0.35] rt 192 0c 
11 2nd gen. (40) HBF4 (40) MeCN:H2O 98:2 [0.35] rt 4 56c 
12 2nd gen. (40) HBF4 (40) MeCN:H2O 98:2 [0.35] rt 23 36 
13 2nd gen. (40) HBF4 (40) MeCN:H2O 98:2 [0.35] 0!4 6 14c 
14 2nd gen. (20) HClO4 (20) MeCN:H2O 98:2 [0.4] rt 6 62 
15 2nd gen. (40) HClO4 (40) MeCN:H2O 98:2 [0.4] rt 18 20c 
16 2nd gen. (40) HClO4 (40) MeCN:H2O 98:2 [0.4] −20 24 17c 
17 2nd gen. (40) HBF4 (40) MeCN:H2O 98:2 [0.4] rt 2.5 68 
18 1st gen. (40) TFA (40) MeCN:H2O 98:2 [0.5] rt 48 0c 
19 2nd gen. (20) HClO4 (20) MeCN:H2O 98:2 [0.6] rt 2 33c 
[a] Reaction followed by TLC. 
[b] Overall yield (including all diastereomers) over two steps (oxidation and IMDA). 
[c] Decomposition/polymerization. 
[d] Additional catalyst and HX (20 mol%, total 40 mol%) used after 48 h. 
[e] Reaction held at −20 oC o/n, then 0 oC o/n, then 5 oC!rt with addition of more catalyst and HX (20 mol%, total 40 
mol%), then 30 oC o/n 
 
Taken together, the data obtained suggest the use of the second-generation 
imidazolidinone catalyst, more acidic co-catalysts (HClO4, HBF4), and a concentrated 
solvent mixtures (0.35 – 0.4 M) to achieve high overall yield at a faster rate (entries 14 & 
17, Table 4.5). The robustness of the optimized conditions was confirmed when applied 
to the model system (Scheme 4.28).  
 
Scheme 4.28. Application of optimized conditions to the model system. 
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Derivatives of MacMillan’s imidazolidinone catalysts55 were synthesized and tested, but 
did not provide comparable results (3 d of reaction time, decomposition). Furthermore, 
other organocatalysts, such as Corey’s oxazaborolidine catalyst, 56  exo-selective 
diarylprolinol silyl ether catalysts,57 L-proline, and Kündig’s chiral ruthenium catalyst58 
all displayed issues in activation of the starting material, which resulted in decomposition 
due to prolonged reaction time regardless of changes in catalyst loading and solvent 
concentration. Lewis acids, such as ZnCl2 and Et2AlCl afforded similar results, where the 
overall yield of the reaction suffered from either slow reaction rate or decomposition 
respectively.  
Although superior in comparison to other organocatalytic IMDAs, optimized conditions 
using MacMillan’s imidazolidinone catalyst posed difficulties, as the diastereoselectivity 
of the reaction remains to be elucidated. The reaction afforded a mixture of 
diastereomeric products that displayed almost identical physical properties, which made 
determination of diastereomeric ratio by 1H NMR analysis impossible. Furthermore, 13C 
NMR showed multiple aldehyde carbons, further suggesting the presence of various 
diastereomers. Attempted separation of individual diastereomers proved to be difficult by 
both manual and automated (HPLC) column chromatography methods.  
In a different approach, the mixture of IMDA cycloadducts was carried on for 
derivatization with 2,4-dinitrophenylhydrazine (2,4-DNPH), since the resultant 
hydrazone products would possess visible chromophores (for UV detection) that could 
aid in the separation process. Furthermore, derivatization could impart relative and 
absolute stereochemical information as well as enantioselectivity of the IMDA reaction 
(Scheme 4.29). Gratifyingly, the major hydrazone derivative was isolated (detected by 
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HRMS and 1H NMR) albeit in small quantities upon HPLC purification. X-ray analysis 
of the derivative should elucidate the desired absolute stereochemical information.  
 
Scheme 4.29. Synthesis of hydrazone derivative. 
 
Alternatively, IMDA by more traditional thermal methods afforded the desired 
cycloadduct in modest yields (Scheme 4.30). As expected, formation of insoluble 
decomposed materials was evident as the reaction progressed. To avoid potential 
polymerization via radical mechanism, catalytic amount of 2,6-di-tert-butyl-4-
methylphenol (BHT) was added as a radical scavenger. The reaction was conducted in a 
sealed tube, using degassed solvent, and heating in a sand bath. There was an apparent 
activation barrier, as the cyclization did not occur at lower temperatures (60-80 oC) even 
after prolonged reaction time (2 days).  
 
Scheme 4.30. Thermal IMDA reaction. 
 
Since insoluble polymer-like materials were recovered after the reaction even with the 
addition of BHT, the polymerization might occur by ionic means. A similar conclusion 
was suggested by Molinski, in his investigation of IMDA in the synthesis of Muironolide 
A. 59  He proposed that the polymerization could be attributed to the tendency of 
terminally unsubstituted 1,3-butadiene moiety in tethered systems to polymerize.59 When 
terminally substituted 1,3-butadiene IMDA substrates were used, Molinski observed a 
dramatic increase in yield. However, the use of terminally unsubstituted 1,3-butadienes in 
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IMDAs are not entirely unprecedented, as Oppolzer illustrated60 the use of terminally 
unsubstituted dieneamides in IMDAs as early as 1975, albeit in modest yields.  
Although further improvement could be made to obtain better results in terms of 
diastereoselectivity, taming the highly unstable IMDA precursor towards IMDA 
cycloaddition was nevertheless an accomplishment on its own.  
 
4.7) Alternative approaches 
 
Due to the apparent instability of the IMDA precursor 44, in which the rate of substrate 
polymerization outcompeted the desired cycloaddition reaction, alternative routes to 
arrive at the 6-5-6-5-6 core of the rostratins were investigated. The observed reactivity of 
44 towards polymerization and/or decomposition could arise from highly reactive nature 
of either the unsubstituted 1,3-butadiene or the α,β-unsaturated aldehyde moieties. 
Therefore, altering the diene or the dienophile with functional groups that may induce 
chemical stability towards undesired side reactions that ultimately result in 
decomposition was explored. Another potential approach would be to switch the position 
of the diene and dienophile on the DKP, which would afford information on the reactivity 
of dienamides in comparison to alkyldienes. Moreover, a double intermolecular DA on 
functionalized DKP could be another option. Finally, alternative methods of 
cycloadditions could be considered, such as cationic radical cyclization and transition 
metal mediated cyclization. 
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4.7.1) Alteration of electron-poor dienophile 
To assess the reactivity of the α,β-unsaturated aldehyde as the dienophile, alternative 
electron-poor dienophiles, such as phenyl sulfone, methyl ester, and methyl ketone could 
be employed in the IMDA reaction (Scheme 4.31).  
 
Scheme 4.31. Use of alternative electron-poor dienophiles for IMDA. 
However, use of such dienophiles would limit the scope of IMDA reaction, since 
organocatalysts that activate via iminium ion formation (prolinols, imidazolidinones) 
cannot be utilized, since esters and ketones are not as reactive as aldehydes. Furthermore, 
use of phenyl sulfone as the dienophile would be even more limited to thermal IMDA 
reactions. Nonetheless, these electron-poor alternative dienophiles could be comparably 
activated towards IMDA.  
The synthesis of methyl ketone DKP derivative 80 could not be achieved using 
previously discussed routes due to the highly reactive nature of methyl ketones towards 
acidic and basic conditions. Efforts to mask the carbonyl by utilizing reduced forms of 
the moiety were not productive due to protecting group orthogonality issues (Scheme 
4.32). Leaving the secondary alcohol unprotected led to decomposition under N-Boc 
removal conditions.  
 
Scheme 4.32. Proposed synthesis of 80. 
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Attention was then given to synthesis of phenyl sulfone and methyl ester derivatives 78 
and 79. The initially proposed synthesis of 78 and 79 was to use cross-metathesis (CM) 
of known common intermediate (−)-8161 and requisite olefins (Scheme 4.33).  
 
Scheme 4.33. Attempted synthesis of 78 and 79 using cross-metathesis. 
 
However, due to insurmountable solubility issues of (−)-81 in solvents that are commonly 
used in CM (hexanes, toluene, CH2Cl2, 1,2-DCE, EtOAc) and other activation issues, the 
corresponding products could not be obtained in synthetically useful yields (Scheme 
4.33). A diverse array of solvents (CH2Cl2, 1,2-DCE, EtOAc, DMC, MeOH, acetone, 
dioxane, and PhMe) and catalysts (Grubbs I & II, Hoveyda-Grubbs I & II, Zhan) were 
examined at various temperatures (refluxing conditions or in microwave reactor) with a 
large excess of the coupling partner olefin (>20 equiv. of methyl acrylate or phenyl vinyl 
sulfone), but none resulted in sufficient quantities of the desired products. Interestingly, 
when the amide nitrogens of (−)-81 was protected with benzyl groups, it was readily 
soluble in standard CM solvents (i.e. CH2Cl2), and the reaction could be run at high 
concentration (0.25 M), which resulted in nearly quantitative yields (Scheme 4.44). 
However, installation of benzyl moieties on the amide nitrogens of (−)-81 or DKPs with 
acyclic substitutions in general, is a well-known unproductive process due to the high 
propensity of the α-proton epimerization to the more thermodynamic stable trans DKP 
under basic conditions. Furthermore, removal of the benzyl groups may become difficult 
at later stages of the synthesis, since it often requires harsh reaction conditions.  
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Scheme 4.44. Synthesis of di-benzyl protected 83. 
 
Fortunately, the phenyl sulfone DKP (−)-78 was accessed using a similar synthetic route 
to (−)-46 starting from a common intermediate 84 (Scheme 4.10) in good yields (Scheme 
4.45). Hydrolysis of the methyl ester (+)-85 to the corresponding acid 87 could be 
achieved only via the use of trimethyltin hydroxide (Me3SnOH), due to tendency of 
phenyl sulfone elimination under basic conditions (LiOH, SiMe3OH, Ba(OH)2"8H2O). 
Formation of trans DKP of (−)-78 was not observed under the reaction conditions.  
 
Scheme 4.45. Synthesis of phenyl sulfone DKP (−)-78. 
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monitored by LRMS). However, prolonged reaction time (>5 days) tend to give rise to 
oxidized side products that were detected by 1H NMR when aliquots of the reaction were 
taken at various time points. The nature of oxidized side products could be from both 66 
and (+)-89, as dienes are notorious for being oxidized upon standing over extended 
periods of time. Interestingly, slight increase in the O2 pressure by conducting the 
reaction under an O2 manifold increased the formation of oxidized side products (Entry 
12, Table 4.6). A Possible reason for using excess 66 in copper-oxidative couplings in 
both TBDPS DKP (−)-46 and sulfone DKP (−)-78 cases could be attributed to oxidation 
of 66 with time. However, since the oxidation of the product DKP of (−)-46 was not 
observed even when the reaction was conducted under slight positive pressure of O2 over 
prolonged period of time, suggests the more reactive nature of (+)-89 under oxidative 
conditions. Increasing copper catalyst loading (1 equiv.), changing copper catalyst 
(Cu(OTf)2), increasing amount of 66 (portion-wise addition, 10 equiv.), addition of 
additives (NMI), and changing solvent mixture (TFE:1,2-DCE) did not result in either 
increase in conversion or yield (Table 4.6). Difference in electronics of the DKP was 
considered, since phenyl sulfones are more electron-withdrawing than allyl TBDPS 
ethers, which would be supported by the relative decrease in pKa value of the amide 
proton of (−)-78 in comparison to (−)-46. If the pKa was indeed lower, addition of 
catalytic amounts of amine additives could improve the yield.41b However, since this was 
not the case (Entry 6, Table 4.6), the pKa difference may not be as pronounced as 
expected. It is possible that the catalytic amount of NMI aided in decomposition of 
material, since phenyl sulfone moieties are prone to elimination under basic conditions. 
Nonetheless, the best yield of (+)-89 was obtained a with slight variation of the 
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previously optimized protocol (6 equiv. of 66) in 3 days (Entry 7, Table 4.6). Due to the 
limited solubility of (−)-78 in organic solvents, which is a testament of increased polarity 
of the DKP, dissolution of (−)-78 had to be ensured prior to addition of other reagents.  
 
Table 4.6. Copper-oxidative coupling optimization for phenyl sulfone derivative. 
 
Entry 66 
(equiv.) 
Cu(OAc)2 
(equiv.) 
Solvent [M] Additive Time 
(d) 
Yielda 
(%) 
1 5 30 DMSO:DCM [0.25] None 1.7 25b 
2 5 30 DMSO:DCE [0.25] None 4 42 
3 5 30 DMSO:DCE [0.25] None 5 35 
4 5 30 25% DMSO:DCM [0.25] None 2.8 0 
5 5 30 DMSO:TFE [0.25] None 4 0 
6 5 20 DMSO:DCM [0.25] NMI (40 mol%) 7 0 
7 6 30 DMSO:DCM [0.25] None 3 48 
8 5 then 1c 30 DMSO:DCM [0.25] None 5 44 
9 5 then 1d 30 DMSO:DCM [0.25] None 16 5 
10 5 then 2e 30 DMSO:DCM [0.25] None 15 38 
11 5 then 2e 20 then 80f DMSO:DCM [0.25] None 19 <5 
12 4 then 2g 30 DMSO:DCM [0.25] None 13 22 
13 10 1 DMSO:DCM [0.25] None 11 0h 
[a] Isolated yield. O2 balloon was used in all cases unless specified. 
[b] Mono-coupled product was also isolated in 40%. 
[c] Additional equivalent of 66 added on day 2. 
[d] Additional equivalent of 66 added on day 6. 
[e] Additional equivalent of 66 added on day 5 then day 9. 
[f] Cu(OTf)2 was used instead. Additional catalyst added on day 3. 
[g] Additional equivalent of 66 added on day 4 and 7. Switched to O2 manifold on day 7. 
[h] Reaction done in sealed tube with a headspace of O2. 
 
With requisite IMDA precursor (+)-89 in hand, thermal IMDA conditions were 
investigated. Various solvents (m-xylenes, chlorobenzene, 1,2-dichlorobenzene, NMP) 
were screened at high temperatures (160-190 oC). The reactions were generally done in 
dilute conditions (0.05 M) in a sealed tube. The reaction was heated using either 
microwave irradiation or sand bath. Microwave irradiation did not necessarily speed up 
the rate of the reaction, as the presence of starting material (along with decomposed 
material) was noted even after seven 1 hour cycles at 160 oC. Therefore, heating in sand 
bath was operationally easier as the rate of conversion of the starting material seemed to 
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be sluggish at high temperatures. Similar to aldehyde IMDA precursor 44, (+)-89 also 
was prone to rapid polymerization/decomposition upon standing. Addition of a catalytic 
amount of BHT as radical inhibitor seemed to minimize extent of polymerization. The 
desired cycloadduct was obtained as a mixture of diastereomers in synthetically 
meaningful yield when NMP was used as solvent, and resulted in less decomposed 
material (Scheme 4.46).  
 
Scheme 4.46. IMDA of sulfone derivative (+)-89. 
 
With the exciting result, a potential formal synthesis to Nicolaou’s key intermediate23 
was envisioned (Scheme 4.47). Presumably, if the IMDA afforded more of the endo 
adduct, the 4,4’-epimer of Nicolaou’s key intermediate could be obtained via 1,2-
elimination of the phenyl sulfone moiety. Alternatively, if any appreciable amount of exo 
adduct could be obtained and isolated, it would afford the exact stereochemistry observed 
in his key intermediate. This reaction has synthetic potential, since facile elimination of 
phenyl sulfone moiety was observed during the synthesis of phenyl sulfone DKP (−)-78.  
 
Scheme 4.47. Possible formal synthesis of 4,4’-epi-epicoccin G. 
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1,3-butadiene trifluoroborate 66 may be useful. One of the ways to install substituents is 
early on the synthesis (Scheme 4.48). The common intermediate alkyne 67 was subjected 
to known one-pot haloboration conditions62 to afford the corresponding pinacol boronate 
91. Subsequent elimination of the mesylate followed by conversion to potassium 
trifluoroborate salt afforded 92 in good yield (Scheme 4.48). 
 
Scheme 4.48. Synthesis of 92. 
 
However, when the chlorosubstituted diene substrate 92 was used in the copper-oxidative 
coupling step with TBDPS DKP (+)-69, no product was formed using the previously 
optimized conditions (Scheme 4.49). In fact, only polymerized protodeboronated diene 
was recovered after 6 days along with unreacted starting material DKP (+)-69. Increasing 
the amount of 92 (10 equiv.) did not afford the coupled product or even the mono-
coupled product. A possible explanation may be that the presence of bulky chloride atom 
on the 2-position of the diene increases sterics of the potassium trifluoroborate salt 92, 
thus preventing the desired reaction to occur. Furthermore, Batey’s original protocol41 did 
not contain any substrates that had electron-withdrawing groups in the potassium 
alkenyltrifluoroborate moiety, possibly because they are less likely to couple under the 
given conditions.  
 
Scheme 4.49. Attempted synthesis of 93. 
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Alternative methods of C-N coupling reactions could be attempted in the future to afford 
the desired product 93. Furthermore, 92 (Scheme 4.48) is an interesting substrate that 
could be of use in other syntheses. 
A terminal substitution on the diene moiety was envisioned next. Particularly, cross-
metathesis (CM) conditions were of interest, since 66 could be utilized as the starting 
material. Although many different types63 of reactions with potassium trifluoroborates as 
the starting materials are known in the literature, they have not been used for CM 
processes to the best of our knowledge. Initial screening of conditions suggested the use 
of excess amount of phenyl vinyl sulfone, and more active Hoveyda-Grubbs II catalyst. 
Since mixtures of potassium trifluoroborates cannot be separated, it was important that 
the transformation would result in 100% conversion of starting material. 1H NMR 
detected no starting material 66, but the presence of the desired product 94 after 6 days 
(Scheme 4.50).  
 
Scheme 4.50. Synthesis of 94. 
 
However, the reaction has problems. For instance, due to small molecular mass of 66, and 
the relatively large molecular mass of the catalyst, 5 mol% catalyst loading is actually a 
large amount of expensive catalyst (at 1 g of 66, 196 mg of HGII). Furthermore, since at 
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which would not be entirely unreasonable, since some amount of protodeboronated 66 
dimers are present after copper-oxidative coupling conditions at 40 oC over few days. 
Nonetheless, potassium trifluoroborate derivative 94 was synthesized in hopes of 
utilization in a different cycloadditioin reaction (Scheme 4.51). If the copper-oxidative 
coupling of 94 with (−)-81 occurred successfully, the diene moiety would then be 
electron-poor, while the dienophile moiety would be relatively less electron-poor. 
Therefore, based on electronic differences, the desired [4+2] cycloaddition could occur 
under thermal conditions. A mixture of diastereomeric products would be obtained, 
which could then be utilized towards the synthesis of Nicolaou’s key intermediate23 under 
elimination conditions as discussed in previous section.  
 
Scheme 4.51. Alternative [4+2] approach. 
 
Although the proposed synthesis was not completed, much synthetic information was 
gained about the reactivity of alkenyl trifluoroborates under CM conditions.  
 
4.7.3) Intermolecular DA considerations 
Alternative approaches in utilizing electron-poor DKPs as dienophiles in intermolecular 
DA cycloadditions with known dienes were considered, in the intent of using the 
resulting cycloadducts for allylic C-H amination64 to furnish the desired 6-5-6-5-6 system 
(Scheme 4.52).  
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Scheme 4.52. Proposed intermolecular DA. 
 
Unfortunately, the desired DA cycloaddition with 3-sulfolene and either the phenyl 
sulfone DKP (−)-78 or methyl ester DKP 79 resulted in either complete recovery of the 
starting material DKP or decomposition. Various solvents (DMF, NMP, DMSO, 
chlorobenzene) were tested at high temperatures (reflux, 200 oC µW irradiation), but 
none led to detectable amount of the desired cycloadduct. Other dienes (Danishefsky’s 
diene, furan) were reacted without much success. This approach does have some potential 
problems, such as controlling the diastereoselectivity of both the DA and the allylic C-H 
amination. It is highly likely to obtain mixture of diastereomers, which may be difficult to 
separate. However, more extensive investigation could be done for this approach.  
 
 
4.7.4) Alternative [4+2] cycloadditions 
So-called unactivated [4+2] cycloadditions could occur in the presence of heat, high 
pressure, transition metals, light, or radical cations just to name a few. In particular, 
transition metal-mediated65 and radical cationic66 cycloadditions were of interest for the 
present study.  
Since the reaction of 66 with varying DKP derivatives (TBDPS DKP (−)-46 and phenyl 
sulfone DKP (−)-78) under copper-oxidative coupling methodology seemed to work 
reasonably well, coupling of 66 with the alkene DKP (−)-81 was investigated using 
previously optimized conditions in hopes of employing the coupled product for transition 
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metal mediated [4+2] reactions. Not surprisingly, similar issues with activation of starting 
material DKP and undesired side reactions were encountered. The best yield was 
obtained using 5 equivalents of 66 (addition of 4 equiv. in the beginning, and additional 1 
equiv. after few days), 30 mol% of Cu(OAc)2, in a mixture of DMSO and CH2Cl2 at 0.24 
M (Scheme 4.53). However, the reaction took 20 days to reach completion at the cost of 
obtaining oxidized side products and a minor amount of mono-coupled product (26%). 
Although subsequent [4+2] cycloaddition of (+)-97 has not been conducted as of yet, it 
has some promise, since such cycloadditions, especially via transition metal-mediation 
are known in the literature.65 
 
Scheme 4.53. Synthesis of alkene DKP (−)-81 for [4+2] cycloaddition. 
 
With promising results, alkynyl DKP (−)-98 was synthesized from L-propargyl glycine 
derivatives using same synthetic sequence employed in the synthesis of alkene DKP (−)-
81 (Scheme 4.54).  
 
Scheme 4.54. Synthesis of (−)-81 and (−)-98. 
 
However, the alkynyl DKP (−)-98 did not successfully couple with 66 under various 
copper-oxidative conditions (Scheme 4.55). 
 
Scheme 4.55. Attempted synthesis of 101 for [4+2] cycloaddition. 
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A possible explanation for this failed attempt could be that the terminal alkyne of the 
DKP is coordinating to the copper as a ligand, consequently inhibiting the desired 
reaction. This hypothesis could be verified by synthesis of terminally substituted alkynyl 
DKPs in the future. Furthermore, solubility issues of (−)-98 were apparent especially in 
comparison to other polar DKPs ((−)-78 and (−)-81). Even with 1:1 ratio of DMSO and 
CH2Cl2, heating of the DKP was needed to achieve dissolution. As discussed earlier, the 
amount of DMSO cannot be increased for the reaction to occur, since over excess of 
DMSO could act as a ligand on copper, thereby shutting down the reaction. Nonetheless, 
if these problems could be resolved, and the subsequent cycloaddition executed, the 
resulting cycloadduct could be used for the synthesis of scabrosins, since it contains the 
unsaturation at 4,4’-positions of the 6-5-6-5-6 framework (Scheme 4.7). 
Activation of (+)-69 towards unactivated DA was considered next. Initial data obtained 
by thermal study67 of (+)-69 under common cycloaddition conditions only resulted in 
apparent removal of TBDPS groups and decomposition of material (Scheme 4.56). Full 
recovery of starting material was obtained when the reaction was heated at significantly 
lower temperatures (60 oC) for extended periods of time (2 weeks), suggesting the 
presence of a significant activation barrier to achieve cyclization. Lewis acid (Cu(OTf)2) 
mediated cycloaddition65b at 80 oC for 7 days did not afford the desired cycloadduct, but 
resulted in removal of the TBDPS groups and decomposition. 
 
Scheme 4.56. Attempted unactivated DA under thermolysis. 
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Next, cationic radical cyclization was investigated. Acidic oxidizers, such as tris(p-
bromophenyl)aminium hexachloroantimonate, generates cationic radicals by abstraction 
of one electron from the system.66a Consequently, the reaction undergoes an electron 
transfer catalysis (ETC), that could result in cycloadducts that could be obtained by 
traditional DA reactions. ETC cycloadditions are believed to have activation barriers of 
1-5 kcal/mol, often 10-60 kcal/mol lower than the corresponding thermal 
cycloadditions.68a Furthermore, ETCs are good for sterically encumbered substrates 
especially when such systems fail under thermal conditions.68b Generally, substrates that 
possess lower redox potentials (electron-rich) are more easily oxidized to a cation radical. 
In terms of mechanism, ETC could be [3+2] or [4+1] (numbers denoting number of 
electrons in the system, Scheme 4.57).  
 
Scheme 4.57. Simplified example of ETC under [3+1] or [4+1]. 
 
[3+2] Cycloadditions are symmetry forbidden, step-wise process, and the radical cation is 
formed from the diene. The diene would be relatively more electron rich in comparison to 
the dienophile for a [3+2] cycloaddition. On the other hand, [4+1] cycloadditions are 
symmetry allowed, concerted process, and radical cations are formed from dienophiles. 
[4+1] Cycloadditions could also occur on systems where the diene and dienophile are 
identical. In addition, vinylcyclobutane could be obtained and subsequent rearrangement 
could lead to the same cycloadduct.68c Dienes that are in the s-cis conformation tend not 
to react via vinylcyclobutane mechanism.68c  
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TBDPS DKP (+)-69 was tested under ETC conditions using tris(p-bromophenyl)aminium 
hexachloroantimonate as catalyst under standard conditions (Scheme 4.58).66 The relative 
redox potential of the diene moiety in comparison to the dienophile on (+)-69 was 
speculated, but not measured, as such process would be difficult on a tethered system 
(using cyclic voltammetry). One possible way to predict the relative redox potential of 
the diene and the dienophile would be via theoretical means (obtaining the relative 
electron density information by calculation). Furthermore, in order for the reaction to take 
place, the redox potential of the substrate has to be lower than that of the catalyst for the 
formation of radical cation. Hence, without such information, the only way to determine 
if the desired reaction would take place was to conduct the actual experiment. In 
comparison to thermolysis, ETCs are known to occur rapidly using small amount of 
catalyst (< 20 mol%) if the redox potential of the substrates are favorable (within 
minutes). However, this was not observed for the present case. Conversion of the starting 
material proceeded only after additional amount of catalyst was added (up to 50 mol%) 
(Scheme 4.58). Even upon stirring overnight with addition of more catalyst (1 equiv. 
total), the reaction failed to reach completion.  
 
Scheme 4.58. Attempted application of ETC. 
 
Although isolation of unreacted starting material was possible by silica gel 
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methylene protons. The reaction was repeated several times (with addition of catalytic 
amount of 2,6-lutidine as acid scavenger to determine if the reaction is taking place via 
acidic mechanism or ETC68d), but in all cases, there seemed to be an activation issue, as 
increased catalyst loading and reaction time were required. These results suggest that the 
current system may not have the favorable redox potential match with the catalyst and/or 
the diene and dienophile. However, since small amount of what could potentially be the 
cycloadduct was detected, there may be potential for utilizing ETC using other catalysts 
(iron-based catalysts) or methods (photoredox). 
 
4.8) Future work 
 
Although the desired double IMDA was accomplished for both aldehyde DKP 44 (using 
MacMillan’s imidazolidinone catalyst and thermolysis) and phenyl sulfone DKP (+)-89 
(using thermolysis) systems, determination of relative and absolute stereochemistry of the 
adducts is needed. Further efforts toward optimization of IMDA conditions using 
MacMillan’s catalyst could be done to obtain high diastereo- and enantioselectivities.  
Furthermore, considerations toward either a formal synthesis (obtaining Nicolaou’s key 
intermediate23) or total synthesis of rostratin A could be made using either the aldehyde 
system or the phenyl sulfone system. Although the yield for the IMDA step (as well as 
the prior copper-oxidative coupling step) using the phenyl sulfone system is not as 
comparable, the route to Nicolaou’s key intermediate is relatively more obviated than the 
aldehyde system (Scheme 4.47). For the aldehyde derivative, assuming the major 
cycloadduct is the endo diastereomer 47, Pinnick oxidation69 followed by a variation of 
Barton’s decarboxylation-oxygenation protocol70 of the resulting carboxylic acid, could 
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furnish alcohol 103 as a mixture of diastereomers (Scheme 4.59). Subsequent oxidation 
would afford the ketone 104 which could be utilized towards the synthesis of (−)-rostratin 
B or 9,9’-epimer of (−)-rostratin B. Alternatively, alcohol moiety of 103 could be 
eliminated, in which case the 4,4’-epimer of Nicolaou’s intermediate could be obtained. 
 
 
Scheme 4.47. Proposed remaining steps. 
 
Another possible approach would be to use photoredox chemistry in place of Barton’s 
decarboxylation-oxygenation protocol. Recently, a visible-light induced photocatalytic 
reaction for oxidative C—C bond cleavage of aldehydes to generate corresponding 
ketones has been reported. 71  This procedure was of interest, since the desired 
decarbonylation-oxygenation transformation of 47 to 104 could occur in single 
transformation. The mechanism presumably goes through the reductive quenching cycle 
(Scheme 4.48). Enamine A could be generated in situ from the aldehyde and secondary 
amine, which would then be oxidized to cation radical B through the reductive quenching 
process. Ru(I) could then be oxidized by oxygen in air to regenerate Ru(II) and 
superoxide species [O2] which would subsequently react with B to yield the final 
product ketone.  
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Scheme 4.48. Proposed mechanism of phodoredox reaction.71 
 
However, the precise mechanism of the reaction is debatable, since oxygen is a known 
quencher of the excited state of Ru(bpy)3Cl2 (via energy transfer), which results in singlet 
oxygen formation. This process would also afford the same C—C cleavage event, 
suggesting mechanism against the involvement of B in the catalytic cycle. Such process 
was proposed by a different group in the same year,72 albeit on α-alkoxy aldehydes. 
Substrates that did not contain the α-alkoxy substituent either afforded poor yields or did 
not work at all.  
A test reaction using one of the substrates reported (Scheme 4.49) in the communication71 
was conducted on an identical scale. Although the reaction presumably reaches near 
completion in 24 h (by GC), this result was not observed even after 48 h. GCMS and 1H 
NMR analysis showed predominant presence of left over starting material and relatively 
minor formation of the product. Similar results were obtained when the reaction was 
conducted under slightly positive pressure of oxygen.  
 
Scheme 4.49. Reported photoredox reaction. 
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Interestingly, the developed methodology in the report71 was based only on the use of 
Ru(bpy)3Cl2 as photocatalyst, and did not mention the use of any other catalysts. 
Therefore, alternative photocatalysts ([Ir(dtbbpy)(ppy)2][PF6] and Fukuzumi’s 
acridinium-based organic salt73) that possess different redox potential were tested and 
resulted in no improvement in terms of conversion. As the protocol used excess of amine 
base, prolonged exposure of cycloadduct 47 to such conditions could be detrimental. This 
was the case when the reaction was applied to the actual system (Scheme 4.50). 
 
Scheme 4.50. Attempted application of photoredox reaction. 
 
The reaction was conducted using slightly increased wattage (20 W) of compact 
fluorescent light bulb (CFL) and iridium-based photocatalyst. Iridium-based catalysts are 
generally known to perform better in terms of oxidation of the enamine to B as well as in 
generating the superoxide species (Scheme 4.48).74 The progress of the reaction was 
monitored via GCMS over 5 days. Although the reaction did eventually reach full 
conversion of starting material over 5 days, no product was observed in the final reaction 
mixture (Scheme 4.50). Instead, 1H NMR and TLC of the reaction mixture suggested 
decomposition of material. These results were expected, since the compound would 
likely decompose under these conditions over prolonged period of time. However, 
presence of the desired ketone product was detected by GCMS during the course of the 
reaction, which suggested that the reaction was taking place, but the slow conversion rate 
decomposed the product. Therefore, further investigation could be done to increase the 
rate of the desired transformation by screening various photocatalysts with different 
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redox potential, method of oxygen delivery, alternative light sources, solvents, and amine 
bases. Extensive screening could also provide information on the possible mechanism of 
the reaction. 
 
4.9) Conclusions 
 
Various efforts toward the synthesis of ETP alkaloids that contain C2 symmetric 6-5-6-5-
6 framework (rostratins, in particular) have been made. Invaluable information on the 
reactivity of DKPs was obtained through the process. In particular, optimization of 
diastereoselective synthesis of acyclic DKPs has been made, which could be a valuable 
addition to the synthesis of DKP in general. Unprecedented application of Batey’s 
copper-oxdative coupling methodology41 in total synthesis was successfully demonstrated 
using newly developed potassium trifluoroborate 1,3-butadiene reagent 66. This C—N 
bond forming protocol is superior in comparison to the alternative well-known method of 
using vinyl iodides and amides under copper catalysis75 for a few reasons. Firstly, vinyl 
iodides (or vinyl halogens) are generally not as stable as potassium alkenyltrifluoroborate 
salts. This difference in stability is even more pronounced for unsubstituted 1,3-
butadienes. For instance, when 66 was reacted under known halodeboronation protocols76 
to convert the vinyl trifluoroborate to corresponding vinyl halogens, the reaction only 
provided decomposed material. Secondly, C—N bond forming methods using vinyl 
iodides are operationally not as simple as the present protocol, since reactions have to be 
set up in the absence of moisture and oxygen (in the glovebox, using Schlenk flasks). 
Finally, copper catalysis using vinyl iodides and amides generally requires heating at 
high temperatures (90-110 oC) in the presence of excess base.75 Such conditions were 
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reported to result in racemization of chiral DKPs (via epimerization of cis to trans) 
during the synthesis of tadalafil analogues.77 Although racemization was minimized when 
the reaction was conducted at low temperatures (14 oC) using reduced amount of base 
and super stoichiometric amount of copper (2 equiv. of CuI) over 15 days, consistently 
satisfactory yields were not obtained.77  
Investigation of the key step—double IMDA cycloaddition also provided important 
information for the potential application of this protocol in the synthesis of other 
structurally similar ETPs. Although the diastereo- and enantioselectivity of the reactions 
remain to be determined, promising yields were obtained using MacMillan’s 
imidazolidinone catalyst at relatively short reaction times (2-6 h). The double IMDA 
reaction is in essence a powerful tool that allows the formation of six new stereocenters 
in one transformation. Moreover, such multiple asymmetric reactions are known to 
generally impart increased enantiomeric excess to the final product in comparison with 
the analogous single transformation. 78  Further investigation of alternative types of 
cycloaddition reactions could be of value as well, not only in terms of providing 
alternative methodology, but also for the completion of first total synthesis of rostratins A 
and B. 
 
4.10) Experimental results 
General Methods. All reactions were performed under an argon atmosphere except 
where otherwise noted. Tetrahydrofuran was distilled over sodium-benzophenone, 
dichloromethane was distilled over calcium hydride, DMF in Acroseal bottles were used 
without further purification prior to use. Flash chromatography was carried out on Merck 
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silica gel 60 (240-400 mesh) using the solvent conditions listed under individual 
experiments. Analytical thin-layer chromatography was performed on Merck silica gel 
(60F-254) plates (0.25 mm). Visualization was effected with ultraviolet light or 
phosphomolybdic acid (PMA) stain. Proton magnetic resonance spectra (1H NMR), 
Carbon magnetic resonance spectra (13C NMR), Fluorine magnetic resonance spectra (19F 
NMR), and Boron magnetic spectra (11B NMR) were performed on a Bruker NMR 
operating at 500, 125, 470, and 128 MHz respectively. All 11B chemical shifts were 
referenced to external BF3"OEt2 (0.0 ppm) with a negative sign indicating an upfield shift. 
Infrared spectra (IR) were obtained on a Perkin-Elmer 281-B spectrometer. High 
resolution mass spectra (HRMS) were obtained on a Micromass Autospec or a Waters 
LCTOF-Xe premier. Optical rotations were measured on a Jasco P-1010 polarimeter. 
 
Allylic alcohol (+)-57. To a stirred solution of the known α,β-
unsaturated aldehyde (+)-534 (5.10 g, 19.823 mmol) in anhydrous MeOH (198 mL) at 
−50 oC was added sodium borohydride (825 mg, 21.805 mmol) in one portion. The 
resulting mixture was left to stir at −50 oC for 30 min. Upon complete conversion of (+)-
53 (monitored by TLC), the reaction was quenched with aqueous sat. NH4Cl (75 mL). 
The resulting layers were separated, and the aqueous layer was extracted with ethyl 
acetate (120 mL, twice). The organic layers were combined, dried over Na2SO4, filtered, 
and concentrated. Purification by silica gel chromatography (35% EtOAc/Hex) afforded 
the product as an oil (4.83 g, 94%).  Rf = 0.3 (50% EtOAc/Hex). α[ ]D
19.9
= +23.46  (c = 1.1 
CH2Cl2). FTIR (thin film) cm-1: 3369, 2978, 2954, 2933, 2870, 1742, 1712, 1518, 1438, 
OMe
O
NHBoc
HO
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1392, 1367, 1278, 1250, 1216, 1168, 1100, 1052, 1021, 973, 855, 781. HRMS (ESI) m/z 
calcd. C12H21NO5 [M+Na]+ 282.1317, found 282.1317. 1H-NMR (500 MHz; CDCl3): δ 
5.80-5.74 (m, 1H), 5.65-5.59 (m, 1H), 5.08-5.04 (m, 1H), 4.43-4.37 (m, 1H), 4.13 (t, J = 
5.7 Hz, 2H), 3.77 (s, 3H), 2.62-2.56 (m, 1H), 2.51-2.45 (m, 1H), 1.47 (s, 9H). 13C-NMR 
(CDCl3, 125 MHz): 172.5, 155.2, 133.6, 125.8, 80.0, 63.1, 53.0, 52.3, 35.3, 28.3. 
 
TBDPS ether (+)-59. To a stirred solution of (+)-57 (2.09 g, 
8.060 mmol) in anhydrous CH2Cl2 (81 mL) was added TBDPSCl (2.52 mL, 9.672 mmol) 
followed by imidazole (658 mg, 9.672 mmol). The resulting mixture was left to stir at 
room temperature overnight. Upon completion, the reaction was diluted with CH2Cl2 
(100 mL), washed with aqueous 10% HCl (50 mL), aqueous sat. NaHCO3 (50 mL), and 
brine (50 mL). The organic layer was dried over MgSO4, filtered, and concentrated. 
Purification by silica gel chromatography (5% ! 10% ! 15% EtOAc/Hex) afforded the 
product as an oil (4.0 g, quant.). Rf = 0.55 (20% EtOAc/Hex). α[ ]D
17.9
= +13.33  (c = 1.0 
CH2Cl2). FTIR (thin film) cm-1: 3437, 3071, 3049, 2956, 2931, 2894, 2857, 1746, 1718, 
1499, 1473, 1461, 1428, 1391, 1365, 1249, 1211, 1168, 1112, 1055, 1027, 972, 823, 740, 
702, 613. HRMS (ESI) m/z calcd. C28H39NO5Si [M+Cl]− 532.2286, found 532.2278. 1H-
NMR (500 MHz; CDCl3): δ 7.75-7.68 (m, 4H), 7.45-7.39 (m, 6H), 5.71-5.56 (m, 2H), 
5.03-4.98 (m, 1H), 4.41-4.36 (m, 1H), 4.18-4.17 (m, 2H), 3.74 (s, 3H), 2.56-2.47 (m, 2H), 
1.46 (s, 9H), 1.08 (s, 9H). 13C-NMR (CDCl3, 125 MHz): 172.5, 155.1, 135.5, 135.4, 
133.6, 133.5, 129.6, 127.6, 123.9, 79.8, 63.9, 53.0, 52.2, 35.1, 28.3, 26.8, 19.2. 
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N-Boc TBDPS ether dipeptide (+)-63. To a 
stirred solution of (+)-59 (2.67 g, 5.365 mmol) in anhydrous THF (90 mL) was added 
potassium trimethylsilanolate (2.06 g, 16.094 mmol) in one portion. The resulting 
mixture was left to stir at room temperature for 2.5 h. Upon full conversion of (+)-59 
(monitored by TLC), aqueous 10% citric acid (30 mL) was added to the reaction and left 
to stir for additional 10 min. The resulting layers were separated, and the aqueous layer 
was extracted with ethyl acetate (50 mL, three times). The organic layers were combined, 
washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated. Purification by 
short plug of silica gel (30% EtOAc/Hex) afforded the corresponding acid 62 as an oil 
(2.59 g, quant.). In a separate reaction vessel, (+)-59 (2.82 g, 5.666 mmol) was dissolved 
in anhydrous CH2Cl2 at room temperature with stirring. The solution was then cooled 
down to 0 oC, and TFA (21 mL, 283.3 mmol) was slowly added to the reaction. The 
resulting mixture was left to stir at 0 oC for 45 min. Upon completion, the solvent was 
evaporated to afford the corresponding amine salt 61 which was used without further 
purification. In a 100 mL round bottom flask charged with a stir bar, 62 (2.59 g, 5.355 
mmol) was dissolved in anhydrous CH2Cl2 (21 mL). The reaction flask was foiled, and 
brought to 0 oC. To this was added a portion of NMM (0.59 mL) followed by BOP (2.84 
g, 6.426 mmol). In a separate round bottom flask, 61 was dissolved in anhydrous CH2Cl2 
(33 mL). To this was added rest of NMM (1.18 mL, total NMM used: 1.77 mL, 16.065 
mmol) and left to stir at room temperature for 5 min. The in situ free-based amine of 61 
was then added to the reaction flask containing 62 via cannula addition. The resulting 
mixture was left to slowly warm to room temperature overnight. The reaction mixture 
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was diluted with ethyl acetate (100 mL), washed with aqueous 10% KHSO4 (30 mL), 
aqueous sat. NaHCO3 (30 mL), and brine (30 mL). The organic layer was dried over 
Na2SO4, filtered, and concentrated. Purification by column chromatography (20% 
EtOAc/Hex) afforded the dipeptide as a colorless oil (3.88 g, 84%). Rf = 0.66 (30% 
EtOAc/Hex). α[ ]D
20.9
= +8.83  (c = 0.45 CH2Cl2). FTIR (thin film) cm-1: 3318, 3071, 3049, 
2999, 2957, 2931, 2893, 2857, 1746, 1714, 1681, 1514, 1473, 1462, 1428, 1390, 1366, 
1249, 1210, 1171, 1112, 1051, 971, 823, 740, 702, 613. HRMS (ESI) m/z calcd. 
C50H66N2O7Si2 [M+Na]+ 885.4306, found 885.4311. 1H-NMR (500 MHz; CDCl3): δ 7.67 
(dd, J = 7.8, 1.3 Hz, 8H), 7.44-7.39 (m, 12H), 6.63-6.59 (m, 1H), 5.70-5.56 (m, 4H), 
4.95-4.90 (m, 1H), 4.67-4.63 (m, 1H), 4.15-4.14 (m, 4H), 3.71 (s, 3H), 2.57-2.52 (m, 3H), 
2.45-2.38 (m, 1H), 1.44 (s, 9H), 1.06 (d, J = 1.0 Hz, 18H).13C-NMR (CDCl3, 125 MHz): 
171.7, 170.9, 155.3, 135.4, 135.2, 134.7, 133.6, 133.5, 133.4, 129.62, 129.61, 127.64, 
127.62, 127.3, 124.7, 123.5, 80.1, 64.0, 63.8, 54.0, 52.2, 51.9, 35.0, 28.2, 26.8, 26.7, 
19.17, 19.15. 
TBDPS ether cis DKP (−)-46. To a stirred 
solution of (+)-63 (9.8 g, 11.352 mmol) in anhydrous CH2Cl2 (45 mL) at −10 oC was 
added TFA (44 mL, 592.3 mmol). The resulting mixture was left to stir at −10 oC for 1 h. 
Upon completion (monitored by TLC), the reaction was diluted with ethyl acetate (125 
mL), quenched with portion-wise addition of aqueous sat. NaHCO3 (200 mL). The 
reaction was warmed to room temperature, and the resulting layers were separated. The 
aqueous layer was extracted with ethyl acetate (150 mL, twice). The organic layers were 
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then combined, washed with brine (150 mL), dried over Na2SO4, filtered, and 
concentrated. The resulting free-based amine was dissolved in MeOH (103 mL) and to 
this was added aqueous NH4OH (5.2 mL). The reaction mixture was left to stir at room 
temperature for 3 d, or until full conversion of the starting material was evident by 1H 
NMR. The reaction was concentrated and directly loaded onto silica gel column for 
purification (5% ! 10% Acetone/CH2Cl2) to afford the desired cis product as an 
amorphous solid (3.56 g, 43%). Rf = 0.32 (30% Acetone/Hex). α[ ]D
19.5
= −78.2  (c = 1.5 
CH2Cl2). FTIR (thin film) cm-1: 3197, 3070, 3050, 2958, 2930, 2892, 2857, 1665, 1471, 
1460, 1427, 1379, 1361, 1331, 1112, 1053, 971, 823, 739, 701, 613. HRMS (ESI) m/z 
calcd. C44H54N2O4Si2 [M+Na]+ 753.3520, found 753.3518. 1H-NMR (500 MHz; CDCl3): 
δ 7.69-7.66 (m, 4H), 7.46-7.39 (m, 6H), 5.78-5.63 (m, 3H), 4.21-4.20 (m, 2H), 3.98-3.95 
(m, 1H), 2.90-2.84 (m, 1H), 2.40-2.33 (m, 1H), 1.08 (s, 9H).13C-NMR (CDCl3, 125 
MHz): 167.2, 135.4, 134.9, 133.46, 133.40, 129.7, 127.7, 123.3, 63.6, 54.0, 36.4, 26.8, 
19.1. 
 
Potassium 1,3-butadiene-1-trifluoroborate salt (66). To a stirred solution 
of 3-butyn-1-ol (2 mL, 26.423 mmol) in anhydrous CH2Cl2 (300 mL) at 0 oC was added 
triethylamine (11 mL, 79.270 mmol) followed by methanesulfonyl chloride (2.66 mL, 
34.350 mmol). The resulting solution was left to stir and warm to room temperature over 
6 h. Upon completion, the reaction mixture was washed with aqueous 1N HCl (100 mL), 
brine (100 mL), dried over MgSO4, filtered, and concentrated to afford the corresponding 
mesylate 67, which was used in the next step without further purification. To a reaction 
H
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vessel charged with a stir bar was added dicyclohexyl borane (538 mg, 3.023 mmol) in a 
glovebox. The vessel was then removed and put under an argon atmosphere. In a separate 
round bottom flask, 67 was dissolved in anhydrous CH2Cl2 (35 mL), and the resulting 
solution was added to the reaction vessel containing dicyclohexyl borane42 via cannula 
addition. The resulting mixture was brought to 0 oC, and to it was added pinacolborane 
(4.61 mL, 31.745 mmol). The reaction was left to stir and warm to room temperature 
overnight. The solvent was concentrated under vacuum, and was re-dissolved in 
anhydrous CH2Cl2 (120 mL). To this was added DBU (11.3 mL, 75.590 mmol), and left 
to stir at room temperature overnight. Upon completion, the solvent was removed, and 
the crude product was directly loaded onto a plug of silica gel column (10% EtOAc/Hex) 
to afford 6843 as a colorless oil. The pinacolboronate ester 68 was immediately dissolved 
in acetonitrile (30 mL), and to it was added aqueous 4.5 M KHF2 (24 mL). The resulting 
mixture was left to stir at room temperature for 30 min. The solvent was evaporated and 
the crude product was suspended in hot acetonitrile (50 mL). Hot gravity filtration 
followed by evaporation of acetonitrile afforded the crude product as a white solid. The 
solid was further purified by trituration with cold diethyl ether (20 mL). Subsequent 
vacuum filtration afforded the desired product as a white solid (3.33 g, 90% over three 
steps). FTIR (neat) cm-1: 3085, 3018, 2987, 2965, 1593, 1260, 1151, 1100, 1013, 973, 
920, 745, 637. 1H-NMR (500 MHz; CDCl3): δ 6.35-6.23 (m, 1H), 5.68 (ddt, J = 15.9, 7.4, 
3.7 Hz, ), 4.96-4.93 (m, 1H), 4.80-4.78 (m, 1H).13C-NMR (acetone-d6, 125 MHz): 142.7, 
136.7, 136.6, 112.6; 11B NMR (128.4 MHz, acetone-d6) δ 3.3 (q); 19F NMR (470.8 MHz, 
acetone-d6) δ −142.0 (q).  
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1,3-Butadiene coupled TBDPS DKP (+)-69. A 
biotage microwave tube was charged with a stir bar, (−)-46 (320 mg, 0.438 mmol), and 
freshly prepared 66 (350 mg, 2.185 mmol), Cu(OAc)2 (24 mg, 0.131 mmol), and 4 Å MS 
(700 mg) on the bench-top. To this was added a 1:1 mixture of 1,2-DCE and DMSO (1.8 
mL). The tube was sealed, and the resulting heterogeneous mixture was left to stir at 40 
oC under O2 atmosphere until full conversion of (−)-46 was evident by TLC analysis. The 
reaction mixture was filtered through a pad of Celite, and was rinsed with portions of 
ethyl acetate (50 mL). The filtrate was concentrated, and directly loaded onto a silica gel 
column for purification (10% EtOAc/Hex) to afford the title compound as a white foam 
(315 mg, 86%). Rf = 0.32 (10% EtOAc/Hex). α[ ]D
24.3
= +67.0  (c = 0.8 CH2Cl2). FTIR 
(thin film) cm-1: 3069, 2950, 2925, 2856, 1676, 1640, 1427, 1405, 1237, 1112, 1057, 997, 
822, 742, 701. HRMS (ESI) m/z calcd. C52H62N2O4Si2 [M+Na]+ 857.4146, found 
857.4125. 1H-NMR (500 MHz; CDCl3): δ 7.70 (dq, J = 6.4, 1.6 Hz, 4H), 7.46-7.39 (m, 
6H), 7.36 (s, 1H), 6.39 (dt, J = 16.8, 10.3 Hz, 1H), 5.90-5.80 (m, 2H), 5.69 (dt, J = 15.3, 
4.5 Hz, 1H), 5.22 (d, J = 16.9 Hz, 1H), 5.12 (d, J = 10.4 Hz, 1H), 4.47 (dd, J = 7.2, 4.9 
Hz, 1H), 4.21 (d, J = 3.4 Hz, 2H), 2.75-2.70 (m, 2H), 1.10 (s, 9H).13C-NMR (CDCl3, 125 
MHz): 163.2, 135.5, 135.49, 135.40, 134.7, 134.3, 133.6, 133.5, 133.4, 129.64, 129.63, 
127.8, 127.6, 125.9, 124.0, 116.7, 115.4, 63.7, 57.9, 36.1, 26.8,19.1. 
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N-Boc TBDPS sarcosine dipeptide (+)-71. To a stirred 
solution of 62 (1.85 g, 3.824 mmol) in anhydrous CH2Cl2 (15 mL) at 0 oC was added 
BOPCl (1.17 g, 4.589 mmol), NMM (1.26 mL, 11.474 mmol), followed by sarcosine 
ethyl ester hydrochloride salt 70 (646 mg, 4.207 mmol). The resulting mixture was left to 
stir and warm to room temperature overnight. Upon completion, the reaction was diluted 
with ethyl acetate (50 mL), washed with aqueous 10% KHSO4 (10 mL), aqueous sat. 
NaHCO3 (10 mL), brine (10 mL), dried over Na2SO4, filtered, and concentrated. 
Purification by silica gel chromatography (30% EtOAc/Hex) afforded the product as an 
oil (2.0 g, 93%). Rf = 0.34 (30% EtOAc/Hex). α[ ]D
21.0
= +6.06  (c = 1.3, CH2Cl2). FTIR 
(thin film) cm-1: 3425, 3314, 3071, 3049, 2961, 2931, 2857, 1748, 1712, 1652, 1487, 
1428, 1406, 1391, 1366, 1250, 1171, 1112, 1051, 972, 823, 741, 704, 690, 614, 505, 491. 
HRMS (ESI) m/z calcd. C32H46N2O6Si [M+H]+ 583.3203, found 583.3210. 1H-NMR 
(500 MHz; CDCl3): δ 7.70-7.68 (m, 4H), 7.45-7.38 (m, 6H), 5.73-5.69 (m, 2H), 5.35 (d, J 
= 8.5 Hz, 1H), 4.73 (q, J = 7.2 Hz, 1H), 4.32 (d, J = 17.1 Hz, 1H), 4.27-4.16 (m, 4H), 
3.90 (d, J = 17.3 Hz, 1H), 3.14 (s, 3H), 2.56-2.46 (m, 1H), 2.46-2.35 (m, 1H), 1.44 (s, 
9H), 1.27 (t, J = 7.1 Hz, 3H), 1.07 (s, 9H).13C-NMR (CDCl3, 125 MHz): 172.4, 168.8, 
155.3, 135.5, 133.72, 133.70, 133.1, 129.6, 127.64, 127.61, 124.5, 79.5, 64.2, 61.2, 50.0, 
49.7, 36.5, 35.8, 28.4, 26.9, 19.2, 14.2. 
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N-Methyl mono TBDPS DKP (+)-65. To a stirred solution of 
(+)-71 (2.0 g, 3.51 mmol) in anhydrous CH2Cl2 (14 mL) at 0 oC was added TFA (14 mL). 
The resulting mixture was left to stir and warm to room temperature over 1 h. Upon 
completion, the reaction was concentrated to afford the corresponding amine salt, which 
was immediately dissolved in EtOH (35 mL). To this was added K2CO3 (1.95 g, 14.07 
mmol), and the resulting mixture was brought to reflux with stirring overnight. The 
reaction mixture was filtered through a pad of Celite, rinsed with EtOH (30 mL), and 
evaporated. Purification by column chromatography (40% Acetone/CH2Cl2) afforded the 
desired product as an amorphous solid (1.5 g, 98%). Rf = 0.4 (40% Acetone/CH2Cl2). 
α[ ]D
22.6
= +1.38  (c = 0.9, CHCl3). FTIR (thin film) cm-1: 3070, 2929, 2856, 1687, 1472, 
1427, 1330, 1259, 1191, 1112, 976, 822, 741, 703, 614, 504. HRMS (ESI) m/z calcd. 
C25H32N2O3Si [M+Na]+ 459.2080, found 459.2063. 1H-NMR (500 MHz; CDCl3): δ 7.75-
7.63 (m, 4H), 7.51-7.39 (m, 6H), 6.67 (s, 1H), 5.76-5.68 (m, 2H), 4.20 (s, 2H), 4.02-4.01 
(m, 1H), 3.93 (q, J = 23.3 Hz, 2H), 2.96 (s, 3H), 2.70-2.66 (m, 1H), 2.59-2.51 (m, 1H), 
1.20-0.95 (m, 9H). 13C-NMR (CDCl3, 125 MHz): 165.5, 165.3, 135.4, 134.9, 133.4, 
133.3, 129.7, 127.6, 122.8, 63.6, 54.7, 51.5, 37.3, 33.7, 26.7, 19.1. 
 
1,3-Butadiene coupled N-Methyl mono TBDPS DKP (+)-72. 
The title compound was synthesized following the procedure used for the synthesis of 
(+)-69. A biotage microwave tube was charged with a stir bar, (+)-65 (350 mg, 0.802 
MeN
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mmol), and freshly prepared 66 (256 mg, 1.603 mmol), Cu(OAc)2 (44 mg, 0.240 mmol), 
and 4 Å MS (500 mg) on the bench-top. To this was added a 1:1 mixture of 1,2-DCE and 
DMSO (3.2 mL). The tube was sealed, and the resulting heterogeneous mixture was left 
to stir at 40 oC under O2 atmosphere until full conversion of (+)-65 was evident by TLC 
analysis. The reaction mixture was filtered through a pad of Celite, and was rinsed with 
portions of ethyl acetate (50 mL). The filtrate was concentrated, and directly loaded onto 
a silica gel column for purification (40% EtOAc/Hex) to afford the title compound as a 
yellow oil (344 mg, 88%). Rf = 0.22 (40% EtOAc/Hex). α[ ]D
21.5
= +2.57  (c = 0.3 CHCl3). 
FTIR (thin film) cm-1: 3070, 2957, 2929, 2856, 1676, 1643, 1429, 1406, 1332, 1276, 
1237, 1112, 1053, 998, 822, 741, 703, 504. HRMS (ESI) m/z calcd. C29H36N2O3Si 
[M+Na]+ 511.2393, found 511.2395. 1H-NMR (500 MHz; CDCl3): δ 7.66-7.64 (m, 4H), 
7.46-7.39 (m, 6H), 7.35 (d, J = 14.7 Hz, 1H), 6.42-6.34 (m, 1H), 5.83 (dd, J = 14.7, 10.4 
Hz, 1H), 5.76-5.65 (m, 2H), 5.23 (d, J = 16.9 Hz, 1H), 5.11 (d, J = 9.9 Hz, 1H), 4.54-4.53 
(m, 1H), 4.22 (d, J = 17.8 Hz, 1H), 4.15 (s, 2H), 3.85-3.81 (m, 1H), 2.96 (s, 3H), 2.82-
2.73 (m, 2H), 1.07 (s, 9H). 13C-NMR (CDCl3, 125 MHz): 165.4, 162.3, 138.0, 135.4, 
134.4, 133.2, 133.1, 129.7, 127.8, 127.7, 125.8, 121.3, 116.4, 114.6, 63.4, 57.8, 51.9, 34.0, 
33.2, 26.8, 19.2. 
 
1,3-Butadiene coupled N-Methyl mono allyl alcohol DKP (+)-73. 
To a stirred solution of (+)-72 (400 mg, 0.818 mmol) in anhydrous THF (8.2 mL) at 0 oC 
was added TBAF (1M in THF, 0.9 mL, 0.900 mmol). The resulting mixture was allowed 
to warm to room temperature over 2.5 h. The solvent was evaporated and directly loaded 
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onto a silica gel column for purification (50% Acetone/CH2Cl2) to afford the title 
compound as a yellow oil (200 mg, 98%). Rf = 0.4 (50% Acetone/CH2Cl2). 
α[ ]D
22.1
= +4.30  (c = 0.5 CH2Cl2). FTIR (thin film) cm-1: 3411, 3083, 3036, 3000, 2924, 
2853, 1669, 1643, 1513, 1435, 1408, 1337, 1278, 1238, 1100, 1085, 1002, 977, 941. 
HRMS (ESI) m/z calcd. C13H18N2O3 [M+Na]+ 273.1215, found 273.1219. 1H-NMR (500 
MHz; CDCl3): δ 7.32 (d, J = 14.7 Hz, 1H), 6.37 (dt, J = 16.9, 10.2 Hz, 1H), 5.82 (dd, J = 
14.7, 10.3 Hz, 1H), 5.75 (dt, J = 15.4, 4.9 Hz, 1H), 5.65-5.59 (m, 1H), 5.23 (d, J = 16.9 
Hz, 1H), 5.11 (d, J = 10.2 Hz, 1H), 4.50 (dd, J = 4.7, 4.6 Hz, 1H), 4.21 (d, J = 18.0 Hz, 
1H), 4.09 (d, J = 4.7 Hz, 2H), 3.89 (d, J = 18.0 Hz, 1H), 3.00 (s, 3H), 2.78-2.68 (m, 2H). 
13C-NMR (CDCl3, 125 MHz): 165.2, 162.5, 135.5, 134.3, 125.7, 123.2, 116.7, 114.8, 
62.5, 57.7, 51.8, 34.1, 33.3. 
 
1,3-Butadiene coupled allyl alcohol DKP (+)-75. To a 
stirred solution of (+)-69 (1.37 g, 1.640 mmol) in anhydrous THF (33 mL) at 0 oC was 
added TBAF (1M in THF, 3.44 mL, 3.444 mmol). The resulting mixture was left to stir at 
0 oC for 2 h, then warmed to room temperature over additional 1 h. Upon completion, the 
reaction was quenched with water (0.5 mL) and concentrated. Purification by silica gel 
column chromatography (20% Acetone/CH2Cl2) afforded the title compound as an oil 
(518 mg, 88%). Rf = 0.3 (20% Acetone/CH2Cl2). α[ ]D
25.9
= +7.36  (c = 0.8 CHCl3). FTIR 
(thin film) cm-1: 3417, 3084, 3035, 3003, 2972, 2924, 2860, 1672, 1640, 1432, 1406, 
1341, 1316, 1286, 1237, 1099, 1000, 974, 939, 898, 756, 665. HRMS (ESI) m/z calcd. 
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C20H26N2O4 [M−H]− 357.1814, found 357.1819. 1H-NMR (500 MHz; CDCl3): δ 7.31 (d, 
J = 14.7 Hz, 1H), 6.41-6.33 (m, 1H), 5.82 (t, J = 7.4 Hz, 1H), 5.79 (d, J = 4.3 Hz, 2H), 
5.28-5.23 (m, 1H), 5.14 (t, J = 8.7 Hz, 1H), 4.47 (dd, J = 8.7, 4.3 Hz, 1H), 4.15 (d, J = 1.4 
Hz, 2H), 2.80-2.76 (m, 1H), 2.73-2.65 (m, 1H). 13C-NMR (CDCl3, 125 MHz): 163.8, 
134.1, 133.9, 125.8, 125.1, 117.0, 115.5, 62.8, 57.8, 35.8. 
 
General procedure for IMDA using MacMillan’s catalyst 
 
To a stirred solution of (+)-75 (0.405 mmol) in anhydrous CH2Cl2 (27 mL) was added 
NaHCO3 (28.32 mmol) followed by Dess-Martin periodinane (2.427 mmol). The reaction 
vessel was kept away from light (foiled), and left to stir vigorously at room temperature 
for 30-40 min. The reaction was quenched with 1:1:1 aqueous sat. 
NaHCO3/brine/Na2SO3 (27 mL) and left to stir until separation of layers was apparent. 
The resulting layers were separated, and the aqueous layer was extracted with CH2Cl2 (20 
mL, three times). The organic layers were combined, dried over MgSO4, filtered, and 
concentrated. The unstable crude bis-aldehyde 44 was immediately loaded onto a short 
silica gel plug (5% Acetone/CH2Cl2) and rapidly separated from excess iodinane. 44 was 
immediately taken onto the next step without further purification. In a separate flask, the 
MacMillan catalyst (0.1618 mmol) and protic acid additive (0.1618 mmol) was dissolved 
in a solution of 98:2 MeCN/H2O (1.2 mL). The resulting solution was quickly added to 
the reaction flask containing 44 and a stir bar. The resulting mixture was left to stir at 
room temperature until full conversion of 44 was apparent by TLC analysis. Upon 
completion, the reaction mixture was directly loaded onto a silica gel column (90% 
EtOAc/Hex ! 100% EtOAc then 5% MeOH/EtOAc) for isolation of the cycloadduct.  
! 385 
General procedure for thermal IMDA 
 
To a biotage microwave tube equipped with a stir bar under argon was added (+)-75 
(0.245 mmol) in a solution of anhydrous m-xylene (4.9 mL) and BHT (0.012 mmol). The 
resulting mixture was immediately placed into a pre-heated sand bath at 130-160 oC, and 
left to stir for 2 d, or until complete consumption of (+)-75 was evident by TLC analysis. 
The reaction mixture was concentrated, and loaded onto a silica gel column (100% 
EtOAc ! 5% MeOH/EtOAc) to isolate the cycloadduct.  
 
N-Methyl mono-aldehyde IMDA precursor (74). Rf = 0.22 (10% 
Acetone/CH2Cl2). 1H-NMR (500 MHz; CDCl3): δ  9.53 (dd, J = 7.6, 0.6 Hz, 1H), 7.31 (d, 
J = 14.7 Hz, 1H), 6.80-6.73 (m, 1H), 6.40-6.32 (m, 1H), 6.20 (ddd, J = 15.6, 7.5, 0.9 Hz, 
1H), 5.81 (dd, J = 14.6, 10.3 Hz, 1H), 5.24 (d, J = 16.9 Hz, 1H), 5.14 (d, J = 10.1 Hz, 1H), 
4.60 (dd, J = 7.2, 4.3 Hz, 1H), 4.15 (d, J = 18.2 Hz, 1H), 3.99-3.95 (m, 1H), 3.02 (s, 3H), 
2.97 (t, J = 5.9 Hz, 1H), 2.95-2.88 (m, 1H). 13C-NMR (CDCl3, 125 MHz): 192.7, 164.2, 
161.6, 148.6, 136.3, 133.9, 125.5, 117.4, 115.1, 56.8, 51.6, 34.6, 33.6. 
 
bis-Aldehyde IMDA precursor (44). Rf = 0.6 (5% 
Acetone/CH2Cl2). 1H-NMR (500 MHz; CDCl3): δ 9.62 (dd, J = 7.5, 0.4 Hz, 1H), 7.32 (d, 
J = 14.8 Hz, 1H), 6.93 (dt, J = 15.4, 7.6 Hz, 1H), 6.41-6.34 (m, 1H), 6.26-6.21 (m, 1H), 
5.80 (dd, J = 14.8, 10.2 Hz, 1H), 5.24 (dd, J = 44.9, 13.5 Hz, 2H), 4.64 (dd, J = 9.8, 4.1 
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Hz, 1H), 3.11-3.05 (m, 1H), 2.85-2.78 (m, 1H). 13C-NMR (CDCl3, 125 MHz): 192.7, 
162.0, 148.9, 135.5, 133.6, 125.1, 118.2, 116.0, 56.7, 36.2. 
 
Mono-IMDA cycloadduct (76). i  Rf = 0.26 (5% MeOH/EtOAc). 
HRMS (ESI) m/z calcd. C13H16N2O3 [M+H]+ 249.1239, found 249.1230. 1H-NMR (500 
MHz; CDCl3): δ 9.82 (s, 1H), 5.81 (d, J = 4.7 Hz, 1H), 5.70-5.62 (m, 1H), 4.40-4.35 (m, 
1H), 4.19-3.91 (m, 3H), 3.00 (s, 3H), 2.71-2.65 (m, 1H), 2.51-2.46 (m, 1H), 2.38-2.32 (m, 
2H), 2.12-2.08 (m, 2H). 13C-NMR (CDCl3, 125 MHz): 201.3, 165.8, 163.6, 136.7, 118.0, 
60.4, 51.4, 49.0, 47.5, 45.9, 33.4, 31.1, 28.9. 
 
Double IMDA bis-aldehyde cycloadduct (47).ii Rf = 0.3 (5% 
MeOH/EtOAc). HRMS (ESI) m/z calcd. C20H22N2O4 [M+H]+ 355.1658, found 355.1674. 
1H-NMR (500 MHz; CDCl3): δ 9.82 (s, 1H), 5.82-5.81 (m, 1H), 5.69-5.61 (m, 1H), 4.39-
4.35 (m, 1H), 4.10-4.01 (m, 1H), 3.05-2.99 (m, 1H), 2.79-2.73 (m, 1H), 2.51-2.47 (m, 
1H), 2.41-2.34 (m, 1H), 2.05-1.98 (m, 2H). 13C-NMR (CDCl3, 125 MHz): 201.2, 166.7, 
136.7, 118.4, 49.1, 46.9, 45.8, 32.2, 29.7, 29.4.  
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
i Reported values for 1H and 13C NMR based on major diastereomer. 
ii Reported values for 1H and 13C NMR based on major diastereomer. 13C NMR spectra 
shows up to 5 different aldehyde peaks of varying intensity, suggesting presence of 
diastereomers.!
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bis-Hydrazone derivatized double 
IMDA cycloadduct (77). To a stirred solution of 47 (31 mg, 0.087 mmol) in anhydrous 
MeOH (0.87 mL) was added 2,4-DNPH (35 mg, 0.175 mmol) followed by AcOH (2 
drops). The resulting mixture was left to stir at room temperature for 4 h. Upon 
completion of the reaction, the solvent was evacuated Purification by HPLC afforded the 
title compound. Rf = 0.57 (100% EtOAc). HRMS (ESI) m/z calcd. C32H30N10O10 [M+H]+ 
715.2225, found 715.2219. 1H-NMR (500 MHz; CDCl3): δ 11.09 (s, 1H), 9.13 (d, J = 2.6 
Hz, 1H), 8.34-8.30 (m, 1H), 7.94 (dd, J = 9.6, 2.4 Hz, 1H), 7.61-7.58 (m, 1H), 5.95-5.88 
(m, 1H), 5.78-5.66 (m, 1H), 5.26-5.23 (m, 1H), 4.52-4.42 (m, 1H), 2.97-2.87 (m, 1H), 
2.85-2.76 (m, 1H), 2.64-2.60 (m, 1H), 2.29-2.22 (m, 2H), 2.09-2.01 (m, 1H). 
 
N-Boc phenyl sulfone methyl ester (+)-85. To a suspension of NaH 
(60% in mineral oil, 543 mg, 16.151 mmol) in anhydrous THF (130 mL) at −10 oC was 
added drop-wise a solution of diethyl (phenylsulfonyl)methylphosphonateiii  (4.72 g, 
16.151 mmol) in anhydrous THF (30 mL). The resulting mixture was stirred for 30 min 
at −10 oC. To this was added a solution of the aldehyde 84 (2.87 g, 12.424 mmol) in 
anhydrous THF (23 mL) drop-wise. The resulting mixture was allowed slowly warm to 
room temperature and left to stir for 4-5 h. Upon completion, cold aqueous 5% NaHSO4 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
iii Yang, P.-Y., Wang, M., He, C. Y., Yao, S. Q. “Proteomic profiling and potential 
cellular target identification of K11777, a clinical cysteine protease inhibitor, in 
Trypanosoma brucei.” Chem. Commun. 2012, 48, 835-837. 
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was added until the pH of the solution reached about 6-7. The resulting biphasic solution 
was concentrated under vacuum and diluted with water (100 mL). The aqueous layer was 
extracted with EtOAc (100 mL, three times), washed with aqueous NaHCO3 (120 mL), 
brine (120 mL), dried over Na2SO4, filtered, and concentrated. Purification by silica gel 
column chromatography (30% ! 40% EtOAc/Hex) afforded the title compound as a 
yellow oil (3.24 g, 71%). Rf = 0.41 (40% EtOAc/Hex). α[ ]D
21.9
= +44.3  (c = 0.75 CHCl3). 
FTIR (thin film) cm-1: 3367, 3050, 2978, 2933, 1712, 1632, 1517, 1447, 1392, 1367, 
1319, 1250, 1218, 1148, 1086, 1054, 1023, 999, 977, 916, 753, 688, 595, 549. HRMS 
(ESI) m/z calcd. C17H23NO6S [M+Na]+ 392.1144, found 392.1147. 1H-NMR (500 MHz; 
CDCl3): δ 7.87 (d, J = 7.6 Hz, 2H), 7.63 (dd, J = 13.3, 5.7 Hz, 1H), 7.58-7.53 (m, 2H), 
6.92-6.86 (m, 1H), 6.42 (d, J = 15.1 Hz, 1H), 5.24-5.23 (m, 1H), 4.49-4.44 (m, 1H), 3.68 
(s, 3H), 2.82-2.77 (m, 1H), 2.68-2.62 (m, 1H), 1.42 (s, 9H). 13C-NMR (CDCl3, 125 
MHz): 171.4, 155.0, 140.7, 140.1, 133.62, 133.47, 129.3, 127.7, 80.4, 52.7, 52.2, 34.5, 
28.2. 
 
N-Boc phenyl sulfone dipeptide (+)-88. To a stirred 
solution of (+)-85 (314 mg, 0.850 mmol) in anhydrous CH2Cl2 (3.4 mL) was added TFA 
(3.4 mL) at room temperature. The resulting mixture was allowed to stir at room 
temperature for 1 h. The solution was concentrated to afford the TFA amine salt 86, 
which was used in the next step without further purification. In a separate reaction vessel, 
(+)-85 (282 mg, 0.763 mmol) was dissolved in anhydrous 1,2-DCE (7.6 mL) at room 
PhO2S NH
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temperature. To this was added Me3SnOH (414 mg, 2.290 mmol), and the resulting 
mixture was brought to 70 oC and left to stir for 7 h. The solvent was evaporated under 
vacuum, and re-dissolved in ethyl acetate (20 mL). The organic layer was washed with 
aqueous 10% KHSO4 (5 mL), brine (5 mL), dried over Na2SO4, filtered, and concentrated 
to afford the acid 87 as an oil, which was carried onto the next step without further 
purification. To a foiled round bottom flask containing 87 dissolved in anhydrous CH2Cl2 
(3 mL) at 0 oC was added BOP (424 mg, 0.959 mmol) followed by a portion of NMM (87 
mL). In a separate round bottom flask containing 86 dissolved in anhydrous CH2Cl2 (5 
mL) was added the remainder of NMM (0.17 mL). The in situ free-based form of 86 was 
then added to the flask containing 87 by cannula addition. The resulting mixture was 
allowed to warm to room temperature and stir overnight. The reaction mixture was 
diluted with ethyl acetate (20 mL), washed with aqueous 10% KHSO4 (5 mL), aqueous 
sat. NaHCO3 (5 mL), and brine (5 mL). The organic layer was dried over Na2SO4, 
filtered, and concentrated. Purification by column chromatography (55% EtOAc/Hex) 
afforded the title compound as an oil (340 mg, 70%). %). Rf = 0.47 (70% EtOAc/Hex). 
α[ ]D
22.4
= +33.1  (c = 0.5 CH2Cl2). FTIR (thin film) cm-1: 3352, 3059, 2979, 1743, 1710, 
1681, 1519, 1447, 1368, 1306, 1290, 1249, 1146, 1085, 1029, 1024, 844, 752, 688, 594, 
548. HRMS (ESI) m/z calcd. C28H34N2O9S2 [M+Na]+ 629.1603, found 629.1604. 1H-
NMR (500 MHz; CDCl3): δ 7.89-7.87 (m, 5H), 7.64-7.61 (m, 2H), 7.54 (t, J = 7.7 Hz, 
3H), 7.06-7.04 (m, 1H), 6.91 (dt, J = 14.9, 7.4 Hz, 1H), 6.84 (dt, J = 14.9, 7.5 Hz, 1H), 
6.43 (dd, J = 14.8, 13.7 Hz, 2H), 5.25-5.17 (m, 1H), 4.67 (td, J = 8.0, 4.8 Hz, 1H), 4.31-
4.27 (m, 1H), 3.68 (s, 3H), 2.84-2.73 (m, 2H), 2.67-2.52 (m, 2H), 1.44 (s, 9H). 13C-NMR 
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(CDCl3, 125 MHz): 170.6, 170.4, 155.5, 141.2, 140.19, 140.13, 139.9, 133.8, 133.57, 
133.51, 133.46, 129.34, 129.31, 127.82, 127.71, 80.90, 52.9, 50.9, 34.2, 33.8, 29.7, 28.2. 
 
 Phenyl sulfone DKP (−)-78. To a stirred solution of (+)-
88 (2.0 g, 3.346 mmol) in anhydrous CH2Cl2 (14 mL) at 0 oC was added TFA (6.2 mL, 
83.648 mmol). The resulting mixture was left to stir at 0 oC for 30 min and at room 
temperature for additional 30 min. Upon completion (monitored by TLC), the reaction 
mixture was concentrated, and the resulting TFA amine salt was used in the subsequent 
step without further purification. To a stirred solution of the TFA amine salt in MeOH 
(51 mL) at 0 oC was added aqueous NH4OH (1.77 mL). The resulting mixture was 
allowed to warm to room temperature and left to stir until complete consumption of 
starting material was apparent (monitored by 1H NMR and TLC). The reaction solution 
was concentrated and diluted with a 2:1 mixture of EtOAc and acetone (150 mL), which 
was washed with brine (20 mL). The organic layer was separated, dried over Na2SO4, 
filtered, and concentrated to afford the title compound (1.2 g, 87% over two steps). Rf = 
0.66 (100% Acetone). α[ ]D
22.8
= −21.0  (c = 0.25 Acetone). FTIR (neat) cm-1: 2360, 2328, 
1680, 1667, 1461, 1446, 1342, 1305, 1145, 1085, 822, 758, 715, 688, 670, 613. HRMS 
(ESI) m/z calcd. C22H22N2O6S2 [M+H]+ 475.0998, found 475.0982. 1H-NMR (500 MHz; 
DMSO-d6): δ 8.37 (t, J = 0.3 Hz, 1H), 7.85 (dd, J = 6.9, 1.2 Hz, 2H), 7.76-7.61 (m, 3H), 
6.90-6.81 (m, 2H), 4.15-4.12 (m, 1H), 2.66-2.63 (m, 2H). 13C-NMR (DMSO-d6, 125 
MHz): 167.8, 142.7, 140.8, 134.0, 133.1, 130.0, 127.6, 53.2, 34.2. 
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Phenyl sulfone IMDA precursor (+)-89. A biotage 
microwave tube was charged with a stir bar, (−)-78 (250 mg, 0.527 mmol), and 1:1 
mixture of 1,2-DCE and DMSO (2.1 mL). To this was added freshly prepared 66 (421 
mg, 2.634 mmol), Cu(OAc)2 (28 mg, 0.158 mmol), and 4 Å MS (840 mg) on the bench-
top. The tube was sealed, and the resulting heterogeneous mixture was left to stir at 40 oC 
under O2 atmosphere until full conversion of (−)-78 was evident by TLC analysis. The 
reaction mixture was filtered through a pad of Celite, and was rinsed with portions of 
ethyl acetate (80 mL). The filtrate was concentrated, and directly loaded onto a silica gel 
column for purification (40% EtOAc/Hex) to afford the title compound as a yellow oil 
(155 mg, 51%). Rf = 0.3 (40% EtOAc/Hex). α[ ]D
21.9
= +154.7  (c = 0.7 CH2Cl2). FTIR 
(film) cm-1: 3057, 2923, 2852, 1673, 1642, 1446, 1433, 1407, 1307, 1238, 1146, 1085, 
1000, 941, 907, 821, 751, 721, 687, 593, 548. HRMS (ESI) m/z calcd. C30H30N2O6S2 
[M+Na]+ 601.1443, found 601.1459.1H-NMR (500 MHz; CDCl3): δ 7.90 (dd, J = 8.0, 0.7 
Hz, 2H), 7.66-7.63 (m, 1H), 7.58-7.54 (m, 2H), 7.27-7.23 (m, 1H), 7.03-6.95 (m, 1H), 
6.56 (d, J = 14.9 Hz, 1H), 6.39-6.30 (m, 1H), 5.81-5.74 (m, 1H), 5.27-5.17 (m, 2H), 4.64-
4.62 (m, 1H), 2.98-2.92 (m, 1H), 2.90-2.82 (m, 1H). 13C-NMR (CDCl3, 125 MHz): 
161.7, 139.8, 139.2, 134.3, 133.68, 133.63, 129.4, 127.8, 125.2, 118.1, 116.3, 56.4, 34.4. 
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Double IMDA bis-phenyl sulfone cycloadduct (90).iv The 
general procedure for thermal IMDA was utilized to obtain the title compound. 1H-NMR 
(500 MHz; CDCl3): δ 7.98-7.90 (m, 2H), 7.73-7.69 (m, 1H), 7.67-7.59 (m, 2H), 5.89-5.72 
(m, 1H), 5.65-5.56 (m, 1H), 4.87-4.73 (m, 1H), 4.34-4.17 (m, 1H), 3.39-3.30 (m, 1H), 
2.89-2.75 (m, 1H), 2.70-2.51 (m, 2H), 2.44-2.33 (m, 2H). 13C-NMR (CDCl3, 125 MHz): 
165.9, 137.3, 134.2, 129.5, 128.8, 124.8, 124.6, 59.5, 54.2, 32.9, 29.2, 27.9, 20.8.  
 
N-Boc alkene dipeptide (+)-99. The general procedure for peptide 
coupling used in the synthesis of (+)-63 and (+)-88 was followed. Rf = 0.61 (40% 
EtOAc/Hex) α[ ]D
20.5
= +0.40  (c = 0.7 CHCl3). FTIR (film) cm-1: 3315, 3079, 3005, 2980, 
2954, 2933, 1747, 1661, 1525, 1438, 1391, 1367, 1274, 1250, 1223, 1203, 1168, 1047, 
1022, 993, 919, 860. HRMS (ESI) m/z calcd. C16H26N2O5 [M+Na]+ 349.1739, found 
349.1724.1H-NMR (500 MHz; CDCl3): δ 6.89-6.88 (m, 1H), 5.70 (ddt, J = 16.9, 9.8, 6.9 
Hz, 1H), 5.62 (dddd, J = 16.8, 6.2, 5.9, 4.3 Hz, 1H), 5.22 (d, J = 7.8 Hz, 1H), 5.11-5.03 
(m, 4H), 4.59 (q, J = 6.4 Hz, 1H), 4.18 (dtd, J = 2.0, 1.0, 0.5 Hz, 1H), 3.68 (s, 3H), 2.56-
2.38 (m, 4H), 1.38 (s, 9H). 13C-NMR (CDCl3, 125 MHz): 171.8, 171.3, 155.5, 133.0, 
132.1, 119.1, 118.8, 79.9, 53.6, 52.3, 51.7, 36.6, 36.3, 28.2. 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
iv Reported values for 1H and 13C NMR based on major diastereomer. 13C NMR spectra 
shows up to 4 different DKP carbonyl peaks of varying intensity, suggesting presence of 
diastereomers. 
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 N-Boc alkyne dipeptide (+)-100. The general procedure for peptide 
coupling used in the synthesis of (+)-63 and (+)-88 was followed. Rf = 0.48 (40% 
EtOAc/Hex). α[ ]D
20.8
= +47.9  (c = 0.5 CH2Cl2). FTIR (film) cm-1: 3295, 2978, 2957, 2932, 
1744, 1679, 1515, 1439, 1392, 1368, 1251, 1222, 1167, 1056, 1023, 852, 648. HRMS 
(ESI) m/z calcd. C16H22N2O5 [M+H]+ 323.1607, found 323.1607.1H-NMR (500 MHz; 
CDCl3): δ 7.15-7.14 (m, 1H), 5.35-5.34 (m, 1H), 4.73 (dt, J = 7.8, 4.6 Hz, 1H), 4.36-4.35 
(m, 1H), 3.79 (s, 3H), 2.83-2.78 (m, 3H), 2.65-2.60 (m, 1H), 2.11 (t, J = 2.5 Hz, 1H), 
2.03 (dd, J = 4.7, 2.1 Hz, 1H), 1.47 (s, 9H). 13C-NMR (CDCl3, 125 MHz): 170.3, 170.0, 
155.2, 80.6, 79.10, 79.08, 71.9, 71.6, 60.3, 53.4, 52.8, 50.9, 28.2, 22.3. 
 
bis-Alkene DKP (−)-81.61 General procedure for DKP synthesis used in 
phenyl sulfone DKP (−)-78 was employed. Rf = 0.45 (10% MeOH/EtOAc). 
α[ ]D
21.2
= −82.19  (c = 0.45 MeOH). FTIR (neat) cm-1: 1667, 1457, 1342, 1206, 1138, 922, 
844, 802, 725. HRMS (ESI) m/z calcd. C10H14N2O2 [M+Na]+ 217.0953, found 
217.0952.1H-NMR (500 MHz; CDCl3): δ 6.56 (dt, J = 0.6, 0.3 Hz, 1H), 5.88-5.73 (m, 
1H), 5.47-5.19 (m, 2H), 4.22-4.01 (m, 1H), 2.87-2.77 (m, 1H), 2.53-2.45 (m, 1H). 13C-
NMR (CDCl3, 125 MHz): 167.4, 132.1, 120.7, 53.9, 37.9. 
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Alkene IMDA precursor (+)-97. A biotage microwave tube was 
charged with a stir bar, (−)-81 (50 mg, 0.257 mmol), and 1:1 mixture of CH2Cl2 and 
DMSO (1 mL). To this was added freshly prepared 66 (205 mg, 1.281 mmol), Cu(OAc)2 
(14 mg, 0.077 mmol), and 4 Å MS (400 mg) on the bench-top. The tube was sealed, and 
the resulting heterogeneous mixture was left to stir at 40 oC under O2 atmosphere until 
full conversion of (−)-81 was evident by TLC analysis. The reaction mixture was filtered 
through a pad of Celite, and was rinsed with portions of ethyl acetate (50 mL). The 
filtrate was concentrated, and directly loaded onto a silica gel column for purification 
(10% EtOAc/Hex) to afford the title compound as a yellow oil (32 mg, 42%). Rf = 0.29 
(10% EtOAc/Hex). α[ ]D
20.9
= +60.9  (c = 0.45 CH2Cl2). FTIR (film) cm-1: 3081, 2922, 
2851, 1676, 1641, 1430, 1404, 1314, 1238, 1096, 998, 936, 895, 845. HRMS (ESI) m/z 
calcd. C18H22N2O2 [M+H]+ 299.1760, found 299.1758.1H-NMR (500 MHz; CDCl3): δ 
7.34 (d, J = 14.7 Hz, 1H), 6.44-6.34 (m, 1H), 6.00-5.88 (m, 1H), 5.87-5.79 (m, 1H), 5.30-
5.12 (m, 4H), 4.51-4.47 (m, 1H), 2.80-2.66 (m, 2H). 13C-NMR (CDCl3, 125 MHz): 163.1, 
134.3, 132.4, 125.9, 119.3, 116.9, 115.5, 57.8, 37.7. 
 
 bis-Alkyne DKP (−)-98. General procedure for DKP synthesis used in 
phenyl sulfone DKP (−)-78 and bis-alkene DKP (−)-81 was employed. Rf = 0.7 (100% 
Acetone). α[ ]D
21.4
= −41.8  (c = 0.25 DMSO). FTIR (neat) cm-1: 3275, 3210, 3094, 2924, 
2853, 1682, 1672, 1440, 1421, 1332, 1223, 1105, 816, 779, 753, 695, 688, 649. 1H-NMR 
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(500 MHz; DMSO-d6): δ  8.22 (s, 1H), 4.04 (t, J = 4.4 Hz, 1H), 2.85 (d, J = 1.8 Hz, 1H), 
2.71-2.67 (m, 1H), 2.57 (dt, J = 16.9, 3.4 Hz, 1H). 13C-NMR (DMSO-d6, 125 MHz): 
166.3, 80.5, 74.3, 53.4, 23.9. 
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Chapter 5: Development of novel 1,2-indanedione fingerprint reagents 
 
 
5.1) Significance and background of latent fingerprint detection 
 
The central dogma of forensic science: “Every contact leaves a trace” was first 
introduced by Edmond Locard, a pioneer of forensic science (also regarded as the 
Sherlock Holmes of France), in what is known as the Locard’s exchange principle.1 
Needless to say, fingerprint detection is a crucial area in forensic science. A variety of 
physical and chemical methods have been developed over the years for the visualization 
of latent (hidden) fingerprints.2 Chemical techniques are amongst the most sensitive 
techniques available today, and can be applied on many surfaces, porous or non-porous 
and on a large variety of materials (paper, plastic, wood, etc.). Of considerable 
importance are chemical techniques applied for paper and related cellulosic materials, 
since our society relies heavily on such materials for official documents, currency 
printing, wrapping, packaging, etc. More specifically, these methods rely upon the 
detection of the amino acids present in natural skin secretions. When a fingerprint is 
deposited on paper substrates, the amino acids are believed to bind to the cellulose of the 
paper, which preserves an impression of the friction ridge patterns.2 These impressions 
are classified into two main groups—visible and latent. Visible marks are remnants of 
colored contaminant on the skin (blood, oil, ink), which leaves a positive visible 
impression. Latent marks, on the other hand, are invisible friction ridge impressions that 
are the result of transfer of skin secretions and non-visible surface contaminants on the 
porous substrates. Of the two, latent fingerprints are the most common type of evidence 
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found at crime scenes, and the most problematic, because they require methods to 
develop fingerprints that can be visualized and recorded.  
For the purpose of latent fingerprint detection, eccrine and sebaceous glands are the most 
important glands that are responsible for skin secretions within the dermis.2 Eccrine 
(sweat) glands are found on the palms of the hands, consequently contributing as the 
major aqueous component of a latent fingerprint. The palms also contain sebaceous 
secretions as a contaminant due to interactions with the face and hair. Varying degrees of 
combination of eccrine and sebaceous glands are present in latent deposits depending on 
the individual (Table 5.1). Human sweat contains a wide range of amino acids, where the 
exact composition depends upon the individual and a variety of other factors including 
general health, diet, gender and age.3 When transferred to the surface of a paper substrate, 
amino acids have a great affinity for cellulose and tend to be stable over a prolonged 
period of time (>20 years).2  
 
Table 5.1. Summarized constituents of eccrine and sebaceous skin secretions.2,3 
Secretion Constituents 
Organic Inorganic 
Eccrine Amino acids Water (>98%) 
Proteins Chloride 
Urea Metal ions (Na+, K+, Ca2+) 
Uric acid Sulfate 
Lactic acid Phosphate 
Sugars Hydrogen carbonate 
Creatinine Ammonia 
Choline  
Sebaceous Glycerides  
Fatty acids  
Wax esters  
Squalene  
Sterol esters  
Sterols  
 
Since the amino acid composition of a fingerprint could vary depending on the individual, 
non-specific amino acid sensitive reagents are often considered for fingerprint detection. 
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According to Bramble and Brennan, there are three key requirements that any successful 
fingerprint detection reagent should have: (1) a suitable medium for the reagent (2) a 
method of transport for the reagent onto the item of interest (spraying, dipping) (3) using 
suitable reaction conditions (without destroying the evidence).4 Generally, amino acid 
sensitive reagents are dissolved in a carrier solvent with or without additives (acetic acid, 
metal salts). An ideal solvent is volatile (to readily dry the substrate), non-toxic, non-
flammable, and non-polar in order to avoid dissolving inks on treated documents.2 For 
these reasons, 1-methoxynonafluorobutane (HFE 7100) is usually the carrier solvent of 
choice, although depending on the reagent, combination of formulations could be used to 
allow dissolution of the reagent. Most known reagents often require heat to develop latent 
fingerprints. Depending on the reagent, the method of heating could be varied, such as 
using an oven, domestic iron, or laundry press.2 Furthermore, in certain cases, humidity 
was found to improve the development of fingerprints.2 Finally, the developed latent 
fingerprint is then examined and recorded for identification. The method of examining 
and recording the developed prints could vary depending on the characteristics of the 
reagent employed. For instance, photoluminescence could be measured by illuminating 
the developed fingerprint with a filtered light source (or laser) and visualizing through 
appropriate filters.2 Although such visualization methods may allow detection of even 
weak prints, it is not favorable, due to utilization of highly specialized and expensive 
instrumentation that are not readily accessible.  
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5.2) Common amino acid sensitive reagents 
 
5.2.1) Ninhydrin 
Although ninhydrin was synthesized and discovered by Ruhemann in 1910,5 it was not 
until the mid 1950s when it was applied as the first amino acid sensitive reagent for the 
detection of latent fingerprints.6 Ruhemann observed a color change after ninhydrin came 
in contact with his skin, leaving a purple mark.5 This purple compound was subsequently 
known as “Ruhemann’s purple.”2 The accepted general mechanism for the reaction of 
ninhydrin and an amino acid was proposed by Friedman and Williams,7 and was later 
confirmed by Grigg8 using X-ray studies (Scheme 5.1). Condensation of the amine 
portion of the amino acid on the central carbonyl of ninhydrin affords Schiff’s base 1, 
which then undergoes decarboxylation (Strecker degradation) to yield resonance-
stabilized 1,3-dipolar species 2 and 3. Subsequent proton transfer followed by hydrolysis 
affords 2-amino intermediate 5. Condensation with another molecule of ninhydrin then 
furnishes Ruhemann’s purple.  
 
Scheme 5.1. Mechanism of Ruhemann’s purple synthesis. 
 
Ninhydrin can be applied to paper substrates by several different ways, but the most 
popular method is dipping the paper into a solution of ninhydrin. Upon exposure to 
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ninhydrin, heat and humidity are applied to accelerate the development process. Since 
prolonged exposure to light could fade ninhydrin developed prints, samples are usually 
allowed to develop in the dark at room temperature in order to obtain maximum 
sensitivity and minimal background staining.9 The main limitation to this procedure is 
that full development of prints could often take weeks. In order to address this issue, 
initial efforts were made to alter the formulation of carrier solvent used to dissolve 
ninhydrin. However, unsatisfactory improvements were made by simple change of 
formulation methods, which ultimately ushered a wide variety of synthetic efforts 
towards generation of ninhydrin analogues.9 Introduction of various substituents and 
extension of the conjugated system in such analogues showed for the first time that these 
modifications could produce an increase in molar extinction coefficients, resulting in 
more sensitive reagents and inducing shifts in the absorption maxima which resulted in 
change in the color of the Ruhemann’s purple complex.9,10 Alternatively, Ruhemann’s 
purple prints could be complexed with various metal salts which could alter the color of 
the print. In 1982, Herod and Menzel observed that ninhydrin developed fingerprints 
changed color as well as became highly fluorescent (observed under an argon laser) when 
treated with zinc chloride solutions.11 This was a pivotal discovery in the realm of 
fingerprint detection. Converting nonfluorescent ninhydrin developed prints into highly 
fluorescent prints allowed for improvement in contrast on a variety of backgrounds as 
well as heightened sensitivity (photoluminescence). Such post-treatment of Ruhemann’s 
purple prints with metals has been widely used since then, especially in the detection of 
weak ninhydrin prints. It has been shown that zinc(II) and cadmium (II) salts complex 
with Ruhemann’s purple to give luminescent products with slightly different properties 
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(Scheme 5.2). Soon thereafter, it was discovered that the intensity of the luminescence 
could be further improved if the prints are cooled in liquid nitrogen prior to observation.12  
 
Scheme 5.2. Complexation of Ruhemann’s purple with metals. 
 
Although the use of fluorescence-based detection methods on ninhydrin/metal treated 
prints have been popular since its discovery, much attention was given to the synthesis of 
novel ninhydrin analogues, with the intention of obtaining highly colored Ruhemann’s 
purple species that also exhibit fluorescence without secondary metal treatment, in order 
to simplify the visualization process. Of the various ninhydrin analogues that were 
synthesized, the most prominent analogues were 1,8-diazafluorene-9-one (DFO) and 1,2-
indanedione, since they produced both color and intense luminescence upon reaction with 
amino acids in fingerprints without requiring further treatment.2  
 
5.2.2) 1,8-Diazafluoren-9-one (DFO) 
Although DFO was known since 1950,13a it was not until 199014 when Grigg and Pounds 
introduced DFO as an alternative amino acid detecting reagent. Although DFO is not a 
direct analogue of ninhydrin, it behaves similarly when reacting with amino acids 
(Scheme 5.3). DFO has only one central carbonyl moiety that is adjacent to two fused 
pyridine rings on each side that act similarly as neighboring dipoles of the 1,3-diketones 
in ninhydrin. Upon reaction with amino acids, it produces a red product, which is 
analogous to Ruhemann’s purple.9,14  
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Scheme 5.3. Proposed reaction mechanism of DFO with an amino acid. 
 
Unlike ninhydrin, DFO developed fingerprints were found to be highly fluorescent 
without secondary post-treatment with metal salts. Although the sensitivity was increased, 
there were practicality issues related with using DFO as a reagent. For instance, although 
commercially available, DFO is significantly more expensive than ninhydrin and requires 
the use of specialized light sources (prints viewed and photographed with a 520 nm 
(green) excitation filter and 590 nm (red) observation filter) for observation of 
fingerprints.9 Furthermore, the development of DFO treated fingerprints requires 
carefully timed application of relatively high temperature (100-180 oC) and dry heat in 
order to avoid thermal decomposition.2,9 In certain cases, DFO failed to develop all the 
prints and hence necessitated a secondary treatment with ninhydrin in order to maximize 
the number and quality of fingerprints. These shortcomings are believed to be the result 
of a slower reaction with amino acids when compared to ninhydrin. Moreover, efforts 
toward developing DFO analogues have not resulted in significant improvements.9,14 
 
5.2.3) 1,2-Indanedione 
In 1997, Joullié reported the ability of 1,2-indanedione to react with amino acids present 
in latent fingerprints.15 The reaction results in a pale pink color with intense room-
temperature luminescence comparable to that of DFO.2,15 Extensive mechanistic studies 
were conducted 16 , 17  in order to elucidate the reaction pathway. In particular, the 
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involvement of 1,3-dipolar species of various geometries has been unequivocally 
confirmed through subsequent cycloaddition studies with N-methylmaleimide.17 The 
proposed mechanism involves similar reaction pathway to that of DFO and ninhydrin that 
involves formation of imine intermediate followed by Strecker degradation to obtain 2-
amino-1-indanone, which could then react further with another equivalent of 1,2-
indanedione to produce a pink Ruhemann’s purple analogue referred to as Joullié’s pink 
(Scheme 5.4).2,18  
 
Scheme 5.4. Proposed reaction mechanism of 1,2-indanedione and an amino acid. 
 
As was the case for ninhydrin, when 1,2-indanedione developed fingerprints were treated 
with zinc or cadmium chloride, the luminescence intensity of the corresponding product 
was increased, and the color of the product became a darker pink color, improving 
contrast.15 Alternatively, zinc chloride could be added in the solution of 1,2-indanedione 
to provide similar results.15a However, inconsistencies in the formulation of 1,2-
indanedione solutions across research labs in the world necessitated an optimized 
protocol that would be universally accepted.2 It was found that depending on the 
formulation, varying results were obtained, suggesting usefulness or lack there of, of 
using 1,2-indanedione as an alternative to ninhydrin or DFO. Moreover, the observed 
discrepancy was suggested to be the result of differing climate of the research labs (it was 
believed that humidity plays a big role on development of fingerprints) and/or varying 
constituents of paper. 19  Formulations from early investigations used methanolic 
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solutions,15 although later research recommended limiting the amount of methanol or 
other alcohols in 1,2-indanedione solutions due to resultant hemiketal formation that 
could interfere in the desired reaction with amino acids.2,17,20 Furthermore, fingerprints 
developed using methanolic solutions often resulted in smudging of the image, thereby 
reducing the detail of the ridges.21 Investigations on the effect of different carrier solvents 
(methanol, petroleum ether, HFE 7100, etc.) on the development of latent fingerprints 
strongly suggested the use of HFE 7100 over other solvents due to increased 
luminescence and lower health and safety risks.2,19,20 In contrast, in some studies, 
petroleum ether based formulation was found to develop fingerprints that were darker in 
color and stronger in luminescence in comparison to HFE 7100 based formulation.22 
However, as suggested from the proposed mechanism of action (Scheme 5.4) use of 
acetic acid as an acidic additive to the formulation is less debated, and is rather well 
accepted to date to produce better results.2 Furthermore, studies suggested the importance 
of relative humidity and moisture content of the paper substrate on the development of 
latent fingerprints, which may explain the observed results obtained from various 
countries with differing climatic conditions.2,19 Although heating of 1,2-indanedione 
treated fingerprints is not necessary (24-48 h at room temperature for development), the 
reaction could be accelerated by heating with either an oven or dry heat/laundry press.2,21 
The most accepted conditions to obtain optimum development is to treat 1,2-indanedione 
developed fingerprints with laundry press at 160-165 oC for 10 seconds.2  
 
In 2011, a study was conducted to elucidate the role of zinc(II) ions and cellulose 
substrates in the reaction of 1,2-indanedione and amino acids.23 As was the case for 
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Ruhemann’s purple, zinc(II) ions were initially thought to form a complex with Joullié’s 
pink upon post treatment.15 However, concentration studies of zinc chloride and its effect 
on development of fingerprints suggested that the primary role of zinc(II) ions in the 1,2-
indanedione-amino acid reaction is that of a Lewis acid catalyst.24 More specifically, a 
minor red shift in the absorption spectrum as well as decrease in luminescence and color 
intensity was observed at high concentrations of zinc chloride, which suggests the 
catalytic role of zinc chloride.24 This hypothesis was formulated primarily through 
anecdotal observations of fingerprints developed using 1,2-indanedione-zinc chloride in 
various forensic laboratories and have not been confirmed in the literature.23 Therefore, a 
careful investigation was conducted23 in order to determine if the reaction of 1,2-
indanedione with amino acids on cellulose proceeds via the same mechanism proposed 
earlier17 which was done in solution. Three amino acids (L-alanine, L-phenylalanine, and 
L-leucine) were chosen for the study and were mixed with cellulose to produce amino 
acid-impregnated cellulose that would mimic the conditions observed on paper 
substrates.23 A solution of 1,2-indanedione with or without catalytic amount of zinc 
chloride (1:2:0 or 10:10:1, or 10:20:1 molar ratios of amino acid-1,2-indanedione-zinc 
chloride was used) was added to the amino acid-impregnated cellulose and was mixed at 
room temperature in the dark for 1 h. The resulting reaction products were extracted and 
analyzed by mass spectrometry (ESI-MS), 13C-MAS-NMR, and UV-Vis.23 Of the three 
amino acids studied, the reaction between L-leucine and 1,2-indanedione/zinc(II) 
(10:10:1 ratio) resulted in the greatest reaction rate, which was implied from the low 
relative abundance of ions attributable to 1,2-indanedione and early stage reaction 
intermediates (the ESI-MS results were obtained via direct injection immediately 
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following extraction of reaction mixture from cellulose).23 Furthermore, an increase in 
the relative abundance of the Joullié’s pink ion was observed with the addition of zinc 
chloride dramatically improving the reaction rate.23 The involvement of a new 
intermediate was subsequently proposed (Scheme 5.5).23 Since the presence of the 
proposed intermediate was never detected in any of the reaction conditions that had zinc 
chloride as an additive, it was suggested that the addition of zinc(II) ions leads to the 
rapid conversion of the proposed intermediate to 2-amino-1-indanone.23 From their 
results, they claimed that zinc chloride acts as a Lewis acid catalyst that stabilizes the 1,3-
dipole intermediate during the hydrolytic conversion to 2-amino-1-indanone in low 
humidity environments.23 Addition of stoichiometric amount of zinc chloride did not 
result in improved luminescence through complex formation, but decreased the rate of 
the reaction and overall yield of Joullié’s pink instead. 
 
Scheme 5.5. Proposed reaction pathway to Joullié’s pink from the imine intermediate.23 
 
In order to further support the involvement of 2-amino-1-indanone moiety in the reaction 
pathway, 2-amino-1-indanone was synthesized using known methods and reacted with 
1,2-indanedione in solution on cellulose at room temperature in a 160 oC oven. UV-Vis 
spectroscopy, fluorescence spectroscopy, and NMR spectroscopy (HSQC) confirmed the 
formation of Joullié’s pink.23 When 2-amino-1-indanone was added to cellulose and 
heated under the same conditions, an unexpected formation of Joullié’s pink was 
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observed, indicating a possible secondary reaction pathway that occurs by slow 
deamination of 2-amino-1-indanone to form 1,2-indanedione under warm humid 
conditions (Scheme 5.5).23 Taken together, these results support the generally accepted 
reaction mechanistic pathway of 1,2-indanedione and amino acids, and suggest a specific 
role of zinc chloride as a Lewis acid catalyst. Furthermore, the success of the 1,2-
indanedione reaction is dependent upon the relative humidity of the laboratory 
environment, since decomposition of Joullié’s pink was observed under excessive 
humidity (nearing saturation of the paper substrate). Prolonged heating at relatively high 
temperatures (70-100 oC) in low humidity conditions was also found to be detrimental in 
the development of fingerprints, as the only products that were formed were non-
fluorescence oligomeric byproducts.23 Finally, the role of cellulose was found to be 
similar to that of a surface catalyst, since it is believed to orient the intermediates in the 
optimum reaction geometry (through hydrogen bonding), and retain water molecules 
close to the reaction site to improve the reaction rate.23 Trace metals present in the 
commercial paper stocks may also act as a Lewis acid catalyst in the same manner as 
zinc(II) ions. Although the presence of Joullié’s pink was identified by mass, UV, and 
fluorescence,23 full characterization still needs to be accomplished in order to validate 
various hypotheses that were proposed to date. For instance, the initial hypothesis of 
complexation of zinc with Joullié’s pink15 cannot be completely disregarded.  
 
In terms of determining the overall performance of 1,2-indanedione as a fingerprint 
detection reagent in comparison to ninhydrin and DFO, there seems to be no clear answer. 
Using a sequence of combination of reagents has been popularized as well, and in certain 
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cases, performed better than using a single reagent.2 A recent study conducted in 
Australia25 evaluated two particular fingerprint detection sequences on porous surfaces: 
1) 1,2-indanedione—ZnCl2 followed by ninhydrin, physical developer (PD) and the lipid 
stain Nile red; and 2) DFO followed by ninhydrin, PD and Nile red. The obtained results 
indicated negligible difference in the performance between the two sequences across all 
paper types and all time periods evaluated. However, when considering individual 
reagents, 1,2-indanedione—ZnCl2 developed better quality fingerprints than DFO.25 In 
terms of enhancement, ninhydrin had a greater enhancement effect on DFO developed 
prints rather than 1,2-indanedione—ZnCl2. Although the use of Nile red was proposed in 
the beginning of the trials, since Nile red did not develop any additional fingerprints at 
the end of each sequence, it was excluded in the sequences.25 The optimum sequence that 
was suggested was the use of 1,2-indanedione—ZnCl2 followed by ninhydrin and PD for 
development of fingerprints on Australian paperstock.25 
 
5.3) Development of alternative fingerprint detecting methods 
 
Although a wide variety of ninhydrin-like compounds have been developed since its 
discovery, considerable portions of latent fingerprints still escape detection. The main 
limitation of the existing methods is their stoichiometric nature: as long as the reaction 
assumes a stoichiometric pathway, there is an upper limit to the sensitivity. Furthermore, 
latent fingerprints often do not contain enough amino acids (or other relevant components 
such as lipids), so even the most sensitive reagents fail to produce a sufficiently 
meaningful mark through a direct chemical reaction with fingerprint components. 
Although much attention has been given to developing optimal formulation conditions, 
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success of developing latent fingerprints seems to depend heavily on environmental 
factors (relative humidity of the laboratory, paper stock of the country, sweat content of 
individual’s fingerprint, etc.) that are difficult to control. Moreover, apart from ninhydrin, 
amino acid sensitive reagents that have been identified thus far26 rely on luminescence in 
order to view latent fingerprints, significantly limiting general accessibility (Table 5.2).  
 
Table 5.2. Conditions for observing photoluminescence of latent fingerprints  
using common amino acid sensitive reagents.2 
Reagent Excitation band Viewing conditions 
Ninhydrin—ZnCl2 490 nm Orange goggles 
DFO 505 nm 
530 nm 
555 nm 
Orange goggles 
Red goggles 
Red goggles 
1,2-Indanedione—ZnCl2 505 nm Orange goggles 
 
There are methods other than using amino acid sensitive chemical reagents in developing 
latent fingerprints. One notable method is the use of silver physical developer (Ag-PD), 
which is a process that utilizes metastable silver colloid that develops latent prints on wet, 
porous surfaces such as paper and cardboard.27 The developer deposits a black silver 
precipitate along the fingerprint ridges by associating or reacting with the lipid material 
present in the fingerprint residue. In a typical formulation, a solution of ferrous and ferric 
ions, also containing citric acid and a detergent, is mixed with a solution of silver nitrate 
to generate a citrate-stabilized silver colloid through an electroless reaction in which the 
Fe2+ ions reduce the Ag+ ions in situ.27 As already mentioned, Ag-PD could be used after 
ninhydrin or other amino acid sensitive reagent processing in order to amplify the 
obtained image or obtain more prints. Prints developed using Ag-PD appear as dark 
ridges on lighter/white background, creating enough contrast that allows visualization 
under visible light. Although the process negates the use of expensive, specialized light 
sources for visualization, it suffers from instability of the developing solution (shelf-life 
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of Ag-PD solution is limited and should be freshly prepared for best results) and poor 
reproducibility.  
 
Multimetal deposition (MMD)28 is a variation of the process, in which a latent fingerprint 
is enhanced by gold nanoparticles stabilized by citrate ions in aqueous medium, and then 
treated with Ag-PD. The gold nanoparticles adhere to the fingerprint residue and are 
believed to catalyze the precipitation of metallic silver from the Ag-PD solution.28 The 
affinity of gold nanoparticles to the fingerprint residue is thought to be the result of an 
ionic interaction between the negatively charged gold colloids and the positively charged 
components of the fingerprint residue at low pH.28 Advantages of using MMD is based 
on its sensitivity, specifically with aged fingerprints, and in the fact that it works on 
porous as well as non-porous surfaces. However, the main drawback of the process is that 
it is considered to be labor-intensive (involving several steps to obtain working solution, 
exposure of prints to six different solutions) and it only produces dark grey to black 
fingerprints, which could be problematic when dealing with dark and/or patterned 
surfaces. Therefore, a modification of the process known as single-metal deposition 
(SMD) was developed, where the enhancement of gold colloids by precipitation of silver 
was replaced by gold-based growth of the nanoparticles.29 Efforts towards discovering 
improved fingerprint development techniques that are based on nanochemical processes 
are ongoing, and they all suggest the involvement of adherence of nanoparticles to 
fingerprint residues.30 
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Based on earlier reports by Vijayamohanan,31 in which dodecanethiol stabilized gold 
nanoparticles were found to be adsorbed onto activated hydrophobic surfaces via 
hydrophobic interactions, Almog reported32 that sebum-rich fingerprint deposits could 
serve as hydrophobic surface for such interactions with various alkanethiol stabilized 
gold nanoparticles. Ag-PD was used as a post-treatment process, in which the gold 
nanoparticles that have been adsorbed onto the fingerprint ridges catalyzes silver 
reduction from the Ag-PD solution, allowing the precipitation of Ag0 on the ridges, 
significantly enhancing the developed fingerprints as a result.32 Although the two step 
development process is similar to MMD, since the nanoparticles adsorb onto the 
fingerprint ridges via hydrophobic interactions rather than ionic interactions, the 
underlying mechanism is considered to be different. Moreover, the average size of the 
gold nanoparticles that were synthesized were of 2-3 nm, which is smaller than the gold 
nanoparticles often used in MMD process (~14 nm).32 Best results were obtained using a 
0.04% (w/v) solution of the alkanethiol stabilized gold nanoparticle solutions in 
petroleum ether. Of the three different lengths of the alkanethiol chain tested (10-, 14-, 
and 18-carbon chains), the longest chain, octadecanethiol, provided the best result, where 
the aggregation of gold nanoparticles occurred fastest and in greatest amount as observed 
by scanning electron microscopy (SEM).32 However, all three chains resulted in positive 
latent fingerprint detection after post treatment with Ag-PD. The obtained results using 
paper substrates translated well onto non-porous surfaces (silicon wafers). To test the 
generality of using metallic nanoparticles, petroleum ether solution of CdSe/ZnS 
nanoparticles (~3 nm size) stabilized by octadecaneamine were synthesized.32 Although 
successful development of fingerprints were obtained for non-porous, silicon wafer 
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substrates, the process did not work for paper substrates. Interestingly, post treatment 
with Ag-PD was unnecessary as the CdSe/ZnS treated fingerprints were fluorescent, and 
consequently visible under UV illumination using optical microscopy.32 
 
In 2010, with the intension of extending his previous findings, Almog reported the 
synthesis of various thiohemiketals of ninhydrin and 1,2-indanedione as potential 
fingerprint developing reagents.18 The premise of the study was to use the known reaction 
of ninhydrin and 1,2-indanedione with amino acids that would furnish the corresponding 
colored Ruhemann’s purple or Joullié’s pink, and by having thioether linkages on the 
compounds, the overall reaction would expel the corresponding thiol alkyl chain that 
would then presumably stay on the fingerprint ridges and react with gold nanoparticles, 
further enhancing the contrast.18 With regards to the synthesis of thiohemiketals, 
formation of thioketals were not observed in the case of ninhydrin even in the presence of 
excess thiol. However, in the case of 1,2-indanedione, formation of only thioketals was 
observed under the same conditions. Several thiohemiketal analogues of ninhydrin were 
synthesized and reported, however, none of the presumably synthesized thioketal of 1,2-
indanedione was reported or characterized.18 A possible reason for this discrepancy may 
be due to the fact that the thioketal version of 1,2-indanedione presumably did not react 
with amino acids or latent fingerprints on paper.18 Nonetheless, the thiohemiketal 
analogues of ninhydrin did react with alanine (stereochemistry not specified) to produce 
Ruhemann’s purple (noticed visually), and the presence of thiols in the reaction mixture 
was detected by GCMS (Scheme 5.6).   
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Scheme 5.6. Reaction of thiohemiketals of ninhydrin and alanine. 
 
Amongst the analogues, there was an apparent difference in the rate of the reaction 
(monitored visibly). For instance, analogues containing longer alkyl chains reacted 
slowly in comparison to shorter chains. Furthermore, the thiohemiketal analogues of 
ninhydrin developed latent fingerprints on paper that was comparable to that of 
ninhydrin.18 The use of ketals of ninhydrin in the reaction with amino acids is not entirely 
unprecedented, since another group reported the reaction of hemiketals of ninhydrin with 
amino acids to form Ruhemann’s purple and two equivalents of alcohol per amino acid as 
early as 1991.33 Nonetheless, since the proposed hypothesis of using the thiohemiketal 
analogues of ninhydrin in conjugation with gold nanoparticles was not tested, the 
viability of this approach remains uncertain.  
 
Shortly thereafter, Almog reported yet another approach34 to develop latent fingerprints 
on paper using a similar protocol, but with a different reagent. A bifunctional reagent was 
devised, in which it is composed of an active polar head (acyl pyridazine) that has high 
affinity to cellulose (main ingredient of paper), and a long alkyl chain tail containing a 
sulfur group at the terminal end that could stabilize gold nanoparticles (Scheme 5.7).  
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Scheme 5.7. Almog’s synthesis of functionalized gold nanoparticles.34 
 
Since the head portion of the molecule that has a long alkylthiol chain adheres 
preferentially to the paper rather than to the sebaceous fingerprint material, further 
treatment with Ag-PD would darken the paper, leaving the fingerprint ridges uncolored, 
resulting in a white on black fingerprint image. This so-called “negative image” was 
hypothesized to be superior in comparison to conventional methods, since the current 
approach is based on interactions with cellulose rather than the sebaceous fingerprint, 
which could be varied depending on the sweat content of the individual (Figure 5.1). 
Although their previous work with octadecanethiol stabilized gold nanoparticles32 
produced good quality fingerprints using conventional methods (gold nanoparticle 
exposure followed by Ag-PD, targeting sebaceous fingerprints, thereby producing black 
on white image), they claim that their process lacked consistency due to variability in 
fingerprint residue composition.34 The desired fingerprint image was obtained rather 
quickly using the new process, where the image was obtained after 5 min of treatment 
with the gold nanoparticles followed by 40-60 s with Ag-PD. Prolonged exposure to Ag-
PD solution resulted in darkening of the entire paper, where the silver eventually 
precipitated on the fingerprint ridges as well. Since the method is based on sebaceous 
fingerprints (lipid containing hydrophobic prints), eccrine fingerprints (amino acid 
containing prints) did not work under the same reaction conditions.  
Br OH
O
8
O
SK
MeCN, 85 oC
18 h, 67%
S OH
O
8
O
SOCl2
CH2Cl2,
reflux
S Cl
O
8
O
HN
N
O
Cl
Cl S N
O
8
O N
O
Cl
Cl
, Et3N
CH2Cl2, 50%
Functionalized AuNPTOAB stabilized AuNPs
O
=
toluene, 24 h+
! 505 
 
 
Figure 5.1. Comparison between conventional fingerprint image (left) and “negative” image (right) 
obtained by Almog et al.34 
 
In an attempt to provide an explanation of the particular interaction that could be 
occurring with acyl pyridazine moiety of the reagent and cellulose of the paper, two 
particular classes of gold nanoparticle ligands were synthesized. The first class had 
functional end groups that are known to form hydrogen bonds (glucose, acetylthioalkoxy 
benzaldehydes, etc.), while the second class had polar end groups that cannot hydrogen 
bond (tetrachlorobenzene). Each compound was functionalized with gold nanoparticles 
and was tested for visualization of sebaceous fingerprints on paper using the same 
methodology. The authors found that negative fingerprint images were obtained by the 
first class (ligands with hydrogen bonding motifs), while conventional, positive 
fingerprint images were obtained by the second class (non-hydrogen bonding motifs). 
None of the aforementioned obtained images or any of the gold nanoparticle derivatives 
(other than their main acyl pyridazine reagent) were characterized or referenced in the 
article.34 Nonetheless, the fingerprint image that was obtained using their bifunctional 
ligand containing an acyl pyridazine moiety suggested successful application of this 
protocol.  
 
More recently, Almog reported another example of negative development of latent 
fingerprints using a slightly different set of reagents.35 The method utilized commercially 
available mercaptocarboxylic acids as ligands to gold nanoparticles rather than the 
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Paper is one of the most frequently tested surfaces for the
detection of latent fingermarks in criminal and terrorist-
related investigations. Despite the plethora of modern
physical and chemical fingerprint-detection techniques,[1]
a considerable portion of the latent fingermarks still escape
detection. A plausible explanation is the remarkable differ-
ence in sweat composition between individual persons.[2] A
potential remedy to this problem could be achieved by
reversing the roles, that is, developing a fingerprint-detection
technique in which paper serves as the substrate for the
interaction with the reagent, while the latent fingermarks will
serve as a mask.
In this work, “negative” fingermarks have been developed
on paper, even after soaking in water, by the application of
a new bifunctional reagent attached to gold nanoparticles
(AuNPs), and then a silver physical developer (Ag-PD). The
bifunctional reagent is composed of an active head, that is,
a polar group with high affinity to cellulose, attached by a long
chain to an active tail containing a sulfur group, which can
stabilize AuNPs. Through the active head, the AuNPs, which
are stabilized by the active tail, adhere preferentially to the
paper cellulose rather than to the fingerprint material, to
which they conventionally bind. Consequently, Ag-PD, which
normally develops sebaceous fingermarks by precipitating
dark silver on the sebaceous material, precipitate preferen-
tially on the gold-coated areas giving rise to the appearance of
uncoloured ridge detail on a dark background. In this
competing process, the paper itself serves as the substrate,
whereas the fingermarks serve as a mask. This process may
increase the overall yield of developed fingermarks as it
bypasses the issue of the remarkable differences in sweat
composition between individual persons.
Functionalized nanoparticles have drawn great interest
during the past decade not only in potential applications as
biomedical, electronic, catalytic, and optical materials, but
also in forensic science, as visualizing reagents for latent
fingermarks.[3]
Accumulative results on a large number of paper items
such as used checks, all of which are supposed to bear latent
fingemarks, have shown that over 50 % escape detection of
identifiable marks.[4] Such observations have led to intensive
research into more-sensitive fingerprint detection techniques.
Paper that has been wetted is a particular challenge since the
amino acids, which are the main substrate for chemical
enhancement of latent fingermarks, are dissolved and
removed by the water.
A silver physical developer (Ag-PD), comprising an
aqueous solution of silver nanoparticles (AgNPs) stabilized
by cationic surfactants, is required to achieve satisfactory
development of such fingermarks. Silver slowly deposits on
the water-insoluble components of the sweat, forming dark
grey to black impressions (Figure 1).[5] Although the tech-
nique is quite sensitive, it suffers from
several inconveniences, including
complexity, lack of reproducibility,
solution instability, and often poor
contrast.[1, 3a,5, 6]
As a result, many forensic labo-
ratories refrain from using this tech-
nique on a routine basis. Latent
fingermark enhancement by gold
nanoparticles stabilized by citrate
ions in aqueous medium, and then
a modified Ag-PD, is currently used
in a process known as colloidal gold
or multimetal deposition (MMD).[7]
AuNPs adhere to the fingermark
residue and catalyze the precipitation
of metallic silver from the Ag-PD solution. The gold
adherence to the fingermark material is explai ed by a
ionic interaction between the negatively charged gold colloids
and the positively charged components of the fingermark
residue at low pH.[7] In a modification known as SMD (single-
metal deposition), the enhancement of gold colloids by
precipitation of silver, was replaced by gold-based growth of
the nanoparticles.[7a] Several other fingerprint techniques that
are also based on nanochemical processes, have been
suggested recently; all of these suggestions involve the
adherence of nanoparticles to the fingerprint material.[1, 3, 8]
Previously we showed that good quality fingermarks were
developed by treatment wi h n organic solution of hydr -
phobic AuNPs stabilized by long chain thiols, and then with
Figure 1. Sebaceous
fingermark developed
by Ag-PD.
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Fingermarks containing relatively little tallow also devel-
oped well. Eccrine fingermarks however, could not be
visualized by this technique, and gave rise to total darkening
of the paper. We assume that pure eccrine material does not
form an efficient mask and therefore does not prevent the
active heads from binding to the paper.
The mechanism of the immobilization of 2 on paper
surface is most likely hydrogen bonding between the active
head and cellulose. To support (or refute) the hydrogen-
bonding hypothesis, we c rried two sets of experiments. The
first set involved the synthesis and testing of AuNPs capped
with bifunctional ligands. Some of the ligands had functional
end groups that are known to form hydrogen bonds (glucose,
acetylthioalkoxy bezaldehydes, and w-mercaptocarboxylic
acids,(should be:…carboxylic groups, respectively) having
hydroxy, formyl, or carboxylic groups) and some had polar
end groups that cannot participate in hydrogen bonding, for
example, te rachlorobenzene, or had no functionalized end
groups at all (long chain thiols, as in Ref. [3b]). Each
functionalized AuNP was tested for the visualization of
sebaceous fingermarks on paper by the described technique.
We found that “negative” fingermarks were developed
exclusively by nanoparticles of the first group ,that is, those
that could form hydrogen bonds, whereas the second group
developed the common “positive” fingermarks.
The s cond set of experiments comprised the removal of
the AuNPs from the treated paper by solvent. The efficiency
of the removal was tested by subsequent dipping in Ag-PD
solution. Fast darkening of the paper indicated that the
removal was incomplete. We found excellent correlation with
the previous set of experiments, that is, effective removal of
AuNPs of the first group (containing hydrogen bonding end
groups) required harsh conditions involving shaking the
paper in Vortex in aqueous methanol, whereas removal of
AuNPs of the second group was achieved by gentle shaking
with petroleum ether.
An alternative explanation to the reversed appearance of
the fingerprints could be cellulose acylation by 1. Compounds
of type 1 are known to be efficient acylating agents for amines
and amino acids[9] and, as we found out, they are also efficient
acylating agents for alcohols. This reaction, however, is slow
and requires heat. No evidence for covalent binding of 1 to
the cellulose hydroxy groups was found by XPS analysis, and
no free pyridazine was found in the post-treatment solution.
Based on the similar behavior of AuNPs stabilized with
the hydrogen-bonding ligands mentioned above, we suggest
that the reversed appearance of the fingerprints results from
interactions of the polar substituent at the other end of the
thiol chain. The process is quite robust, and even partially
degraded Ag-PD solutions produce good results.
Notably, the VMD (vapour metal deposition) technique
also develops negative fingermarks, but on nonporous
surfaces, particularly polyethylene and polypropylene. This
method, which is based on vapour-phase coating with gold,
and then zinc, under high vacuum, is considered the most
sensitive fingerprint technique for these substances.[10]
In summary, by modifying the thiolic ligands, which
stabilize the AuNPs, we were able to reverse the affinity of
the AuNPs to the substrate, and hence to develop good
quality negative fingermarks. The method presented here
differs from existing techniques that are based on nano-
technology, by a major characteristic: the substrate for this
reaction is paper itself and not the fingermarks; gold is
attached preferentially to the paper and the fingermarks
develop in a reversed mode, that is, the reaction occurs
around the ridges and between them, but not on them.
Optimization of this process is underway.
Experimental Section
Sebum-rich (sebaceous) fingermarks were obtained from several
volunteers by rubbing their fingers against the forehead and stamping
them onto A4 paper strips. The paper strips bearing the sebaceous
prints were immersed in an acetonitrile solution of 2 containing 0.5%
dimethylsulfoxide (prepared by dissolving the AuNPs in a small
amount of dimethylsulfoxide and diluting with acetonitrile) for
periods ranging from 10 s to 5 min, followed by development with
Ag-PD. Best results were obtained by immersion in Ag-PD for
approximately 50 s. Yet, the decision of when the fingerprint is
sufficiently developed should be made by observation. It is important
to rinse the paper in water immediately after the Ag-PD treatment.
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previously mentioned acyl pyridazine containing ligand. There are apparent advantages 
in using commercially available mercaptocarboxylic acids—namely the fact that they are 
commercially available, thus not requiring synthesis and purification to obtain the ligand. 
Furthermore, the solvent mixture (CH3CN/DMSO) utilized for the formulation of their 
previous ligand34 was an undesirable system for document examinations, since it 
dissolved ink.35 Since most mercaptocarboxylic acids that were examined are soluble in 
water, such problem was not encountered (Figure 5.2). Mercaptocarboxylic acids retain 
the desired bifunctional behavior of the ligand, since the carboxylic acid serves as the 
active head that hydrogen bonds to cellulose, and the thiol serves as the active tail that 
binds to gold nanoparticles, resulting in negative fingerprint images. Although seemingly 
unconventional, there is precedent36 in using a variety of mercatocarboxylic acids as 
ligands to gold nanoparticles. 
 
Figure 5.2. Mercaptocarboxylic acids and salts examined by Almog.35 
 
All the gold nanoparticle functionalized mercaptocarboxylic ligands were dissolved in 
water (in the case of 10-carbon chain mercaptocarboxylic ligand, minimal amount of 
THF was used for dissolution and was further diluted with water to obtain 5% v/v THF in 
water) for the formulation. Apart from functionalized gold nanoparticles of 5-carbon and 
10-carbon chain mercaptocarboxylic ligands, the desired negative fingerprint image was 
obtained after post treatment with Ag-PD. Best results were obtained using 3-
mercaptopropionic acid as the ligand, since fresh and 14 month old latent sebaceous 
fingerprints were developed with good contrast and resolution. However, gold 
nanoparticles capped with 6-mercaptohexanoic acid (5-carbon chain ligand) failed to 
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develop fingerprints, as the entire paper was stained without any distinction. Interestingly, 
gold nanoparticles capped with 11-mercaptoundecanoic acid produced a positive 
fingerprint image, in which the gold nanoparticles was preferentially bound to the 
sebaceous ridges of the fingerprint rather than to the cellulose, which was in line with 
their previous studies.32 Although there was no explanation provided for the failure of 6-
mercaptohexanoic acid as a ligand for fingerprint development, the obtained results 
suggested that the appearance of the fingerprint as positive or negative could be tuned via 
the length of ligand on gold nanoparticles.35 
 
5.4) Design and synthesis of novel 1,2-indanedione reagents 
 
5.4.1) Proposed methodology and design of novel bifunctional reagent 
As discussed in previous sections, the use of amino acid detecting reagents alone for the 
development of latent fingerprints on paper is not advantageous due to their 
stoichiometric nature. Since amino acids and the sweat content on a given fingerprint 
varies drastically depending on the individual and the climate, this prevents even the most 
sensitive reagents from producing sufficiently meaningful mark through direct chemical 
reaction. As long as the reaction assumes a stoichiometric pathway, where an equivalent 
of the reagent (i.e. ninhydrin) reacts with an equivalent of the substrate (amino acid), 
there is an upper limit to the sensitivity. Furthermore, other factors such as relative 
humidity of the laboratory in which the development is conducted, formulation 
conditions, accessibility to specialized equipment (light sources such as lasers) could 
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affect the outcome. Therefore, utilization of nanotechnology, such as the MMD process, 
for the development of latent fingerprints could be a promising alternative.  
 
In this context, development of a new highly sensitive, non-stoichiometric gold 
nanoparticle-based technology following the basic principle of MMD was envisioned. In 
particular, employing bifunctional reagents similar to that of Almog’s34,35 where one end 
of the reagent would react with the fingerprint ridges, while the other end would react 
with gold nanoparticles were envisaged. Since these novel reagents would act as ligands 
on the gold nanoparticles, in theory, each gold nanoparticle could have many of these 
ligands appended on them, where the opposite end would seek out amino acids of the 
fingerprint, thereby increasing the sensitivity via catalytic amplification. The resulting 
ternary complex could then catalyze silver deposition from the Ag-PD, generating a high-
contrast fingermark that could be visualized without the use of specialized light source.  
 
In terms of the bifunctional reagent design, based on the well-known use of 1,2-
indanedione and our particular familiarity of the reagent, 1,2-indanedione was selected as 
the “head” portion of the bifunctional reagent. The “tail” portion would be a long 
alkylthiol chain that is connected to the aromatic ring of 1,2-indanedione. Taken together, 
the 1,2-indanedione portion would react with amino acids of the fingerprint, and long 
alkylthiol chain would act as stabilizing ligands on gold nanoparticles (Figure 5.3). 
Unlike previously mentioned bifunctional reagents that could only target either amino 
acids or hydrophobic lipids, this reagent could in theory react with both amino acids 
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(eccrine) as well as lipids (sebaceous) of the fingerprint, increasing the likelihood of 
latent fingerprint detection on paper substrates.   
 
Figure 5.3. General schematic for proposed development of latent fingerprints. 
 
5.4.2) First-generation synthesis 
A general route for synthesizing 1,2-indanedione derivatives was developed using 
commercially available 5-hydroxyindanone as the starting material (Scheme 5.8). Side 
chain attachment followed by removal of TBS group afforded the corresponding alchols 
6 and 7, which was subsequently transformed into the thioester 8 and 9 by Mitsunobu 
reaction. Oxime formation using previously developed methods15,17 followed by 
conversion to the corresponding ketone15,17 furnished the functionalized 1,2-indanedione 
derivative 14. Although generation of three particular derivatives with varying side chain 
lengths (n = 10, 12, 14) was envisioned using this methodology, unexpected problems 
were encountered during the last two steps of the synthesis, thereby limiting the overall 
efficiency of the synthetic sequence.  
 
Scheme 5.8. First generation synthesis of 1,2-indanedione analogues. 
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In particular, for the oxime formation step, various solvents were screened (CH2Cl2, THF, 
EtOH, EtOH:CH2Cl2), and the best result was obtained using THF. In terms of the 
reagent, comparable results were obtained using isopentyl nitrite instead of n-butyl nitrite. 
The main side reactions that were in competition with the desired transformation were the 
cleavage of the C-O bond in the molecule and removal of the thioacetate group. These 
unfavorable processes could be attributed to the presence of protic acid (HCl) in the 
reaction. Similar problems were encountered in the final step of the synthetic sequence, 
since HCl in aqueous conditions was used. Furthermore, the final product was found to 
be unstable on silica gel during the duration of the column chromatography, which did 
not allow effective separation of the desired product from the side products. Other 
reactions using different set of reagents were explored in hopes of avoiding the use of 
protic acids. In particular, oxidative deoximating reactions37 were investigated using 
Dess-Martin periodinane (DMP), MnO2, and dichloramine-T.38 Oxidation by MnO2 
proved to be sluggish and did not result in full conversion of the starting material. As for 
DMP and dichloramine-T, although the desired product was detected in the reaction 
mixture (verified by 1H NMR, 13C NMR, and LRMS), the pure product was unable to be 
isolated via silica gel chromatography (due to instability) from the side products of the 
oxidation. As an alternative, resin bound pyridinium dichromate [poly(vinylpyridinium 
dichromate)] was synthesized39 and tested, but the reaction failed to reach full conversion 
even after prolonged period of time (1 week). Other deoximation methods, such as 
deoximation by hydrolysis with copper chloride40 only resulted in side chain cleaved 
material.  
! 511 
 
Interestingly, when the present protocol was applied to a derivative bearing a 
polyethylene glycol (PEG) side chain (Scheme 5.9), side chain cleavage was not 
observed for the last two steps of the synthesis. This could be attributed to hydrogen 
bonding interactions in solution that may orient the PEG chain in a manner to protect the 
C-O bond linkage. Based on previous synthesis, minor changes were made in the 
synthetic sequence to ensure good yields. For instance, the Mitsunobu step was not 
utilized due to inconsistency in yield amongst the analogues (Scheme 5.8). Instead, 
alcohol 16 was converted to the tosylate, which was then substituted by thioacetate to 
afford 17 (Scheme 5.9). Use of TMSCl in place of HCl for the oxime formation step 
furnished the desired oxime 18 in excellent yield. Subsequent deoximation under the 
same conditions used in prior synthesis afforded the desired 1,2-indanedione analogue 19 
in good yield. Silica gel column chromatography was not required for the last two steps, 
since a simple aqueous work-up allowed the isolation of pure material. Although side 
chain cleaved side product was not observed, minor presence of acetate removed thiol 
1,2-indanedione product was observed by NMR and LCMS. However, removal of the 
acetate group was not a major concern, since such process takes place in the following 
step (functionalizing gold nanoparticles with 1,2-indanedione analogue as ligand) in situ.   
 
Scheme 5.9. Synthesis of 1,2-indanedione PEG analogue. 
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Although the 1,2-indanedione PEG side chain analogue afforded synthetically good 
results, an improved protocol for attaching alkyl side chains was desired. The PEG side 
chain could display enhanced solubility in water or other polar solvents, while as long 
alkyl side chains could display the opposite solubility, which would ultimately allow the 
investigation of various formulations for development of latent fingerprints.  
 
5.4.3) Second-generation synthesis 
Variation in the bond linkage between the phenyl ring of 1,2-indanedione and the side 
chain was deemed necessary, in order to circumvent the undesirable side reactions that 
were occurring under aqueous protic acid conditions in the last step of the synthesis. An 
alternative solution to the problem was devised, in which a C-C bond linkage was 
substituted for the problematic C-O bond. The well-known Suzuki-Miyaura reaction was 
employed to form the desired C-C bond between the sp2 carbon of the aromatic ring and 
the sp3 carbon of the alkyl chain using a known protocol.41 In particular, commercially 
available 5-bromo-1-indanone was coupled with a 10-carbon chain potassium 
alkyltrifluoroborate using slightly modified version of the palladium catalyst (Scheme 
5.10). The requisite side chain was synthesized following the synthetic sequence used by 
Dreher and Molander.41 The use of Buchwald’s 1st generation preformed palladium 
catalyst (RuPhosPd(II)phenethylamine) 42  was of particular interest due to ease of 
operation. Aryl bromide was used instead of aryl chloride, since aryl bromides are 
generally considered to be more reactive as an electrophile in comparison to aryl 
chlorides. The desired coupled product 20 was obtained in comparable yields using the 
modified version of the protocol.41 
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Scheme 5.10. Suzuki-Miyaura coupling of 5-bromo-1-indanone and alkyltrifluoroborate. 
 
Since 5-bromo-1-indanone was more expensive than the chloro- derivative at the time, 
quick optimization of the reaction was conducted (Table 5.3). Although the original 
protocol was proved to be general41 in terms of the nature of the electrophile (Br, Cl, I, 
OTf), a clear difference between the aryl bromide and the chloride was observed in the 
present case, especially when the 1st generation RuPhos precatalyst was used (Entries 1 & 
2, Table 5.3). The aryl chloride was unable to react even under higher preformed catalyst 
loadings (Entry 3, Table 5.3). Interestingly, when palladium acetate was used instead, the 
reaction was able to proceed with the aryl chloride as the substrate. Minor differences 
were observed amongst the different types of phosphine catalyst, although SPhos gave 
the best yield (Entries 4,6,7, Table 5.3). Increasing the amount of palladium acetate did 
not improve the yield (Entry 5, Table 5.3). The 2nd generation SPhos precatalyst43 
afforded comparable results, suggesting the improved reactivity in comparison to the 1st 
generation preformed catalyst (Entry 8, Table 5.3). 
 
Table 5.3. Optimization of cross-coupling reaction. 
 
Entry X Pd source Ligand (mol%) Yieldb 
1 Br 1st generation RuPhos precatalyst (2 mol%) - 80% 
2 Cl 1st generation RuPhos precatalyst (2 mol%) - No reaction 
3 Cl 1st generation RuPhos precatalyst (10 mol%) - No reaction 
4 Cl Pd(OAc)2 (2 mol%) RuPhos (4 mol%) 62% 
5 Cl Pd(OAc)2 (4 mol%) RuPhos (8 mol%) 49% 
6 Cl Pd(OAc)2 (2 mol%) SPhos (4 mol%) 70% 
7 Cl Pd(OAc)2 (2 mol%) XPhos (4 mol%) 49% 
8 Cl 2nd generation SPhos precatalystc (2 mol%) - 57% 
[a] Reaction conditions: 1 equiv. electrophile, 1 equiv. trifluoroborate, 3 equiv. K2CO3, at 0.25 M concentration. 
[b] Isolated yield. 
[c] Chloro(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II). 
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With the optimized condition in hand, synthesis of potassium alkyltrifluoroborate side 
chains of varying lengths was commenced. Based on the PEG side chain analogue 
synthesis (Scheme 5.9), appending a tosylate moiety at the opposite end of the alkyl 
trifluoroborate chain was desired in order to achieve synthetic efficiency. Accordingly, 
following the general procedure,41 various alkyl side chains were synthesized in good 
yields (Scheme 5.11). Apart from 12- and 14-carbon chain starting materials, 
commercially available alcohols were used as starting materials. Tosylation of the alcohol 
followed by iridium-mediated borylation afforded the corresponding pinacol boronate 
esters in good yields. Conversion of the boronate esters to the corresponding potassium 
trifluoroborates resulted in acceptable yields of the final side chain products. 
 
Scheme 5.11. Synthesis of potassium trifluoroborate alkyl side chains. 
 
With the requisite alkyl side chains, the synthesis of 1,2-indanedione analogues was 
conducted following the general synthetic sequence (Scheme 5.12). Slight variability in 
terms of yield was observed for the cross-coupling reaction, which may be attributed to 
the various side chain lengths. In general, longer side chains afforded modest yields in 
comparison to shorter ones. Subsequent displacement of the tosylate with potassium 
thioacetate generated analogues 41-45 in good yields. Formation of the oxime followed 
by conversion to the desired 1,2-indanedione occurred in near quantitative yields without 
the need of performing silica gel column chromatography purifications. Similar to 
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previous syntheses (Scheme 5.9), removal of thioacetate group was observed as a minor 
side product in the last step.  
 
Scheme 5.12. Second generation synthesis of 1,2-indanedione analogues. 
 
The second-generation synthesis was proved to be more synthetically efficient in 
comparison to the first-generation synthesis not only in terms of number of steps (5 steps 
vs. 4 steps), but also in terms of overall yield. Furthermore, by changing the linkage 
between the aromatic ring of the 1,2-indanedione and the side chain, the undesired side 
reactions were not observed, allowing ease of isolation of the desired material by simple 
aqueous work-up conditions rather than column chromatography purification.  
 
5.5) Progress towards developing latent fingerprints using 1,2-indanedione 
analogues 
 
In order to assess the ability of the newly generated 1,2-indanedione analogues to detect 
amino acids, a spot test was performed. The spot test consisted of using a strip of 
Whatman filter paper that has been impregnated with drops of a weak solution of L-
leucine (0.2% w/v in a mixture of 3:7 dioxane/water), which was air-dried. The paper 
substrate was then dipped into solutions containing either ninhydrin (0.05% w/v solution 
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solution of 1,2-indandione in petroleum ether with a drop of AcOH and catalytic amount 
of ZnCl2), or the 10-carbon chain analogue 53 (0.05% w/v solution of 53 in petroleum 
ether with a drop of AcOH and catalytic amount of ZnCl2). The treated paper strip was 
then air-dried and heated using a steam iron until the spots were visible (1 min). As 
expected, the ninhydrin treated substrates displayed the characteristic purple colored 
spots where L-leucine was present (Figure 5.4b). 1,2-Indanedione treated substrates 
displayed light orange to pink colored spots in comparison. However, paper substrates 
treated with 53 initially showed almost no visible color development (Figure 5.4a). The 
spots were made visible only after subsequent post treatment with ninhydrin (Figure 
5.4b). Such practices are well-documented in the literature,2 where weakly developed 
fingerprints are augmented by post treatment with ninhydrin. Likewise, when 1,2-
indanedione treated substrate was post treated with ninhydrin, the color of the spots 
changed to a darker hue (Figure 5.4b). In all cases, the observed contrast for the 
developed spots increased over time when the samples were place in an environment 
away from light (Figure 5.4c).  
a)  b)  c)  
Figure 5.4. Spot test results; a) Initial treatment with 53 (left), post treatment with ninhydrin (right) b) 
Ninhydrin (left), 1,2-indanedione with ninhydrin post treatment (middle), 53 with ninhydrin post treatment 
(right) c) After 24 h. 
 
The results obtained from the spot test with L-leucine suggest that the activity of 1,2-
indanedione portion of 53 with amino acids is retained in the presence of a long alkyl side 
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chain. With this promising result in hand, 53 was chosen as the representative ligand to 
be functionalized onto gold nanoparticles. Functionalization of gold nanoparticles with 
53 was first attempted following a modified Brust protocol44 used by Almog.34 Although 
the synthesis of gold nanoparticles stabilized by tetraoctylammonium bromide was 
evident (observation of characteristic deep red color upon reduction with NaBH4), 
subsequent ligand exchange with 53 was unsuccessful. An alternative protocol45 to 
synthesize gold colloids stabilized by dodecyldimethylammonium bromide (DDAB) 
followed by ligand exchange was tested. The protocol was part of a study that was 
conducted to test the efficacy of digestive ripening with various alkanethiols. Since 
digestive ripening is a method used to transform highly polydispersed gold nanoparticles 
to monodispersed gold nanoparticles of decreased average particle size, relatively lower 
concentration of the surfactant (DDAB) was purposefully used for the study. The authors 
reasoned that by using a low concentration of DDAB, the removal of DDAB would be 
easier before the digestive ripening step, and it would also lead to highly polydispersed 
gold nanoparticles that could be used to observe the decrease in polydispersity after 
disgestive ripening. Likewise, for the present system, the use of lower concentration of 
DDAB could allow the subsequent ligand exchange with 53 to occur more easily. 
However, the digestive ripening step was not followed, since the effect of polydispersity 
of gold nanoparticles on the development on latent fingerprints on paper has not been 
determined. Nonetheless, when the protocol was applied in the current system using 53, 
the desired functionalized gold nanoparticles were successfully obtained, albeit with 
prolonged reaction time for ligand exchange. Longer reaction time was expected, since 
majority of 53 still contained the thioacetate moiety as opposed to the thiol group, which 
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readily forms strong bonds with gold nanoparticles.46 Various attempts were made for the 
removal of the acetate group with no success. Conditions used to convert thioesters to 
thiols require the use of aqueous media in protic acid or nucleophilic conditions, which 
only led to the formation of undesired corresponding acetals or decomposition of the 
material. The precise size of the acquired gold nanoparticles was not determined, since it 
was assumed that highly polydispersed gold colloids would be obtained. UV-Vis data 
(λmax = ~530 nm) supported the presence of gold nanoparticles, since the observed λmax 
was in the region that is characteristic of gold nanoparticles.  
 
With the promising result in hand, detection of latent fingerprint on paper was attempted, 
following Almog’s general procedure.34 Fingerprints were deposited on a paper substrate 
(fingerprints that are not “charged” with oily residue (sebaceous) and the paper was 
subsequently soaked in an aqueous solution of maleic acid for about 5 min to eliminate 
calcium carbonate on paper. If the calcium carbonate is not removed, the entire paper 
turns black upon treatment with Ag-PD (i.e. spontaneous silver deposition). The treated 
paper substrate was air-dried, and dipped into a solution of the functionalized gold 
nanoparticles in acetonitrile for about 10 min. Subsequent post treatment with Ag-PD 
solution for 1-2 min gave rise to visible fingerprint ridges (Figure 5.5).  
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Figure 5.5. Latent fingerprints developed on paper substrate (original image-left, photo enhanced 
contrast image-right). 
 
Since a “positive” fingerprint image was obtained, in which the silver deposition was 
more apparent on the ridges of the fingerprint in comparison to the background, the 
desired reaction of the 1,2-indanedione portion of 53 with the amino acid residue of the 
fingerprint may be taking precedence over the reaction of 1,2-indanedione with cellulose. 
Furthermore, although fingerprints that were not “charged” (eccrine fingerprints) were 
deposited, due to the presence of along alkyl chain on 53, the observed image could be 
further amplified by hydrophobic interactions as well.34,35  
 
5.6) Conclusions 
 
Novel 1,2-indanedione analogues were successfully synthesized using a concise, four-
step protocol. The 10-carbon chain 1,2-indanedione analogue 53 was functionalized onto 
gold nanoparticles and used to develop latent fingerprints on paper substrates. With the 
promising preliminary results at hand, further efforts toward optimization of the 
development protocol will be made. For instance, the effect of gold nanoparticle 
dispersity on fingerprint development could be studied using the 1,2-indanedione 
analogues of varying chain lengths. Formulation of the functionalized gold nanoparticle 
could be optimized as well in order to use solvents that will produce acceptable images 
without dissolving ink. Use of other sulfur containing compounds as ligands to gold 
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nanoparticles could be investigated, since the use of thioacetates resulted in prolonged 
reaction times. Moreover, much work remains to be done in order to fully elucidate the 
mechanism in which the newly developed reagents are undergoing with residues of latent 
fingerprints.  
 
Development of latent fingerprints on paper is still an ongoing research area, since there 
is no universal reagent that detects fingerprints. The outcome of the developed fingerprint 
could vary on many external factors that are difficult to control. For instance, a recent 
study using 1,2-indanedione with ZnCl2 suggested that there is a correlation between the 
grade and the age of the developed print, age of the donor, and the washing of hands.47 In 
order to address such issues, existing fingerprint developing processes, such as Ag-PD,48 
are still evolving to achieve optimal formulation conditions. With the rapid advances in 
nanotechnology, there is a high demand for developing methods using modified MMD 
processes. Therefore, the proposed current approach in using functionalized 1,2-
indanedione analogues as tunable ligands on gold nanoparticles followed by Ag-PD 
processing could be an important contribution to the area of latent fingerprint detection 
on paper.  
 
5.7) Experimental results 
 
General Methods. All reactions were performed under an argon atmosphere except 
where otherwise noted. Tetrahydrofuran was distilled over sodium-benzophenone, 
dichloromethane was distilled over calcium hydride, DMF in Acroseal bottles were used 
without further purification prior to use. Flash chromatography was carried out on Merck 
silica gel 60 (240-400 mesh) using the solvent conditions listed under individual 
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experiments. Analytical thin-layer chromatography was performed on Merck silica gel 
(60F-254) plates (0.25 mm). Visualization was effected with ultraviolet light or 
phosphomolybdic acid (PMA) stain. Proton magnetic resonance spectra (1H NMR), 
Carbon magnetic resonance spectra (13C NMR), Fluorine magnetic resonance spectra (19F 
NMR), and Boron magnetic spectra (11B NMR) were performed on a Bruker NMR 
operating at 500, 125, 470, and 128 MHz respectively. All 11B chemical shifts were 
referenced to external BF3!OEt2 (0.0 ppm) with a negative sign indicating an upfield shift. 
Infrared spectra (IR) were obtained on a Perkin-Elmer 281-B spectrometer. High 
resolution mass spectra (HRMS) were obtained on a Micromass Autospec or a Waters 
LCTOF-Xe premier. Optical rotations were measured on a Jasco P-1010 polarimeter. 5-
hydroxy-1,2-indanedione was prepared following the procedure by Petrovskaia.i All other 
starting materials and reagents were purchased from Sigma-Aldrich, TCI, Acros, or 
Strem unless specified.  
 
General procedure for alkyl side chain synthesis for first generation synthesis 
 
Following the protocol reported by Suzuki et al,ii to a solution of the diol (5.74 mmol) 
dissolved in cyclohexane (25 mL) at room temperature was added aqueous HBr (141.4 
mmol). The resulting mixture was brought to reflux with stirring for 6 h or until 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
i O. G. Petrovskaia, “Design and synthesis of chromogenic and fluorogenic reagents for 
amino acid detection.” University of Pennsylvania, Philadelphia, PA, 1999.  
ii Luu, B., Bagnard, D., Hanibali, M., Yamada, M., Suzuki, H. Hydroquinone long-chain 
derivative and/or phenoxy long-chain derivative and pharmaceutical preparation 
comprising the same. EP1854777 (A1), November 14, 2007.!!
HBr (aq.)
cyclohexane, reflux
TBDMSCl,
imidazole
CH2Cl2
HO(CH2)nOH HO(CH2)nBr
n=10, 74%
n=12, 88%
TBSO(CH2)nBr
n=10, 90%
n=12, 94%
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completion (monitored by TLC). The reaction mixture was cooled to room temperature 
and extracted with diethyl ether. The organic layers were combined and washed with 
aqueous sat. NaHCO3, brine, and dried over MgSO4. Filtration followed by concentration 
under vacuum afforded a clear oil. Further purification by silica gel chromatography 
afforded the desired product. 1H NMR spectra of the 10- and 12-carbon derivative were 
in good accordance with the reported data.1  
To a solution of the bromoalcohol (4.216 mmol) in anhydrous CH2Cl2 (10 mL) was 
added TBDMSCl (6.324 mmol) followed by imidazole (6.324 mmol) at room 
temperature. The resulting solution was left to stir for 48 h at room temperature. After 
removal of the solvent, the residue was dissolved in ethyl acetate and washed with 
aqueous 10% KHSO4 and dried over Na2SO4, filtered, and concentrated. Silica gel 
chromatography purification afforded the desired product as a clear, colorless oil. 1H 
NMR spectra of 10- and 12-carbon derivative were in good accordance with the reported 
data.iii,iv  
General procedure for chain attachment for first generation synthesis 
 
To a stirred solution of 5-hydroxy-1-indanone (100 mg, 0.675 mmol) in anhydrous 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
iii Goulaouic-Dubois, C., Guggisberg, A., Hesse, M. “Samarium diiodide induced ring 
enlargement of azidocyclododecanones to various marocyclic lactams.” Tetrahedron 
1995, 51, 12035-12046.  
iv Maharvi, G. M., Edwards, A. O., Fauq, A. H. “Chemical synthesis of deuterium-labeled 
and unlabeled very long chain polyunsaturated fatty acids.” Tetrahedron Lett. 2010, 51, 
6426-6428.!
O
HO
Br(CH2)nOTBS, 
K2CO3, 18-crown-6
Acetone, Δ
O
O
(CH2)nTBSO
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acetone (20 mL) was added the 10-carbon chain (261 mg, 0.742 mmol), K2CO3 (233 mg, 
1.687 mmol), and 18-crown-6 (1.3 mg, 0.005 mmol). The resulting mixture was brought 
to reflux and left to stir for 24 h. The solvent was evaporated, dissolved in CH2Cl2 (30 
mL), washed with H2O (10 mL), back-extracted the aqueous layer with CH2Cl2 (10 mL, 3 
times). The organic layers were combined and dried over MgSO4, filtered, and 
concentrated. Silica gel chromatography purification (10% Ethyl acetate/Hexanes) 
afforded the chain attached indanone 6.  
10-Carbon chain TBS ether (6). Rf 0.28 (10% EtOAc/Hex); 1H 
NMR: (500 MHz, CDCl3) δ 7.70 (d, J = 9.13 Hz, 1H), 6.91 (dd, J = 6.1, 2.1 Hz, 2H), 
4.05 (t, J = 6.5 Hz, 2H), 3.64 (t, J = 6.5 Hz, 2H), 3.09 (dd, J = 7.46, 4.21 Hz, 2H), 2.70-
2.67 (m, 2H), 1.86-1.81 (m, 2H), 1.61-1.44 (m, 6H), 1.44-1.28 (m, 8H), 1.04 (s, 9H), 0.13 
(s, 6H); 13C NMR: (125 MHz, CDCl3) δ 205.2, 164.9, 158.1, 130.2, 125.3, 115.6, 110.3, 
68.4, 63.3, 63.0, 36.4, 32.84, 32.79, 29.5, 29.45, 29.38, 29.3, 29.0, 25.9, 25.8, 25.76, 
25.71, 18.35; IR (cm-1): 2929, 2856, 1709, 1601, 1489, 1471, 1443, 1406, 1388, 1360, 
1332, 1303, 1257, 1143, 1100, 1006, 836, 812, 775; ΗRMS (ESI) m/z calculated for 
C25H42O3Si (M + Na)
+: 441.2801, found: 441.2808.  
12-Carbon chain TBS ether (7). Rf 0.57 (20% EtOAc/Hex); 1H 
NMR: (500 MHz, CDCl3) δ 7.71-7.69 (m, 1H), 6.92-6.90 (m, 2H), 4.04 (t, J = 6.51 Hz, 
2H), 3.61 (td, J = 6.63, 0.98 Hz, 2H), 3.11-3.09 (m, 2H), 2.70-2.67 (m, 2H), 1.84-1.81 (m, 
2H), 1.54-1.47 (m, 4H), 1.39-1.27 (m, 14H), 0.91 (s, 9H), 0.06 (s, 6H); 13C NMR: (125 
O
O(CH2)10TBSO
O
O(CH2)12TBSO
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MHz, CDCl3) δ 205.2, 164.9, 158.1, 130.2, 125.3, 115.6, 110.3, 68.5, 63.3, 36.4, 32.9, 
29.6, 29.5, 29.4, 29.3, 29.1, 26.0, 25.9, 25.86, 25.81, 18.4; IR (cm-1): 2924, 2853, 1701, 
1608, 1583, 1475, 1438, 1388, 1329, 1259, 1244, 1146, 1101, 1019, 875, 835, 773; 
ΗRMS (ESI) m/z calculated for C27H46O3Si (M + Na)
+: 469.3114, found: 469.3120.  
General procedure for TBS removal for first generation synthesis 
 
A solution of 10-carbon chain TBS ether 6 (2.7 g, 6.544 mmol) in 3:3:1 mixture of acetic 
acid:THF:H2O (170 mL) was stirred at room temperature overnight. Ethyl acetate (200 
mL) was added to the reaction mixture. The organic layer was carefully washed with 5% 
aq. NaHCO3 (100 mL) to neturalize the solution (checked by pH). The organic layer was 
then washed with 1M HCl (100 mL), brine, dried over MgSO4, filtered and concentrated. 
Silica gel chromatography purification (30% " 50% EtOAc/Hexanes) afforded the 
desired alcohol 8.  
10-Carbon chain alcohol (8). Rf 0.72 (30% Acetone/Hex); 1H 
NMR: (500 MHz, CDCl3) δ 7.70 (d, J = 9.14 Hz, 1H), 6.92-6.90 (m, 2H), 4.05 (t, J = 
6.54 Hz, 2H), 3.66 (td, J = 6.63, 0.93 Hz, 2H), 3.11-3.09 (m, 2H), 2.70-2.68 (m, 2H), 
1.85-1.80 (m, 2H), 1.61-1.56 (m, 2H), 1.50-1.44 (m, 4H), 1.41-1.32 (m, 10H); 13C NMR: 
(125 MHz, CDCl3) δ 205.2, 164.9, 158.1, 130.3, 125.3, 115.6, 110.3, 68.4, 63.0, 36.4, 
32.8, 29.51, 29.46, 29.4, 29.3, 29.0, 25.9, 25.8, 25.7; IR (cm-1): 3411, 2916, 2851, 1686, 
O
O
(CH2)n
AcOH: THF: H2O
TBSO
O
O
(CH2)nHO
O
O(CH2)10HO
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1672, 1607, 1595, 1469, 1439, 1401, 1339, 1305, 1259, 1106, 1092, 1049, 1019, 859, 836, 
811, 716; ΗRMS (ESI) m/z calculated for C19H28O3 (M + H)
+: 305.2117, found: 
305.2129. 
12-Carbon chain alcohol (9). Rf 0.21 (2% EtOAc/CH2Cl2); 1H 
NMR: (500 MHz, CDCl3) δ 7.69 (d, J = 9.33 Hz, 1H), 6.92-6.90 (m, 2H), 4.04 (t, J = 
6.54 Hz, 2H), 3.69-3.65 (m, 2H), 3.11-3.09 (m, 2H), 2.72-2.67 (m, 2H), 1.87-1.80 (m, 
2H), 1.62-1.56 (m, 4H), 1.52-1.45 (m, 2H), 1.42-1.28 (m, 14H), 1.26-1.21 (m, 1H); 13C 
NMR: (125 MHz, CDCl3) δ 205.3, 164.8, 158.1, 130.1, 125.3, 115.6, 110.2, 68.4, 63.0, 
36.4, 32.7, 29.6, 29.5, 29.4, 29.3, 29.0, 25.9, 25.8, 25.7; IR (cm-1): 3420, 2915, 2851, 
1686, 1672, 1605, 1583, 1473, 1439, 1401, 1336, 1305, 1258, 1147, 1107, 1094, 1055, 
1039, 1023, 1000, 860, 834, 810, 715, 651, 568; ΗRMS (ESI) m/z calculated for 
C21H32O3 (M + Na)
+: 355.2249, found: 355.2255. 
General procedure for Mitsunobu reaction for first generation synthesis 
 
To a mixture of the 10-carbon chain alcohol 8 (90 mg, 0.2956 mmol) and PPh3 (116 mg, 
0.4435 mmol) in anhydrous THF was added drop-wise DEAD (70 mL, 0.4435 mmol). 
After 5 min, thioacetic acid (42 mL, 0.5913 mmol) was added, and the resulting mixture 
was stirred at room temperature for 20 h. The solvent was concentrated. Silica gel column 
chromatography purification (30% EtOAc/Hexanes) afforded the desired product 10.  
O
O(CH2)12HO
O
O
(CH2)nHO
MeCOSH, 
DEAD, PPh3
THF
O
O
(CH2)nS
O
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10-Carbon chain thioacetate (10). Rf 0.62 (30% Acetone/Hex); 
1H NMR: (500 MHz, CDCl3) δ 7.67 (d, J = 9.06 Hz, 1H), 6.89 (t, J = 2.23 Hz, 2H), 4.03 
(t, J = 6.52 Hz, 2H), 3.08 (t, J = 5.82 Hz, 2H), 2.86 (t, J = 7.36 Hz, 2H), 2.68-2.65 (m, 
2H), 2.23, (s, 3H), 1.84-1.76 (m, 2H), 1.57 (dt, J = 14.59, 7.30 Hz, 2H), 1.49-1.42 (m, 
2H), 1.36-1.24 (m, 12H); 13C NMR: (125 MHz, CDCl3) δ 205.1, 195.9, 164.8, 158.0, 
130.1, 125.2, 115.5, 110.2, 68.4, 36.3, 30.5, 29.4, 29.37, 39.30, 29.2, 29.1, 29.0, 28.7, 
28.3, 25.9, 25.8, 24.9, 14.0; IR (cm-1): 2918, 2851, 1755, 1698, 1607, 1594, 1470, 1433, 
1414, 1305, 1254, 1141, 1119, 1089, 1043, 1014, 968, 855, 830, 807, 717, 636; ΗRMS 
(ESI) m/z calculated for C21H30O3S (M + H)
+: 363.1994, found: 363.1984. 
12-Carbon chain thioacetate (11). Rf 0.65 (2% EtOAc/CH2Cl2); 
1H NMR: (500 MHz, CDCl3) δ 7.69 (d, J = 8.99 Hz, 1H), 6.92-6.90 (m, 2H), 4.04 (t, J = 
6.55, 2H), 3.11-3.09 (m, 2H), 2.88 (t, J = 7.35, 2H), 2.68 (ddd, J = 5.96, 4.08, 1.83 Hz, 
2H), 2.33 (s, 3H), 1.86-1.80 (m, 2H), 1.61-1.55 (m, 2H), 1.51-1.45 (m, 2H), 1.43-1.25 (m, 
14H); 13C NMR: (125 MHz, CDCl3) δ 205.2, 195.9, 164.8, 158.0, 130.1, 125.2, 115.5, 
110.2, 68.4, 63.9, 38.9, 36.3, 30.5, 29.47, 29.40, 29.2, 29.1, 29.05, 29.03, 28.9, 28.8, 28.7, 
28.3, 25.9, 25.8, 24.9, 14.0; IR (cm-1): 2915, 2850, 1755, 1698, 1606, 1487, 1470, 1433, 
1414, 1354, 1329, 1305, 1254, 1141, 1089, 1038, 1021, 987, 951, 853, 830, 807, 716, 634, 
595; ΗRMS (ESI) m/z calculated for C23H34O3S (M + Na)
+: 413.2126, found: 413.2140. 
 
 
O
O(CH2)10AcS
O
O(CH2)12AcS
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General procedure for oxime formation for first generation synthesis 
 
To a solution of 10-carbon thioacetate 10 (86 mg, 0.2372 mmol) in THF (0.5 mL) was 
added conc. HCl (0.13 mL, 4.278 mmol) followed by nButyl nitrite (77 mL, 0.658 mmol). 
The resulting mixture was left to stir at room temperature for 2 h (or until completion 
monitored by TLC). Ethyl acetate (5 mL) was added to the reaction mixture, and the 
organic layer was washed with H2O (1 mL), washed with brine (1 mL), dried over 
MgSO4, filtered, and concentrated. Silica gel chromatography purification (30% 
EtOAc/Hexanes " 40% " 50%) afforded the desired product 12.  
10-Carbon chain oxime (12). Rf 0.28 (40% EtOAc/Hex); 1H 
NMR: (500 MHz, CDCl3) δ7.85 (d, J = 8.5 Hz, 1H), 6.97-6.94 (m, 2H), 4.08 (t, J = 6.5 
Hz, 2H), 3.82 (s, 2H), 2.88 (t, J = 7.4 Hz, 2H), 2.34 (s, 3H), 1.87-1.81 (m, 2H), 1.61-1.46 
(m, 14H), 1.41-1.29 (m, 19H); 13C NMR: (125 MHz, CDCl3) δ 196.2, 187.7, 165.8, 155.2, 
149.9, 131.0, 136.6, 116.1, 110.5, 68.6, 30.5, 29.4, 29.3, 29.2, 29.1, 29.0, 28.9, 28.7, 28.4, 
25.8; IR (cm-1): 3232, 2925, 2853, 1692, 1601, 1578, 1468, 1344, 1278, 1248, 1108, 1037, 
905, 770, 686, 628; ΗRMS (ESI) m/z calculated for C21H29NO4S (M + H)
+: 392.1896, 
found: 392.1882. 
12-Carbon chain oxime (13). Rf 0.36 (40% EtOAc/Hex); 1H 
nBuONO, HCl
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O
O
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NMR: (500 MHz, CDCl3) δ 7.84 (d, J = 8.4 Hz, 1H), 6.96 (s, 1H), 6.94 (s, 1H), 4.08 (t, J 
= 6.5 Hz, 2H), 3.82 (s, 2H), 2.88 (t, J = 7.4 Hz, 2H), 2.34 (s, 3H), 1.87-1.81 (m, 2H), 1.57 
(sextet, J = 6.4 Hz, 2H), 1.51-1.45 (m, 2H), 1.38-1.29 (m, 15H).; 13C NMR: (125 MHz, 
CDCl3) δ 196.2, 187.7, 166.0, 155.5, 149.9, 131.1, 126.7, 116.2, 110.6, 68.7, 30.6, 29.49, 
29.43, 29.29, 29.15, 29.13, 29.08, 28.99, 28.81, 28.4, 25.92, 25.90; IR (cm-1): 2923, 2852, 
1692, 1645, 1601, 1579, 1489, 1471, 1343, 1297, 1248, 1109, 1095, 1037, 771, 684, 628; 
ΗRMS (ESI) m/z calculated for C23H33NO4S (M + Na)
+: 442.2028, found: 442.2038. 
General procedure for synthesis of 1,2-indanedione derivative for first generation 
synthesis 
 
To a suspension of the 10-carbon chain oxime 12 (893 mg, 2.281 mmol) in aqueous 
formaldehyde (37% in water) (8.6 mL, 116.3 mmol), was added conc. HCl (17 mL, 559.5 
mmol). The resulting suspension was vigorously stirred at room temperature overnight. 
The reaction mixture was diluted with CH2Cl2 (20 mL), basified until pH ~5 using 
aqueous NaHCO3. The aqueous layer was separated and extracted with CH2Cl2 (10 mL, 3 
times). The organic layers were combined and washed with brine (10 mL), dried over 
MgSO4, filtered, and concentrated.  
10-Carbon chain 1,2-indanedione analogue (14). Rf 0.6 (40% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.89 (d, J = 8.6 Hz, 1H), 7.00-6.95 (m, 2H), 
HCl, 36% HCHO (aq.)
O
O
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4.11 (t, J = 6.5 Hz, 2H), 3.57 (s, 2H), 2.87 (t, J = 7.4 Hz, 2H), 2.33 (s, 3H), 1.88-1.82 (m, 
2H), 1.57 (dt, J = 14.6, 7.3 Hz, 2H), 1.49-1.45 (m, 2H), 1.37-1.31 (m, 10H); 13C NMR: 
(125 MHz, CDCl3) δ 200.4, 196.0, 184.6, 166.7, 149.7, 131.3, 128.2, 116.9, 110.7, 69.9, 
36.7, 30.6, 29.6, 29.4, 29.38, 29.32, 29.1, 29.09, 29.03, 28.8, 28.7, 25.8; IR (cm-1): 3413, 
2826, 2853, 1710, 1691, 1599, 1261, 1105.  
Synthesis of functionalized PEG chain 
 
To a stirred solution of tetraethyleneglycol (1 mL, 5.766 mmol) in anhydrous CH2Cl2 (58 
mL) at 0 oC was added Ag2O (2 g, 8.649 mmol) and KI (0.19 mg, 1.154 mmol) followed 
by portion-wise addition of TsCl (1.2 g, 6.343 mmol). The resulting mixture was kept at 
0 oC for 10 min. The reaction mixture was then filtered through a pad of silica gel and 
evaporated. Silica gel chromatography purification (30% Acetone/CH2Cl2) afforded the 
tosylated PEG chain as a colorless oil (1.21 g, 60%). 1H NMR spectra obtained was in 
good accordance with the reported data.v  
To a stirred solution of tosylated PEG chain (1.11 g, 3.186 mmol) in anhydrous CH2Cl2 
(16 mL) was added TBSCl (0.72 g, 4.779 mmol) followed by imidazole (0.33 g, 4.779 
mmol). The resulting mixture was left to stir at room temperature overnight. The reaction 
was diluted with ethyl acetate (40 mL), washed with aqueous 10% KHSO4 (15 mL). The 
organic layer was separated, and dried over Na2SO4, filtered, and concentrated. Silica gel 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
v Rubinshtein, M., James, C. R., Young, J. L., Ma, Y. J., Kobayashi, Y., Gianneschi, N. 
C., Yang, J. “Facile procedure for generating side chain functionalized poly(α-hydroxy 
acid) copolymers from aldehydes via a versatile passerini-type condensation.” Org. Lett. 
2010, 12, 3560-3563. 
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1) Ag2O, TsCl, KI, CH2Cl2, 0 oC, 60%
2) TBSCl, imidazole, CH2Cl2, quant.
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chromatography purification (40% EtOAc/Hexanes) afforded the desired functionalized 
PEG chain as a colorless oil (1.47 g, quant.). 1H NMR spectra obtained was in good 
accordance with the reported data.vi 
TBS ether PEG chain indanone (15). To a 
stirred solution of 5-hydroxy-1-indanone (300 mg, 2.025 mmol) in anhydrous acetone (61 
mL) was added the functionalized PEG chain (1.0 g, 2.227 mmol), K2CO3 (0.7 g, 5.06 
mmol), and 18-crown-6 (4 mg, 0.014 mmol). The resulting mixture was brought to reflux 
and left to stir overnight. The solvent was evaporated, dissolved in CH2Cl2 (30 mL), 
washed with H2O (10 mL), back-extracted the aqueous layer with CH2Cl2 (10 mL, 3 
times). The organic layers were combined and dried over MgSO4, filtered, and 
concentrated. Silica gel chromatography purification (40% EtOAc/Hexanes) afforded the 
desired product as a yellow oil (759 mg, 85%). Rf 0.23 (40% EtOAc/Hex); 1H NMR: 
(500 MHz, CDCl3) δ 7.69 (dd, J = 9.19, 1.88 Hz, 1H), 6.93 (dd, J = 7.20, 1.87 Hz, 2H), 
4.23-4.21 (m, 2H), 3.90 (td, J = 4.80, 1.45 Hz, 2H), 3.79-3.74 (m, 4H), 3.71 (dd, J = 2.85, 
1.64 Hz, 2H), 3.67 (d, J = 1.82 Hz, 4H), 3.57 (td, J = 5.43, 1.88 Hz, 2H), 3.09 (t, J = 5.39 
Hz, 2H), 2.68 (ddt, J = 5.75, 3.95, 1.96 Hz, 2H), 0.90 (d, J = 1.96 Hz, 9H), 0.07 (d, J = 
1.95 Hz, 6H); 13C NMR: (125 MHz, CDCl3) δ 205.2, 164.4, 158.0, 130.5, 125.2, 115.6, 
110.4, 72.6, 70.8, 70.7, 70.68, 70.63, 69.4, 67.7, 62.6, 36.3, 25.9, 25.8, 25.6, 18.3, -5.2; 
IR (cm-1): 2928, 1705, 1601, 1488, 1471, 1462, 1443, 1407, 1388, 1360, 1350, 1332, 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
vi  Gutiérrez-Nava, M., Masson, P., Nierengarten, J.-F. “Synthesis of copolymers 
alternating oligophenylenevinylene subunits and fullerene moieties.” Tetrahedron Lett. 
2003, 44, 4487-4490. 
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1304, 1258, 1103, 1030, 1006, 953, 835, 811, 778, 710, 660, 592; ΗRMS (ESI) m/z 
calculated for C23H38O6Si (M + H)
+: 439.2516, found 439.2523.  
PEG chain indanone (16). To a stirred solution of 
the TBS ether 15 (659 mg, 1.502 mmol) in anhydrous THF (8 mL) at 0 oC was added 
TBAF (1M in THF, 3.76 mL, 3.756 mmol). The resulting mixture was kept at 0 oC for 2 
h then slowly warmed to room temperature for additional 2 h. The reaction mixture was 
diluted with ethyl acetate (20 mL), washed with H2O (10 mL) and brine (10 mL). The 
organic layer was separated and dried over Na2SO4, filtered, and concentrated. Silica gel 
chromatography purification afforded the alcohol (425 mg, 87%). Rf 0.23 (40% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.70 (d, J = 9.24 Hz, 1H), 6.95-6.93 (m, 
2H), 4.23 (t, J = 4.82 Hz, 2H), 3.90 (t, J = 4.81 Hz, 2H), 3.77-3.67 (m, 11H), 3.63 (dd, J 
= 5.12, 3.96 Hz, 2H), 3.10 (t, J = 5.91 Hz, 2H), 2.70-2.68 (m, 2H); 13C NMR: (125 MHz, 
CDCl3) δ; 205.2, 164.4, 158.0, 130.5, 125.3, 115.7, 110.4, 72.4, 70.8, 70.7, 70.6, 70.3, 
69.5, 67.7, 61.7, 36.4, 25.8; IR (cm-1): 3449, 3062, 3023, 2919, 2872, 1701, 1599, 1488, 
1442, 1406, 1348, 1334, 1305, 1259, 1198, 1127, 1104, 1090, 1032, 953, 885, 837, 809, 
710, 650, 592; ΗRMS (ESI) m/z calculated for C17H24O6 (M + Na)
+: 347.1471, found: 
347.1464. 
Thioacetate PEG chain indanone (17). To a 
stirred mixture of the alcohol 16 (420 mg, 1.294 mmol) in pyridine (13 mL) at −5 oC was 
added TsCl (617 mg, 3.237 mmol). The resulting mixture was kept at −5 oC for 1 h, then 
O
HO O O O O
O
S O O O O
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warmed to room temperature over 4 h. The reaction was quenched with 1N HCl (10 mL), 
and extracted with ethyl acetate (30 mL). The organic layer was washed with 1N HCl (10 
mL, three times), aqueous NaHCO3 (10 mL), and brine (10 mL). The organic layer was 
dried over Na2SO4, filtered, and concentrated to afford the crude tosylated product, which 
was carried on to the next step without further purification. To a stirred solution of the 
tosylate in anhydrous acetonitrile (78 mL) was added potassium thioacetate (286 mg, 
2.504 mmol) in one portion. The resulting mixture was brought to 60 oC and left to stir 
overnight. The reaction was quenched with H2O (160 mL), and the aqueous layer was 
extracted with CH2Cl2 (200 mL, two times). The combined organic layers were washed 
with brine (100 mL) and dried over Na2SO4, filtered, and concentrated. Silica gel 
chromatography purification (70% EtOAc/Hexanes) afforded the product as a yellow oil 
(370 mg, 77%). Rf 0.6 (80% EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.66 (d, J = 
9.13 Hz, 1H), 6.91 (t, J = 2.97 Hz, 2H), 4.20 (t, J = 4.79 Hz, 2H), 3.88 (dd, J = 5.17, 4.39 
Hz, 2H), 3.74-3.57 (m, 10H), 3.09-3.06 (m, 4H), 2.67-2.64 (m, 2H) 2.31 (s, 3H); 13C 
NMR: (125 MHz, CDCl3) δ 205.1, 195.3, 164.3, 157.9, 130.4, 125.2, 115.6, 110.3, 70.8, 
70.6, 70.4, 70.2, 69.6, 69.4, 67.7, 36.3, 30.4, 28.7, 25.7; IR (cm-1): 2920, 2869, 1701, 
1691, 1599, 1487, 1441, 1353, 1332, 1303, 1257, 1196, 1102, 1088, 1055, 1030, 953, 868, 
836, 808, 709, 626, 592; ΗRMS (ESI) m/z calculated for C19H26O6S (M + Na)
+: 405.1348, 
found: 405.1332. 
Thioacetate PEG chain oxime (18). To a 
flask charged with 17 (100 mg, 0.261 mmol) and a stir bar at −20 oC was added TMSCl 
O
S O O O O
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(33 mL, 0.261 mmol) followed by drop-wise addition of isoamyl nitrite (35 mL, 0.261 
mmol). The resulting mixture was left to stir at −20 oC for 30 min. The reaction was 
quenched with H2O (1 mL), extracted with ethyl acetate (3 mL), dried over Na2SO4, 
filtered, and concentrated to afford the desired product. Rf 0.2 (80% EtOAc/Hex); 1H 
NMR: (500 MHz, CDCl3) δ 7.78 (d, J = 10 Hz, 1H), 6.94 (d, J = 10 Hz, 1H), 6.88 (s, 1H), 
4.26 (t, J = 5 Hz, 2H), 3.89 (t, J = 5 Hz, 2H), 3.74-3.53 (m, 13H), 3.06 (t, J = 5 Hz, 2H), 
2.33 (s, 3H); 13C NMR: (125 MHz, CDCl3) δ 195.5, 187.7, 165.4, 155.2, 149.7, 131.3, 
136.5, 116.2, 110.7, 70.8, 70.7, 70.5, 70.2, 69.7, 69.4, 67.9, 41.6, 30.5, 28.7, 28.3, 22.5; 
ΗRMS (ESI) m/z calculated for C19H25NO7S (M + Na)
+: 434.1249, found: 434.1261. 
Thioacetate PEG chain 1,2-indanedione 
(19). To a flask charged with 18 (25 mg, 0.061 mmol) and a stir bar was added 
formaldehyde (37% in water) (500 mL) and conc. HCl (0.1 mL). The resulting 
suspension was vigorously stirred overnight. The reaction mixture was diluted with 
CH2Cl2 (2 mL), basified until pH ~5 using aqueous NaHCO3. The aqueous layer was 
separated and extracted with CH2Cl2 (1 mL, 3 times). The organic layers were combined 
and washed with brine (1 mL), dried over MgSO4, filtered, and concentrated. Rf 0.4 (80% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.89 (d, J = 8.58 Hz, 1H), 7.04-7.00 (m, 
2H), 4.29 (t, J = 4.44 Hz, 2H), 3.93 (t, J = 4.28 Hz, 2H), 3.76-3.58 (m, 12H), 3.08 (t, J = 
6.49 Hz, 2H), 2.33 (s, 3H); 13C NMR: (125 MHz, CDCl3) δ 200.3, 195.4, 184.7, 166.3, 
149.7, 131.3, 128.1, 116.9, 111.0, 70.9, 70.6, 70.5, 70.2, 70.0, 69.7, 69.2, 68.2, 36.7, 30.5, 
29.6, 28.7; IR (cm-1): 2871, 1761, 1713, 1600, 1489, 1452, 1350, 1257, 1104, 1052, 954, 
O
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841; ΗRMS (ESI) m/z calculated for C19H24O7S (M + H)
+: 397.1321, found: 397.1318. 
General procedure for synthesis of potassium alkyltrifluoroborate side chains 
 
To a stirred solution of 9-decen-1-ol (3 mL, 16.702 mmol) in anhydrous CH2Cl2 (30 mL) 
was added triethylamine (3.5 mL, 25.053 mmol) followed by DMAP (82 mg, 0.668 
mmol) and TsCl (3.18 g, 16.702 mmol). The resulting mixture was left to stir at room 
temperature overnight. The reaction was diluted with water (10 mL) and extracted with 
chloroform (10 mL, three times). The combined organic layers were washed with 
aqueous sat. NH4Cl (10 mL), separated, dried over MgSO4, filtered, and concentrated. 
Silica gel column chromatography purification (30% EtOAc/Hexanes) afforded 23 as an 
oil (4.73, 91%).  
A 100 mL round bottom flask was charged with [Ir(cod)Cl]2 (146 mg, 0.217 mmol), dppe 
(173 mg, 0.434 mmol), and a stir bar in a glovebox. The flask was then removed and to it 
was added a solution of the tosylate 23 (4.5 g, 14.495 mmol) in anhydrous CH2Cl2 (48 
mL) via cannula addition. The resulting mixture was brought to 0 oC, followed by drop-
wise addition of pinacolborane (3.15 mL, 21.742 mmol). The reaction mixture was left to 
stir and allowed to warm to room temperature overnight. The reaction was quenched by 
water (15 mL), left to stir for 5 min, and the resulting mixture was separated. The 
aqueous layer was extracted with diethyl ether (15 mL, three times). The combined 
organic layers were dried over MgSO4, filtered, and concentrated. Purification by silica 
OH
n
TsCl, 
Et3N, DMAP
CH2Cl2
OTs
n
21: n=3, 96%
22: n=6, 81%
23: n=8, quant.
24: n=10, 88%
25: n=12, 80%
 [Ir(cod)Cl]2, 
dppe, HBpin  KHF2 (aq.)OTs
n
pinB
26: n=3, 90%
27: n=6, quant.
28: n=8, 95%
29: n=10, 88%
30: n=12, quant.
OTs
n
KF3B
31: n=3, 96%
32: n=6, 77%
33: n=8, 70%
34: n=10, 88%
35: n=12, 60%
CH2Cl2 MeOH, 0 oC
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gel chromatography (15% EtOAc/Hexanes) afforded the product 28 as an oil (6.12 g, 
97%).  
To a stirred solution of 28 (4.5 g, 10.357 mmol) in acetonitrile (14 mL) was added 
aqueous 4.5 M KHF2 (14 mL). The resulting mixture was left to stir at room temperature 
for 1 h. The solution was concentrated, and put under vacuum overnight. Hot acetonitrile 
(100 mL) was added to the solid and filtered by hot gravity filtration (or alternatively, 
soxhlet extraction). The filtrate was evaporated, re-dissolved in small amount of cold 
diethyl ether (20 mL) and filtered to afford the desired potassium alkyltrifluoroborate salt 
33.  
8-Carbon chain pinacolboronate ester (27). Rf 0.65 (20% EtOAc/Hex); 
1H NMR: (500 MHz, CDCl3) δ 7.79 (d, J = 8.31 Hz, 2H), 7.35 (d, J = 8.51 Hz, 2H), 4.04-
4.00 (m, 2H), 2.45 (s, 3H), 1.69-1.59 (m, 4H), 1.39-1.22 (m, 20H), 0.75 (t, J = 7.82 Hz, 
2H); 13C NMR: (125 MHz, CDCl3) δ 144.5, 133.1, 129.7, 127.8, 82.8, 70.6, 32.1, 31.6, 
29.0, 28.9, 28.8, 28.7, 25.2, 24.7, 23.8, 22.5, 21.5, 14.0; 11B NMR (128.4 MHz, CDCl3) δ 
33.68; IR (cm-1): 2977, 2928, 2857, 1598, 1495, 1466, 1363, 1320, 1272, 1213, 1188, 
1177, 1145, 1098, 1019, 966, 936, 845, 815, 664, 577, 555; ΗRMS (ESI) m/z calculated 
for C21H35BO5S (M + H)
+: 411.2377, found: 411.2372. 
8-Carbon chain potassium trifluoroborate salt (32). 1H NMR: (500 
MHz, acetone-d6) δ 7.81 (d, J = 8.18 Hz, 2H), 7.50 (d, J = 8.29 Hz, 2H), 4.05 (t, J = 6.41 
Hz, 2H), 2.47 (s, 3H), 1.63 (dt, J = 14.26, 6.90 Hz, 2H), 1.38-1.15 (m, 10H), 0.88 (t, J = 
7.05 Hz, 2H); 13C NMR: (125 MHz, acetone-d6) δ 145.7, 134.6, 130.9, 128.7, 83.5, 71.6, 
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32.9, 32.5, 26.1, 25.3, 25.29, 25.25, 24.8, 23.3, 21.5, 14.4; 11B NMR (128.4 MHz, 
acetone-d6) δ 6.03; IR (cm
-1): 2916, 2850, 1362, 1175, 1095, 964, 944, 835, 810, 720, 
669, 650; ΗRMS (ESI) m/z calculated for C15H23BF3O3S (M – K
+)+: 351.1413, found: 
351.1406. 
10-Carbon chain pinacolboronate ester (28). Rf 0.43 (10% EtOAc/Hex); 
1H NMR: (500 MHz, CDCl3) δ 7.76 (d, J = 8.36 Hz, 2H), 7.34-7.32 (m, 2H), 3.99 (t, J = 
6.52 Hz, 2H), 2.42 (s, 3H), 1.60 (dt, J = 14.42, 6.99 Hz, 2H), 1.40-1.34 (m, 2H), 1.26-
1.18 (m, 24H), 0.73 (t, J = 7.79 Hz, 2H); 13C NMR: (125 MHz, CDCl3) δ 114.5, 133.0, 
129.6, 127.7, 82.7, 70.5, 32.2, 31.7, 29.25, 29.23, 29.1, 28.7, 28.6, 25.1, 24.6, 23.8, 22.5, 
21.5; 11B NMR (128.4 MHz, CDCl3) δ 33.87; IR (cm
-1): 2977, 2855, 1598, 1495, 1466, 
1371, 1320, 1271, 1212, 1188, 1177, 1145, 1098, 1019, 1004, 966, 920, 882, 832, 815, 
790, 776, 723, 688, 664, 577, 555; ΗRMS (ESI) m/z calculated for C23H39BO5S (M + 
H)+: 439.2690, found: 439.2685. 
10-Carbon chain potassium trifluoroborate salt (33). 1H NMR: (500 
MHz, acetone-d6) δ 7.84-7.81 (m, 2H), 7.52-7.49 (m, 2H), 4.06 (dt, J = 10.63, 5.0 Hz, 
2H), 2.47 (s, 3H), 1.66-1.60 (m, 2H), 1.29-1.18 (m, 14H), 0.15-0.12 (m, 2H); 13C NMR: 
(125 MHz, acetone-d6) δ 145.8, 134.5, 130.9, 128.7, 74.8, 71.6, 34.6, 30.8, 30.5, 26.6, 
26.1, 25.3, 25.2, 21.6; 11B NMR (128.4 MHz, acetone-d6) δ 6.06; 
19F NMR (470.8 MHz, 
acetone-d6) δ −140.95; IR (cm
-1): 2918, 2852, 1358, 1188, 1175, 1094, 965, 904, 836, 
809, 784, 627.  
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12-Carbon chain pinacolboronate ester (29). Rf 0.34 (10% EtOAc/Hex); 
1H NMR: (500 MHz, CDCl3) δ 7.72 (d, J = 8.32 Hz, 2H), 7.32 (d, J = 8.51 Hz, 2H), 4.00 
(t, J = 6.54 Hz, 2H), 2.43 (s, 3H), 1.61 (dt, J = 14.43, 7.00 Hz, 2H), 1.40-1.17 (m, 30H), 
0.74 (t, J = 7.77, 2H); 13C NMR: (125 MHz, CDCl3) δ 144.4, 133.2, 129.6, 127.7, 82.7, 
70.5, 32.2, 29.5. 29.4, 29.3, 29.2, 28.8, 28.7, 25.2, 24.7, 23.8, 21.4; 11B NMR (128.4 
MHz, CDCl3) δ 33.68; IR (cm
-1): 2977, 2925, 2853, 1598, 1466, 1364, 1319, 1212, 1188, 
1176, 1145, 1098, 1019, 966, 912, 846, 814, 790, 763, 732, 688, 665, 651, 641, 625; 
ΗRMS (ESI) m/z calculated for C25H43BO5S (M + Na)
+: 489.2822, found: 489.2825. 
12-Carbon chain potassium trifluoroborate salt (34). 1H NMR: (500 
MHz, DMSO-d6) δ 7.78 (d, J = 8.1 Hz, 2H), 7.49 (d, J = 7.9 Hz, 2H), 4.00 (t, J = 6.2 Hz, 
2H), 2.43 (s, 3H), 1.53 (t, J = 6.7 Hz, 2H), 1.19 (s, 18H), -0.04--0.10 (m, 2H); 13C NMR: 
(125 MHz, DMSO-d6) δ 144.8, 132.5, 130.1, 127.5, 70.8, 33.1, 29.4, 29.2, 29.1, 28.9, 
28.8, 28.1, 28.0, 25.6, 24.6, 21.0; 11B NMR (128.4 MHz, DMSO-d6) δ 6.42; IR (cm-1): 
2917, 2850, 1598, 1468, 1363, 1298, 1248, 1188, 1175, 1096, 1021, 965, 946, 918, 836, 
809, 793, 720, 669, 642, 626.  
14-Carbon chain pinacolboronate ester (30). Rf 0.67 (20% EtOAc/Hex); 
1H NMR: (500 MHz, CDCl3) δ 7.80 (d, J = 7.80 Hz, 2H), 7.35 (d, J = 7.98 Hz, 2H), 4.05-
4.02 (m, 2H), 2.46 (s, 3H), 1.67-1.61 (m, 2H), 1.41 (ddd, J = 12.36, 6.78, 6.30 Hz, 2H), 
1.30-1.22 (m, 32H), 0.77 (t, J = 7.75 Hz, 2H); 13C NMR: (125 MHz, CDCl3) δ 144.5, 
133.3, 129.7, 129.5, 127.8, 127.0, 82.8, 70.6, 41.9, 32.4, 29.6, 29.58, 29.55, 29.4, 29.38, 
29.36, 28.9, 28.7, 25.3, 24.7, 23.9, 21.5, 14.1; IR (cm-1): 2977, 2925, 2854, 1598, 1466, 
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1367, 1321, 1188, 1177, 1145, 1097, 1020, 966, 814, 714, 663, 577, 554; ΗRMS (ESI) 
m/z calculated for C27H47BO5S (M + H)
+: 494.3316, found: 495.3318. 
14-Carbon chain potassium trifluoroborate salt (35). 1H NMR: (500 
MHz, DMSO-d6) δ 7.78 (d, J = 8.2 Hz, 2H), 7.48 (d, J = 7.8 Hz, 2H), 4.00 (t, J = 6.3 Hz, 
2H), 2.42 (s, 3H), 1.57-1.52 (m, 2H), 1.21-1.16 (m, 22H), -0.06--0.12 (m, 2H); 13C NMR: 
(125 MHz, DMSO-d6) δ 144.7, 132.5, 130.1, 127.5, 89.7, 84.5, 70.8, 33.1, 29.4, 29.2, 
29.1, 29.0, 28.9, 28.8, 28.7, 28.1, 28.0, 25.6, 24.9, 24.6, 21.0; ; 11B NMR (128.4 MHz, 
acetone) δ 4.63; IR (cm-1): 2916, 2850, 1364, 1176, 1095, 965, 923, 835, 809, 793, 719, 
670.  
 
14-Carbon alkene tosylate (25). To a stirred solution of 12-carbon chain 
bromoalkane (3.57 g, 9.407 mmol) in anhydrous DMSO (21 mL) was added lithium 
acetylide ethylenediamine complex (1.12 g, 12.229 mmol). The resulting mixture was left 
to stir at room temperature for 6 h. The reaction was quenched with aqueous sat. NH4Cl 
(10 mL). The aqueous layer was extracted with diethyl ether (20 mL, three times). The 
combined organic layers were washed with water (10 mL), brine (10 mL), and dried over 
MgSO4, filtered, and concentrated. Purification by silica gel chromatography (100% 
Hexanes " 5% EtOAc/Hexanes) afforded the known alkyne (2.79 g, 91%). To a solution 
of the alkyne (2.79 g, 8.595 mmol) in ethyl acetate (43 mL) was added Lindlar’s catalyst 
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Br
3
H
Li H2N
NH2
•
DMSO, 91%
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3
1. H2, Lindlar cat.
    quinoline, 
    EtOAc, quant.
2. TBAF, THF, quant.
3. TsCl, Et3N, DMAP,
    CH2Cl2 25
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(249 mg, 1.203 mmol) followed by quinoline (1 mL, 8.595 mmol). The resulting mixture 
was stirred under H2 at room temperature overnight. The reaction mixture was filtered 
through a bed of Celite and washed with ethyl acetate (10 mL, three times). The filtrate 
was concentrated. Purification by silica gel chromatography (100% Hexanes " 5% 
EtOAc/Hexanes) afforded the known alkene as a yellow oil (2.8 g, quant.). To a stirred 
solution of the TBS ether alkene (2.13 g, 6.521 mmol) in anhydrous THF (44 mL) was 
added TBAF (1M in THF, 13 mL, 13.042 mmol). The resulting solution was stirred at 
room temperature for 3 h. The solvent was concentrated and directly loaded onto a silica 
gel column (20% EtOAc/Hexanes) and afforded the corresponding alcohol (1.38 g, 
quant.). The desired tosylate 25 was synthesized using the first step of the general 
procedure to synthesize potassium alkyltrifluoroborate side chains. Rf 0.53 (10% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.80 (d, J = 7.92 Hz, 2H), 7.36 (d, J = 8.24 
Hz, 2H), 5.87-5.79 (m, 1H), 5.03-4.93 (m, 2H), 4.03 (td, J = 6.53, 0.72 Hz, 2H), 2.46 (s, 
3H), 2.08-2.03 (m, 2H), 1.68-1.62 (m, 2H), 1.41-1.23 (m, 18H); 13C NMR: (125 MHz, 
CDCl3) δ 144.5, 139.2, 133.3, 129.7, 127.8, 114.0, 70.6, 33.7, 29.5, 29.4, 29.3, 29.1, 28.9, 
28.8, 25.6, 25.3, 21.6; IR (cm-1): 2977, 2918, 2850, 1641, 1597, 1495, 1474, 1397, 1357, 
1309, 1294, 1190, 1174, 1097, 1042, 1019, 984, 956, 930, 917, 840, 816, 794, 718, 707, 
668, 578, 555, 531, 503; ΗRMS (ESI) m/z calculated for C21H34O3S (M + H)
+: 367.2307, 
found: 367.2306. 
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General procedure for side chain coupling for second generation synthesis 
 
A microwave tube was charged with 5-chloro-1-indanone (100 mg, 0.600 mmol), 10-
carbon-potassium alkyltrifluoroborate chain 33 (240 mg, 0.600 mmol), Pd(OAc)2 (3 mg, 
0.012 mmol), RuPhos (12 mg, 0.025 mmol), K2CO3 (249 mg, 1.801 mmol), and a stir bar. 
The cap was sealed, and evacuated and purged with Ar (3 cycles). Degassed toluene:H2O 
mixture (3 mL) was then added to the microwave tube via syringe and the resulting 
reaction mixture was heated to 90 oC for 36 h. (For larger scale operation, the reaction 
was set up in a glovebox.) H2O (1 mL) was added to the reaction, stirred for 5 min, and 
the resulting layers were separated. The aqueous layer was extracted with ethyl acetate (2 
mL, three times). The organic layers were combined, dried over Na2SO4, filtered, and 
concentrated. Purification by silica gel chromatography (20% EtOAc/Hexanes) afforded 
the coupled product 38 as an amorphous solid (178 mg, 67%).  
10-Carbon chain TBS ether indanone (20). Rf 0.37 (40% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.68 (d, J = 7.84 Hz, 1H), 7.28 (s, 1H), 
7.20 (d, J = 7.76 Hz, 1H), 3.61 (t, J = 6.31 Hz, 2H), 3.12 (t, J = 5.77 Hz, 2H), 2.69 (dd, J 
= 10.17, 4.62, 4H), 1.64 (q, J = 7.08, 2H), 1.51 (q, J = 6.55 Hz, 2H), 1.33-1.29 (m, 12H), 
0.90 (s, 9H), 0.05 (s, 6H); 13C NMR: (125 MHz, CDCl3) δ 206.5, 155.6, 150.7, 135.0, 
127.9, 126.3, 123.5, 63.2, 36.4, 32.8, 31.2, 29.5, 29.45, 29.42, 29.3, 29.2, 25.9, 25.7, 25.6, 
18.3, -5.0; IR (cm-1): 2928, 2855, 1714, 1609, 1470, 1463, 1442, 1406, 1387, 1329, 1280, 
O
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1254, 1230, 1098, 1029, 1006, 835, 813, 775, 711; ΗRMS (ESI) m/z calculated for 
C25H42O2Si (M + Na)
+: 425.2852, found: 425.2849. 
5-Carbon chain tosylate indanone (36). Rf 0.23 (20% EtOAc/Hex); 
1H NMR: (500 MHz, CDCl3) δ 7.78 (d, J = 8.30 Hz, 2H), 7.67 (d, J = 7.85 Hz, 1H), 7.36-
7.34 (m, 2H), 7.25 (s, 1H), 7.15 (d, J = 7.86 Hz, 1H), 4.03 (t, J = 6.41 Hz, 2H), 3.11 (t, J 
= 5.86 Hz, 2H), 2.70-2.65 (m, 4H), 2.45 (s, 3H), 1.76-1.59 (m, 4H), 1.45-1.36 (m. 2H); 
13C NMR: (125 MHz, CDCl3) 206.5, 155.7, 149.8, 144.6, 135.1, 133.1, 129.7, 127.9, 
127.8, 126.8, 123.6, 70.2, 36.8, 36.0, 30.4, 28.6, 25.6, 24.9, 21.6; IR (cm-1): 2932, 2860, 
1708, 1608, 1494, 1440, 1403, 1357, 1281, 1188, 1176, 1097, 1030, 948, 903, 815, 663, 
576, 554; ΗRMS (ESI) m/z calculated for C21H24O4S (M + H)
+: 373.1474, found: 
373.1473. 
8-Carbon chain tosylate indanone (37). Rf 0.24 (20% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.80 (d, J = 8.2 Hz, 2H), 7.68 (d, J = 7.8 Hz, 
1H), 7.35 (d, J = 8.2 Hz, 2H), 7.19 (d, J = 7.9 Hz, 1H), 4.03 (t, J = 6.5 Hz, 2H), 3.12 (t, J 
= 5.9 Hz, 2H), 2.68 (dd, J = 10.3, 4.8 Hz, 4H), 2.46 (s, 3H), 1.64 (dq, J = 14.4, 7.2 Hz, 
4H), 1.35-1.25 (m, 9H).; 13C NMR: (125 MHz, CDCl3) 206.5, 155.6, 150.5, 144.5, 135.0, 
133.2, 129.7, 127.9, 127.8, 126.3, 123.5, 70.5, 36.3, 36.2, 31.1, 29.1, 29.0, 28.8, 28.7, 
25;6, 25.2, 21.5; IR (cm-1): 2928, 2856, 1709, 1608, 1495, 1441, 1403, 1359, 1289, 1229, 
1188, 1176, 1097, 1030, 941, 815, 664, 577, 555; ΗRMS (ESI) m/z calculated for 
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C24H30O4S (M + H)
+: 414.1943, found: 414.1943. 
10-Carbon chain tosylate indanone (38). Rf 0.26 (20% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.70, (d, J = 8.27 Hz, 2H), 7.64 (d, J = 7.85 
Hz, 1H), 7.32 (d, J = 8.29 Hz, 2H), 7.26 (s, 1H), 7.17 (d, J = 7.85 Hz, 1H), 4.00 (t, J = 
6.50 Hz, 2H), 3.08 (t, J = 5.82 Hz, 2H), 2.68-2.64 (m, 4H), 2.42 (s, 3H), 1.65 (dt, J = 
14.25, 6.95 Hz, 4H), 1.29-1.21 (m, 12H); 13C NMR: (125 MHz, CDCl3) 206.5, 155.6, 
150.6, 144.5, 134.8, 133.0, 129.6, 127.8, 127.6, 126.2, 123.3, 70.5, 36.3, 36.2, 31.1, 29.2, 
29.1, 29.0, 28.7, 28.6, 25.5, 25.1, 21.4; IR (cm-1): 2927, 2854, 1709, 1609, 1495, 1465, 
1441, 1404, 1359, 1282, 1188, 1176, 1097, 1030, 1020, 957, 927, 814, 664, 576, 555; 
ΗRMS (ESI) m/z calculated for C26H34O4S (M + Na)
+: 465.2076, found: 465.2079. 
12-Carbon chain tosylate indanone (39). Rf 0.39 (20% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.80 (d, J = 8.0 Hz, 2H), 7.68 (d, J = 7.9 Hz, 
1H), 7.35 (d, J = 8.2 Hz, 2H), 7.20 (d, J = 7.8 Hz, 1H), 4.04-4.02 (m, 2H), 3.12 (t, J = 5.8 
Hz, 2H), 2.71-2.68 (m, 4H), 2.46 (s, 3H), 1.69-1.62 (m, 4H), 1.32-1.23 (m, 17H); 13C 
NMR: (125 MHz, CDCl3) 206.6, 155.6, 150.7, 144.5, 135.0, 133.2, 129.7, 127.9, 127.8, 
126.3, 123.5, 70.6, 36.3, 31.2, 29.5, 29.45, 29.4, 29.3, 29.2, 28.8, 28.7, 25.6, 25.2, 21.5; 
IR (cm-1): 2977, 2922, 2849, 1704, 1607, 1470, 1434, 1393, 1356, 1323, 1296, 1281, 
1246, 1186, 1173, 1097, 1030, 949, 837, 815, 670, 576, 556, 532; ΗRMS (ESI) m/z 
calculated for C28H38O4S (M + H)
+: 471.2569, found: 471.2550. 
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14-Carbon chain tosylate indanone (40). Rf 0.45 (20% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.79 (d, J = 8.3 Hz, 2H), 7.67 (d, J = 7.8 Hz, 
1H), 7.36-7.34 (m, 2H), 7.28 (d, J = 0.8 Hz, 1H), 7.19 (d, J = 7.9 Hz, 1H), 4.02 (t, J = 6.5 
Hz, 2H), 3.11 (t, J = 5.9 Hz, 2H), 2.71-2.67 (m, 4H), 2.45 (s, 3H), 1.69-1.59 (m, 6H), 
1.36-1.18 (m, 18H).; 13C NMR: (125 MHz, CDCl3) 206.6, 155.6, 150.7, 144.5, 134.9, 
133.1, 129.7, 127.9, 126.3, 123.4, 70.6, 36.3, 31.2, 29.6, 29.5, 29.47, 29.41, 29.39, 29.3, 
29.2, 28.8, 28.7, 25.6, 25.2, 21.5; IR (cm-1): 2917, 2851, 1712, 1607, 1472, 1433, 1360, 
1228, 1186, 1171, 1095, 1030, 977, 955, 832, 807, 794, 719, 689, 668, 644; ΗRMS (ESI) 
m/z calculated for C30H42O4S (M + Na)
+: 521.2702, found: 521.2698. 
General procedure for thioacetate synthesis 
 
To a stirred solution of tosylate 38 (173 mg, 0.391 mmol) in anhydrous acetonitrile (25 
mL) was added potassium thioacetate (89 mg, 0.782 mmol) in one portion. The resulting 
mixture was then brought to 60 oC and left to stir overnight. The reaction was quenched 
by addition of H2O (40 mL), and extracted with CH2Cl2 (50 mL, three times). Organic 
layers were then combined, washed with brine (50 mL), dried over Na2SO4, filtered, and 
concentrated. Purification by silica gel chromatography (15% EtOAc/Hexanes) afforded 
43 as an amorphous solid (114 mg, 84%).  
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5-Carbon chain thioacetate indanone (41). Rf 0.39 (20% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.65 (d, J = 7.8 Hz, 1H), 7.26 (s, 1H), 7.16 
(dd, J = 7.8, 0.6 Hz, 1H), 3.09 (t, J = 5.9 Hz, 2H), 2.84 (t, J = 7.3 Hz, 2H), 2.69-2.64 (m, 
4H), 2.30 (s, 3H), 1.68-1.56 (m, 4H), 1.43-1.37 (m, 2H).; 13C NMR: (125 MHz, CDCl3) 
206.6, 195.9, 155.7, 150.2, 135.1, 127.9, 126.4, 123.6, 36.4, 36.1, 30.68, 30.63, 29.3, 28.9, 
28.3, 25.7; IR (cm-1): 2930, 2857, 1710, 1608, 1435, 1353, 1330, 1284, 1230, 1134, 1104, 
1030, 956, 813, 627, 586; ΗRMS (ESI) m/z calculated for C16H20O2S (M + H)
+: 
277.1262, found: 277.1264. 
8-Carbon chain thioacetate indanone (42). Rf 0.65 (30% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.65 (d, J = 7.8 Hz, 1H), 7.26 (s, 1H), 7.17 
(d, J = 7.8 Hz, 1H), 3.09 (t, J = 5.7 Hz, 2H), 2.84 (t, J = 7.3 Hz, 2H), 2.66 (q, J = 6.7 Hz, 
4H), 2.30 (s, 3H), 1.62 (q, J = 7.1 Hz, 2H), 1.55 (quintet, J = 7.2 Hz, 2H), 1.31-1.23 (m, 
8H); 13C NMR: (125 MHz, CDCl3) 206.3, 195.7, 155.5, 150.4, 134.9, 127.8, 126.2, 123.4, 
36.3, 36.2, 31.0, 30.4, 30.0, 29.3, 29.1, 29.0, 28.9, 28.8, 28.5, 25.5; IR (cm-1): 3009, 2926, 
2854, 1694, 1608, 1439, 1353, 1330, 1282, 1245, 1230, 1192, 1133, 1105, 1030, 954, 886, 
835, 814, 763, 724, 673, 627, 586; ΗRMS (ESI) m/z calculated for C19H26O2S (M + H)
+: 
319.1732, found: 319.1729. 
10-Carbon chain thioacetate indanone (43). Rf 0.57 (20% 
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EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.67 (d, J = 7.9 Hz, 1H), 7.28 (s, 1H), 7.19 
(d, J = 7.9 Hz, 1H), 3.11 (t, J = 5.8 Hz, 2H), 2.86 (t, J = 7.4 Hz, 2H), 2.69-2.66 (m, 4H), 
2.32 (s, 3H), 1.63 (dt, J = 14.7, 7.4 Hz, 2H), 1.56 (dq, J = 14.3, 7.0 Hz, 2H), 1.31 (dd, J = 
21.5, 15.0 Hz, 10H); 13C NMR: (125 MHz, CDCl3) 206.5, 195.9, 155.6, 150.6, 134.9, 
127.9, 126.2, 123.4, 36.3, 31.2, 30.5, 29.4, 29.3, 29.1, 29.0, 28.9, 28.7, 25.6; IR (cm-1): 
2921, 2851, 1697, 1686, 1608, 1469, 1444, 1352, 1334, 1294, 1234, 1132, 1106, 1031, 
958, 818, 766, 721, 638; ΗRMS (ESI) m/z calculated for C21H30O2S (M + Na)
+: 369.1864, 
found: 369.1865. 
12-Carbon chain thioacetate indanone (44). Rf 0.63 (20% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ  7.69 (d, J = 7.8 Hz, 1H), 7.29 (s, 1H), 7.21 
(d, J = 7.8 Hz, 1H), 3.13 (dd, J = 7.6, 4.1 Hz, 2H), 2.88 (t, J = 7.4 Hz, 2H), 2.72-2.69 (m, 
4H), 2.34 (s, 3H), 1.72-1.62 (m, 2H), 1.61-1.54 (m, 2H), 1.37-1.28 (m, 16H); 13C NMR: 
(125 MHz, CDCl3) 206.6, 196.0, 155.6, 150.7, 135.0, 128.0, 126.3, 123.5, 36.4, 31.2, 
30.6, 29.6, 29.5, 29.49, 29.43, 29.2, 29.1, 29.0, 28.8, 25.7; IR (cm-1): 2917, 2851, 1701, 
1686, 1607, 1470, 1443, 1352, 1334, 1295, 1273, 1231, 1193, 1135, 1106, 1031, 959, 903, 
818, 766, 719, 639; ΗRMS (ESI) m/z calculated for C23H34O2S (M + Na)
+: 397.2177, 
found: 397.2177. 
14-Carbon chain thioacetate indanone (45). Rf 0.5 (20% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.69 (d, J = 7.8 Hz, 1H), 7.29 (s, 1H), 7.21 
O
(CH2)12AcS
O
(CH2)14AcS
! 546 
(d, J = 7.8 Hz, 1H), 3.12 (dd, J = 5.9, 5.7 Hz, 2H), 2.88 (t, J = 7.4 Hz, 2H), 2.71-2.69 (m, 
4H), 2.34 (s, 3H), 1.71-1.62 (m, 2H), 1.61-1.55 (m, 4H), 1.38-1.27 (m, 18H); 13C NMR: 
(125 MHz, CDCl3) 206.6, 196.0, 155.6, 150.8, 135.0, 128.0, 126.3, 123.5, 36.4, 31.3, 
30.6, 29.6, 29.56, 29.53, 29.49, 29.46, 29.2, 29.15, 29.11, 28.8, 25.7; IR (cm-1): 2916, 
2849, 1701, 1686, 1607, 1469, 1442, 1428, 1234, 1120, 1030, 958, 818, 654; ΗRMS 
(ESI) m/z calculated for C25H38O2S (M + Na)
+: 425.2490, found: 425.2498. 
General procedure for oxime synthesis 
 
To a stirred solution of indanone 43 (398 mg, 1.148 mmol) in anhydrous CH2Cl2 (5 mL) 
at −20 oC was added TMSCl (0.15 mL, 1.148 mmol) followed by drop-wise addition of 
isoamy nitrite (0.15 mL, 1.148 mmol). The resulting mixture was left to stir at −20 oC for 
1 h. The reaction was quenched by addition of H2O (1 mL), and the layers were separated. 
The aqueous layer was extracted with CH2Cl2 (3 mL, three times), and the organic layers 
were combined. The organic layer was washed with brine (2 mL), dried over MgSO4, 
filtered, and concentrated to afford the oxime 48 (420 mg, quant.). 
5-Carbon chain thioacetate oxime (46). Rf 0.3 (40% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.82 (d, J = 7.9 Hz, 1H), 7.34 (s, 1H), 7.27 
(d, J = 8.0 Hz, 1H), 3.85 (s, 2H), 2.88 (t, J = 7.3 Hz, 2H), 2.73 (t, J = 7.7 Hz, 2H), 2.34 (s, 
3H), 1.73-1.60 (m, 5H), 1.47-1.42 (m, 2H).; 13C NMR: (125 MHz, CDCl3) δ 196.1, 189.2, 
TMSCl,
isoamylnitrite
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155.4, 152.3, 147.4, 135.8, 128.7, 126.5, 124.7, 36.4, 30.67, 30.56, 29.3, 28.9, 28.32, 
28.26; IR (cm-1): 3497, 3386, 2925, 2858, 1707, 1688, 1649, 1608, 1491, 1340, 1279, 
1139, 1112, 1043, 948, 922, 910, 843; ΗRMS (ESI) m/z calculated for C16H19NO3S (M + 
Na)+: 328.0983, found: 328.0993. 
8-Carbon chain thioacetate oxime (47). Rf 0.36 (40% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.82 (d, J = 7.9 Hz, 1H), 7.33 (s, 1H), 7.26 
(d, J = 8.0 Hz, 1H), 3.85 (s, 2H), 2.87 (t, J = 7.4 Hz, 2H), 2.72 (t, J = 7.7 Hz, 2H), 2.34 (s, 
3H), 1.69-1.63 (m, 2H), 1.60-1.54 (m, 2H), 1.34-1.28 (m, 9H); 13C NMR: (125 MHz, 
CDCl3) 196.2, 189.0, 155.4, 152.6, 147.2, 135.7, 128.6, 126.4, 124.6, 36.6, 31.0, 30.6, 
29.4, 29.2, 29.1, 29.0, 28.9, 28.6, 28.2; IR (cm-1): 3247, 2922, 2852, 1726, 1686, 1655, 
1608, 1469, 1434, 1407, 1332, 1302, 1273, 1126, 1109, 1037, 959, 946, 924, 905, 832, 
773, 755, 691, 634; ΗRMS (ESI) m/z calculated for C19H25NO3S (M + Na)
+: 370.1453, 
found: 370.1453. 
10-Carbon chain thioacetate oxime (48). Rf 0.39 (40% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ  7.81 (d, J = 7.9 Hz, 1H), 7.33 (s, 1H), 7.26 
(d, J = 7.9 Hz, 1H), 3.85 (s, 2H), 2.87 (t, J = 7.4 Hz, 2H), 2.71 (t, J = 7.7 Hz, 2H), 2.34 (s, 
3H), 1.66 (dq, J = 13.8, 6.9 Hz, 3H), 1.60-1.54 (m, 3H), 1.34-1.28 (m, 11H).; 13C NMR: 
(125 MHz, CDCl3) 196.2, 189.2, 155.3, 152.8, 147.3, 135.6, 128.7, 126.4, 124.5, 36.6, 
31.1, 30.6, 29.4, 29.37, 29.34, 29.2, 29.1, 29.0, 28.7, 28.2; IR (cm-1): 3248, 2919, 2851, 
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1725, 1685, 1655, 1609, 1581, 1469, 1435, 1409, 1352, 1331, 1302, 1269, 1201, 1132, 
1111, 1037, 958, 923, 907, 833, 774, 755, 690, 665, 637; ΗRMS (ESI) m/z calculated for 
C21H29NO3S (M + Na)
+: 376.1922, found: 376.1940. 
12-Carbon chain thioacetate oxime (49). Rf 0.5 (40% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.82 (d, J = 7.9 Hz, 1H), 7.34 (s, 1H), 7.26 
(s, 1H), 3.85 (s, 2H), 2.88 (t, J = 7.4 Hz, 2H), 2.72 (t, J = 7.7 Hz, 2H), 2.34 (s, 3H), 1.70-
1.64 (m, 2H), 1.60-1.54 (m, 2H), 1.36-1.27 (m, 17H); 13C NMR: (125 MHz, CDCl3) 
196.2, 189.0, 155.4, 152.7, 147.2, 135.7, 128.7, 126.4, 124.5, 36.6, 31.1, 30.6, 29.53, 29.5, 
29.46, 29.42, 29.3, 29.2, 29.1, 29.0, 28.7, 28.2; IR (cm-1): 3258, 2916, 2851, 1726, 1685, 
1655, 1610, 1581, 1470, 1406, 1353, 1332, 1303, 1272, 1113, 1037, 960, 922, 906, 832, 
755, 756, 689, 640; ΗRMS (ESI) m/z calculated for C23H33NO3S (M + Na)
+: 426.2079, 
found: 426.2081. 
14-Carbon chain thioacetate oxime (50). Rf 0.53 (40% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.81 (d, J = 7.8 Hz, 1H), 7.33 (s, 1H), 7.28 
(d, J = 2.7 Hz, 1H), 3.85 (s, 2H), 2.87 (t, J = 7.2 Hz, 2H), 2.72 (t, J = 7.3 Hz, 2H), 2.33 (s, 
3H), 1.67-1.63 (m, 2H), 1.60-1.54 (m, 2H), 1.34-1.32 (m, 21H); 13C NMR: (125 MHz, 
CDCl3) 196.2, 189.1, 155.3, 152.7, 147.3, 135.7, 128.7, 126.4, 124.5, 36.6, 31.1, 30.6, 
29.57, 29.53, 29.4, 29.3, 29.2, 29.1, 29.0, 28.7, 28.2; IR (cm-1): 3252, 2916, 2849, 1726, 
1685, 1655, 1609, 1470, 1435, 1353, 1332, 1303, 1270, 1139, 1120, 1037, 959, 923, 907, 
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833, 774, 754, 690, 663, 639; ΗRMS (ESI) m/z calculated for C25H37NO3S (M + Na)
+: 
454.2392, found: 454.2387. 
General procedure for 1,2-indanedione synthesis 
 
To a stirred solution of 47 (189 mg, 0.543 mmol) in CH2Cl2 (5.4 mL) was added aqueous 
formaldehyde (37% in water, 0.3 mL) followed by conc. HCl (0.6 mL). The resulting 
mixture was left to stir at room temperature overnight. The reaction was quenched with 
cold H2O (5 mL), and the layers were separated. The aqueous layer was extracted with 
CH2Cl2 (5 mL, three times), and the organic layers were combined. The organic layer was 
washed with brine (5 mL), dried over MgSO4, filtered, and concentrated to afford 52 as a 
mixture with thioacetate removed thiol, which was used without further purification.  
5-Carbon chain thioacetate 1,2-indanedione (51). Rf 0.52 (40% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.84 (d, J = 7.9 Hz, 1H), 7.37 (s, 1H), 7.31 
(d, J = 7.9 Hz, 1H), 3.60 (s, 2H), 2.87 (t, J = 7.3 Hz, 2H), 2.75 (t, J = 7.7 Hz, 2H), 2.33 (s, 
3H), 1.74-1.60 (m, 6H), 1.48-1.41 (m, 4H); 13C NMR: (125 MHz, CDCl3) 200.2, 195.8, 
186.4, 154,0, 146.9, 135.1, 129.2, 126.9, 125.7, 36.6, 36.5, 30.5, 30.3, 29.2, 28.7, 28.2; 
IR (cm-1): 2932, 2858, 1764, 1719, 1688, 1609, 1437, 1391, 1353, 1263, 1134, 949, 837, 
752, 627; ΗRMS (ESI) m/z calculated for C16H18O3S (M + H)+: 291.1055, found: 
291.1060. 
O
(CH2)n
AcS
N
OH
HCl,
36% HCHO (aq.)
O
(CH2)n
AcS
O +
O
(CH2)n
HS
O
(minor)
CH2Cl2
O
(CH2)5AcS
O
! 550 
8-Carbon chain thioacetate 1,2-indanedione (52). Rf 0.6 (40% 
EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.83 (d, J = 7.9 Hz, 1H), 7.37 (s, 1H), 7.31 
(d, J = 8.0 Hz, 1H), 3.60 (s, 2H), 2.85 (t, J = 7.4 Hz, 2H), 2.74 (t, J = 7.7 Hz, 2H), 2.32 (s, 
3H), 1.70-1.64 (m, 3H), 1.56 (dt, J = 14.6, 7.3 Hz, 3H), 1.35 (dd, J = 13.3, 5.8 Hz, 6H).; 
13C NMR: (125 MHz, CDCl3) 200.3, 195.9, 186.4, 154.4, 146.8, 135.1, 129.2, 126.9, 
125.6, 36.8, 36.5, 30.8, 30.5, 29.4, 29.1, 29.0, 28.9, 28.8, 28.6; IR (cm-1): 3520, 2421, 
3354, 3050, 2921, 2852, 2254, 1900, 1768, 1714, 1613, 1580, 1468, 1434, 1386, 1354, 
1329, 1304, 1261, 1203, 1118, 1099, 951, 824, 755, 724, 667, 632; ΗRMS (ESI) m/z 
calculated for C19H24O3S (M + H)+: 333.1524, found: 333.1521. 
10-Carbon chain thioacetate 1,2-indanedione (53). Rf 0.65 
(40% EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.86 (d, J = 7.9 Hz, 1H), 7.38 (s, 1H), 
7.33 (d, J = 7.9 Hz, 1H), 3.61 (s, 2H), 2.89-2.86 (m, 2H), 2.76 (t, J = 7.7 Hz, 2H), 2.34 (s, 
3H), 1.72-1.64 (m, 3H), 1.62-1.54 (m, 3H), 1.38-1.28 (m, 10H); 13C NMR: (125 MHz, 
CDCl3) 200.3, 196.0, 186.4, 154.6, 146.8, 135.1, 129.2, 126.9, 125.7, 36.9, 36.6, 30.9, 
30.6, 29.6, 29.4, 29.37, 29.34, 29.2, 29.1, 29.0, 28.7; IR (cm-1): 2920, 2851, 1765, 1715, 
1686, 1612, 1468, 1435, 1352, 1331, 1302, 1268, 1201, 1117, 1098, 954, 923, 907, 833, 
774, 755, 690, 637; ΗRMS (ESI) m/z calculated for C21H28O3S (M + Na)+: 383.1657, 
found: 383.1644. 
O
(CH2)8AcS
O
O
(CH2)10AcS
O
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12-Carbon chain thioacetate 1,2-indanedione (54). Rf 0.71 
(40% EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.85 (d, J = 7.9 Hz, 1H), 7.38 (s, 1H), 
7.33-7.32 (m, 1H), 3.61 (s, 2H), 2.87 (t, J = 7.3 Hz, 2H), 2.75 (t, J = 7.7 Hz, 2H), 2.34 (s, 
3H), 1.71-1.65 (m, 3H), 1.60-1.54 (m, 3H), 1.36-1.27 (m, 14H).; 13C NMR: (125 MHz, 
CDCl3) 200.4, 196.0, 186.4, 154.6, 146.8, 135.1, 129.2, 126.9, 125.7, 36.9, 36.5, 30.9, 
30.6, 29.5, 29.49, 29.45, 249.41, 29.3, 29.2, 29.1, 29.0, 28.7; IR (cm-1): 2918, 2850, 1766, 
1716, 1694, 1611, 1469, 1434, 1384, 1353, 1328, 1304, 1267, 1136, 1118, 951, 8223, 718, 
630; ΗRMS (ESI) m/z calculated for C23H32O3S (M + Na)+: 411.1970, found: 411.1973. 
14-Carbon chain thioacetate 1,2-indanedione (55). Rf 0.7 
(40% EtOAc/Hex); 1H NMR: (500 MHz, CDCl3) δ 7.85 (d, J = 8.0 Hz, 1H), 7.38 (s, 1H), 
7.33 (d, J = 8.0 Hz, 1H), 3.61 (s, 2H), 2.87 (t, J = 7.4 Hz, 2H), 2.75 (t, J = 7.7 Hz, 2H), 
2.33 (s, 3H), 1.71-1.54 (m, 8H), 1.36-1.27 (m, 16H); 13C NMR: (125 MHz, CDCl3) 200.4, 
196.0, 186.4, 154.6, 146.8, 135.1, 129.2, 126.9, 125.7, 36.9, 36.5, 30.9, 30.6, 29.6, 29.5, 
29.47, 29.43, 29.3, 29.2, 29.1, 29.0, 28.7; IR (cm-1): 2919, 2849, 1765, 1719, 1693, 1610, 
1470, 1437, 1385, 1351, 1328, 1262, 1118, 948, 823, 718, 630; ΗRMS (ESI) m/z 
calculated for C25H36O3S (M + Na)+: 439.2283, found: 439.2278. 
General procedure for synthesis and functionalization of AuNPs with 1,2-
indanedione analogues 
Following Klabunde’s procedure,45 a solution of dodecyldimethylammonium bromide 
(0.02 M) was prepared in 2.5 mL of anhydrous toluene. To this was added AuCl3 (8.5 
O
(CH2)12AcS
O
O
(CH2)14AcS
O
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mg), and the resulting mixture was sonicated until complete dissolution was evident 
(homogeneous dark orange solution). Freshly prepared 9.4 M aqueous solution of NaBH4 
(50 µL) was quickly added to the vortex of the vigorously stirring solution. The resulting 
mixture was left to stir vigorously for additional 15-20 min to afford the “as-prepared” 
gold colloid. In a separate vial containing 53 (151 mg, 0.420 mmol) dissolved in 
anhydrous toluene (2 mL) was added to the solution containing gold colloid via syringe. 
The resulting mixture was left to stir vigorously for 24 h at room temperature to allow 
ligand exchange. The functionalized AuNPs were isolated by precipitation with ethanol 
(10 mL). The tube containing the functionalized AuNPs were centrifugated at 5000 rpm 
for 5 min cycles three times. After each cycle, the supernatant was decanted and 
discarded, and fresh EtOH (10 mL) was added. After final centrifugation, the supernatant 
was decanted, and the resulting AuNPs were dried under vacuum. The dried AuNPs were 
redispersed in acetonitrile (2.5 mL) to be used as part of the working solution for 
fingerprint development.  
General procedure for development of fingerprints on paper 
Following Almog’s procedure,34 the paper substrate containing latent fingerprint deposits 
was immersed in an aqueous solution of maleic acid (2.5% w/v in water) for 10 min or 
until no bubbles were apparent. The paper was then air-dried, and subsequently immersed 
in the working solution containing functionalized AuNPs (5 min-30 min). The paper was 
air-dried, and immersed in the Ag-PD solution (Arrowhead Scientific Inc.) until visible 
marks appeared (1-2 min). The paper substrate was then removed and washed with two 
successive water baths: Milli-Q followed by tap water.  
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5.9) Appendix D. Nuclear Magnetic Resonance, Infrared, and UV-Vis Spectra 
Relevant to Chapter 5 
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UV Absorption spectra of 53 (10C IND) in CH2Cl2 and gold nanoparticles 
functionalized with 53 (10C IND AuNP) in CH2Cl2. 
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